{"PMC7163617": [["IntroductionOver the past few years a useful reaction chemistry of the organometallic compounds of the heavier alkaline earths (M = Ca, Sr and Ba) has begun to emerge.1 Studies within our group, and elsewhere, have demonstrated the application of heavier group\u20102 species to the catalytic hydroamination,2 hydrophosphination,3 hydrosilylation,4 and polymerization5 of substrates containing unsaturated carbon\u2013carbon bonds.", [["Ca", "CHEMICAL", 132, 134], ["Ba", "CHEMICAL", 143, 145], ["Ca", "CHEMICAL", 132, 134], ["Sr", "CHEMICAL", 136, 138], ["Ba", "CHEMICAL", 143, 145], ["unsaturated carbon\u2013carbon", "CHEMICAL", 389, 414], ["alkaline earths", "SIMPLE_CHEMICAL", 111, 126], ["M = Ca", "SIMPLE_CHEMICAL", 128, 134], ["unsaturated carbon\u2013carbon bonds", "SIMPLE_CHEMICAL", 389, 420], ["the heavier alkaline earths", "PROBLEM", 99, 126], ["Ca", "TEST", 132, 134], ["1 Studies", "TEST", 167, 176], ["the catalytic hydroamination", "TEST", 274, 302], ["3 hydrosilylation", "TREATMENT", 324, 341], ["polymerization5 of substrates", "TREATMENT", 348, 377], ["unsaturated", "OBSERVATION_MODIFIER", 389, 400], ["carbon\u2013carbon bonds", "OBSERVATION", 401, 420]]], ["In addition, a number of group\u20102 mediated catalytic reactions have been reported that employ substrates containing carbon\u2013heteroatom multiple bonds.", [["group\u20102 mediated catalytic reactions", "PROBLEM", 25, 61]]], ["These include the polymerization of lactides and lactones,6 the trimerisation of phenyl isocyanate,7 the dimerisation of aldehydes (Tischenko reaction)8 and the hydrophosphination of 1,3\u2010carbodiimides.9", [["lactides and lactones", "CHEMICAL", 36, 57], ["phenyl isocyanate,7", "CHEMICAL", 81, 100], ["aldehydes", "CHEMICAL", 121, 130], ["Tischenko", "CHEMICAL", 132, 141], ["1,3\u2010carbodiimides", "CHEMICAL", 183, 200], ["lactides", "CHEMICAL", 36, 44], ["lactones", "CHEMICAL", 49, 57], ["phenyl isocyanate,7", "CHEMICAL", 81, 100], ["aldehydes", "CHEMICAL", 121, 130], ["Tischenko", "CHEMICAL", 132, 141], ["1,3\u2010carbodiimides", "CHEMICAL", 183, 200], ["lactides", "SIMPLE_CHEMICAL", 36, 44], ["lactones", "SIMPLE_CHEMICAL", 49, 57], ["phenyl isocyanate,7", "SIMPLE_CHEMICAL", 81, 100], ["aldehydes", "SIMPLE_CHEMICAL", 121, 130], ["Tischenko reaction)8", "SIMPLE_CHEMICAL", 132, 152], ["1,3\u2010carbodiimides", "SIMPLE_CHEMICAL", 183, 200], ["the polymerization of lactides", "TREATMENT", 14, 44], ["lactones", "TREATMENT", 49, 57], ["phenyl", "TREATMENT", 81, 87], ["aldehydes (Tischenko reaction)", "TREATMENT", 121, 151], ["the hydrophosphination of 1,3\u2010carbodiimides", "TREATMENT", 157, 200]]]], "PMC1978280": [["This included the development of methods and databases, quantitative structure\u2013activity relationships (QSARs), similarity searching, pharmacophores, homology models and other molecular modelling, machine learning, data mining, network analysis and data analysis tools that all use a computer.", [["methods and databases", "TEST", 33, 54], ["network analysis", "TEST", 227, 243], ["data analysis", "TEST", 248, 261]]], ["We have also previously introduced how some of these methods can be used for virtual ligand- and target-based screening and virtual affinity profiling.", [["these methods", "TREATMENT", 47, 60], ["virtual ligand", "TEST", 77, 91], ["based screening", "TEST", 104, 119], ["virtual affinity profiling", "TEST", 124, 150]]], ["In this second part of the review, we will greatly expand on the applications of these methods to many different target proteins and complex properties, and discuss the pharmacological space covered by some of these in silico efforts.", [["these methods", "TREATMENT", 81, 94], ["the pharmacological space", "TREATMENT", 165, 190]]], ["In the process, we will detail the success of in silico methods at identifying new pharmacologically active molecules for many targets and highlight the resulting enrichment factors when screening active drug-like databases.", [["new pharmacologically active molecules", "PROBLEM", 79, 117], ["the resulting enrichment factors", "PROBLEM", 149, 181]]], ["We will finally discuss some of the advantages and disadvantages of in silico methods with respect to in vitro and in vivo methods for pharmacology research.Drug target examples ::: Examples of in silico pharmacology ::: Pharmacological space coveredEnzymes:The ubiquitin regulatory pathway, in which ubiquitin is conjugated and deconjugated with substrate proteins, represents a source of many potential targets for modulation of cancer and other diseases (Wong et al., 2003).", [["cancer", "ANATOMY", 431, 437], ["cancer", "DISEASE", 431, 437], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 301, 310], ["cancer", "CANCER", 431, 437], ["ubiquitin", "PROTEIN", 301, 310], ["substrate proteins", "PROTEIN", 347, 365], ["silico methods", "TREATMENT", 71, 85], ["The ubiquitin regulatory pathway", "TREATMENT", 258, 290], ["substrate proteins", "TREATMENT", 347, 365], ["modulation of cancer", "PROBLEM", 417, 437], ["other diseases", "PROBLEM", 442, 456], ["cancer", "OBSERVATION", 431, 437]]], ["The recent crystal structure of a mammalian de-ubiquitinating enzyme HAUSP, which specifically de-ubiquitinates the ubiquitinated p53 protein, may also assist in drug development despite the peptidic nature of its substrate (Hu et al., 2002).", [["HAUSP", "GENE_OR_GENE_PRODUCT", 69, 74], ["p53", "GENE_OR_GENE_PRODUCT", 130, 133], ["mammalian de-ubiquitinating enzyme", "PROTEIN", 34, 68], ["HAUSP", "PROTEIN", 69, 74], ["ubiquitinated p53 protein", "PROTEIN", 116, 141], ["a mammalian de-ubiquitinating enzyme HAUSP", "PROBLEM", 32, 74], ["the ubiquitinated p53 protein", "PROBLEM", 112, 141], ["crystal structure", "OBSERVATION", 11, 28], ["p53 protein", "OBSERVATION", 130, 141]]], ["Novel non-peptidic inhibitors of the protease ubiquitin isopeptidase, which not only de-ubiquitinates p53 but other general ubiquitinated proteins as well, were discovered recently using a simple pharmacophore-based search of the National Cancer Institute (NCI) database (Mullally et al., 2001; Mullally and Fitzpatrick, 2002).", [["Cancer", "DISEASE", 239, 245], ["p53", "GENE_OR_GENE_PRODUCT", 102, 105], ["protease ubiquitin isopeptidase", "PROTEIN", 37, 68], ["p53", "PROTEIN", 102, 105], ["general ubiquitinated proteins", "PROTEIN", 116, 146], ["Novel non-peptidic inhibitors", "TREATMENT", 0, 29], ["the protease ubiquitin isopeptidase", "TREATMENT", 33, 68], ["other general ubiquitinated proteins", "PROBLEM", 110, 146]]], ["These inhibitors had IC50 values in the low micromolar range and caused cell death independent of the tumour suppressor p53, which is mutated in greater than 50% of all cancers (hence, p53 inhibition per se may not represent an optimal target for modulation).", [["cell", "ANATOMY", 72, 76], ["tumour", "ANATOMY", 102, 108], ["cancers", "ANATOMY", 169, 176], ["tumour", "DISEASE", 102, 108], ["cancers", "DISEASE", 169, 176], ["cell", "CELL", 72, 76], ["tumour", "CANCER", 102, 108], ["p53", "GENE_OR_GENE_PRODUCT", 120, 123], ["cancers", "CANCER", 169, 176], ["p53", "GENE_OR_GENE_PRODUCT", 185, 188], ["tumour suppressor p53", "PROTEIN", 102, 123], ["p53", "PROTEIN", 185, 188], ["These inhibitors", "TEST", 0, 16], ["IC50 values", "TEST", 21, 32], ["cell death", "PROBLEM", 72, 82], ["the tumour suppressor p53", "TREATMENT", 98, 123], ["all cancers", "PROBLEM", 165, 176], ["p53 inhibition", "TREATMENT", 185, 199], ["low micromolar", "OBSERVATION_MODIFIER", 40, 54], ["cell death", "OBSERVATION", 72, 82], ["cancers", "OBSERVATION", 169, 176]]], ["The ubiquitin isopeptidase inhibitors shikoccin, dibenzylideneacetone, curcumin and the more recently described punaglandins from coral indicate that a sterically accessible \u03b1,\u03b2-unsaturated ketone is essential for bioactivity (Verbitski et al., 2004).", [["shikoccin", "CHEMICAL", 38, 47], ["dibenzylideneacetone", "CHEMICAL", 49, 69], ["curcumin", "CHEMICAL", 71, 79], ["punaglandins", "CHEMICAL", 112, 124], ["\u03b1,\u03b2-unsaturated ketone", "CHEMICAL", 174, 196], ["shikoccin", "CHEMICAL", 38, 47], ["dibenzylideneacetone", "CHEMICAL", 49, 69], ["curcumin", "CHEMICAL", 71, 79], ["punaglandins", "CHEMICAL", 112, 124], ["\u03b1,\u03b2-unsaturated ketone", "CHEMICAL", 174, 196], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 4, 13], ["shikoccin", "SIMPLE_CHEMICAL", 38, 47], ["dibenzylideneacetone", "SIMPLE_CHEMICAL", 49, 69], ["curcumin", "SIMPLE_CHEMICAL", 71, 79], ["punaglandins", "SIMPLE_CHEMICAL", 112, 124], ["\u03b1,\u03b2-unsaturated ketone", "SIMPLE_CHEMICAL", 174, 196], ["The ubiquitin isopeptidase inhibitors shikoccin", "TREATMENT", 0, 47], ["dibenzylideneacetone", "TREATMENT", 49, 69], ["curcumin", "TREATMENT", 71, 79], ["\u03b2-unsaturated ketone", "TEST", 176, 196]]], ["All these molecules represent valuable leads for further chemical optimization.Drug target examples ::: Examples of in silico pharmacology ::: Pharmacological space coveredAromatase (cytochrome P450 (CYP)19) is a validated target for breast cancer.", [["breast cancer", "ANATOMY", 234, 247], ["breast cancer", "DISEASE", 234, 247], ["Aromatase", "GENE_OR_GENE_PRODUCT", 172, 181], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 183, 198], ["CYP)19", "GENE_OR_GENE_PRODUCT", 200, 206], ["breast cancer", "CANCER", 234, 247], ["Aromatase", "PROTEIN", 172, 181], ["cytochrome P450 (CYP)19", "PROTEIN", 183, 206], ["further chemical optimization", "TREATMENT", 49, 78], ["Pharmacological space coveredAromatase (cytochrome P450 (CYP)", "TREATMENT", 143, 204], ["breast cancer", "PROBLEM", 234, 247], ["molecules", "OBSERVATION", 10, 19], ["breast", "ANATOMY", 234, 240], ["cancer", "OBSERVATION", 241, 247]]], ["A ligand-based pharmacophore was generated with three non-steroidal inhibitors.", [["three non-steroidal inhibitors", "TREATMENT", 48, 78]]], ["This model could recognize known inhibitors from an in-house library and was further refined by the addition of molecular shape.", [["molecular shape", "OBSERVATION", 112, 127]]], ["The hits were also filtered with other pharmacophores for toxicity-related proteins, before testing.", [["toxicity", "DISEASE", 58, 66], ["other pharmacophores", "TREATMENT", 33, 53], ["toxicity", "PROBLEM", 58, 66], ["related proteins", "PROBLEM", 67, 83], ["testing", "TEST", 92, 99]]], ["Two out of the three compounds were ultimately found to be micromolar inhibitors (Schuster et al., 2006).Drug target examples ::: Examples of in silico pharmacology ::: Pharmacological space coveredA structure-based Catalyst pharmacophore was developed for acetylcholine esterase, which was subsequently used to search a natural product database.", [["acetylcholine", "CHEMICAL", 257, 270], ["acetylcholine", "CHEMICAL", 257, 270], ["acetylcholine esterase", "GENE_OR_GENE_PRODUCT", 257, 279], ["acetylcholine esterase", "PROTEIN", 257, 279], ["Pharmacological space", "PROBLEM", 169, 190], ["A structure-based Catalyst pharmacophore", "TREATMENT", 198, 238], ["acetylcholine esterase", "PROBLEM", 257, 279]]], ["The strategy identified scopoletin and scopolin as hits and were later shown to have moderate in vivo activity (Rollinger et al., 2004).", [["scopoletin", "CHEMICAL", 24, 34], ["scopoletin", "CHEMICAL", 24, 34], ["scopolin", "CHEMICAL", 39, 47], ["scopoletin", "SIMPLE_CHEMICAL", 24, 34], ["scopolin", "SIMPLE_CHEMICAL", 39, 47], ["scopolin", "PROTEIN", 39, 47], ["scopoletin", "TREATMENT", 24, 34], ["scopolin", "TREATMENT", 39, 47], ["scopoletin", "OBSERVATION", 24, 34], ["moderate", "OBSERVATION_MODIFIER", 85, 93]]], ["The same database was also screened against cyclooxygenase (COX)-1 and COX-2 structure-based pharmacophores, leading to the identification of known COX inhibitors.", [["cyclooxygenase (COX)-1", "GENE_OR_GENE_PRODUCT", 44, 66], ["COX-2", "GENE_OR_GENE_PRODUCT", 71, 76], ["COX", "GENE_OR_GENE_PRODUCT", 148, 151], ["cyclooxygenase (COX)-1", "PROTEIN", 44, 66], ["COX", "PROTEIN", 71, 74], ["COX", "PROTEIN", 148, 151], ["cyclooxygenase", "TEST", 44, 58], ["COX", "TEST", 60, 63], ["COX", "TEST", 71, 74], ["based pharmacophores", "PROBLEM", 87, 107], ["known COX inhibitors", "TREATMENT", 142, 162], ["COX inhibitors", "OBSERVATION", 148, 162]]], ["These represent examples where a combination of ethnopharmacological and computational approaches may aid drug discovery (Rollinger et al., 2005).Drug target examples ::: Examples of in silico pharmacology ::: Pharmacological space coveredA combined ligand-based and structure-based approach was taken to gaining structural insights into the human 5-lipoxygenase (LOX).", [["5-lipoxygenase", "CHEMICAL", 348, 362], ["human", "ORGANISM", 342, 347], ["5-lipoxygenase", "GENE_OR_GENE_PRODUCT", 348, 362], ["LOX", "GENE_OR_GENE_PRODUCT", 364, 367], ["human 5-lipoxygenase", "PROTEIN", 342, 362], ["LOX", "PROTEIN", 364, 367], ["human", "SPECIES", 342, 347], ["human", "SPECIES", 342, 347], ["Pharmacological space", "PROBLEM", 210, 231], ["A combined ligand", "TREATMENT", 239, 256]]], ["A Catalyst qualitative HipHop model was created with 16 different molecules that resulted in a five-feature pharmacophore.", [["A Catalyst qualitative HipHop model", "TREATMENT", 0, 35], ["Hip", "ANATOMY", 23, 26]]], ["A homology model of the enzyme was based on two soybean LOX enzymes and one rabbit LOX enzyme.", [["LOX", "GENE_OR_GENE_PRODUCT", 56, 59], ["rabbit", "ORGANISM", 76, 82], ["LOX", "GENE_OR_GENE_PRODUCT", 83, 86], ["soybean LOX enzymes", "PROTEIN", 48, 67], ["rabbit LOX enzyme", "PROTEIN", 76, 93], ["rabbit", "SPECIES", 76, 82], ["rabbit", "SPECIES", 76, 82], ["the enzyme", "TEST", 20, 30], ["two soybean LOX enzymes", "TEST", 44, 67], ["one rabbit LOX enzyme", "TEST", 72, 93]]], ["Molecular docking was then used to update and refine the pharmacophore to a four-feature model that could also be visualized in the homology model of 5-LOX.", [["5-LOX", "GENE_OR_GENE_PRODUCT", 150, 155], ["LOX", "PROTEIN", 152, 155]]], ["As a result of these models, amino-acid residues in the binding site were suggested as targets for site-directed mutagenesis while virtual screening with the pharmacophore had suggested compounds with a phenylthiourea or pyrimidine-5-carboxylate group for testing (Charlier et al., 2006).", [["amino-acid", "CHEMICAL", 29, 39], ["phenylthiourea", "CHEMICAL", 203, 217], ["pyrimidine-5-carboxylate", "CHEMICAL", 221, 245], ["amino-acid", "CHEMICAL", 29, 39], ["phenylthiourea", "CHEMICAL", 203, 217], ["pyrimidine-5-carboxylate", "CHEMICAL", 221, 245], ["amino-acid", "SIMPLE_CHEMICAL", 29, 39], ["phenylthiourea", "SIMPLE_CHEMICAL", 203, 217], ["pyrimidine-5-carboxylate", "SIMPLE_CHEMICAL", 221, 245], ["amino-acid residues", "TREATMENT", 29, 48], ["the binding site", "PROBLEM", 52, 68], ["virtual screening", "TEST", 131, 148], ["a phenylthiourea or pyrimidine", "TREATMENT", 201, 231]]], ["Homology models for the human 12-LOX and 15-LOX have also been used with the flexible ligand docking programme Glide (Schr\u00f6dinger Inc.) to perform virtual screening of 50 000 compounds.", [["human", "ORGANISM", 24, 29], ["12-LOX", "GENE_OR_GENE_PRODUCT", 30, 36], ["15-LOX", "GENE_OR_GENE_PRODUCT", 41, 47], ["human 12-LOX and 15-LOX", "PROTEIN", 24, 47], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29], ["virtual screening", "TEST", 147, 164]]], ["Out of 20 compounds tested, 8 had inhibitory activity and several were in the low micromolar range (Kenyon et al., 2006).Drug target examples ::: Examples of in silico pharmacology ::: Pharmacological space coveredMore than 30 years of research on renin have not been enough to deliver a marketed drug that inhibits this enzyme.", [["renin", "GENE_OR_GENE_PRODUCT", 248, 253], ["renin", "PROTEIN", 248, 253], ["enzyme", "PROTEIN", 321, 327], ["Pharmacological space", "TREATMENT", 185, 206], ["this enzyme", "TEST", 316, 327]]], ["In spite of this, renin remains an attractive yet elusive target for hypertension (Fisher and Hollenberg, 2001; Stanton, 2003).", [["hypertension", "DISEASE", 69, 81], ["renin", "GENE_OR_GENE_PRODUCT", 18, 23], ["renin", "PROTEIN", 18, 23], ["hypertension", "PROBLEM", 69, 81]]], ["In this respect, application of structure-based design leads to the identification of new non-peptidic inhibitors of human renin.", [["human", "ORGANISM", 117, 122], ["renin", "GENE_OR_GENE_PRODUCT", 123, 128], ["human renin", "PROTEIN", 117, 128], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["new non-peptidic inhibitors of human renin", "TREATMENT", 86, 128]]], ["These molecules include aliskiren (Rahuel et al., 2000; Torres et al., 2003), piperidines, including Ro-0661168 (Guller et al., 1999; Oefner et al., 1999; Vieira et al., 1999), and related 3,4-disubstituted piperidines (Marki et al., 2001).", [["aliskiren", "CHEMICAL", 24, 33], ["piperidines", "CHEMICAL", 78, 89], ["Ro-0661168", "CHEMICAL", 101, 111], ["3,4-disubstituted piperidines", "CHEMICAL", 189, 218], ["aliskiren", "CHEMICAL", 24, 33], ["piperidines", "CHEMICAL", 78, 89], ["Ro-0661168", "CHEMICAL", 101, 111], ["3,4-disubstituted piperidines", "CHEMICAL", 189, 218], ["aliskiren", "SIMPLE_CHEMICAL", 24, 33], ["piperidines", "SIMPLE_CHEMICAL", 78, 89], ["3,4-disubstituted piperidines", "SIMPLE_CHEMICAL", 189, 218], ["aliskiren", "TREATMENT", 24, 33], ["piperidines", "TREATMENT", 78, 89], ["disubstituted piperidines", "TREATMENT", 193, 218]]], ["Interestingly, these piperidines bind to and stabilize a different conformer of the protein termed \u2018open renin' (Bursavich and Rich, 2002), whereas aliskiren binds to \u2018closed renin'.", [["piperidines", "CHEMICAL", 21, 32], ["aliskiren", "CHEMICAL", 148, 157], ["piperidines", "CHEMICAL", 21, 32], ["aliskiren", "CHEMICAL", 148, 157], ["piperidines", "SIMPLE_CHEMICAL", 21, 32], ["renin", "GENE_OR_GENE_PRODUCT", 105, 110], ["aliskiren", "SIMPLE_CHEMICAL", 148, 157], ["renin", "GENE_OR_GENE_PRODUCT", 175, 180], ["renin", "PROTEIN", 175, 180], ["these piperidines bind", "TREATMENT", 15, 37], ["the protein", "TREATMENT", 80, 91], ["aliskiren binds", "TREATMENT", 148, 163]]], ["Since these latter structure-based design efforts, there have been remarkably very few published attempts at computer-aided design of novel renin inhibitors.", [["renin", "GENE_OR_GENE_PRODUCT", 140, 145], ["renin", "PROTEIN", 140, 145], ["novel renin inhibitors", "TREATMENT", 134, 156], ["remarkably", "OBSERVATION_MODIFIER", 67, 77], ["very", "OBSERVATION_MODIFIER", 78, 82], ["few", "OBSERVATION_MODIFIER", 83, 86]]], ["A single early QSAR was derived for a series of chain-modified peptide analogues of angiotensinogen.", [["angiotensinogen", "GENE_OR_GENE_PRODUCT", 84, 99], ["angiotensinogen", "PROTEIN", 84, 99], ["a series of chain", "TREATMENT", 36, 53], ["modified peptide analogues of angiotensinogen", "TREATMENT", 54, 99]]], ["The activity of these molecules was found to correlate with Kier's first-order molecular connectivity index descriptor and molecular weight but not with lipophilicity as measured by logP (Khadikar et al., 2005).", [["Kier's", "TEST", 60, 66]]], ["Another computational method for renin drug discovery used the de novo design software GrowMol, which could apparently regenerate 3,4-disubstituted piperidines in 1% of the grown structures (Bursavich and Rich, 2002).", [["GrowMol", "CHEMICAL", 87, 94], ["3,4-disubstituted piperidines", "CHEMICAL", 130, 159], ["3,4-disubstituted piperidines", "CHEMICAL", 130, 159], ["renin", "GENE_OR_GENE_PRODUCT", 33, 38], ["GrowMol", "SIMPLE_CHEMICAL", 87, 94], ["3,4-disubstituted piperidines", "SIMPLE_CHEMICAL", 130, 159], ["disubstituted piperidines", "TREATMENT", 134, 159]]], ["An attempt to use a Catalyst pharmacophore to discover new renin inhibitors was described in the early 1990s (Van Drie, 1993).", [["renin", "GENE_OR_GENE_PRODUCT", 59, 64], ["renin", "PROTEIN", 59, 64], ["a Catalyst pharmacophore", "TREATMENT", 18, 42], ["new renin inhibitors", "TREATMENT", 55, 75]]], ["Several novel molecules from the Pomona database (an early three-dimensional (3D) molecule database) were found that mapped to a renin pharmacophore but apparently were not tested in vitro.", [["renin", "GENE_OR_GENE_PRODUCT", 129, 134], ["renin", "PROTEIN", 129, 134], ["Several novel molecules", "PROBLEM", 0, 23], ["the Pomona database", "TEST", 29, 48], ["a renin pharmacophore", "TEST", 127, 148]]], ["More recently, a LigandFit docking study with a crystal structure of the \u2018open renin' form was able to detect 10 known inhibitors seeded in a library of 1000 compounds within the top 8.4% when using a consensus scoring function.", [["renin", "GENE_OR_GENE_PRODUCT", 79, 84], ["\u2018open renin' form", "PROTEIN", 73, 90], ["a LigandFit docking study", "TEST", 15, 40]]], ["Four examples of high-scoring compounds that were not tested as inhibitors fulfilled the pharmacophore derived from the X-ray data, consisting of four hydrophobes, a hydrogen bond donor or positive ionizable feature as well as excluded volumes (Krovat and Langer, 2004).", [["hydrogen", "CHEMICAL", 166, 174], ["high-scoring compounds", "PROBLEM", 17, 39], ["the X-ray data", "TEST", 116, 130], ["four hydrophobes", "PROBLEM", 146, 162], ["a hydrogen bond donor", "TREATMENT", 164, 185], ["positive ionizable feature", "PROBLEM", 189, 215], ["high", "OBSERVATION_MODIFIER", 17, 21], ["hydrogen bond", "OBSERVATION", 166, 179], ["ionizable feature", "OBSERVATION", 198, 215]]], ["Another study has used similarity searching of the MDDR database (for over 100 000 compounds) using 10 renin inhibitors and was able to produce enrichment factors that were 17-fold greater than random (Hert et al., 2004).", [["renin", "GENE_OR_GENE_PRODUCT", 103, 108], ["renin", "PROTEIN", 103, 108], ["Another study", "TEST", 0, 13], ["10 renin inhibitors", "TREATMENT", 100, 119], ["enrichment factors", "PROBLEM", 144, 162]]], ["Genetic algorithms have also been used for class discrimination between renin inhibitors and non-inhibitors in a subset of the MDDR using a small number of interpretable descriptors.", [["renin", "GENE_OR_GENE_PRODUCT", 72, 77], ["MDDR", "CANCER", 127, 131], ["renin", "PROTEIN", 72, 77], ["Genetic algorithms", "TEST", 0, 18], ["renin inhibitors", "TREATMENT", 72, 88], ["non-inhibitors", "TREATMENT", 93, 107], ["small", "OBSERVATION_MODIFIER", 140, 145]]], ["Among them, amide bond count, molecular weight and hydrogen bond donor counts were found to be much higher in renin inhibitors (Ganguly et al., 2006).", [["hydrogen", "CHEMICAL", 51, 59], ["amide", "CHEMICAL", 12, 17], ["hydrogen", "CHEMICAL", 51, 59], ["hydrogen", "SIMPLE_CHEMICAL", 51, 59], ["renin", "GENE_OR_GENE_PRODUCT", 110, 115], ["renin", "PROTEIN", 110, 115], ["amide bond count", "TEST", 12, 28], ["molecular weight", "TEST", 30, 46], ["hydrogen bond donor counts", "TEST", 51, 77]]], ["The recent publications on novel renin inhibitors represent a considerable amount of new information that could be used for further QSAR model development and database searching efforts in order to derive novel starting scaffolds for optimization.Drug target examples ::: Examples of in silico pharmacology ::: Pharmacological space coveredCathepsin D is an aspartic protease found mainly in lysosomes, which may have a role in \u03b2-amyloid precursor protein release and hence may well be a target for Alzheimer's disease.", [["lysosomes", "ANATOMY", 392, 401], ["Alzheimer's disease", "DISEASE", 499, 518], ["renin", "GENE_OR_GENE_PRODUCT", 33, 38], ["Cathepsin D", "GENE_OR_GENE_PRODUCT", 340, 351], ["lysosomes", "CELLULAR_COMPONENT", 392, 401], ["\u03b2-amyloid precursor protein", "GENE_OR_GENE_PRODUCT", 428, 455], ["renin", "PROTEIN", 33, 38], ["Cathepsin D", "PROTEIN", 340, 351], ["aspartic protease", "PROTEIN", 358, 375], ["\u03b2-amyloid precursor protein", "PROTEIN", 428, 455], ["novel renin inhibitors", "TREATMENT", 27, 49], ["further QSAR model development", "TREATMENT", 124, 154], ["novel starting scaffolds", "TREATMENT", 205, 229], ["Pharmacological space", "PROBLEM", 311, 332], ["Cathepsin D", "TREATMENT", 340, 351], ["an aspartic protease", "TREATMENT", 355, 375], ["\u03b2-amyloid precursor protein release", "TREATMENT", 428, 463], ["Alzheimer's disease", "PROBLEM", 499, 518]]], ["Cathepsin D may also be elevated in breast cancer and ovarian cancer hence a means to modulate this activity could be beneficial in these diseases.", [["breast cancer", "ANATOMY", 36, 49], ["ovarian cancer", "ANATOMY", 54, 68], ["breast cancer", "DISEASE", 36, 49], ["ovarian cancer", "DISEASE", 54, 68], ["Cathepsin D", "GENE_OR_GENE_PRODUCT", 0, 11], ["breast cancer", "CANCER", 36, 49], ["ovarian cancer", "CANCER", 54, 68], ["Cathepsin D", "PROTEIN", 0, 11], ["Cathepsin D", "PROBLEM", 0, 11], ["elevated in breast cancer", "PROBLEM", 24, 49], ["ovarian cancer", "PROBLEM", 54, 68], ["these diseases", "PROBLEM", 132, 146], ["may also be", "UNCERTAINTY", 12, 23], ["elevated", "OBSERVATION_MODIFIER", 24, 32], ["breast", "ANATOMY", 36, 42], ["cancer", "OBSERVATION", 43, 49], ["ovarian", "ANATOMY", 54, 61], ["cancer", "OBSERVATION", 62, 68], ["diseases", "OBSERVATION", 138, 146]]], ["There has been a brief overview of Cathepsin D in a comprehensive review of protease inhibitors (Leung et al., 2000).", [["Cathepsin D", "GENE_OR_GENE_PRODUCT", 35, 46], ["Cathepsin D", "PROTEIN", 35, 46], ["Cathepsin D", "TREATMENT", 35, 46], ["protease inhibitors", "TREATMENT", 76, 95]]], ["A combination of a structure-based design algorithm and combinatorial chemistry has been successfully applied to finding novel molecules for Cathepsin D in the nanomolar range (Kick et al., 1997).", [["Cathepsin D", "GENE_OR_GENE_PRODUCT", 141, 152], ["Cathepsin D", "PROTEIN", 141, 152], ["combinatorial chemistry", "TEST", 56, 79], ["Cathepsin D in the nanomolar range", "TREATMENT", 141, 175]]], ["Structures based on pepstatin (a 3.8 pM inhibitor (Baldwin et al., 1993)) yielded a 6\u20137% hit rate.", [["pepstatin", "CHEMICAL", 20, 29], ["pepstatin", "CHEMICAL", 20, 29], ["pepstatin", "SIMPLE_CHEMICAL", 20, 29], ["pepstatin", "TREATMENT", 20, 29], ["a 3.8 pM inhibitor", "TREATMENT", 31, 49]]], ["These molecules were tested in vitro using hippocampal slices and were shown to block the formation of hyperphosphorylated Tau fragments (Bi et al., 2000).", [["hippocampal slices", "ANATOMY", 43, 61], ["hippocampal slices", "MULTI-TISSUE_STRUCTURE", 43, 61], ["Tau", "GENE_OR_GENE_PRODUCT", 123, 126], ["hyperphosphorylated Tau fragments", "PROTEIN", 103, 136], ["hippocampal slices", "TEST", 43, 61], ["hyperphosphorylated Tau fragments", "PROBLEM", 103, 136], ["hyperphosphorylated Tau fragments", "OBSERVATION", 103, 136]]], ["There have been relatively few computational studies to date on Cathepsin D and other related aspartic proteases such as renin and \u03b2-secretase.", [["Cathepsin D", "GENE_OR_GENE_PRODUCT", 64, 75], ["renin", "GENE_OR_GENE_PRODUCT", 121, 126], ["\u03b2-secretase", "GENE_OR_GENE_PRODUCT", 131, 142], ["Cathepsin D", "PROTEIN", 64, 75], ["aspartic proteases", "PROTEIN", 94, 112], ["renin", "PROTEIN", 121, 126], ["\u03b2-secretase", "PROTEIN", 131, 142], ["computational studies", "TEST", 31, 52], ["Cathepsin D", "TREATMENT", 64, 75], ["other related aspartic proteases", "PROBLEM", 80, 112], ["renin", "TEST", 121, 126], ["\u03b2-secretase", "PROBLEM", 131, 142], ["relatively", "OBSERVATION_MODIFIER", 16, 26], ["few", "OBSERVATION_MODIFIER", 27, 30]]], ["One study has used molecular dynamics and free energy analyses (MM-PBSA) of Cathepsin D inhibitor interactions to suggest new substitutions that may improve binding (Huo et al., 2002).", [["Cathepsin D", "GENE_OR_GENE_PRODUCT", 76, 87], ["Cathepsin D", "PROTEIN", 76, 87], ["One study", "TEST", 0, 9], ["free energy analyses", "TEST", 42, 62], ["Cathepsin D inhibitor interactions", "TREATMENT", 76, 110], ["new substitutions", "PROBLEM", 122, 139], ["new", "OBSERVATION_MODIFIER", 122, 125], ["substitutions", "OBSERVATION", 126, 139]]], ["A genetic algorithm-based de novo design tool, ADAPT has also been used to rediscover active Cathepsin D molecules, by placing key fragments in the correct positions (Pegg et al., 2001).", [["ADAPT", "CHEMICAL", 47, 52], ["Cathepsin D", "GENE_OR_GENE_PRODUCT", 93, 104], ["Cathepsin D molecules", "PROTEIN", 93, 114], ["A genetic algorithm", "TEST", 0, 19], ["active Cathepsin D molecules", "TREATMENT", 86, 114], ["fragments", "OBSERVATION", 131, 140]]], ["Computational models may aid in the selection of novel ligands for protease inhibition that are non-peptidic and selective.", [["protease", "PROTEIN", 67, 75], ["novel ligands", "TREATMENT", 49, 62], ["protease inhibition", "TREATMENT", 67, 86], ["non-peptidic", "PROBLEM", 96, 108]]], ["Using the structural features of eight published inhibitors for Cathepsin D (Huo et al., 2002), a five-feature pharmacophore was derived consisting of three hydrophobes and two hydrogen bond acceptors (r=0.98).", [["hydrogen", "CHEMICAL", 177, 185], ["Cathepsin D", "SIMPLE_CHEMICAL", 64, 75], ["Cathepsin D", "PROTEIN", 64, 75], ["eight published inhibitors", "TREATMENT", 33, 59], ["Cathepsin D", "TREATMENT", 64, 75], ["two hydrogen bond acceptors", "TREATMENT", 173, 200]]], ["This pharmacophore was used to search a molecule database and selected 10 molecules out of 11 441 present.", [["a molecule database", "TEST", 38, 57]]], ["In contrast, a similarity search at the 95% level using ChemFinder (CambridgeSoft, Cambridge, MA, USA) suggested 16 different molecules.", [["ChemFinder", "TEST", 56, 66]]], ["All of these were selected for testing in vitro.", [["testing", "TEST", 31, 38]]], ["The pharmacophore produced four hits (40% hit rate) and the similarity search generated five hits (31% hit rate), where at least one replicate showed greater than 40% inhibition (Ekins et al., 2004a).", [["the similarity search", "TEST", 56, 77], ["hit rate", "TEST", 103, 111]]], ["In silico evaluation of the ADME properties for all active compounds estimated that the molecules would be well absorbed, although some were predicted to have solubility and CYP2D6 inhibition problems.Drug target examples ::: Examples of in silico pharmacology ::: Pharmacological space coveredPharmacophore- and structure-based approaches have been used to optimize an acyl urea hit for human glycogen phosphorylase.", [["acyl urea", "CHEMICAL", 370, 379], ["glycogen", "CHEMICAL", 394, 402], ["acyl urea", "CHEMICAL", 370, 379], ["CYP2D6", "GENE_OR_GENE_PRODUCT", 174, 180], ["acyl urea", "SIMPLE_CHEMICAL", 370, 379], ["human", "ORGANISM", 388, 393], ["glycogen phosphorylase", "GENE_OR_GENE_PRODUCT", 394, 416], ["human glycogen phosphorylase", "PROTEIN", 388, 416], ["human", "SPECIES", 388, 393], ["human", "SPECIES", 388, 393], ["silico evaluation", "TEST", 3, 20], ["all active compounds", "PROBLEM", 48, 68], ["solubility and CYP2D6 inhibition problems", "TREATMENT", 159, 200], ["Pharmacological space coveredPharmacophore", "TREATMENT", 265, 307], ["structure-based approaches", "TREATMENT", 313, 339], ["an acyl urea", "TEST", 367, 379], ["human glycogen phosphorylase", "TREATMENT", 388, 416]]], ["A Catalyst HypoGen five-feature pharmacophore was developed and used to guide further analogue synthesis.", [["A Catalyst HypoGen", "TREATMENT", 0, 18], ["further analogue synthesis", "TREATMENT", 78, 104]]], ["These compounds showed a good correlation with prediction (r=0.71).", [["prediction", "TEST", 47, 57]]], ["An X-ray structure for one molecule was used to confirm the predicted binding conformation.", [["An X-ray structure", "TEST", 0, 18]]], ["Ultimately, a comparative molecular field analysis (CoMFA) model was generated with all molecules synthesized and was found to be complementary to the X-ray structure.", [["a comparative molecular field analysis (CoMFA) model", "TEST", 12, 64]]], ["The outcome of this study was a molecule with good cellular activity that could inhibit blood glucose levels in vivo in rat (Klabunde et al., 2005).Drug target examples ::: Examples of in silico pharmacology ::: Pharmacological space coveredThe human sirtuin type 2, a target for controlling aging and some cancers, deacetylates \u03b1-tubulin and has been crystallized at high resolution.", [["cellular", "ANATOMY", 51, 59], ["blood", "ANATOMY", 88, 93], ["cancers", "ANATOMY", 307, 314], ["glucose", "CHEMICAL", 94, 101], ["cancers", "DISEASE", 307, 314], ["glucose", "CHEMICAL", 94, 101], ["cellular", "CELL", 51, 59], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["glucose", "SIMPLE_CHEMICAL", 94, 101], ["rat", "ORGANISM", 120, 123], ["human", "ORGANISM", 245, 250], ["sirtuin type 2", "GENE_OR_GENE_PRODUCT", 251, 265], ["cancers", "CANCER", 307, 314], ["\u03b1-tubulin", "GENE_OR_GENE_PRODUCT", 329, 338], ["human sirtuin type 2", "PROTEIN", 245, 265], ["\u03b1-tubulin", "PROTEIN", 329, 338], ["rat", "SPECIES", 120, 123], ["human", "SPECIES", 245, 250], ["rat", "SPECIES", 120, 123], ["human", "SPECIES", 245, 250], ["this study", "TEST", 15, 25], ["blood glucose levels", "TEST", 88, 108], ["Pharmacological space", "TREATMENT", 212, 233], ["The human sirtuin type 2", "TREATMENT", 241, 265], ["some cancers", "PROBLEM", 302, 314], ["deacetylates \u03b1-tubulin", "TREATMENT", 316, 338], ["cancers", "OBSERVATION", 307, 314]]], ["This structure has been used for docking the Maybridge database and returned a small hit list from which 15 compounds were tested and 5 showed activity at the micromolar level (Tervo et al., 2004).Drug target examples ::: Examples of in silico pharmacology ::: Pharmacological space coveredCatechol O-methyltransferase is a target for Parkinson's disease and there is currently a crystal structure of the enzyme that has been used to generate a homology model of the human enzyme.", [["Parkinson's disease", "DISEASE", 335, 354], ["O", "CHEMICAL", 299, 300], ["Catechol O-methyltransferase", "GENE_OR_GENE_PRODUCT", 290, 318], ["human", "ORGANISM", 467, 472], ["Catechol O-methyltransferase", "PROTEIN", 290, 318], ["enzyme", "PROTEIN", 405, 411], ["human enzyme", "PROTEIN", 467, 479], ["human", "SPECIES", 467, 472], ["human", "SPECIES", 467, 472], ["the Maybridge database", "TEST", 41, 63], ["Pharmacological space coveredCatechol O-methyltransferase", "TREATMENT", 261, 318], ["Parkinson's disease", "PROBLEM", 335, 354], ["the human enzyme", "TEST", 463, 479], ["small", "OBSERVATION_MODIFIER", 79, 84]]], ["This model was used to dock with FlexX software several catechins from tea and understand the structure-activity relationship (SAR) for these molecules and their metabolites, which had been tested in vitro.", [["FlexX", "CHEMICAL", 33, 38], ["catechins", "CHEMICAL", 56, 65], ["FlexX", "CHEMICAL", 33, 38], ["catechins", "CHEMICAL", 56, 65], ["FlexX", "SIMPLE_CHEMICAL", 33, 38], ["catechins", "SIMPLE_CHEMICAL", 56, 65], ["tea", "ORGANISM_SUBDIVISION", 71, 74]]], ["Ultimately, the combination of in vitro and computational work indicated that the galloyl group on catechins, the distance between Lys 144 on the enzyme, and the reacting catecholic hydroxy group were important for inhibition (Chen et al., 2005).Kinases: ::: Examples of in silico pharmacology ::: Pharmacological space coveredThe kinases represent an attractive family of over 500 targets for the pharmaceutical industry, with several drugs approved recently.", [["galloyl", "CHEMICAL", 82, 89], ["catechins", "CHEMICAL", 99, 108], ["Lys 144", "CHEMICAL", 131, 138], ["catecholic hydroxy", "CHEMICAL", 171, 189], ["galloyl", "CHEMICAL", 82, 89], ["catechins", "CHEMICAL", 99, 108], ["Lys", "CHEMICAL", 131, 134], ["catecholic hydroxy", "CHEMICAL", 171, 189], ["galloyl", "SIMPLE_CHEMICAL", 82, 89], ["catechins", "SIMPLE_CHEMICAL", 99, 108], ["Lys 144", "SIMPLE_CHEMICAL", 131, 138], ["catecholic hydroxy", "SIMPLE_CHEMICAL", 171, 189], ["kinases", "PROTEIN", 331, 338], ["catechins", "TEST", 99, 108], ["Lys", "TEST", 131, 134], ["the enzyme", "TEST", 142, 152], ["the reacting catecholic hydroxy group", "TREATMENT", 158, 195], ["Pharmacological space", "TREATMENT", 298, 319], ["several drugs", "TREATMENT", 428, 441]]], ["Kinase space has been mapped using selectivity data for small molecules to create a chemogenomic dendrogram for 43 kinases that showed the highly homologous kinases to be inhibited similarly by small molecules (Vieth et al., 2004).", [["Kinase", "GENE_OR_GENE_PRODUCT", 0, 6], ["43 kinases", "PROTEIN", 112, 122], ["Kinase space", "PROBLEM", 0, 12], ["selectivity data", "TEST", 35, 51], ["small molecules", "PROBLEM", 56, 71], ["a chemogenomic dendrogram", "TEST", 82, 107], ["the highly homologous kinases", "PROBLEM", 135, 164], ["homologous kinases", "OBSERVATION", 146, 164], ["small", "OBSERVATION_MODIFIER", 194, 199]]], ["Virtual screening methods have been applied quite widely for kinases to date (Fischer, 2004).", [["kinases", "PROTEIN", 61, 68], ["Virtual screening methods", "TEST", 0, 25]]], ["The structure-based design method has produced new potent inhibitors of CDK1 starting from the highly similar apo CDK2 and the positioning of olomoucine.", [["olomoucine", "CHEMICAL", 142, 152], ["olomoucine", "CHEMICAL", 142, 152], ["CDK1", "GENE_OR_GENE_PRODUCT", 72, 76], ["apo CDK2", "GENE_OR_GENE_PRODUCT", 110, 118], ["olomoucine", "SIMPLE_CHEMICAL", 142, 152], ["CDK1", "PROTEIN", 72, 76], ["apo CDK2", "PROTEIN", 110, 118], ["olomoucine", "PROTEIN", 142, 152], ["new potent inhibitors of CDK1", "PROBLEM", 47, 76], ["olomoucine", "TREATMENT", 142, 152], ["new", "OBSERVATION_MODIFIER", 47, 50], ["potent", "OBSERVATION_MODIFIER", 51, 57], ["apo CDK2", "OBSERVATION", 110, 118]]], ["A few amino-acid residues were mutated to conform to the CDK1 sequence.", [["amino-acid", "CHEMICAL", 6, 16], ["amino-acid", "CHEMICAL", 6, 16], ["amino-acid", "SIMPLE_CHEMICAL", 6, 16], ["CDK1", "GENE_OR_GENE_PRODUCT", 57, 61], ["CDK1 sequence", "DNA", 57, 70], ["A few amino-acid residues", "TREATMENT", 0, 25], ["the CDK1 sequence", "TEST", 53, 70], ["few", "OBSERVATION_MODIFIER", 2, 5], ["acid residues", "OBSERVATION", 12, 25]]], ["MacroModel was used to energy minimize molecules in the ATP pocket and visual inspection suggested points for molecular modification on the ligand.", [["ATP", "CHEMICAL", 56, 59], ["ATP", "CHEMICAL", 56, 59], ["ATP", "SIMPLE_CHEMICAL", 56, 59], ["MacroModel", "TREATMENT", 0, 10], ["the ATP pocket", "PROBLEM", 52, 66], ["visual inspection", "TEST", 71, 88], ["molecular modification on the ligand", "PROBLEM", 110, 146], ["ATP pocket", "OBSERVATION", 56, 66]]], ["Very quickly, design efforts guided ligand optimization to improve activity from 4.5 \u03bcM to 25 nM (Furet et al., 2000).", [["ligand optimization", "TREATMENT", 36, 55]]], ["A more recent CDK1/cyclin B homology model was also used to manually dock ligands, which enabled progression from alsterpaullone with an IC50 of 35 nM to a derivative with an IC50 of 0.23 nM (Kunick et al., 2005).Kinases: ::: Examples of in silico pharmacology ::: Pharmacological space coveredA structure-based in silico screening method was pursued for the Syk C-terminal SH2 domain using DOCK to find low molecular weight fragments for each binding site with millimolar binding affinity.", [["alsterpaullone", "CHEMICAL", 114, 128], ["alsterpaullone", "CHEMICAL", 114, 128], ["CDK1", "GENE_OR_GENE_PRODUCT", 14, 18], ["cyclin B", "GENE_OR_GENE_PRODUCT", 19, 27], ["alsterpaullone", "SIMPLE_CHEMICAL", 114, 128], ["Syk", "GENE_OR_GENE_PRODUCT", 359, 362], ["CDK1", "PROTEIN", 14, 18], ["cyclin B", "PROTEIN", 19, 27], ["Syk C-terminal SH2 domain", "PROTEIN", 359, 384], ["DOCK", "PROTEIN", 391, 395], ["cyclin B homology model", "TREATMENT", 19, 42], ["an IC50", "TREATMENT", 134, 141], ["an IC50", "TEST", 172, 179], ["Pharmacological space", "PROBLEM", 265, 286], ["silico screening method", "TEST", 315, 338], ["the Syk C-terminal SH2 domain", "PROBLEM", 355, 384], ["low molecular weight fragments", "PROBLEM", 404, 434], ["each binding site", "PROBLEM", 439, 456], ["millimolar binding affinity", "PROBLEM", 462, 489]]], ["The fragments were then linked to result in molecules in the 38\u2013350 \u03bcM range, which is a starting point for further lead optimization (Niimi et al., 2001).Kinases: ::: Examples of in silico pharmacology ::: Pharmacological space coveredA pseudoreceptor model was built with a set of 27 epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors with the flexible atom receptor model method.", [["fragments", "ANATOMY", 4, 13], ["tyrosine", "CHEMICAL", 326, 334], ["tyrosine", "CHEMICAL", 326, 334], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 286, 318], ["EGFR", "GENE_OR_GENE_PRODUCT", 320, 324], ["epidermal growth factor receptor", "PROTEIN", 286, 318], ["EGFR", "PROTEIN", 320, 324], ["The fragments", "PROBLEM", 0, 13], ["further lead optimization", "TREATMENT", 108, 133], ["Pharmacological space", "PROBLEM", 207, 228], ["A pseudoreceptor model", "TREATMENT", 236, 258], ["a set of 27 epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors", "TREATMENT", 274, 352], ["the flexible atom receptor model method", "TREATMENT", 358, 397], ["fragments", "OBSERVATION", 4, 13]]], ["The top 15 models created had high r2 and q2 and were also validated with a six-molecule test set.", [["r2", "DNA", 35, 37], ["q2", "DNA", 42, 44], ["a six-molecule test set", "TEST", 74, 97]]], ["The pseudoreceptor was also in accord with a crystal structure of CDK2 (Peng et al., 2003).Kinases: ::: Examples of in silico pharmacology ::: Pharmacological space coveredVirtual screening using DOCK with the crystal structure of the Lck SH2 domain was used to screen two million commercially available molecules.", [["CDK2", "GENE_OR_GENE_PRODUCT", 66, 70], ["DOCK", "SIMPLE_CHEMICAL", 196, 200], ["Lck", "GENE_OR_GENE_PRODUCT", 235, 238], ["CDK2", "PROTEIN", 66, 70], ["DOCK", "PROTEIN", 196, 200], ["Lck SH2 domain", "PROTEIN", 235, 249], ["Pharmacological space", "TREATMENT", 143, 164], ["Virtual screening", "TEST", 172, 189], ["the Lck SH2 domain", "TEST", 231, 249]]], ["Extensive filtering was required to result in a manageable hit list using molecular weight and diversity.", [["Extensive filtering", "PROBLEM", 0, 19], ["filtering", "OBSERVATION", 10, 19]]], ["Fluorescence titrations of some of these compounds suggested the KD values were in the low micromolar range (Huang et al., 2004).", [["Fluorescence titrations", "TEST", 0, 23], ["these compounds", "TEST", 35, 50], ["the KD values", "TEST", 61, 74], ["low micromolar", "OBSERVATION_MODIFIER", 87, 101]]], ["The same group also took a similar approach to discover inhibitors of ERK2 by screening 800 000 compounds computationally and testing in vitro 80 of them (Hancock et al., 2005).", [["ERK2", "GENE_OR_GENE_PRODUCT", 70, 74], ["ERK2", "PROTEIN", 70, 74], ["screening", "TEST", 78, 87], ["testing", "TEST", 126, 133]]], ["Five of these molecules inhibited cell proliferation and two were shown by fluorescence titration to bind ERK2 with KD values, which were in the low micromolar range.", [["cell", "ANATOMY", 34, 38], ["cell", "CELL", 34, 38], ["ERK2", "GENE_OR_GENE_PRODUCT", 106, 110], ["ERK2", "PROTEIN", 106, 110], ["fluorescence titration", "TEST", 75, 97], ["KD values", "TEST", 116, 125], ["inhibited cell proliferation", "OBSERVATION", 24, 52], ["low micromolar", "OBSERVATION_MODIFIER", 145, 159]]], ["In both cases, docking of the active molecules suggested orientations for verification by X-ray crystallography (Hancock et al., 2005).Kinases: ::: Examples of in silico pharmacology ::: Pharmacological space coveredThe Ligand Scout method was used with BCR-ABL tyrosine kinase to find STI-571 (imatinib, Gleevec) in a single and multiple conformation database (Wolber and Langer, 2005).", [["tyrosine", "CHEMICAL", 262, 270], ["STI-571", "CHEMICAL", 286, 293], ["imatinib", "CHEMICAL", 295, 303], ["Gleevec", "CHEMICAL", 305, 312], ["tyrosine", "CHEMICAL", 262, 270], ["STI-571", "CHEMICAL", 286, 293], ["imatinib", "CHEMICAL", 295, 303], ["Gleevec", "CHEMICAL", 305, 312], ["BCR-ABL tyrosine kinase", "GENE_OR_GENE_PRODUCT", 254, 277], ["STI-571", "SIMPLE_CHEMICAL", 286, 293], ["imatinib", "SIMPLE_CHEMICAL", 295, 303], ["Gleevec", "SIMPLE_CHEMICAL", 305, 312], ["BCR", "PROTEIN", 254, 257], ["ABL tyrosine kinase", "PROTEIN", 258, 277], ["X-ray crystallography", "TEST", 90, 111], ["Pharmacological space", "PROBLEM", 187, 208], ["BCR", "TEST", 254, 257], ["ABL tyrosine kinase", "TREATMENT", 258, 277], ["STI", "TEST", 286, 289], ["imatinib, Gleevec", "TREATMENT", 295, 312]]], ["A structurally related three-substituted benzamidine derivative of STI-571 was suggested by structure-based design and when manually docked into the binding site and energy minimized, it was shown to form favourable interactions with a hydrophobic pocket.Kinases: ::: Examples of in silico pharmacology ::: Pharmacological space coveredCK2 and PKD are part of the COP9 signalosome and can control stability of p53 and c-Jun, which are important for tumour development.", [["tumour", "ANATOMY", 449, 455], ["STI-571", "CHEMICAL", 67, 74], ["tumour", "DISEASE", 449, 455], ["benzamidine", "CHEMICAL", 41, 52], ["STI-571", "CHEMICAL", 67, 74], ["three-substituted benzamidine derivative", "SIMPLE_CHEMICAL", 23, 63], ["STI-571", "SIMPLE_CHEMICAL", 67, 74], ["coveredCK2", "GENE_OR_GENE_PRODUCT", 329, 339], ["PKD", "GENE_OR_GENE_PRODUCT", 344, 347], ["COP9", "GENE_OR_GENE_PRODUCT", 364, 368], ["p53", "GENE_OR_GENE_PRODUCT", 410, 413], ["c-Jun", "GENE_OR_GENE_PRODUCT", 418, 423], ["tumour", "CANCER", 449, 455], ["coveredCK2", "PROTEIN", 329, 339], ["PKD", "PROTEIN", 344, 347], ["COP9 signalosome", "PROTEIN", 364, 380], ["p53", "PROTEIN", 410, 413], ["c", "PROTEIN", 418, 419], ["Jun", "PROTEIN", 420, 423], ["substituted benzamidine derivative of STI", "TREATMENT", 29, 70], ["a hydrophobic pocket", "PROBLEM", 234, 254], ["Pharmacological space coveredCK2", "TREATMENT", 307, 339], ["PKD", "PROBLEM", 344, 347], ["the COP9 signalosome", "TREATMENT", 360, 380], ["p53 and c-Jun", "PROBLEM", 410, 423], ["hydrophobic pocket", "OBSERVATION", 236, 254]]], ["Curcumin, besides being an inhibitor of ubiquitin isopeptidase (Mullally et al., 2001; Mullally and Fitzpatrick, 2002) and activator protein-1 (Tsuchida et al., 2006), also inhibits CK2 and PKD.", [["Curcumin", "CHEMICAL", 0, 8], ["Curcumin", "CHEMICAL", 0, 8], ["Curcumin", "SIMPLE_CHEMICAL", 0, 8], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 40, 49], ["activator protein-1", "GENE_OR_GENE_PRODUCT", 123, 142], ["CK2", "GENE_OR_GENE_PRODUCT", 182, 185], ["PKD", "GENE_OR_GENE_PRODUCT", 190, 193], ["ubiquitin isopeptidase", "PROTEIN", 40, 62], ["activator protein-1", "PROTEIN", 123, 142], ["CK2", "PROTEIN", 182, 185], ["PKD", "PROTEIN", 190, 193], ["Curcumin", "TREATMENT", 0, 8], ["activator protein", "TEST", 123, 140], ["PKD", "PROBLEM", 190, 193], ["PKD", "OBSERVATION", 190, 193]]], ["Using curcumin and emodin as reference structures against which a database of over a million molecules was screened by means of 2D and 3D similarity searches retrieved 35 molecules.", [["curcumin", "CHEMICAL", 6, 14], ["emodin", "CHEMICAL", 19, 25], ["curcumin", "CHEMICAL", 6, 14], ["emodin", "CHEMICAL", 19, 25], ["curcumin", "SIMPLE_CHEMICAL", 6, 14], ["emodin", "SIMPLE_CHEMICAL", 19, 25], ["curcumin", "TREATMENT", 6, 14], ["emodin", "TREATMENT", 19, 25], ["a million molecules", "TREATMENT", 83, 102]]], ["For example, piceatannol was more potent than curcumin against both CK2 and PKD, with IC50 values of 2.5 and 0.5 \u03bcM, respectively (Fullbeck et al., 2005).", [["piceatannol", "CHEMICAL", 13, 24], ["curcumin", "CHEMICAL", 46, 54], ["piceatannol", "CHEMICAL", 13, 24], ["curcumin", "CHEMICAL", 46, 54], ["piceatannol", "SIMPLE_CHEMICAL", 13, 24], ["curcumin", "SIMPLE_CHEMICAL", 46, 54], ["CK2", "GENE_OR_GENE_PRODUCT", 68, 71], ["PKD", "GENE_OR_GENE_PRODUCT", 76, 79], ["CK2", "PROTEIN", 68, 71], ["PKD", "PROTEIN", 76, 79], ["piceatannol", "TREATMENT", 13, 24], ["PKD", "TEST", 76, 79], ["IC50 values", "TEST", 86, 97], ["CK2", "OBSERVATION", 68, 71], ["PKD", "ANATOMY", 76, 79]]], ["Obviously, these examples suggest there has been some success in finding active molecules for kinases, but interestingly in few of these studies is selectivity toward other kinases accounted for.", [["kinases", "PROTEIN", 94, 101], ["kinases", "PROTEIN", 173, 180], ["kinases", "TEST", 94, 101], ["these studies", "TEST", 131, 144], ["other kinases", "TEST", 167, 180], ["some", "OBSERVATION_MODIFIER", 49, 53], ["success", "OBSERVATION", 54, 61]]], ["Ultimately, for therapeutic success activity toward several kinases (but selectivity toward others) may be required.Drug-metabolizing enzymes and transporters: ::: Examples of in silico pharmacology ::: Pharmacological space coveredMathematical models describing quantitative structure\u2013metabolism relationships were pioneered by Hansch et al. (1968) using small sets of similar molecules and a few molecular descriptors.", [["kinases", "PROTEIN", 60, 67], ["Drug-metabolizing enzymes", "PROTEIN", 116, 141], ["Pharmacological space", "PROBLEM", 203, 224]]], ["Later, Lewis and co-workers provided many QSAR and homology models for the individual human CYPs (Lewis, 2000).", [["human", "ORGANISM", 86, 91], ["CYPs", "CELL", 92, 96], ["human CYPs", "PROTEIN", 86, 96], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91]]], ["As more sophisticated computational modelling tools became available, we have seen a growth in the number of available models (de Groot and Ekins, 2002b; de Graaf et al., 2005; de Groot, 2006) and the size of the data sets they encompass.", [["size", "OBSERVATION_MODIFIER", 201, 205]]], ["Some more recent methods are also incorporating water molecules into the binding sites when docking molecules into these enzymes and these may be important as hydrogen bond mediators with the binding site amino acids (Lill et al., 2006).", [["amino acids", "CHEMICAL", 205, 216], ["hydrogen", "CHEMICAL", 159, 167], ["amino acids", "CHEMICAL", 205, 216], ["amino acids", "AMINO_ACID", 205, 216], ["enzymes", "PROTEIN", 121, 128], ["hydrogen bond mediators", "PROTEIN", 159, 182], ["these enzymes", "TEST", 115, 128], ["hydrogen bond mediators", "TREATMENT", 159, 182]]], ["Docking methods can also be useful for suggesting novel metabolites for drugs.", [["Docking methods", "TREATMENT", 0, 15], ["drugs", "TREATMENT", 72, 77]]], ["A recent example used a homology model of CYP2D6 and docked metoclopramide as well as 19 other drugs to show a good correlation between IC50 and docking score r2=0.61 (Yu et al., 2006).", [["metoclopramide", "CHEMICAL", 60, 74], ["metoclopramide", "CHEMICAL", 60, 74], ["CYP2D6", "SIMPLE_CHEMICAL", 42, 48], ["metoclopramide", "SIMPLE_CHEMICAL", 60, 74], ["a homology model of CYP2D6", "TREATMENT", 22, 48], ["docked metoclopramide", "TREATMENT", 53, 74], ["19 other drugs", "TREATMENT", 86, 100], ["IC50", "TEST", 136, 140], ["docking score r2", "TEST", 145, 161]]], ["A novel aromatic N-hydroxy metabolite was suggested as the major metabolite and confirmed in vitro.", [["N-hydroxy", "CHEMICAL", 17, 26], ["N-hydroxy", "CHEMICAL", 17, 26], ["aromatic N-hydroxy", "SIMPLE_CHEMICAL", 8, 26], ["A novel aromatic N-hydroxy metabolite", "PROBLEM", 0, 37]]], ["Now that several crystal structures of the mammalian CYPs are available, they have been found to compare quite favourably to the prior computational models (Rowland et al., 2006).", [["CYPs", "GENE_OR_GENE_PRODUCT", 53, 57], ["mammalian CYPs", "PROTEIN", 43, 57], ["several", "OBSERVATION_MODIFIER", 9, 16], ["crystal", "OBSERVATION_MODIFIER", 17, 24], ["mammalian CYPs", "OBSERVATION", 43, 57]]], ["However, for some enzymes like CYP3A4, where there is both ligand and protein promiscuity, there may be difficulty in making reliable predictions with some computational approaches such as docking with the available crystal structures (Ekroos and Sjogren, 2006).", [["CYP3A4", "GENE_OR_GENE_PRODUCT", 31, 37], ["enzymes", "PROTEIN", 18, 25], ["CYP3A4", "PROTEIN", 31, 37], ["some enzymes", "TEST", 13, 25], ["both ligand and protein promiscuity", "PROBLEM", 54, 89], ["protein promiscuity", "OBSERVATION", 70, 89]]], ["Hence, multiple pharmacophores or models may be necessary for this and other enzymes (Ekins et al., 1999a, 1999b), as it has been indicated by others more recently (Mao et al., 2006).Drug-metabolizing enzymes and transporters: ::: Examples of in silico pharmacology ::: Pharmacological space coveredThe UDP-glucuronosyltransferases are a class of versatile enzymes involved in the elimination of drugs by catalysing the conjugation of glucuronic acid to substrates bearing a suitable functional group, so called phase II enzymes.", [["UDP", "CHEMICAL", 303, 306], ["glucuronic acid", "CHEMICAL", 435, 450], ["UDP", "CHEMICAL", 303, 306], ["glucuronic acid", "CHEMICAL", 435, 450], ["UDP-glucuronosyltransferases", "SIMPLE_CHEMICAL", 303, 331], ["glucuronic acid", "SIMPLE_CHEMICAL", 435, 450], ["phase II enzymes", "GENE_OR_GENE_PRODUCT", 512, 528], ["Drug-metabolizing enzymes", "PROTEIN", 183, 208], ["phase II enzymes", "PROTEIN", 512, 528], ["other enzymes", "TEST", 71, 84], ["Pharmacological space", "PROBLEM", 270, 291], ["versatile enzymes", "TEST", 347, 364], ["drugs", "TREATMENT", 396, 401], ["glucuronic acid", "TREATMENT", 435, 450], ["phase II enzymes", "TEST", 512, 528]]], ["There have been numerous QSAR and pharmacophore models that have been generated with relatively small data sets for rat and human enzymes.", [["rat", "ORGANISM", 116, 119], ["human", "ORGANISM", 124, 129], ["rat and human enzymes", "PROTEIN", 116, 137], ["rat", "SPECIES", 116, 119], ["human", "SPECIES", 124, 129], ["rat", "SPECIES", 116, 119], ["human", "SPECIES", 124, 129], ["pharmacophore models", "TEST", 34, 54], ["human enzymes", "TEST", 124, 137], ["numerous", "OBSERVATION_MODIFIER", 16, 24]]], ["The pharmacophores for the human UGT1A1, UGT1A4 and UGT1A9 all have in common two hydrophobes and a glucuronidation feature, while UGT1A9 has an additional hydrogen bond acceptor feature (Smith et al., 2004; Sorich et al., 2004).", [["UGT1A9", "CHEMICAL", 131, 137], ["hydrogen", "CHEMICAL", 156, 164], ["human", "ORGANISM", 27, 32], ["UGT1A1", "GENE_OR_GENE_PRODUCT", 33, 39], ["UGT1A4", "GENE_OR_GENE_PRODUCT", 41, 47], ["UGT1A9", "GENE_OR_GENE_PRODUCT", 52, 58], ["UGT1A9", "SIMPLE_CHEMICAL", 131, 137], ["human UGT1A1, UGT1A4 and UGT1A9", "DNA", 27, 58], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["the human UGT1A1", "TEST", 23, 39], ["UGT1A4", "TEST", 41, 47], ["UGT1A9", "TEST", 52, 58]]], ["Sulfotransferases, a second class of conjugating enzymes, have been crystallized (Dajani et al., 1999; Gamage et al., 2003) and a QSAR method has also been used to predict substrate affinity to SULT1A3 (Dajani et al., 1999).", [["Sulfotransferases", "CHEMICAL", 0, 17], ["Sulfotransferases", "GENE_OR_GENE_PRODUCT", 0, 17], ["SULT1A3", "SIMPLE_CHEMICAL", 194, 201], ["Sulfotransferases", "PROTEIN", 0, 17], ["conjugating enzymes", "PROTEIN", 37, 56], ["conjugating enzymes", "TEST", 37, 56], ["a QSAR method", "TREATMENT", 128, 141]]], ["To the best of our knowledge, computational models for other isozymes have not been developed.", [["isozymes", "PROTEIN", 61, 69], ["other isozymes", "PROBLEM", 55, 69]]], ["In general, conjugating enzymes have generally been infrequently targeted for in silico models.", [["conjugating enzymes", "PROTEIN", 12, 31], ["conjugating enzymes", "TEST", 12, 31]]], ["Perhaps because of a paucity of in vitro data and limited diversity of molecules tested, they have been less widely applied in industry.Drug-metabolizing enzymes and transporters: ::: Examples of in silico pharmacology ::: Pharmacological space coveredThe computational modelling of drug transporters has been thoroughly reviewed by numerous groups (Zhang et al., 2002a, 2002b; Chang and Swaan, 2005) and will not be addressed here in detail.", [["Drug-metabolizing enzymes", "PROTEIN", 136, 161], ["a paucity of in vitro data", "PROBLEM", 19, 45], ["Pharmacological space", "TREATMENT", 223, 244], ["drug transporters", "TREATMENT", 283, 300], ["paucity", "OBSERVATION_MODIFIER", 21, 28], ["less", "OBSERVATION_MODIFIER", 104, 108], ["widely", "OBSERVATION_MODIFIER", 109, 115]]], ["Various transporter models have also been applied to database searching to discover substrates and inhibitors (Langer et al., 2004; Pleban et al., 2005; Chang et al., 2006b) and increase the efficiency of in vitro screening (Chang et al., 2006a) or enrichment over random screening.", [["Various transporter models", "TREATMENT", 0, 26], ["substrates and inhibitors", "TREATMENT", 84, 109], ["random screening", "TEST", 265, 281]]], ["A pharmacophore model of the Na+/D-glucose co-transporter found in renal proximal tubules was derived indirectly using phlorizin analogues with the DISCO programme to superpose molecules.", [["renal proximal tubules", "ANATOMY", 67, 89], ["Na+", "CHEMICAL", 29, 32], ["glucose", "CHEMICAL", 35, 42], ["phlorizin", "CHEMICAL", 119, 128], ["Na+", "CHEMICAL", 29, 32], ["D-glucose", "CHEMICAL", 33, 42], ["phlorizin", "CHEMICAL", 119, 128], ["Na+", "SIMPLE_CHEMICAL", 29, 32], ["D-glucose", "SIMPLE_CHEMICAL", 33, 42], ["renal proximal tubules", "MULTI-TISSUE_STRUCTURE", 67, 89], ["phlorizin", "SIMPLE_CHEMICAL", 119, 128], ["Na+/D-glucose co-transporter", "PROTEIN", 29, 57], ["superpose molecules", "PROTEIN", 167, 186], ["the Na+", "TEST", 25, 32], ["D-glucose co-transporter", "TREATMENT", 33, 57], ["phlorizin analogues", "TREATMENT", 119, 138], ["the DISCO programme", "TREATMENT", 144, 163], ["renal", "ANATOMY", 67, 72], ["proximal", "ANATOMY_MODIFIER", 73, 81]]], ["This enabled an estimate of the size of the binding site to be obtained.", [["the binding site", "PROBLEM", 40, 56], ["size", "OBSERVATION_MODIFIER", 32, 36]]], ["In contrast to more recent studies with transporter pharmacophores, this model was not tested or used for database searching (Wielert-Badt et al., 2000).Receptors: ::: Examples of in silico pharmacology ::: Pharmacological space coveredThere are more than 20 different families of receptors that are present in the plasma membrane, altogether representing over 1000 proteins of the receptorome (Strachan et al., 2006).", [["plasma membrane", "ANATOMY", 315, 330], ["plasma membrane", "CELLULAR_COMPONENT", 315, 330], ["transporter pharmacophores", "TREATMENT", 40, 66], ["database searching", "TEST", 106, 124], ["Pharmacological space", "TREATMENT", 207, 228], ["plasma membrane", "ANATOMY", 315, 330]]], ["However, it should be noted that to date we have only characterized and found agonists and antagonists for a small percentage of the receptorome.", [["antagonists", "TREATMENT", 91, 102], ["small", "OBSERVATION_MODIFIER", 109, 114]]], ["The \u03b1-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor is central to many central nervous system (CNS) pathologies and ligands have been synthesized as anticonvulsants and neuroprotectants.", [["central nervous system", "ANATOMY", 82, 104], ["CNS", "ANATOMY", 106, 109], ["\u03b1-amino-3-hydroxy-5-methyl-4-isoxazole propionate", "CHEMICAL", 4, 53], ["\u03b1-amino-3-hydroxy-5-methyl-4-isoxazole propionate", "CHEMICAL", 4, 53], ["\u03b1-amino-3-hydroxy-5-methyl-4-isoxazole propionate", "SIMPLE_CHEMICAL", 4, 53], ["central nervous system", "ANATOMICAL_SYSTEM", 82, 104], ["CNS", "ANATOMICAL_SYSTEM", 106, 109], ["The \u03b1-amino", "TEST", 0, 11], ["methyl", "TREATMENT", 24, 30], ["isoxazole propionate receptor", "TREATMENT", 33, 62], ["anticonvulsants", "TREATMENT", 160, 175], ["neuroprotectants", "TREATMENT", 180, 196], ["central", "ANATOMY_MODIFIER", 82, 89], ["nervous system", "ANATOMY", 90, 104]]], ["There is currently no 3D structure information and therefore a four-point Catalyst HIPHOP pharmacophore was developed with 14 antagonists.", [["a four-point Catalyst HIPHOP pharmacophore", "TREATMENT", 61, 103], ["14 antagonists", "TREATMENT", 123, 137], ["no", "UNCERTAINTY", 19, 21]]], ["This was then used to search the Maybridge database and select eight compounds for testing of which six of these were found to be active in vivo as anticonvulsants (Barreca et al., 2003).Receptors: ::: Examples of in silico pharmacology ::: Pharmacological space coveredSerotonin plays a role in many physiological systems, from the CNS to the intestinal wall.", [["CNS", "ANATOMY", 333, 336], ["intestinal wall", "ANATOMY", 344, 359], ["Serotonin", "CHEMICAL", 270, 279], ["Serotonin", "CHEMICAL", 270, 279], ["Serotonin", "GENE_OR_GENE_PRODUCT", 270, 279], ["CNS", "ANATOMICAL_SYSTEM", 333, 336], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 344, 359], ["testing", "TEST", 83, 90], ["anticonvulsants", "TREATMENT", 148, 163], ["Pharmacological space", "PROBLEM", 241, 262], ["active", "OBSERVATION", 130, 136], ["CNS", "ANATOMY", 333, 336], ["intestinal wall", "ANATOMY", 344, 359]]], ["Along with its many receptors, it has a major developmental function regulating cardiovascular morphogenesis.", [["cardiovascular", "ANATOMY", 80, 94], ["cardiovascular", "ANATOMICAL_SYSTEM", 80, 94], ["developmental function", "OBSERVATION", 46, 68], ["cardiovascular morphogenesis", "OBSERVATION", 80, 108]]], ["The 5-HT2 receptor family are G protein-coupled 7-transmembrane spanning receptors with 5-HT2B expressed in cardiovascular, gut, brain tissues, as well as human carcinoid tumors (Nebigil et al., 2000).", [["cardiovascular", "ANATOMY", 108, 122], ["gut", "ANATOMY", 124, 127], ["brain tissues", "ANATOMY", 129, 142], ["carcinoid tumors", "ANATOMY", 161, 177], ["carcinoid tumors", "DISEASE", 161, 177], ["5-HT2 receptor", "GENE_OR_GENE_PRODUCT", 4, 18], ["G protein", "GENE_OR_GENE_PRODUCT", 30, 39], ["5-HT2B", "GENE_OR_GENE_PRODUCT", 88, 94], ["cardiovascular", "ANATOMICAL_SYSTEM", 108, 122], ["gut", "ORGANISM_SUBDIVISION", 124, 127], ["brain tissues", "TISSUE", 129, 142], ["human", "ORGANISM", 155, 160], ["carcinoid tumors", "CANCER", 161, 177], ["5-HT2 receptor family", "PROTEIN", 4, 25], ["G protein-coupled 7-transmembrane spanning receptors", "PROTEIN", 30, 82], ["HT2B", "PROTEIN", 90, 94], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 155, 160], ["G protein", "TEST", 30, 39], ["transmembrane spanning receptors", "TEST", 50, 82], ["human carcinoid tumors", "PROBLEM", 155, 177], ["cardiovascular", "ANATOMY", 108, 122], ["gut", "ANATOMY", 124, 127], ["brain tissues", "ANATOMY", 129, 142], ["carcinoid tumors", "OBSERVATION", 161, 177]]], ["In recent years, this receptor has been implicated in the valvular heart disease defects caused by the now banned \u2018fen-phen' treatment of patients.", [["valvular", "ANATOMY", 58, 66], ["heart", "ANATOMY", 67, 72], ["valvular heart disease defects", "DISEASE", 58, 88], ["fen-phen", "CHEMICAL", 115, 123], ["fen-phen", "CHEMICAL", 115, 123], ["heart", "ORGAN", 67, 72], ["fen-phen", "SIMPLE_CHEMICAL", 115, 123], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["the valvular heart disease defects", "PROBLEM", 54, 88], ["fen-phen' treatment", "TREATMENT", 115, 134], ["valvular heart", "ANATOMY", 58, 72], ["disease", "OBSERVATION", 73, 80]]], ["The primary metabolite, norfenfluramine, potently stimulates 5-HT2B (Fitzgerald et al., 2000; Rothman et al., 2000).", [["norfenfluramine", "CHEMICAL", 24, 39], ["5-HT2B", "CHEMICAL", 61, 67], ["norfenfluramine", "CHEMICAL", 24, 39], ["norfenfluramine", "SIMPLE_CHEMICAL", 24, 39], ["5-HT2B", "SIMPLE_CHEMICAL", 61, 67], ["norfenfluramine", "TREATMENT", 24, 39]]], ["Computational modelling of this receptor has been limited to date.", [["this receptor", "TREATMENT", 27, 40]]], ["A traditional QSAR study used a small number of tetrahydro-\u03b2-carboline derivatives as antagonists of the rat 5-HT2B contractile receptor in the rat stomach fundus (Singh and Kumar, 2001).", [["stomach fundus", "ANATOMY", 148, 162], ["tetrahydro-\u03b2-carboline", "CHEMICAL", 48, 70], ["tetrahydro-\u03b2-carboline", "CHEMICAL", 48, 70], ["tetrahydro-\u03b2-carboline derivatives", "SIMPLE_CHEMICAL", 48, 82], ["rat", "ORGANISM", 105, 108], ["5-HT2B contractile receptor", "GENE_OR_GENE_PRODUCT", 109, 136], ["rat", "ORGANISM", 144, 147], ["stomach fundus", "MULTI-TISSUE_STRUCTURE", 148, 162], ["rat 5-HT2B contractile receptor", "PROTEIN", 105, 136], ["rat", "SPECIES", 105, 108], ["rat", "SPECIES", 144, 147], ["A traditional QSAR study", "TEST", 0, 24], ["tetrahydro-\u03b2-carboline derivatives", "TREATMENT", 48, 82], ["antagonists", "TREATMENT", 86, 97], ["HT2B contractile receptor", "TREATMENT", 111, 136], ["small", "OBSERVATION_MODIFIER", 32, 37], ["stomach", "ANATOMY", 148, 155]]], ["A 3D-QSAR with GRID-GOLPE using 38 (aminoalkyl)benzo and heterocycloalkanones as antagonists of the human receptor resulted in very poor model statistics, possibly owing to the limited range of activity measured and the fact that the data corresponded to a functional response that is likely more complex (Brea et al., 2002).", [["GRID-GOLPE", "CHEMICAL", 15, 25], ["benzo", "CHEMICAL", 47, 52], ["heterocycloalkanones", "CHEMICAL", 57, 77], ["38 (aminoalkyl)benzo and heterocycloalkanones", "CHEMICAL", 32, 77], ["GRID-GOLPE", "SIMPLE_CHEMICAL", 15, 25], ["38 (aminoalkyl)benzo", "SIMPLE_CHEMICAL", 32, 52], ["heterocycloalkanones", "SIMPLE_CHEMICAL", 57, 77], ["human", "ORGANISM", 100, 105], ["human receptor", "PROTEIN", 100, 114], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["GRID-GOLPE using 38 (aminoalkyl)benzo", "TREATMENT", 15, 52], ["heterocycloalkanones", "TREATMENT", 57, 77], ["antagonists", "TREATMENT", 81, 92], ["the human receptor", "TREATMENT", 96, 114], ["likely", "UNCERTAINTY", 285, 291], ["more complex", "OBSERVATION_MODIFIER", 292, 304]]], ["Neither of these models was validated with external predictions.", [["external predictions", "TREATMENT", 43, 63]]], ["On the basis of bacteriorhodopsin and rhodopsin, homology models for the mouse and human 5-HT2B receptor have been combined with site-directed mutagenesis.", [["bacteriorhodopsin", "GENE_OR_GENE_PRODUCT", 16, 33], ["rhodopsin", "GENE_OR_GENE_PRODUCT", 38, 47], ["mouse", "ORGANISM", 73, 78], ["human", "ORGANISM", 83, 88], ["5-HT2B receptor", "GENE_OR_GENE_PRODUCT", 89, 104], ["bacteriorhodopsin", "PROTEIN", 16, 33], ["rhodopsin", "PROTEIN", 38, 47], ["mouse and human 5-HT2B receptor", "PROTEIN", 73, 104], ["mouse", "SPECIES", 73, 78], ["human", "SPECIES", 83, 88], ["mouse", "SPECIES", 73, 78], ["human", "SPECIES", 83, 88], ["bacteriorhodopsin and rhodopsin", "TREATMENT", 16, 47], ["human 5-HT2B receptor", "TREATMENT", 83, 104]]], ["The bacteriorhodopsin structure provided more reliable models, which confirmed an aromatic box hypothesis for ligand interaction along transmembrane domains 3, 6, 7 with serotonin (Manivet et al., 2002).", [["transmembrane", "ANATOMY", 135, 148], ["serotonin", "CHEMICAL", 170, 179], ["serotonin", "CHEMICAL", 170, 179], ["serotonin", "SIMPLE_CHEMICAL", 170, 179], ["transmembrane domains 3, 6, 7", "PROTEIN", 135, 164], ["an aromatic box hypothesis", "PROBLEM", 79, 105], ["transmembrane domains", "TEST", 135, 156], ["bacteriorhodopsin structure", "OBSERVATION", 4, 31], ["aromatic box", "OBSERVATION", 82, 94]]], ["A more recent 5-HT2B homology model based on the rhodopsin-based model of the rat 5-HT2A was used to determine the sites of interaction for norfenfluramine following molecular dynamics simulations.", [["5-HT2A", "CHEMICAL", 82, 88], ["norfenfluramine", "CHEMICAL", 140, 155], ["5-HT2A", "CHEMICAL", 82, 88], ["norfenfluramine", "CHEMICAL", 140, 155], ["rhodopsin", "GENE_OR_GENE_PRODUCT", 49, 58], ["rat", "ORGANISM", 78, 81], ["5-HT2A", "SIMPLE_CHEMICAL", 82, 88], ["norfenfluramine", "SIMPLE_CHEMICAL", 140, 155], ["rhodopsin", "PROTEIN", 49, 58], ["rat 5-HT2A", "DNA", 78, 88], ["rat", "SPECIES", 78, 81], ["norfenfluramine", "TREATMENT", 140, 155]]], ["Site-directed mutagenesis showed that Val 2.53 was implicated in high-affinity binding through van der Waals interactions and the ligand methyl groups (Setola et al., 2005).", [["Val 2.53", "CHEMICAL", 38, 46], ["methyl", "CHEMICAL", 137, 143], ["Val", "CHEMICAL", 38, 41], ["methyl", "CHEMICAL", 137, 143], ["Val 2.53", "SIMPLE_CHEMICAL", 38, 46], ["ligand methyl", "SIMPLE_CHEMICAL", 130, 143]]], ["There is certainly an opportunity to develop further QSAR models for this receptor in order to rapidly screen libraries of molecules to identify undesirable potent inhibitors.Receptors: ::: Examples of in silico pharmacology ::: Pharmacological space coveredThe serotonin 5-HT1A receptor has been frequently modelled.", [["serotonin", "CHEMICAL", 262, 271], ["serotonin", "CHEMICAL", 262, 271], ["serotonin 5-HT1A receptor", "GENE_OR_GENE_PRODUCT", 262, 287], ["serotonin 5-HT1A receptor", "PROTEIN", 262, 287], ["further QSAR models", "TEST", 45, 64], ["this receptor", "TREATMENT", 69, 82], ["undesirable potent inhibitors", "TREATMENT", 145, 174], ["Pharmacological space", "TREATMENT", 229, 250], ["The serotonin 5-HT1A receptor", "TREATMENT", 258, 287]]], ["For example, a conformational study of four ligands defined a pharmacophore of the antagonist site using SYBYL (Hibert et al., 1988).", [["a conformational study", "TEST", 13, 35]]], ["The model resulting from such an active analogue approach was used in molecule design and predicted molecule stereospecificity.", [["an active analogue approach", "TREATMENT", 30, 57]]], ["More recently, a series of over 700 homology models were iteratively created based on the crystal structure of the bovine rhodopsin that were in turn tuned by FlexX docking of known ligands.", [["bovine", "ORGANISM", 115, 121], ["rhodopsin", "GENE_OR_GENE_PRODUCT", 122, 131], ["FlexX", "SIMPLE_CHEMICAL", 159, 164], ["bovine rhodopsin", "PROTEIN", 115, 131], ["FlexX", "PROTEIN", 159, 164], ["bovine", "SPECIES", 115, 121], ["the bovine rhodopsin", "TREATMENT", 111, 131], ["bovine rhodopsin", "OBSERVATION", 115, 131], ["known ligands", "OBSERVATION", 176, 189]]], ["The final model was used in a virtual screening simulation that was enriched with inhibitors, compared with random selection and from this the authors suggested its utility for a real virtual screen (Nowak et al., 2006).", [["a virtual screening simulation", "TEST", 28, 58], ["inhibitors", "TREATMENT", 82, 92], ["random selection", "TEST", 108, 124], ["a real virtual screen", "TEST", 177, 198]]], ["A homology model of the 5-HT1A receptor has also been used with DOCK to screen a library of 10 000 compounds seeded with 34 5-HT1A ligands.", [["5-HT1A receptor", "GENE_OR_GENE_PRODUCT", 24, 39], ["DOCK", "SIMPLE_CHEMICAL", 64, 68], ["5-HT1A", "SIMPLE_CHEMICAL", 124, 130], ["5-HT1A receptor", "PROTEIN", 24, 39], ["DOCK", "PROTEIN", 64, 68]]], ["Ninety percent of these active compounds were ranked in the top 1000 compounds (Becker et al., 2006), representing a significant enrichment.", [["a significant enrichment", "PROBLEM", 115, 139], ["active", "OBSERVATION_MODIFIER", 24, 30], ["compounds", "OBSERVATION_MODIFIER", 31, 40], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["enrichment", "OBSERVATION", 129, 139]]], ["The same model was used to screen a library of 40 000 vendor compounds and select 78 for testing, of which 16 had activities below 5 \u03bcM, one possessing 1 nM affinity.", [["testing", "TEST", 89, 96]]], ["Structure-based in silico optimization was then performed to improve selectivity with other GPCRs and optimize the pharmacokinetic (PK) profile.", [["silico optimization", "TEST", 19, 38], ["other GPCRs", "TEST", 86, 97]]], ["However, as this proceeded, the molecules were found to have affinity for the human ether a-go-go-related gene (hERG), and this was subsequently computationally assessed using a homology model that pointed to adjusting the hydrophobicity.", [["ether", "CHEMICAL", 84, 89], ["human", "ORGANISM", 78, 83], ["ether", "SIMPLE_CHEMICAL", 84, 89], ["human ether a-go-go-related gene", "DNA", 78, 110], ["hERG", "DNA", 112, 116], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["a homology model", "TREATMENT", 176, 192], ["the hydrophobicity", "PROBLEM", 219, 237]]], ["The resulting clinical candidate had good target and antitarget selectivity and backup compounds were selected in the same way (Becker et al., 2006).Receptors: ::: Examples of in silico pharmacology ::: Pharmacological space coveredAnother early computer-aided pharmacophore generated with SYBYL using a set of selective and non-selective analogues was used to design agonists for 5-HT1D as antimigraine agents with selectivity against 5-HT2A (linked to undesirable changes in blood pressure) (Glen et al., 1995).Receptors: ::: Examples of in silico pharmacology ::: Pharmacological space coveredA range of typical and atypical antipsychotics bind to the 5-HT6 receptor.", [["blood", "ANATOMY", 477, 482], ["SYBYL", "CHEMICAL", 290, 295], ["5-HT1D", "CHEMICAL", 381, 387], ["5-HT2A", "CHEMICAL", 436, 442], ["5-HT1D", "CHEMICAL", 381, 387], ["SYBYL", "SIMPLE_CHEMICAL", 290, 295], ["5-HT1D", "SIMPLE_CHEMICAL", 381, 387], ["antimigraine agents", "SIMPLE_CHEMICAL", 391, 410], ["5-HT2A", "SIMPLE_CHEMICAL", 436, 442], ["blood", "ORGANISM_SUBSTANCE", 477, 482], ["5-HT6 receptor", "GENE_OR_GENE_PRODUCT", 655, 669], ["SYBYL", "PROTEIN", 290, 295], ["5-HT6 receptor", "PROTEIN", 655, 669], ["backup compounds", "TREATMENT", 80, 96], ["Pharmacological space", "TREATMENT", 203, 224], ["SYBYL", "TREATMENT", 290, 295], ["selective and non-selective analogues", "TREATMENT", 311, 348], ["antimigraine agents", "TREATMENT", 391, 410], ["blood pressure", "TEST", 477, 491], ["Pharmacological space", "PROBLEM", 567, 588], ["atypical antipsychotics bind", "TREATMENT", 619, 647]]], ["Based on the structure of bovine rhodopsin, homology models of the human and rodent 5-HT6 receptors were constructed and used to dock ligands that were known to exhibit species differences in binding (Hirst et al., 2003).", [["bovine", "ORGANISM", 26, 32], ["rhodopsin", "GENE_OR_GENE_PRODUCT", 33, 42], ["human", "ORGANISM", 67, 72], ["5-HT6 receptors", "GENE_OR_GENE_PRODUCT", 84, 99], ["bovine rhodopsin", "PROTEIN", 26, 42], ["human and rodent 5-HT6 receptors", "PROTEIN", 67, 99], ["bovine", "SPECIES", 26, 32], ["human", "SPECIES", 67, 72], ["rodent", "SPECIES", 77, 83], ["human", "SPECIES", 67, 72], ["bovine rhodopsin", "TREATMENT", 26, 42], ["rodent 5-HT6 receptors", "TREATMENT", 77, 99], ["bovine rhodopsin", "OBSERVATION", 26, 42]]], ["Following sequence alignment, amino-acid residues were identified for mutation and the rationalization of these mutations and their effects on ligand binding were obtained from the docking studies.", [["amino-acid", "CHEMICAL", 30, 40], ["amino-acid", "CHEMICAL", 30, 40], ["amino-acid", "AMINO_ACID", 30, 40], ["sequence alignment", "TEST", 10, 28], ["amino-acid residues", "TREATMENT", 30, 49], ["mutation", "PROBLEM", 70, 78], ["these mutations", "PROBLEM", 106, 121], ["their effects on ligand binding", "PROBLEM", 126, 157], ["the docking studies", "TEST", 177, 196]]], ["The models generated were in good agreement with the in vitro data and could be used for further molecule design.", [["further molecule design", "TREATMENT", 89, 112]]], ["This study was a good example where computational, molecular biology and traditional pharmacology methods were combined (Hirst et al., 2003).Receptors: ::: Examples of in silico pharmacology ::: Pharmacological space coveredThe Na+, K+-ATPase is a receptor for cardiotonic steroids, which in turn inhibit the ATPase and cation transport and have ionotropic actions.", [["Na+", "CHEMICAL", 228, 231], ["K", "CHEMICAL", 233, 234], ["steroids", "CHEMICAL", 273, 281], ["Na+", "CHEMICAL", 228, 231], ["K", "CHEMICAL", 233, 234], ["steroids", "CHEMICAL", 273, 281], ["Na+, K+-ATPase", "GENE_OR_GENE_PRODUCT", 228, 242], ["cardiotonic steroids", "SIMPLE_CHEMICAL", 261, 281], ["ATPase", "GENE_OR_GENE_PRODUCT", 309, 315], ["cation", "SIMPLE_CHEMICAL", 320, 326], ["Na+, K+-ATPase", "PROTEIN", 228, 242], ["ATPase", "PROTEIN", 309, 315], ["This study", "TEST", 0, 10], ["Pharmacological space", "PROBLEM", 195, 216], ["The Na+", "TEST", 224, 231], ["a receptor", "TREATMENT", 246, 256], ["cardiotonic steroids", "TREATMENT", 261, 281], ["cation transport", "TREATMENT", 320, 336], ["ionotropic actions", "TREATMENT", 346, 364]]], ["Although the effects of digitalis have been known for hundreds of years, a molecular understanding has remained absent until recently.", [["digitalis", "CHEMICAL", 24, 33], ["digitalis", "SIMPLE_CHEMICAL", 24, 33], ["absent", "OBSERVATION", 112, 118]]], ["A homology model was generated with the SERCA1a crystal structure and tested with nine cardiac glycosides (Keenan et al., 2005).", [["cardiac", "ANATOMY", 87, 94], ["the SERCA1a crystal structure", "TREATMENT", 36, 65], ["nine cardiac glycosides", "TREATMENT", 82, 105]]], ["The model was also mutated to mimic the rat receptor and showed how oubain would orient differently in these models, perhaps explaining the species difference in affinity.", [["rat", "ORGANISM", 40, 43], ["rat receptor", "PROTEIN", 40, 52], ["rat", "SPECIES", 40, 43], ["the species difference in affinity", "PROBLEM", 136, 170]]], ["These models also suggested amino acids that could be experimentally mutated to validate the hypothesis for the binding site identification, although this has yet to be tested.Receptors: ::: Examples of in silico pharmacology ::: Pharmacological space coveredThe dopamine receptors have been implicated in Parkinson's disease and schizophrenia.", [["amino acids", "CHEMICAL", 28, 39], ["dopamine", "CHEMICAL", 263, 271], ["Parkinson's disease", "DISEASE", 306, 325], ["schizophrenia", "DISEASE", 330, 343], ["amino acids", "CHEMICAL", 28, 39], ["dopamine", "CHEMICAL", 263, 271], ["amino acids", "AMINO_ACID", 28, 39], ["dopamine receptors", "GENE_OR_GENE_PRODUCT", 263, 281], ["dopamine receptors", "PROTEIN", 263, 281], ["amino acids", "PROBLEM", 28, 39], ["the binding site", "PROBLEM", 108, 124], ["Pharmacological space", "TREATMENT", 230, 251], ["The dopamine receptors", "TREATMENT", 259, 281], ["Parkinson's disease", "PROBLEM", 306, 325], ["schizophrenia", "PROBLEM", 330, 343], ["Parkinson's disease", "OBSERVATION", 306, 325], ["schizophrenia", "OBSERVATION", 330, 343]]], ["Unfortunately, no crystal structure is currently available and thus the search for new antagonists has used QSAR models.", [["crystal structure", "PROBLEM", 18, 35], ["new antagonists", "TREATMENT", 83, 98], ["QSAR models", "TEST", 108, 119], ["no", "UNCERTAINTY", 15, 17], ["crystal structure", "OBSERVATION", 18, 35]]], ["A set of 48 compounds was used with four different QSAR methods (CoMFA, simulated annealing-partial least square (PLS), k-nearest neighbours (kNN) and SVM), and training as well as testing statistics were generated.", [["testing statistics", "TEST", 181, 199]]], ["SVM and kNN models were also used to mine compound databases of over 750 000 molecules that resulted in 54 consensus hits.", [["SVM", "TEST", 0, 3], ["kNN models", "TEST", 8, 18]]], ["Five of these hits were known to bind the receptor and were not in the training set, while other suggested hits did not contain the catechol group normally seen in most dopamine inhibitors (Oloff et al., 2005).Receptors: ::: Examples of in silico pharmacology ::: Pharmacological space coveredThe \u03b11A receptor is a target for controlling vascular tone and therefore useful for antihypertensive agents.", [["vascular", "ANATOMY", 338, 346], ["catechol", "CHEMICAL", 132, 140], ["dopamine", "CHEMICAL", 169, 177], ["catechol", "CHEMICAL", 132, 140], ["dopamine", "CHEMICAL", 169, 177], ["catechol", "SIMPLE_CHEMICAL", 132, 140], ["dopamine", "SIMPLE_CHEMICAL", 169, 177], ["\u03b11A receptor", "GENE_OR_GENE_PRODUCT", 297, 309], ["vascular", "MULTI-TISSUE_STRUCTURE", 338, 346], ["\u03b11A receptor", "PROTEIN", 297, 309], ["most dopamine inhibitors", "TREATMENT", 164, 188], ["Pharmacological space", "TREATMENT", 264, 285], ["antihypertensive agents", "TREATMENT", 377, 400], ["vascular", "ANATOMY", 338, 346]]], ["A novel approach for ligand-based screening called multiple feature tree (MTree) describes the training set molecules as a feature tree descriptor derived from a topological molecular graph that is then aligned in a pairwise fashion (Hessler et al., 2005).", [["ligand-based screening", "TEST", 21, 43], ["the training set molecules", "TREATMENT", 91, 117], ["a topological molecular graph", "PROBLEM", 160, 189]]], ["A set of six antagonists was used to derive a model with this method and was compared with a Catalyst pharmacophore model.", [["six antagonists", "TREATMENT", 9, 24], ["a Catalyst pharmacophore model", "TREATMENT", 91, 121]]], ["Both approaches identified a central positive ionizable feature flanked by hydrophobic regions at either end.", [["hydrophobic regions", "PROTEIN", 75, 94], ["a central positive ionizable feature", "PROBLEM", 27, 63], ["central", "OBSERVATION_MODIFIER", 29, 36], ["positive", "OBSERVATION_MODIFIER", 37, 45], ["ionizable feature", "OBSERVATION", 46, 63], ["hydrophobic", "OBSERVATION_MODIFIER", 75, 86]]], ["Within the top 1% of the database, MTree had an enrichment factor that was over twice that obtained with Catalyst (Hessler et al., 2005).Nuclear receptors: ::: Examples of in silico pharmacology ::: Pharmacological space coveredNuclear receptors constitute a family of ligand-activated transcription factors of paramount importance for the pharmaceutical industry since many of its members are often considered as double-edged swords (Shi, 2006).", [["Nuclear", "ANATOMY", 137, 144], ["Nuclear receptors", "PROTEIN", 137, 154], ["Nuclear receptors", "PROTEIN", 228, 245], ["ligand-activated transcription factors", "PROTEIN", 269, 307], ["an enrichment factor", "PROBLEM", 45, 65], ["Pharmacological space", "PROBLEM", 199, 220], ["enrichment", "OBSERVATION", 48, 58]]], ["On the one hand, because of their important regulatory role in a variety of biological processes, mutations in nuclear receptors are associated with many common human diseases such as cancer, diabetes and osteoporosis and thus, they are also considered highly relevant therapeutic targets.", [["nuclear", "ANATOMY", 111, 118], ["cancer", "ANATOMY", 184, 190], ["cancer", "DISEASE", 184, 190], ["diabetes", "DISEASE", 192, 200], ["osteoporosis", "DISEASE", 205, 217], ["nuclear", "CELLULAR_COMPONENT", 111, 118], ["human", "ORGANISM", 161, 166], ["cancer", "CANCER", 184, 190], ["nuclear receptors", "PROTEIN", 111, 128], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 161, 166], ["mutations in nuclear receptors", "PROBLEM", 98, 128], ["many common human diseases", "PROBLEM", 149, 175], ["cancer", "PROBLEM", 184, 190], ["diabetes", "PROBLEM", 192, 200], ["osteoporosis", "PROBLEM", 205, 217], ["cancer", "OBSERVATION", 184, 190], ["diabetes", "OBSERVATION", 192, 200], ["osteoporosis", "OBSERVATION", 205, 217]]], ["On the other hand, nuclear receptors act also as regulators of some the CYP enzymes responsible for the metabolism of pharmaceutically relevant molecules, as well as transporters that can mediate drug efflux, and thus they are also regarded as potential therapeutic antitargets (off-targets).Nuclear receptors: ::: Examples of in silico pharmacology ::: Pharmacological space coveredExamples of the use of target-based virtual screening to identify novel small molecule modulators of nuclear receptors have been recently reported.", [["nuclear", "ANATOMY", 19, 26], ["Nuclear", "ANATOMY", 292, 299], ["nuclear", "ANATOMY", 484, 491], ["CYP enzymes", "GENE_OR_GENE_PRODUCT", 72, 83], ["nuclear receptors", "PROTEIN", 19, 36], ["CYP enzymes", "PROTEIN", 72, 83], ["Nuclear receptors", "PROTEIN", 292, 309], ["nuclear receptors", "PROTEIN", 484, 501], ["the CYP enzymes", "TEST", 68, 83], ["virtual screening", "TEST", 419, 436], ["novel small molecule modulators of nuclear receptors", "PROBLEM", 449, 501], ["small", "OBSERVATION_MODIFIER", 455, 460], ["molecule modulators", "OBSERVATION", 461, 480]]], ["Using the available structure of the oestrogen receptor subtype \u03b1 (ER\u03b1) in its antagonist conformation, a homology model of the retinoic acid receptor \u03b1 (RAR\u03b1) was constructed (Schapira et al., 2000).", [["retinoic acid", "CHEMICAL", 128, 141], ["oestrogen", "CHEMICAL", 37, 46], ["retinoic acid", "CHEMICAL", 128, 141], ["oestrogen receptor subtype \u03b1", "GENE_OR_GENE_PRODUCT", 37, 65], ["ER\u03b1", "GENE_OR_GENE_PRODUCT", 67, 70], ["retinoic acid receptor \u03b1", "GENE_OR_GENE_PRODUCT", 128, 152], ["RAR\u03b1", "GENE_OR_GENE_PRODUCT", 154, 158], ["oestrogen receptor subtype \u03b1", "PROTEIN", 37, 65], ["ER\u03b1", "PROTEIN", 67, 70], ["retinoic acid receptor \u03b1", "PROTEIN", 128, 152], ["RAR\u03b1", "PROTEIN", 154, 158], ["the retinoic acid receptor", "TEST", 124, 150]]], ["Using this homology model, virtual screening of a compound library lead to the identification of two novel RAR\u03b1 antagonists in the micromolar range.", [["RAR\u03b1 antagonists", "GENE_OR_GENE_PRODUCT", 107, 123], ["RAR\u03b1", "PROTEIN", 107, 111], ["virtual screening", "TEST", 27, 44], ["a compound library lead", "PROBLEM", 48, 71], ["micromolar range", "OBSERVATION", 131, 147]]], ["The same approach was later applied to discover 14 novel and diverse micromolar antagonists of the thyroid hormone receptor (Schapira et al., 2000).", [["thyroid hormone receptor", "GENE_OR_GENE_PRODUCT", 99, 123], ["thyroid hormone receptor", "PROTEIN", 99, 123], ["diverse micromolar antagonists", "TREATMENT", 61, 91], ["the thyroid hormone receptor", "TREATMENT", 95, 123], ["thyroid", "ANATOMY", 99, 106]]], ["By means of a procedure designed particularly to select compounds fitting onto the LxxLL peptide-binding surface of the oestrogen receptor, novel ER\u03b1 antagonists were identified (Shao et al., 2004).", [["oestrogen", "CHEMICAL", 120, 129], ["LxxLL", "GENE_OR_GENE_PRODUCT", 83, 88], ["oestrogen receptor", "GENE_OR_GENE_PRODUCT", 120, 138], ["ER\u03b1 antagonists", "GENE_OR_GENE_PRODUCT", 146, 161], ["oestrogen receptor", "PROTEIN", 120, 138], ["ER", "PROTEIN", 146, 148], ["a procedure", "TREATMENT", 12, 23], ["the LxxLL peptide", "TEST", 79, 96], ["the oestrogen receptor", "TREATMENT", 116, 138], ["novel ER\u03b1 antagonists", "TREATMENT", 140, 161]]], ["Since poor displacement of 17\u03b2-estradiol was observed in the ER-ligand competition assay, these compounds may represent new classes of ER\u03b1 antagonists, with the potential to provide an alternative to current anti-oestrogen therapies.", [["17\u03b2-estradiol", "CHEMICAL", 27, 40], ["17\u03b2-estradiol", "CHEMICAL", 27, 40], ["17\u03b2-estradiol", "SIMPLE_CHEMICAL", 27, 40], ["ER", "GENE_OR_GENE_PRODUCT", 61, 63], ["ER\u03b1 antagonists", "GENE_OR_GENE_PRODUCT", 135, 150], ["anti-oestrogen", "SIMPLE_CHEMICAL", 208, 222], ["ER", "PROTEIN", 61, 63], ["poor displacement", "PROBLEM", 6, 23], ["ER\u03b1 antagonists", "TREATMENT", 135, 150], ["current anti-oestrogen therapies", "TREATMENT", 200, 232], ["displacement", "OBSERVATION_MODIFIER", 11, 23], ["may represent", "UNCERTAINTY", 106, 119], ["new", "OBSERVATION_MODIFIER", 120, 123]]], ["The discovery of three low micromolar hits for ER\u03b2 displaying over 100-fold binding selectivity with respect to ER\u03b1 was also recently reported using database screening (Zhao and Brinton, 2005).", [["ER\u03b2", "GENE_OR_GENE_PRODUCT", 47, 50], ["ER\u03b1", "GENE_OR_GENE_PRODUCT", 112, 115], ["ER\u03b2", "PROTEIN", 47, 50], ["ER\u03b1", "PROTEIN", 112, 115], ["three low micromolar hits", "PROBLEM", 17, 42], ["database screening", "TEST", 149, 167], ["low micromolar", "OBSERVATION_MODIFIER", 23, 37], ["hits", "OBSERVATION", 38, 42]]], ["A final example reports the identification and optimization of a novel family of peroxisome proliferator-activated receptors-\u03b3 partial agonists based upon pyrazol-4-ylbenzenesulfonamide after employing structure-based virtual screening, with good selectivity profile against the other subtypes of the same nuclear receptor group (Lu et al., 2006).Ion channels: ::: Examples of in silico pharmacology ::: Pharmacological space coveredTherapeutically important channels include voltage-gated ion channels for potassium, sodium and calcium that are present in the outer membrane of many different cells such as those responsible for the electrical excitability and signalling in nerve and muscle cells (Terlau and Stuhmer, 1998).", [["nuclear", "ANATOMY", 306, 313], ["outer membrane", "ANATOMY", 561, 575], ["cells", "ANATOMY", 594, 599], ["nerve", "ANATOMY", 676, 681], ["muscle cells", "ANATOMY", 686, 698], ["pyrazol-4-ylbenzenesulfonamide", "CHEMICAL", 155, 185], ["potassium", "CHEMICAL", 507, 516], ["sodium", "CHEMICAL", 518, 524], ["calcium", "CHEMICAL", 529, 536], ["pyrazol-4-ylbenzenesulfonamide", "CHEMICAL", 155, 185], ["potassium", "CHEMICAL", 507, 516], ["sodium", "CHEMICAL", 518, 524], ["calcium", "CHEMICAL", 529, 536], ["peroxisome proliferator-activated receptors-\u03b3", "GENE_OR_GENE_PRODUCT", 81, 126], ["pyrazol-4-ylbenzenesulfonamide", "SIMPLE_CHEMICAL", 155, 185], ["potassium", "SIMPLE_CHEMICAL", 507, 516], ["sodium", "SIMPLE_CHEMICAL", 518, 524], ["calcium", "SIMPLE_CHEMICAL", 529, 536], ["outer membrane", "CELLULAR_COMPONENT", 561, 575], ["cells", "CELL", 594, 599], ["nerve", "CELL", 676, 681], ["muscle cells", "CELL", 686, 698], ["peroxisome proliferator-activated receptors", "PROTEIN", 81, 124], ["voltage-gated ion channels", "PROTEIN", 476, 502], ["nerve and muscle cells", "CELL_TYPE", 676, 698], ["the identification", "TEST", 24, 42], ["peroxisome proliferator", "TREATMENT", 81, 104], ["activated receptors", "TREATMENT", 105, 124], ["partial agonists", "TREATMENT", 127, 143], ["pyrazol", "TREATMENT", 155, 162], ["virtual screening", "TEST", 218, 235], ["Pharmacological space", "PROBLEM", 404, 425], ["potassium, sodium and calcium", "TEST", 507, 536], ["the electrical excitability", "PROBLEM", 630, 657], ["signalling in nerve and muscle cells", "PROBLEM", 662, 698], ["nerve", "ANATOMY", 676, 681], ["muscle cells", "ANATOMY", 686, 698]]], ["These represent validated therapeutic targets for anaesthesia, CNS and cardiovascular diseases (Kang et al., 2001).", [["CNS", "ANATOMY", 63, 66], ["cardiovascular", "ANATOMY", 71, 85], ["cardiovascular diseases", "DISEASE", 71, 94], ["CNS", "ANATOMICAL_SYSTEM", 63, 66], ["cardiovascular", "ANATOMICAL_SYSTEM", 71, 85], ["anaesthesia", "TREATMENT", 50, 61], ["CNS and cardiovascular diseases", "PROBLEM", 63, 94], ["cardiovascular", "ANATOMY", 71, 85]]], ["A recent review has discussed the various QSAR methods such as pharmacophores, CoMFA, SVM, 2D-QSAR, Genetic Programming, Self Organizing Maps and recursive partitioning that have been applied to most ion channels (Aronov et al., 2006) in the absence of crystal structures.", [["Genetic Programming", "TREATMENT", 100, 119], ["Self Organizing Maps", "TREATMENT", 121, 141], ["recursive partitioning", "TREATMENT", 146, 168]]], ["To date L-type calcium channels and hERG appear to have been the most extensively studied channels in this regard.", [["calcium", "CHEMICAL", 15, 22], ["calcium", "CHEMICAL", 15, 22], ["L-type calcium", "GENE_OR_GENE_PRODUCT", 8, 22], ["hERG", "GENE_OR_GENE_PRODUCT", 36, 40], ["L-type calcium channels", "PROTEIN", 8, 31], ["hERG", "PROTEIN", 36, 40]]], ["In contrast, there are far fewer examples of computational models for the sodium channel.", [["sodium", "CHEMICAL", 74, 80], ["sodium", "CHEMICAL", 74, 80], ["sodium channel", "SIMPLE_CHEMICAL", 74, 88], ["sodium channel", "PROTEIN", 74, 88], ["the sodium channel", "TREATMENT", 70, 88]]], ["These three classes of ion channels have been studied as they represent either therapeutic targets or antitargets to be avoided.Ion channels: ::: Examples of in silico pharmacology ::: Pharmacological space coveredFor example, one of many models for the hERG potassium channel has compared three different methods with the same set of molecules for training and a test set.", [["potassium", "CHEMICAL", 259, 268], ["potassium", "CHEMICAL", 259, 268], ["ion channels", "PROTEIN", 23, 35], ["hERG potassium channel", "PROTEIN", 254, 276], ["ion channels", "TREATMENT", 23, 35], ["antitargets", "TREATMENT", 102, 113], ["Pharmacological space", "TREATMENT", 185, 206], ["the hERG potassium channel", "TREATMENT", 250, 276], ["a test set", "TEST", 362, 372], ["ion channels", "OBSERVATION_MODIFIER", 23, 35]]], ["Recursive partitioning, Sammon maps and Kohonen maps were used with atom path lengths (Ekins et al., 2006).", [["Sammon maps", "DNA", 24, 35], ["Kohonen maps", "DNA", 40, 52], ["Recursive partitioning", "PROBLEM", 0, 22], ["Sammon maps", "TREATMENT", 24, 35], ["Kohonen maps", "TREATMENT", 40, 52]]], ["The average classification quality was high for both training and test selections.", [["test selections", "TEST", 66, 81]]], ["The Sammon mapping technique outperformed the Kohonen maps in classification of compounds from the external test set.", [["Kohonen maps", "DNA", 46, 58], ["The Sammon mapping technique", "TREATMENT", 0, 28], ["the external test set", "TEST", 95, 116]]], ["The quantitative predictions for recursive partitioning could be filtered using a Tanimoto similarity to remove molecules that were markedly different to the training set (Willett, 2003).", [["a Tanimoto similarity", "TREATMENT", 80, 101]]], ["In addition, a subset of molecules can also be compared, with those highlighted in blue representing close neighbours and those in red being more distant (Figure 1b).Transcription factors: ::: Examples of in silico pharmacology ::: Pharmacological space coveredA cyclic decapeptide with activity against the AP-1 transcription factor was used to derive a 3D pharmacophore to which low energy conformations of non-peptidic compounds were compared.", [["AP-1", "GENE_OR_GENE_PRODUCT", 308, 312], ["Transcription factors", "PROTEIN", 166, 187], ["AP-1 transcription factor", "PROTEIN", 308, 333], ["Pharmacological space", "PROBLEM", 232, 253], ["A cyclic decapeptide", "TREATMENT", 261, 281], ["a 3D pharmacophore", "TREATMENT", 353, 371], ["low energy conformations of non-peptidic compounds", "PROBLEM", 381, 431]]], ["New 1-thia-4-azaspiro[4,5]decane and benzophenone derivatives with activity in binding and cell-based assays were discovered as AP-1 inhibitors in a lead hopping approach (Tsuchida et al., 2006).Antibacterials: ::: Examples of in silico pharmacology ::: Pharmacological space coveredTwenty deoxythymidine monophosphate analogues were used along with docking to generate a pharmacophore for Mycobacterium tuberculosis thymidine monophosphosphate kinase inhibitors with the Catalyst software.", [["cell", "ANATOMY", 91, 95], ["1-thia-4-azaspiro[4,5]decane", "CHEMICAL", 4, 32], ["benzophenone", "CHEMICAL", 37, 49], ["deoxythymidine monophosphate", "CHEMICAL", 290, 318], ["thymidine", "CHEMICAL", 417, 426], ["1-thia-4-azaspiro[4,5]decane", "CHEMICAL", 4, 32], ["benzophenone", "CHEMICAL", 37, 49], ["deoxythymidine monophosphate", "CHEMICAL", 290, 318], ["thymidine", "CHEMICAL", 417, 426], ["1-thia-4-azaspiro[4,5]decane", "SIMPLE_CHEMICAL", 4, 32], ["benzophenone derivatives", "SIMPLE_CHEMICAL", 37, 61], ["cell", "CELL", 91, 95], ["AP-1", "GENE_OR_GENE_PRODUCT", 128, 132], ["deoxythymidine monophosphate analogues", "SIMPLE_CHEMICAL", 290, 328], ["thymidine monophosphosphate kinase inhibitors", "SIMPLE_CHEMICAL", 417, 462], ["Mycobacterium tuberculosis", "SPECIES", 390, 416], ["Mycobacterium tuberculosis", "SPECIES", 390, 416], ["thia", "TEST", 6, 10], ["azaspiro[4,5]decane", "TREATMENT", 13, 32], ["benzophenone derivatives", "TREATMENT", 37, 61], ["activity in binding", "PROBLEM", 67, 86], ["cell-based assays", "TEST", 91, 108], ["AP", "TEST", 128, 130], ["Pharmacological space", "TREATMENT", 254, 275], ["Twenty deoxythymidine monophosphate analogues", "TREATMENT", 283, 328], ["a pharmacophore", "TREATMENT", 370, 385], ["Mycobacterium tuberculosis thymidine monophosphosphate kinase inhibitors", "TREATMENT", 390, 462]]], ["A final model was used to screen a large database spiked with known inhibitors.", [["known inhibitors", "TREATMENT", 62, 78]]], ["The model was suggested to have an enrichment factor of 17, which is highly significant.", [["an enrichment factor", "TEST", 32, 52], ["enrichment", "OBSERVATION", 35, 45], ["highly", "OBSERVATION_MODIFIER", 69, 75], ["significant", "OBSERVATION_MODIFIER", 76, 87]]], ["In addition, the model was used to rapidly screen half a million compounds in an effort to discover new inhibitors (Gopalakrishnan et al., 2005).Antivirals: ::: Examples of in silico pharmacology ::: Pharmacological space coveredNeuroamidase is a major surface protein in influenza virus.", [["surface", "ANATOMY", 253, 260], ["Neuroamidase", "CHEMICAL", 229, 241], ["Neuroamidase", "GENE_OR_GENE_PRODUCT", 229, 241], ["influenza virus", "ORGANISM", 272, 287], ["Neuroamidase", "PROTEIN", 229, 241], ["major surface protein", "PROTEIN", 247, 268], ["influenza virus", "SPECIES", 272, 287], ["influenza virus", "SPECIES", 272, 287], ["new inhibitors", "TREATMENT", 100, 114], ["Pharmacological space coveredNeuroamidase", "TREATMENT", 200, 241], ["a major surface protein in influenza virus", "PROBLEM", 245, 287], ["influenza virus", "OBSERVATION", 272, 287]]], ["A structure-based approach was used to generate Catalyst pharmacophores and these in turn were used for a database search and aided the discovery of known inhibitors.", [["A structure-based approach", "TREATMENT", 0, 26], ["Catalyst pharmacophores", "TREATMENT", 48, 71], ["a database search", "TEST", 104, 121], ["known inhibitors", "TREATMENT", 149, 165]]], ["The hit lists were also very selective (Steindl and Langer, 2004).Antivirals: ::: Examples of in silico pharmacology ::: Pharmacological space coveredHuman rhinovirus 3C protease is an antirhinitis target.", [["Human", "ORGANISM", 150, 155], ["rhinovirus 3C", "ORGANISM", 156, 169], ["Human rhinovirus 3C protease", "PROTEIN", 150, 178], ["Human", "SPECIES", 150, 155], ["Human rhinovirus 3C", "SPECIES", 150, 169], ["Pharmacological space", "PROBLEM", 121, 142], ["Human rhinovirus 3C protease", "TREATMENT", 150, 178], ["an antirhinitis target", "TREATMENT", 182, 204]]], ["A structure-based pharmacophore was developed initially around AG 7088 but this proved too restrictive.", [["AG 7088", "CHEMICAL", 63, 70], ["AG", "TEST", 63, 65]]], ["A second pharmacophore was developed from seven peptidic inhibitors using the Catalyst HIPHOP method.", [["A second pharmacophore", "PROBLEM", 0, 22], ["seven peptidic inhibitors", "TREATMENT", 42, 67], ["the Catalyst HIPHOP method", "TREATMENT", 74, 100]]], ["This hypothesis was useful in searching the world drug index database to retrieve compounds with known antiviral activity and several novel compounds were selected from other databases with good fits to the pharmacophore, indicative that they would be worth testing although these ultimate testing validation data were not presented (Steindl et al., 2005a).", [["known antiviral activity", "PROBLEM", 97, 121], ["several novel compounds", "PROBLEM", 126, 149], ["worth testing", "TEST", 252, 265], ["these ultimate testing validation data", "TEST", 275, 313], ["antiviral activity", "OBSERVATION", 103, 121]]], ["Human rhinovirus coat protein is another target for antirhinitis.", [["antirhinitis", "DISEASE", 52, 64], ["Human", "ORGANISM", 0, 5], ["rhinovirus", "ORGANISM", 6, 16], ["Human rhinovirus coat protein", "PROTEIN", 0, 29], ["Human", "SPECIES", 0, 5], ["Human rhinovirus", "SPECIES", 0, 16], ["Human rhinovirus coat protein", "TEST", 0, 29], ["antirhinitis", "PROBLEM", 52, 64]]], ["A combined pharmacophore, docking approach and PCA-based clustering was used.", [["A combined pharmacophore", "TREATMENT", 0, 24], ["docking approach", "TREATMENT", 26, 42], ["PCA-based clustering", "TREATMENT", 47, 67]]], ["A pharmacophore was generated from the structure and shape of a known inhibitor and tested for its ability to find known inhibitors in a database.", [["A pharmacophore", "TREATMENT", 0, 15], ["a known inhibitor", "TREATMENT", 62, 79], ["known inhibitors", "PROBLEM", 115, 131]]], ["Ultimately, after screening the Maybridge database, 10 compounds were suggested that were then docked and scored.", [["screening", "TEST", 18, 27], ["the Maybridge database", "TEST", 28, 50]]], ["Six compounds were tested and found to inhibit viral growth.", [["viral growth", "PROBLEM", 47, 59]]], ["However, the majority of them were found to be cytotoxic or had poor solubility (Steindl et al., 2005b).", [["cytotoxic", "PROBLEM", 47, 56], ["poor solubility", "PROBLEM", 64, 79], ["cytotoxic", "OBSERVATION_MODIFIER", 47, 56]]], ["The Ligand Scout approach was tested on the rhinovirus serotype 16 and was able to find known inhibitors in the PDB (Wolber and Langer, 2005).Antivirals: ::: Examples of in silico pharmacology ::: Pharmacological space coveredThe SARS coronavirus 3C-like proteinase has been addressed as a potential drug design target.", [["rhinovirus", "ORGANISM", 44, 54], ["SARS coronavirus 3C-like proteinase", "PROTEIN", 230, 265], ["rhinovirus serotype 16", "SPECIES", 44, 66], ["SARS coronavirus", "SPECIES", 230, 246], ["the rhinovirus serotype", "TREATMENT", 40, 63], ["Pharmacological space", "PROBLEM", 197, 218], ["The SARS coronavirus 3C", "PROBLEM", 226, 249], ["proteinase", "TREATMENT", 255, 265], ["PDB", "ANATOMY", 112, 115]]], ["A pharmacophore model and drug-like rules were used to narrow the hit list.", [["A pharmacophore model", "TREATMENT", 0, 21], ["pharmacophore model", "OBSERVATION", 2, 21]]], ["Forty compounds were tested and three were found with micromolar activity, the best being calmidazolium at 61 \u03bcM (Liu et al., 2005), perhaps a starting point for further optimization.Antivirals: ::: Examples of in silico pharmacology ::: Pharmacological space coveredA pharmacophore has also been developed to predict the hepatitis C virus RNA-dependent RNA polymerase inhibition of diketo acid derivatives.", [["calmidazolium", "CHEMICAL", 90, 103], ["diketo acid", "CHEMICAL", 383, 394], ["calmidazolium", "CHEMICAL", 90, 103], ["diketo acid", "CHEMICAL", 383, 394], ["calmidazolium", "SIMPLE_CHEMICAL", 90, 103], ["hepatitis C virus", "ORGANISM", 322, 339], ["diketo acid derivatives", "SIMPLE_CHEMICAL", 383, 406], ["hepatitis C virus RNA", "RNA", 322, 343], ["RNA polymerase", "PROTEIN", 354, 368], ["hepatitis C virus", "SPECIES", 322, 339], ["hepatitis C virus", "SPECIES", 322, 339], ["micromolar activity", "PROBLEM", 54, 73], ["calmidazolium", "TREATMENT", 90, 103], ["further optimization", "TREATMENT", 162, 182], ["Pharmacological space", "PROBLEM", 238, 259], ["the hepatitis C virus RNA", "PROBLEM", 318, 343], ["diketo acid derivatives", "TREATMENT", 383, 406], ["hepatitis", "OBSERVATION", 322, 331]]], ["A Catalyst HypoGen model was derived with 40 molecules with activities over three log orders to result in a five-feature pharmacophore model.", [["A Catalyst HypoGen model", "TREATMENT", 0, 24]]], ["This was in turn tested with 19 compounds from the same data set as well as nine diketo acid derivatives, for which the predicted and experimental data were in good agreement (Di Santo et al., 2005).Other therapeutic targets: ::: Examples of in silico pharmacology ::: Pharmacological space coveredThe integrin VLA-4 (\u03b14\u03b21) is a target for autoimmune and inflammatory diseases such as asthma and rheumatoid arthritis.", [["diketo acid", "CHEMICAL", 81, 92], ["autoimmune and inflammatory diseases", "DISEASE", 340, 376], ["asthma", "DISEASE", 385, 391], ["rheumatoid arthritis", "DISEASE", 396, 416], ["diketo acid", "CHEMICAL", 81, 92], ["diketo acid derivatives", "SIMPLE_CHEMICAL", 81, 104], ["integrin VLA-4", "GENE_OR_GENE_PRODUCT", 302, 316], ["\u03b14\u03b21", "GENE_OR_GENE_PRODUCT", 318, 322], ["integrin VLA-4", "PROTEIN", 302, 316], ["\u03b14\u03b21", "PROTEIN", 318, 322], ["nine diketo acid derivatives", "TREATMENT", 76, 104], ["Pharmacological space", "TEST", 269, 290], ["The integrin VLA", "TEST", 298, 314], ["autoimmune and inflammatory diseases", "PROBLEM", 340, 376], ["asthma", "PROBLEM", 385, 391], ["rheumatoid arthritis", "PROBLEM", 396, 416], ["autoimmune", "OBSERVATION", 340, 350], ["inflammatory", "OBSERVATION", 355, 367], ["asthma", "OBSERVATION", 385, 391], ["rheumatoid arthritis", "OBSERVATION", 396, 416]]], ["The search for antagonists has included using a Catalyst pharmacophore derived from the X-ray crystal structure of a peptidic inhibitor (Singh et al., 2002b).", [["antagonists", "TREATMENT", 15, 26], ["a Catalyst pharmacophore", "TREATMENT", 46, 70], ["a peptidic inhibitor", "TREATMENT", 115, 135]]], ["Hence, a peptide was used to derive non-peptide inhibitors that were active in vivo.", [["a peptide", "TREATMENT", 7, 16], ["non-peptide inhibitors", "TREATMENT", 36, 58]]], ["A second study by the same group used CoMFA with a set of 29 antagonists with activity from 1 to 662 nM to generate a model with good internal validation statistics that was subsequently used to indicate favourable regions for molecule substituent changes (Singh et al., 2002a).", [["A second study", "TEST", 0, 14], ["molecule substituent changes", "PROBLEM", 227, 255], ["favourable", "OBSERVATION_MODIFIER", 204, 214]]], ["It is unclear whether the CoMFA model was also successful for design of further molecules.Other therapeutic targets: ::: Examples of in silico pharmacology ::: Pharmacological space coveredIt is possible to use approved drugs as a starting point for drug discovery for other diseases.", [["further molecules", "PROBLEM", 72, 89], ["Pharmacological space", "TREATMENT", 160, 181], ["drugs", "TREATMENT", 220, 225], ["other diseases", "PROBLEM", 269, 283]]], ["For example, the list of World Health Organization essential drugs has been searched to try to find leads for prion diseases using 2D Tanimoto similarity or 3D searching with known inhibitors.", [["prion diseases", "DISEASE", 110, 124], ["prion diseases", "PROBLEM", 110, 124], ["2D Tanimoto similarity", "TREATMENT", 131, 153], ["known inhibitors", "TREATMENT", 175, 191]]], ["This work to date has suggested compounds, yet they appear not to have been tested, so the approach has not been completely validated (Lorenzen et al., 2005).Other therapeutic targets: ::: Examples of in silico pharmacology ::: Pharmacological space coveredProtein\u2013protein interactions are key components of cellular signalling cascades, the selective interruption of which would represent a sought after therapeutic mechanism to modulate various diseases (Tesmer, 2006).", [["cellular", "ANATOMY", 308, 316], ["cellular", "CELL", 308, 316], ["Pharmacological space coveredProtein\u2013protein interactions", "TREATMENT", 228, 285], ["cellular signalling cascades", "PROBLEM", 308, 336], ["various diseases", "PROBLEM", 439, 455], ["cellular signalling cascades", "OBSERVATION", 308, 336], ["selective", "OBSERVATION_MODIFIER", 342, 351]]], ["However, such pharmacological targets have been difficult for in silico methods to derive small molecule inhibitors owing to generally quite shallow binding sites.", [["silico methods", "TREATMENT", 65, 79], ["small molecule inhibitors", "TREATMENT", 90, 115], ["shallow binding", "OBSERVATION", 141, 156]]], ["The G-protein G\u03b2\u03b3 complex can regulate a number of signalling proteins via protein\u2013protein interactions.", [["G-protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["G\u03b2\u03b3", "GENE_OR_GENE_PRODUCT", 14, 17], ["G-protein", "PROTEIN", 4, 13], ["G\u03b2\u03b3 complex", "PROTEIN", 14, 25], ["signalling proteins", "PROTEIN", 51, 70]]], ["The search for small molecules to interfere with the G\u03b2\u03b3-protein\u2013protein interaction has been targeted using FlexX docking and consensus scoring of 1990 molecules from the NCI diversity set database (Bonacci et al., 2006).", [["G\u03b2\u03b3-protein\u2013protein", "GENE_OR_GENE_PRODUCT", 53, 72], ["FlexX", "SIMPLE_CHEMICAL", 109, 114], ["FlexX", "PROTEIN", 109, 114], ["small molecules", "PROBLEM", 15, 30], ["the G\u03b2\u03b3-protein\u2013protein interaction", "PROBLEM", 49, 84], ["FlexX docking", "TREATMENT", 109, 122]]], ["After testing 85 compounds as inhibitors of the G\u03b21\u03b32-SIRK peptide, nine compounds were identified with IC50 values from 100 nM to 60 \u03bcM.", [["G\u03b21", "GENE_OR_GENE_PRODUCT", 48, 51], ["\u03b32", "PROTEIN", 51, 53], ["testing", "TEST", 6, 13], ["inhibitors", "TREATMENT", 30, 40], ["the G\u03b21", "TEST", 44, 51], ["IC50 values", "TEST", 104, 115]]], ["Further substructure searching was used to identify similar compounds to one of the most potent inhibitors to build a SAR.", [["the most potent inhibitors", "TREATMENT", 80, 106]]], ["These efforts may eventually lead to more potent lead compounds.Complex property modelling ::: Pharmacological space coveredUp to this point, we have generally considered in silico pharmacology models that essentially relate to a single target protein and either the discovery of molecules as agonists, antagonists or with other biological activity after database searching and in vitro testing or following searching of databases seeded with molecules of known activity for the target.", [["Pharmacological space", "TREATMENT", 95, 116], ["a single target protein", "PROBLEM", 228, 251], ["antagonists", "TREATMENT", 303, 314], ["database searching", "TEST", 355, 373], ["vitro testing", "TEST", 381, 394]]], ["However, there are many complex properties that have been modelled in silico and these will be briefly discussed here.", [["many", "OBSERVATION_MODIFIER", 19, 23], ["complex", "OBSERVATION_MODIFIER", 24, 31]]], ["It should also be pointed out that while several physicochemical properties such as ClogP and water solubility have been extensively studied, the training sets for these models are in the 1000s or tens of thousands of molecules, while other complex properties have generally used much smaller training sets in the range of hundreds of molecules.Complex property modelling ::: Pharmacological space coveredFor example, a measure of molecule clearance would be indicative of elimination half-life that would naturally be of value for selecting candidates.", [["ClogP", "CHEMICAL", 84, 89], ["ClogP", "SIMPLE_CHEMICAL", 84, 89], ["water", "SIMPLE_CHEMICAL", 94, 99], ["ClogP and water solubility", "TREATMENT", 84, 110], ["these models", "TEST", 164, 176], ["Pharmacological space", "TREATMENT", 376, 397], ["molecule clearance", "TEST", 431, 449]]], ["The intrinsic clearance has therefore been used as a measure of the enzyme activity toward a compound and this may involve multiple enzymes.", [["enzymes", "PROTEIN", 132, 139], ["multiple enzymes", "TEST", 123, 139], ["intrinsic clearance", "OBSERVATION", 4, 23]]], ["Some of the earliest models for this property includes a CoMFA model of the CYP-mediated metabolism of chlorinated volatile organic compounds, likely representative of CYP2E1 (Waller et al., 1996).", [["CYP", "GENE_OR_GENE_PRODUCT", 76, 79], ["chlorinated volatile organic compounds", "SIMPLE_CHEMICAL", 103, 141], ["CYP2E1", "GENE_OR_GENE_PRODUCT", 168, 174], ["CYP", "PROTEIN", 76, 79], ["CYP2E1", "PROTEIN", 168, 174], ["the CYP", "TEST", 72, 79], ["chlorinated volatile organic compounds", "PROBLEM", 103, 141], ["organic compounds", "OBSERVATION", 124, 141]]], ["A more generic set of molecules with clearance data derived from human hepatocytes has been used to predict human in vivo clearance using multiple linear regression, PCA, PLS, Neural Networks with leave-one-out cross-validation (Schneider et al., 1999).", [["hepatocytes", "ANATOMY", 71, 82], ["human", "ORGANISM", 65, 70], ["hepatocytes", "CELL", 71, 82], ["human", "ORGANISM", 108, 113], ["human hepatocytes", "CELL_TYPE", 65, 82], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 108, 113], ["clearance data", "TEST", 37, 51], ["multiple linear regression", "TREATMENT", 138, 164], ["PCA", "TREATMENT", 166, 169]]], ["Microsomal and hepatocyte clearance data sets have also been used separately to generate Catalyst pharmacophores, which were then tested by predicting the opposing data set.", [["Microsomal", "ANATOMY", 0, 10], ["hepatocyte", "ANATOMY", 15, 25], ["Microsomal", "CELL", 0, 10], ["hepatocyte", "CELL", 15, 25], ["Microsomal and hepatocyte clearance data", "TEST", 0, 40], ["hepatocyte", "ANATOMY", 15, 25]]], ["This method assumes there are some pharmacophore features intrinsic to the molecules that dictate intrinsic clearance (Ekins and Obach, 2000).Complex property modelling ::: Pharmacological space coveredA second complex property is the volume of distribution that is a function of the extent of drug partitioning into tissue versus plasma and there have been several attempts at modelling this property (Lombardo et al., 2002, 2004).", [["tissue", "ANATOMY", 317, 323], ["plasma", "ANATOMY", 331, 337], ["tissue", "TISSUE", 317, 323], ["plasma", "ORGANISM_SUBSTANCE", 331, 337], ["some pharmacophore features", "PROBLEM", 30, 57], ["Pharmacological space", "PROBLEM", 173, 194], ["second complex", "OBSERVATION_MODIFIER", 204, 218], ["volume", "OBSERVATION_MODIFIER", 235, 241], ["drug partitioning", "OBSERVATION", 294, 311]]], ["This property, along with the plasma half-life, determines the appropriate dose of a drug.", [["plasma", "ANATOMY", 30, 36], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["a drug", "TREATMENT", 83, 89]]], ["For example, 253 diverse drugs from the literature were used with eight molecular descriptors with Sammon and Kohonen mapping methods.", [["diverse drugs", "TREATMENT", 17, 30], ["Sammon and Kohonen mapping methods", "TREATMENT", 99, 133]]], ["Recently, a set of 384 drugs with literature volume of distribution at steady-state data was used with a mixture discriminant analysis-random forest method and 31 molecular descriptors to generate a predictive model.", [["drugs", "TREATMENT", 23, 28], ["a mixture discriminant analysis", "TEST", 103, 134], ["random forest method", "TEST", 135, 155]]], ["This model was tested with 23 molecules, resulting in a geometric mean fold error of 1.78, which was comparable to the values for other predictions for this property from animal, in vitro, or other methods (Lombardo et al., 2006).Complex property modelling ::: Pharmacological space coveredA third property, the plasma half-life determined by numerous ADME properties has also been modelled with Sammon and Kohonen maps using data for 458 drugs from the literature and four molecular descriptors.", [["plasma", "ANATOMY", 312, 318], ["plasma", "ORGANISM_SUBSTANCE", 312, 318], ["a geometric mean fold error", "TEST", 54, 81], ["Pharmacological space", "PROBLEM", 261, 282], ["drugs", "TREATMENT", 439, 444]]], ["Like the previously described volume of distribution models, these models appeared to classify correctly 80% of the compounds (Balakin et al., 2005).Complex property modelling ::: Pharmacological space coveredA fourth complex property is renal clearance, which assumes the excretion of the unchanged drug that takes place only by this route, hence this represents a method of monitoring the proportion of drug metabolized.", [["renal", "ANATOMY", 238, 243], ["renal", "ORGAN", 238, 243], ["Pharmacological space", "PROBLEM", 180, 201], ["renal clearance", "PROBLEM", 238, 253], ["renal", "ANATOMY", 238, 243], ["clearance", "OBSERVATION", 244, 253], ["unchanged", "OBSERVATION_MODIFIER", 290, 299], ["drug", "OBSERVATION", 300, 304]]], ["The models were tested with 20 molecules and one using soft independent modelling of class analogies and Molconn-Z descriptors obtained 85% correct classification between the two classes (0\u201320 and 20\u2013100%) (Doddareddy et al., 2006).Complex property modelling ::: Pharmacological space coveredA fifth example of a complex property is the protein\u2013ligand interaction and appropriate scoring functions for which several methods have been developed such as force fields, empirical and knowledge-based approaches (see also Ekins et al., 2007).", [["Pharmacological space", "PROBLEM", 263, 284]]], ["Recently, a Kernel partial least squares (K-PLSs) QSAR approach has been used along with a genetic algorithm feature selection method for the distance-dependent atom pair descriptors from the 61 or 105 small molecule training sets with binding affinity data and the proteins they bind to.", [["a Kernel partial least squares (K-PLSs) QSAR approach", "TREATMENT", 10, 63], ["binding affinity data", "TEST", 236, 257]]], ["Bootstrapping, scrambling the data and external test sets were used to test the models (Deng et al., 2004).", [["scrambling the data", "TEST", 15, 34], ["external test sets", "TEST", 39, 57]]], ["In essence, such K-PLS QSAR models across many proteins perhaps isolate the key molecular descriptors that relate to the highest affinity interactions.", [["such K-PLS QSAR models", "PROBLEM", 12, 34], ["many proteins", "PROBLEM", 42, 55]]], ["It will be interesting to see whether such models can continue to be generated with the much larger binding affinity data sets that are now available.Complex property modelling ::: Pharmacological space coveredA final example of a complex property is the Vmax of an enzyme that has been modelled on a few occasions (Hirashima et al., 1997; Mager et al., 1982; Ghafourian and Rashidi, 2001; Sipila and Taskinen, 2004).", [["Pharmacological space", "PROBLEM", 181, 202], ["an enzyme", "TEST", 263, 272], ["Ghafourian", "TEST", 360, 370], ["Rashidi", "TEST", 375, 382], ["Sipila", "TEST", 390, 396]]], ["This value will depend on the properties of the compound in question and will be influenced by the steric properties of the active site as well as the ease of expulsion of the leaving group from the active site.", [["active", "OBSERVATION", 124, 130], ["active site", "OBSERVATION", 199, 210]]], ["Balakin et al. (2004), have recently used neural network methods to model the Vmax data for N-dealkylation mediated by CYP2D6 and CYP3A4, using whole molecules, centroid of the reaction and leaving group-related descriptors.", [["neural network", "ANATOMY", 42, 56], ["N-dealkylation", "CHEMICAL", 92, 106], ["N", "CHEMICAL", 92, 93], ["neural network", "MULTI-TISSUE_STRUCTURE", 42, 56], ["CYP2D6", "GENE_OR_GENE_PRODUCT", 119, 125], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 130, 136], ["CYP2D6", "PROTEIN", 119, 125], ["CYP3A4", "PROTEIN", 130, 136], ["N-dealkylation", "TREATMENT", 92, 106], ["the reaction", "PROBLEM", 173, 185]]], ["These models were also used to predict small sets of molecules not included in training.", [["small sets of molecules", "PROBLEM", 39, 62]]], ["Ultimately, many other reactions and the evaluation of other enzymes will be necessary.", [["enzymes", "PROTEIN", 61, 68], ["many other reactions", "PROBLEM", 12, 32], ["the evaluation", "TEST", 37, 51], ["other enzymes", "TEST", 55, 68]]], ["Similarly, larger test sets are required for all the above complex property models to provide further confidence in the models in terms of their utility and applicability.Uses of in silico pharmacology ::: Current scope, limitations, and trendsWe propose a general schema for in silico pharmacology, which is shown in Figure 2.", [["larger test sets", "TEST", 11, 27], ["Current scope", "TEST", 206, 219], ["larger", "OBSERVATION_MODIFIER", 11, 17]]], ["These roles include finding new antagonists or agonists for a target using an array of methods either in the absence or presence of a structure for the target.", [["new antagonists", "TREATMENT", 28, 43], ["agonists", "TREATMENT", 47, 55], ["an array of methods", "TREATMENT", 75, 94]]], ["Computational methods may also aid in understanding the underlying biology using network/pathways based on annotated data (signalling cascades), determining the connectivity of drug as a network with targets to understand selectivity, integration with other models for PK/PD (pharmacodynamic) and ultimately the emergence of systems in silico pharmacology.", [["PD", "DISEASE", 272, 274], ["PK", "GENE_OR_GENE_PRODUCT", 269, 271], ["PK/PD (pharmacodynamic)", "TREATMENT", 269, 292]]], ["Obviously, we have taken more of a pharmaceutical bias in this review but we would argue these methods are equally amenable and should be considered to discover new chemical probes for the academic pharmacologist as opposed to lead molecules for optimization to become drugs.", [["a pharmaceutical bias", "TREATMENT", 33, 54], ["drugs", "TREATMENT", 269, 274]]], ["Some of the advantages of in silico pharmacology and in silico methods in general are the reduction in the number of molecules made and tested through database searching to find inhibitors or substrates, increased speed of experiments through reliable prediction of most pharmaceutical properties from molecule structure alone and ultimately reductions in animal and reagent use.", [["inhibitors", "TREATMENT", 178, 188], ["reductions", "OBSERVATION_MODIFIER", 342, 352]]], ["We must however consider the multiple optimization of numerous predicted properties, possibly either weighting in silico pharmacology models by importance (or confidence in the model and or data), as well as data set size and diversity.", [["size", "OBSERVATION_MODIFIER", 217, 221]]], ["For example, even with the recent availability of crystal structures for several mammalian drug-metabolizing enzymes, there is still considerable difficulty in reliable metabolism predictions.", [["mammalian drug-metabolizing enzymes", "PROTEIN", 81, 116], ["metabolizing enzymes", "TEST", 96, 116], ["considerable difficulty in reliable metabolism predictions", "PROBLEM", 133, 191], ["metabolism predictions", "OBSERVATION", 169, 191]]], ["Our focus thus far has been on the creation of many in silico pharmacology models for human properties, yet as pharmacology uses animals for much in vivo testing and subcellular preparations from several species for in vitro experiments, we need models from other species both to understand differences as well as enable better scaling between them.", [["subcellular", "ANATOMY", 166, 177], ["human", "ORGANISM", 86, 91], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["vivo testing", "TEST", 149, 161], ["subcellular preparations", "TREATMENT", 166, 190]]], ["A widely discussed disadvantage of in silico methods is the applicability of the model, which will now be discussed further.Defining in silico model applicability domain ::: Current scope, limitations, and trendsSome of the in silico pharmacology methods that can be used have similar limitations to models used in other areas, such as those for predicting physicochemical and ADME/Tox properties.", [["Tox", "SIMPLE_CHEMICAL", 382, 385], ["Current scope", "TEST", 174, 187], ["ADME/Tox properties", "TEST", 377, 396], ["widely", "OBSERVATION_MODIFIER", 2, 8]]], ["For example, models may be generated with a narrow homologous series of pharmacologically relevant molecules (local model) or a structurally diverse range of molecules (global model).", [["a narrow homologous series", "PROBLEM", 42, 68], ["pharmacologically relevant molecules", "PROBLEM", 72, 108], ["structurally", "OBSERVATION_MODIFIER", 128, 140], ["diverse", "OBSERVATION_MODIFIER", 141, 148]]], ["The applicability domain of the local model may be much narrower than for the global model such that changing to a new chemical series will result in prediction failure.", [["a new chemical series", "PROBLEM", 113, 134], ["prediction failure", "PROBLEM", 150, 168], ["may be", "UNCERTAINTY", 44, 50], ["much narrower", "OBSERVATION_MODIFIER", 51, 64], ["failure", "OBSERVATION", 161, 168]]], ["However, global models may also fail if the predicted molecule falls far enough away from representative molecules in the training set.", [["the predicted molecule falls", "PROBLEM", 40, 68]]], ["From many of the in silico pharmacology model examples described above, the QSAR models are generally local in nature and this will limit lead hopping to new structural series, whereas global models may be more useful for this feature.", [["the QSAR models", "PROBLEM", 72, 87], ["new structural series", "TEST", 154, 175], ["generally", "OBSERVATION_MODIFIER", 92, 101], ["local", "OBSERVATION_MODIFIER", 102, 107]]], ["To our knowledge, there has not been a specific analysis of the applicability domain specifically for in silico pharmacology models (other than for those examples described above) to the same degree as there has been for physicochemical properties like solubility and logP.", [["P.", "SPECIES", 271, 273]]], ["The applicability domain of pharmacophore models have not been addressed either as the focus has primarily been on statistical QSAR methods.Defining in silico model applicability domain ::: Current scope, limitations, and trendsAs we shift toward hybrid or meta-computational methods (that integrate several modelling approaches and algorithms) for predicting from molecular structure the possible physicochemical and pharmacological properties, then these could be used to provide prediction confidence by consensus.", [["The applicability domain of pharmacophore models", "PROBLEM", 0, 48], ["Current scope", "TEST", 190, 203], ["hybrid or meta-computational methods", "TREATMENT", 247, 283], ["algorithms", "TEST", 333, 343]]], ["The docking methods with homology models for certain proteins of pharmacological interest could be used alongside QSAR or pharmacophore models if these are also available.", [["pharmacophore models", "TEST", 122, 142]]], ["There have been numerous occasions in the study of drug-metabolizing enzymes were QSAR and homology models have been combined or used to validate each other (de Groot et al., 2002a; de Graaf et al., 2005; de Groot, 2006).Defining in silico model applicability domain ::: Current scope, limitations, and trendsDrug metabolism is a good example as several simultaneous outcomes (for example, metabolites) often occur, a condition not normally found in other pharmacological assays where a single set of conditions yields a single outcome.", [["Drug", "SIMPLE_CHEMICAL", 309, 313], ["drug-metabolizing enzymes", "PROTEIN", 51, 76], ["the study", "TEST", 38, 47], ["Current scope", "TEST", 271, 284], ["Drug metabolism", "PROBLEM", 309, 324], ["numerous", "OBSERVATION_MODIFIER", 16, 24]]], ["It is here that the classification into specific (\u2018local') and comprehensive (\u2018global') methods finds its clearest use (see Figure 3), with local methods being applicable to simple biological systems such as a single enzyme or a single enzymatic activity (Testa and Kr\u00e4mer, 2006).", [["enzyme", "PROTEIN", 217, 223], ["local methods", "TREATMENT", 140, 153], ["a single enzyme", "TEST", 208, 223]]], ["The production of regioselective metabolites (for example, hydroxylation to a phenol and an alcohol) is usually predictable from such methods, but that of different routes (for example, oxidation versus glucuronidation) is not.", [["phenol", "CHEMICAL", 78, 84], ["alcohol", "CHEMICAL", 92, 99], ["phenol", "CHEMICAL", 78, 84], ["alcohol", "CHEMICAL", 92, 99], ["phenol", "SIMPLE_CHEMICAL", 78, 84], ["alcohol", "SIMPLE_CHEMICAL", 92, 99], ["hydroxylation", "TREATMENT", 59, 72]]], ["This is where global algorithms (that is, applicable to versatile biological systems) are most useful in their potential capacity to encompass all or most metabolic reactions and offer predictions, which are much closer to the in vivo situation.Observations and caveats ::: Current scope, limitations, and trendsIt is readily apparent that in a minority of papers we have found that computational approaches have resulted in predicted lead compounds for testing without the authors providing further experimental verification of biological activity (Krovat and Langer, 2004; Langer et al., 2004; Steindl and Langer, 2004; Gopalakrishnan et al., 2005; Lorenzen et al., 2005; Steindl et al., 2005a; Amin and Welsh, 2006).", [["Current scope", "TEST", 274, 287], ["testing", "TEST", 454, 461]]], ["This is an interesting observation as for many years computational studies were generally performed after synthesis of molecules, and essentially provided illustrative pictures and explanation of the data.", [["computational studies", "TEST", 53, 74], ["synthesis of molecules", "PROBLEM", 106, 128], ["the data", "TEST", 196, 204]]], ["As the models may only have a limited prediction domain so perhaps in future we will see some discussion of the predicted molecules and their distance from the training set or some other measure of how far the predictions can be extended.Observations and caveats ::: Current scope, limitations, and trendsMany of the molecules identified by virtual screening techniques have not been tested in vitro to ensure that they are not false positives that may actually be involved in molecule aggregation.", [["Current scope", "TEST", 267, 280], ["virtual screening techniques", "TEST", 341, 369], ["false positives", "PROBLEM", 428, 443], ["molecule aggregation", "PROBLEM", 477, 497]]], ["These types of molecules have been termed so-called \u2018promiscuous inhibitors', occurring as micromolar inhibitors of several proteins (McGovern et al., 2002; McGovern and Shoichet, 2003; Seidler et al., 2003).", [["micromolar inhibitors", "TREATMENT", 91, 112]]], ["From reviewing the literature, we suggest it would be worth researchers either implementing filters for \u2018promiscuous inhibitors' or performing rigorous experimental verification of their predicted bioactive molecules to rule out this possibility.Observations and caveats ::: Current scope, limitations, and trendsPublication bias perhaps also limits the number of examples of failures of computational methods that are published (if any).", [["\u2018promiscuous inhibitors", "TREATMENT", 104, 127], ["rigorous experimental verification", "TEST", 143, 177], ["Current scope", "TEST", 275, 288], ["Publication bias", "PROBLEM", 313, 329], ["computational methods", "TREATMENT", 388, 409], ["failures", "OBSERVATION", 376, 384]]], ["It would certainly be very useful to know the existence of difficult targets for modelling with different methods, as this apparently is a process of trial and error for each investigator currently.Observations and caveats ::: Current scope, limitations, and trendsIn summary, in this and the accompanying review (Ekins et al., 2007), we have presented our interpretation of in silico pharmacology and described how the field has developed so far and is used for: discovery of molecules that bind to many different targets and display bioactivity, prediction of complex properties and the understanding of the underlying metabolic and network interactions.", [["Current scope", "TEST", 227, 240]]], ["While we have not explicitly discussed PK/PD, whole organ, cell or disease simulations in this review, we recognize they too are an important component of the computer-aided drug design approach (Noble and Colatsky, 2000; Gomeni et al., 2001; Kansal, 2004) and may be more widely integrated with other in silico pharmacology methods described previously (Ekins et al., 2005).ConclusionThe brief history of in silico pharmacology has taken perhaps a rather predictable route with computational models applied to many of the most important biological targets where they have the capacity to be used to search large databases and quickly suggest molecules for testing.", [["organ", "ANATOMY", 52, 57], ["cell", "ANATOMY", 59, 63], ["PK", "GENE_OR_GENE_PRODUCT", 39, 41], ["organ", "ORGAN", 52, 57], ["cell", "CELL", 59, 63], ["PK/PD", "TREATMENT", 39, 44], ["disease simulations", "PROBLEM", 67, 86], ["computational models", "TREATMENT", 479, 499], ["the capacity", "PROBLEM", 573, 585], ["testing", "TEST", 657, 664]]], ["Many of the examples we have presented have demonstrated significant enrichments over random selection of molecules and so far these have been the most plentiful types of metrics that are routinely used to validate in silico models.", [["significant enrichments", "PROBLEM", 57, 80], ["significant", "OBSERVATION_MODIFIER", 57, 68], ["enrichments", "OBSERVATION", 69, 80], ["most plentiful", "OBSERVATION_MODIFIER", 147, 161]]], ["First, biological entities are nonlinear systems showing \u2018chaotic behaviour'.", [["chaotic behaviour'", "PROBLEM", 58, 76]]], ["As such, there is no relation between the magnitude of the input and the magnitude of the output, with even the most minuscule differences between initial conditions rapidly translating into major differences in the output.", [["the output", "TEST", 86, 96], ["the output", "TEST", 212, 222], ["magnitude", "OBSERVATION_MODIFIER", 73, 82], ["output", "OBSERVATION_MODIFIER", 90, 96], ["most minuscule", "OBSERVATION_MODIFIER", 112, 126], ["major", "OBSERVATION_MODIFIER", 191, 196], ["differences", "OBSERVATION_MODIFIER", 197, 208], ["output", "OBSERVATION_MODIFIER", 216, 222]]]], "PMC7150305": [["IntroductionThe growth and elaboration of the field of global health law over the last two decades has been a notable development in global health policy.", [["growth", "OBSERVATION_MODIFIER", 16, 22], ["notable", "OBSERVATION_MODIFIER", 110, 117]]], ["Traditionally, public health was viewed as a realm of almost exclusive national jurisdiction, and multilateral cooperation in this realm was restricted to discrete areas.", [["discrete", "OBSERVATION_MODIFIER", 155, 163], ["areas", "OBSERVATION", 164, 169]]], ["Public health law today remains predominantly domestic and national, but the field of global health law is extant and growing.", [["predominantly", "OBSERVATION_MODIFIER", 32, 45], ["domestic", "OBSERVATION", 46, 54], ["growing", "OBSERVATION_MODIFIER", 118, 125]]], ["Through the codification of binding global health law standards that regulate interstate behavior and national conduct as well as the creation of other global norms that influence state actions, global health law has expanding significance in national public health law and policy.IntroductionThe domain of global health law now encompasses increasingly diverse concerns, including aspects of biomedical science and human reproduction/cloning; organ transplantation and xenotransplantation; infectious and noncommunicable diseases; the control of the safety of health services; food and pharmaceuticals in international trade; access to medicines; and the control of addictive and harmful substances such as tobacco and narcotics.", [["organ", "ANATOMY", 444, 449], ["infectious and noncommunicable diseases", "DISEASE", 491, 530], ["human", "ORGANISM", 416, 421], ["organ", "ORGAN", 444, 449], ["tobacco", "ORGANISM", 708, 715], ["narcotics", "SIMPLE_CHEMICAL", 720, 729], ["human", "SPECIES", 416, 421], ["human", "SPECIES", 416, 421], ["tobacco", "SPECIES", 708, 715], ["biomedical science", "TREATMENT", 393, 411], ["human reproduction/cloning", "TREATMENT", 416, 442], ["organ transplantation", "TREATMENT", 444, 465], ["xenotransplantation", "TREATMENT", 470, 489], ["infectious and noncommunicable diseases", "PROBLEM", 491, 530], ["medicines", "TREATMENT", 637, 646], ["harmful substances", "TREATMENT", 681, 699], ["narcotics", "TREATMENT", 720, 729], ["diverse", "OBSERVATION_MODIFIER", 354, 361], ["infectious", "OBSERVATION_MODIFIER", 491, 501]]], ["Global health law is also increasingly linked to other traditional areas of international legal concern.", [["health law", "OBSERVATION", 7, 17]]], ["Environmental law and the control of toxic pollutants, arms control and the banning of weapons of mass destruction, human rights law, nuclear safety and radiation protection, international drug control, customs law, and occupational health and safety are increasingly recognized as inextricably connected to public health.", [["nuclear", "ANATOMY", 134, 141], ["human", "ORGANISM", 116, 121], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121], ["toxic pollutants", "PROBLEM", 37, 53], ["arms control", "TREATMENT", 55, 67], ["mass destruction", "PROBLEM", 98, 114], ["radiation protection", "TREATMENT", 153, 173], ["mass", "OBSERVATION", 98, 102]]], ["Finally, the role of two international organizations, the World Health Organization (WHO) and the World Trade Organization (WTO), in the contemporary development of international law is considered in connection with examples of lawmaking with important public health and public health policy implications.Globalization and the Expanding Domain of International Health Law ::: The Evolution of Global Health LawIt is widely recognized that contemporary globalization is contributing to the expansion of the field of global health law.", [["Global", "OBSERVATION_MODIFIER", 393, 399], ["Health LawIt", "OBSERVATION", 400, 412], ["expansion", "OBSERVATION_MODIFIER", 489, 498]]], ["Although increasing global integration is not an entirely new phenomenon, contemporary globalization has had an unprecedented impact on global public health and is creating new and increasingly difficult governance needs and health policy-making challenges.", [["increasing global integration", "PROBLEM", 9, 38], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["global", "OBSERVATION_MODIFIER", 20, 26], ["integration", "OBSERVATION", 27, 38], ["new", "OBSERVATION_MODIFIER", 58, 61], ["phenomenon", "OBSERVATION", 62, 72], ["new", "OBSERVATION_MODIFIER", 173, 176]]], ["Globalization has contributed to the rapid decline in the practical capacity of sovereign states to address public health challenges through unilateral national action alone and expanded the need for health governance structures that transcend traditional and increasingly inadequate national approaches.Globalization and the Expanding Domain of International Health Law ::: The Evolution of Global Health LawTreaty law, often referred to as conventional international law, has received new prominence as a mechanism or a tool that can be used by states to facilitate multilateral cooperation in this era of globalization, as states increasingly recognize the need for international cooperation to attain national public health objectives for which domestic law and other policy responses are increasingly inadequate (Taylor, 2004).", [["the rapid decline", "PROBLEM", 33, 50], ["unilateral national action", "TREATMENT", 141, 167], ["health governance structures", "TREATMENT", 200, 228], ["new prominence", "PROBLEM", 487, 501], ["rapid", "OBSERVATION_MODIFIER", 37, 42], ["decline", "OBSERVATION_MODIFIER", 43, 50], ["Global", "OBSERVATION_MODIFIER", 392, 398], ["Health LawTreaty", "OBSERVATION", 399, 415], ["new", "OBSERVATION_MODIFIER", 487, 490], ["prominence", "OBSERVATION", 491, 501]]], ["For example, rapid worldwide dissemination of recent advances in scientific knowledge and technology has encouraged international cooperation in a wide range of treaties, including those concerning the safety of chemicals, pesticides, and food, and the disposal of hazardous wastes.Globalization and the Expanding Domain of International Health Law ::: The Evolution of Global Health LawGlobalization has increased the need for new, formalized frameworks for international cooperation, including international law, to address emerging global health threats.", [["rapid", "OBSERVATION_MODIFIER", 13, 18], ["worldwide", "OBSERVATION_MODIFIER", 19, 28], ["Global", "OBSERVATION_MODIFIER", 370, 376], ["Health LawGlobalization", "OBSERVATION", 377, 400], ["increased", "OBSERVATION_MODIFIER", 405, 414]]], ["For example, the dynamics of globalization have created fertile global breeding conditions for the cross-border spread of emerging threats to health, such as weapons of mass destruction, including bioterrorism; emerging and reemerging infectious diseases; and the vectors of noncommunicable diseases including tobacco, alcohol, and obesity.Globalization and the Expanding Domain of International Health Law ::: The Evolution of Global Health LawIn addition, globalization has expanded global interest in codifying new international commitments to protect the health status of populations in low-income and emerging market states that have not benefited from globalization \u2013 the so-called losers of globalization.", [["infectious diseases", "DISEASE", 235, 254], ["noncommunicable diseases", "DISEASE", 275, 299], ["alcohol", "CHEMICAL", 319, 326], ["obesity", "DISEASE", 332, 339], ["alcohol", "CHEMICAL", 319, 326], ["tobacco", "ORGANISM", 310, 317], ["alcohol", "SIMPLE_CHEMICAL", 319, 326], ["tobacco", "SPECIES", 310, 317], ["tobacco", "SPECIES", 310, 317], ["created fertile global breeding conditions", "PROBLEM", 48, 90], ["mass destruction", "PROBLEM", 169, 185], ["bioterrorism", "PROBLEM", 197, 209], ["noncommunicable diseases", "PROBLEM", 275, 299], ["obesity", "PROBLEM", 332, 339], ["fertile", "OBSERVATION_MODIFIER", 56, 63], ["global", "OBSERVATION_MODIFIER", 64, 70], ["breeding conditions", "OBSERVATION", 71, 90], ["mass", "OBSERVATION", 169, 173], ["obesity", "OBSERVATION", 332, 339], ["Global", "OBSERVATION_MODIFIER", 428, 434], ["Health LawIn", "OBSERVATION", 435, 447], ["expanded", "OBSERVATION_MODIFIER", 476, 484], ["global", "OBSERVATION_MODIFIER", 485, 491], ["interest", "OBSERVATION_MODIFIER", 492, 500]]], ["For example, the need to promote more equitable innovation and universal access in health-care products, including medicines, pharmaceuticals, diagnostics, and medical devices, is generating ongoing debate about the efficacy of codifying a new international instrument on medical research and design.Globalization and the Expanding Domain of International Health Law ::: The Evolution of Global Health LawBecause of the momentum of globalization, states must increasingly turn to international cooperation in order to protect and promote domestic health.", [["medicines", "TREATMENT", 115, 124], ["medical devices", "TREATMENT", 160, 175], ["Global", "OBSERVATION_MODIFIER", 388, 394]]], ["Consequently, we are likely to see wider use of international legal instruments in this century to control the risks and threats to health associated with globalization and, perhaps, to take advantage of the opportunities to improve world health that have been afforded by global change.", [["international legal instruments", "TREATMENT", 48, 79]]], ["For example, the WHO International Health Regulations (IHRs), the sole international legal instrument designed to provide a framework for multilateral efforts to combat infectious diseases, were revised in 2005 to address the increasing threat posed by the transnationalization of infectious diseases and to incorporate newly developed mechanisms for international coordination and response.", [["infectious diseases", "DISEASE", 169, 188], ["infectious diseases", "DISEASE", 281, 300], ["infectious diseases", "PROBLEM", 169, 188], ["infectious diseases", "PROBLEM", 281, 300], ["infectious", "OBSERVATION", 281, 291]]], ["In addition, in 2011, the Member States of WHO adopted the Pandemic Influenza Preparedness (PIP) Framework to facilitate the sharing of influenza viruses and increase access to vaccines and antiviral medications in low- and middle-income countries.Health and Human Rights ::: The Evolution of Global Health LawThe evolution of global health law in the last two decades is very much tied to the protection and promotion of human rights related to physical and mental integrity.", [["Influenza", "DISEASE", 68, 77], ["influenza viruses", "DISEASE", 136, 153], ["Human", "ORGANISM", 259, 264], ["human", "ORGANISM", 422, 427], ["Human", "SPECIES", 259, 264], ["human", "SPECIES", 422, 427], ["human", "SPECIES", 422, 427], ["the Pandemic Influenza Preparedness (PIP) Framework", "TREATMENT", 55, 106], ["influenza viruses", "PROBLEM", 136, 153], ["vaccines", "TREATMENT", 177, 185], ["antiviral medications", "TREATMENT", 190, 211], ["Global", "OBSERVATION_MODIFIER", 293, 299], ["Health Law", "OBSERVATION", 300, 310], ["global", "OBSERVATION_MODIFIER", 327, 333], ["health law", "OBSERVATION", 334, 344]]], ["Although global health law is largely utilized as a mechanism to protect and expand state interests in an era of global interdependence, it is also conceived of and employed as a framework or tool for protecting the rights of individuals and, perhaps, creating a more just and equitable world (Meier, 2011).Health and Human Rights ::: The Evolution of Global Health LawThe preamble to the WHO Constitution, the first international expression of the right to health, declares that \u201c[t]he enjoyment of the right of the highest attainable standard of health is one of the fundamental rights of every human being without distinction or race, religion, political belief, economic or social condition.\u201d", [["Human", "ORGANISM", 318, 323], ["human", "ORGANISM", 597, 602], ["Human", "SPECIES", 318, 323], ["human", "SPECIES", 597, 602], ["human", "SPECIES", 597, 602], ["Global", "OBSERVATION_MODIFIER", 352, 358], ["Health Law", "OBSERVATION", 359, 369], ["right", "ANATOMY_MODIFIER", 449, 454], ["right", "ANATOMY_MODIFIER", 504, 509]]], ["The principal international legal basis for the right to health is found in the core instruments of international human rights law promulgated under the auspices of the United Nations: the International Bill of Rights, which consists of the Universal Declaration of Human Rights (1948), the International Covenant on Economic, Social and Cultural Rights (1966) (ICESCR), and the International Covenant on Civil and Political Rights (1966).Health and Human Rights ::: The Evolution of Global Health LawRead in conjunction with Article 2, Article 12 of the ICESCR, the most significant binding legal expression of the right to health, provides, among other things, that each state \u2018undertakes to take steps,\u2019 to the maximum extent of its available resources and with a view toward progressive achievement, toward \u201cthe highest attainable standards of physical and mental health of all individuals, without discrimination.\u201d", [["human", "ORGANISM", 114, 119], ["Human", "ORGANISM", 266, 271], ["Human", "ORGANISM", 450, 455], ["human", "SPECIES", 114, 119], ["Human", "SPECIES", 266, 271], ["Human", "SPECIES", 450, 455], ["human", "SPECIES", 114, 119], ["right", "ANATOMY_MODIFIER", 48, 53], ["Global", "OBSERVATION_MODIFIER", 484, 490], ["Health LawRead", "OBSERVATION", 491, 505], ["right", "ANATOMY_MODIFIER", 616, 621]]], ["Beyond this broad formulation, however, Article 12 is replete with ambiguity.", [["this broad formulation", "TREATMENT", 7, 29]]], ["The Covenant neither defines \u2018health\u2019 nor the particular obligations of states necessary to realize the right to health.Health and Human Rights ::: The Evolution of Global Health LawNo subsequent binding international legal instrument has provided an authoritative interpretation of the Covenant.", [["Human", "ORGANISM", 131, 136], ["Human", "SPECIES", 131, 136], ["right", "ANATOMY_MODIFIER", 104, 109], ["Global", "OBSERVATION_MODIFIER", 165, 171]]], ["In 2000 the Committee on Economic, Social and Cultural Rights to the ICESCR adopted General Comment 14, a detailed explanatory commentary on the right to health under Article 12 of the Covenant.", [["the Covenant", "TREATMENT", 181, 193]]], ["Among other things, the broadly formulated General Comment 14 sets forth that the right to health is not simply a right to be healthy, but rather a robust human right extending not only to access to health-care services but also to the underlying determinants of health, including an access to safe water and adequate sanitation, occupational health and environmental conditions, and access to health-related education and information.", [["human", "ORGANISM", 155, 160], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 155, 160], ["right", "ANATOMY_MODIFIER", 82, 87]]], ["In addition, some observers, including the United States, have directly questioned the legal authority of the Committee on Economic, Social and Cultural Rights, a committee established by a decision of ECOSOC and not pursuant to the Covenant, to issue authoritative interpretations of the ICESCR.Health and Human Rights ::: The Evolution of Global Health LawAn important concern with the formulation of the right to health is whether it is an individual or a collective standard reflecting the health-related interests of communities.", [["Human", "ORGANISM", 307, 312], ["Human", "SPECIES", 307, 312], ["Global", "OBSERVATION_MODIFIER", 341, 347], ["right", "ANATOMY_MODIFIER", 407, 412]]], ["As a human right, the conventional interpretation of the right to health pertains to individual and not collective claims.", [["human", "ORGANISM", 5, 10], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["right", "ANATOMY_MODIFIER", 11, 16], ["right", "ANATOMY_MODIFIER", 57, 62]]], ["However, in public health practice, the right to health is often used to refer to public or community health.", [["right", "ANATOMY_MODIFIER", 40, 45]]], ["There can also be tension between the idea of the collective right to health and the exercise of other human rights, including liberty, physical integrity, and privacy.Health and Human Rights ::: The Evolution of Global Health LawDespite the long historical linkage, the strong connection between health and human rights has only recently received significant attention.", [["human", "ORGANISM", 103, 108], ["Human", "ORGANISM", 179, 184], ["human", "ORGANISM", 308, 313], ["human", "SPECIES", 103, 108], ["Human", "SPECIES", 179, 184], ["human", "SPECIES", 308, 313], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 308, 313], ["tension", "OBSERVATION", 18, 25], ["right", "ANATOMY_MODIFIER", 61, 66], ["Global", "OBSERVATION_MODIFIER", 213, 219], ["strong", "OBSERVATION_MODIFIER", 271, 277]]], ["A number of emerging global concerns, including HIV/AIDS and women's health issues, including rape and other forms of violence against women, brought the intrinsic connection between health and human rights to the forefront of international policy concern beginning in the late 1980s and early 1990s.", [["HIV/AIDS", "DISEASE", 48, 56], ["violence", "DISEASE", 118, 126], ["women", "ORGANISM", 61, 66], ["women", "ORGANISM", 135, 140], ["human", "ORGANISM", 194, 199], ["HIV", "SPECIES", 48, 51], ["women", "SPECIES", 61, 66], ["women", "SPECIES", 135, 140], ["human", "SPECIES", 194, 199], ["HIV", "SPECIES", 48, 51], ["human", "SPECIES", 194, 199], ["HIV/AIDS", "PROBLEM", 48, 56]]], ["Of particular importance was a pioneering human rights approach to the global HIV/AIDS pandemic adopted by WHO in the late 1980s.", [["HIV/AIDS pandemic", "DISEASE", 78, 95], ["human", "ORGANISM", 42, 47], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["HIV", "SPECIES", 78, 81], ["a pioneering human rights approach", "TREATMENT", 29, 63]]], ["It is widely recognized that this novel emphasis on the linkage between public health and human rights law had a groundbreaking impact in that it compelled governments to be publicly accountable on an international stage for their actions against persons living with HIV/AIDS.", [["HIV/AIDS", "DISEASE", 267, 275], ["human", "ORGANISM", 90, 95], ["persons", "ORGANISM", 247, 254], ["human", "SPECIES", 90, 95], ["persons", "SPECIES", 247, 254], ["human", "SPECIES", 90, 95]]], ["(Ultimately, this innovative global political approach to public health issues publicly highlighted for the very first time the underlying legal responsibility of governments to protect and promote the health of their populations and has served as a forerunner for increasingly widespread links between human rights and other public health issues (Mann and Tarantola, 1998).)Health and Human Rights ::: The Evolution of Global Health LawThe domain of health and human rights has expanded significantly under the auspices of agencies and organs of the United Nations and other international organizations.", [["organs", "ANATOMY", 537, 543], ["human", "ORGANISM", 303, 308], ["Human", "ORGANISM", 386, 391], ["human", "ORGANISM", 462, 467], ["organs", "ORGAN", 537, 543], ["human", "SPECIES", 303, 308], ["Human", "SPECIES", 386, 391], ["human", "SPECIES", 462, 467], ["human", "SPECIES", 303, 308], ["human", "SPECIES", 462, 467], ["Global", "OBSERVATION_MODIFIER", 420, 426], ["Health Law", "OBSERVATION", 427, 437]]], ["Specific international legal instruments addressing the rights of particular populations, such as persons with HIV/AIDS, women, children, migrant workers, and refugees, have been adopted.", [["HIV/AIDS", "DISEASE", 111, 119], ["persons", "ORGANISM", 98, 105], ["women", "ORGANISM", 121, 126], ["children", "ORGANISM", 128, 136], ["persons", "SPECIES", 98, 105], ["HIV", "SPECIES", 111, 114], ["women", "SPECIES", 121, 126], ["children", "SPECIES", 128, 136]]], ["For example, on 13 December 2006 the United Nations General Assembly adopted the Convention on the Rights of Persons with Disabilities.Health and Human Rights ::: The Evolution of Global Health LawOther contemporary developments are contributing to the further elaboration of international legal instruments in the realm of health and human rights, including, in particular, globalization.", [["Human", "ORGANISM", 146, 151], ["human", "ORGANISM", 335, 340], ["Persons", "SPECIES", 109, 116], ["Human", "SPECIES", 146, 151], ["human", "SPECIES", 335, 340], ["human", "SPECIES", 335, 340], ["Global", "OBSERVATION_MODIFIER", 180, 186]]], ["For example, widespread recognition of growing inequalities in health status and differential access to medical advances in rich and poor states has expanded interest in the relationship between social and economic rights and health.", [["widespread", "OBSERVATION_MODIFIER", 13, 23], ["growing", "OBSERVATION_MODIFIER", 39, 46], ["inequalities", "OBSERVATION_MODIFIER", 47, 59]]], ["Of particular concern is the impact of international intellectual property protection under the WTO Trade-Related Aspects of Intellectual Property (TRIPS) Agreement, discussed in the section titled \u2018The World Trade Organization, International Law and Global Health,\u2019 in restricting access to essential medicines, particularly HIV/AIDS antiretrovirals, in low-income countries.", [["HIV/AIDS", "DISEASE", 326, 334], ["HIV", "SPECIES", 326, 329], ["international intellectual property protection", "TREATMENT", 39, 85], ["essential medicines", "TREATMENT", 292, 311], ["HIV/AIDS antiretrovirals", "TREATMENT", 326, 350]]], ["The unprecedented human catastrophe posed by HIV/AIDS led the international community to adopt a number of nonbinding resolutions at the United Nations General Assembly, the former United Nations Commission on Human Rights and the WHO specifying the relationship between HIV/AIDS, human rights, and access to medicines.", [["HIV/AIDS", "DISEASE", 45, 53], ["HIV/AIDS", "DISEASE", 271, 279], ["human", "ORGANISM", 18, 23], ["HIV", "ORGANISM", 45, 48], ["Human", "ORGANISM", 210, 215], ["human", "ORGANISM", 281, 286], ["human", "SPECIES", 18, 23], ["Human", "SPECIES", 210, 215], ["HIV", "SPECIES", 271, 274], ["human", "SPECIES", 281, 286], ["human", "SPECIES", 18, 23], ["HIV", "SPECIES", 45, 48], ["HIV", "SPECIES", 271, 274], ["human", "SPECIES", 281, 286], ["HIV/AIDS", "TREATMENT", 271, 279], ["medicines", "TREATMENT", 309, 318]]], ["In June 2006, the United Nations General Assembly adopted a Political Declaration on AIDS (UN Res. 60/262) reaffirming that access to medicines in the context of pandemics, including HIV/AIDS, is one of the fundamental elements to achieving full realization for everyone of the international right to health.", [["AIDS", "DISEASE", 85, 89], ["pandemics", "DISEASE", 162, 171], ["HIV/AIDS", "DISEASE", 183, 191], ["HIV", "SPECIES", 183, 186], ["HIV", "SPECIES", 183, 186], ["medicines", "TREATMENT", 134, 143], ["pandemics", "PROBLEM", 162, 171], ["HIV/AIDS", "PROBLEM", 183, 191], ["right", "ANATOMY_MODIFIER", 292, 297]]], ["In May 2013 the UN Special Rapporteur on the right to health issued a report analyzing existing international challenges toward realizing access to medicines within a right to health framework and called upon the international community to shift from the \u2018dominant market-oriented paradigm\u2019 to promote access to medicine (A/HRC/23/42).", [["medicines", "TREATMENT", 148, 157], ["right", "ANATOMY_MODIFIER", 45, 50]]], ["Following the release of the report in June 2013, the UN Human Rights Council adopted a resolution on access to medicines (A/HRC/RES/23/14) broadly recognizing that access to medicines is one of the fundamental elements in achieving progressively the full realization of the right to everyone to the enjoyment of the highest attainable standard of physical and mental health.Health and Human Rights ::: The Evolution of Global Health LawGlobalization is also furthering the elaboration of international instruments in this realm because increasing global integration is compounding the impact of other contemporary global developments associated with health status and human rights.", [["RES", "CHEMICAL", 129, 132], ["Human", "ORGANISM", 57, 62], ["Human", "ORGANISM", 386, 391], ["human", "ORGANISM", 669, 674], ["Human", "SPECIES", 57, 62], ["Human", "SPECIES", 386, 391], ["human", "SPECIES", 669, 674], ["human", "SPECIES", 669, 674], ["medicines", "TREATMENT", 112, 121], ["A/HRC/RES", "TREATMENT", 123, 132], ["medicines", "TREATMENT", 175, 184], ["right", "ANATOMY_MODIFIER", 275, 280], ["Global", "OBSERVATION_MODIFIER", 420, 426], ["Health LawGlobalization", "OBSERVATION", 427, 450]]], ["An interesting recent development in this realm is the negotiation and adoption of the 2010 WHO Global Code of Practice on the International Recruitment of Health Personnel discussed in the section \u2018The World Health Organization.\u2019Health and Human Rights ::: The Evolution of Global Health LawAs a further example, the links between scientific progress, global diffusion of new technologies and human rights is also receiving increased attention in the elaboration of international legal instruments.", [["Human", "ORGANISM", 241, 246], ["human", "ORGANISM", 394, 399], ["Human", "SPECIES", 241, 246], ["human", "SPECIES", 394, 399], ["human", "SPECIES", 394, 399], ["Global", "OBSERVATION_MODIFIER", 275, 281], ["new", "OBSERVATION_MODIFIER", 373, 376]]], ["For instance, the implications of advances in biotechnology for the protection of human rights and human dignity have been a topic of interest by international and regional organizations, including consideration of bans on novel technologies.", [["human", "ORGANISM", 82, 87], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 99, 104], ["the protection of human rights and human dignity", "TREATMENT", 64, 112], ["novel technologies", "TREATMENT", 223, 241]]], ["In 1997 the United Nations Educational, Scientific and Cultural Organization (UNESCO) adopted a nonbinding instrument, the Universal Declaration on the Human Genome and Human Rights, and in 2003 it adopted the International Declaration on Genetic Data.", [["Human", "ORGANISM", 152, 157], ["Human", "ORGANISM", 169, 174], ["Human", "SPECIES", 152, 157], ["Human", "SPECIES", 169, 174], ["a nonbinding instrument", "TREATMENT", 94, 117]]], ["In addition, in the wake of failed treaty negotiations, in 2005 the United Nations General Assembly adopted a declaration urging Member States to prohibit reproductive cloning as incompatible with human rights.", [["human", "ORGANISM", 197, 202], ["human", "SPECIES", 197, 202], ["human", "SPECIES", 197, 202]]], ["At the regional level, the Council of Europe adopted a Convention on the Protection of Human Rights and Human Dignity with regard to the Application of Biology and Medicine: the Convention on Human Rights and Biomedicine in 1997.", [["Human", "ORGANISM", 87, 92], ["Human", "ORGANISM", 104, 109], ["Human", "ORGANISM", 192, 197], ["Human", "SPECIES", 87, 92], ["Human", "SPECIES", 104, 109], ["Human", "SPECIES", 192, 197]]], ["Four protocols to the Convention \u2013 separate agreements \u2013 on human cloning, biomedical research, transplantation of organs and tissues, and genetic testing for health purposes have also been adopted by the Council of Europe between 1998 and 2008.", [["organs", "ANATOMY", 115, 121], ["tissues", "ANATOMY", 126, 133], ["human", "ORGANISM", 60, 65], ["organs", "ORGAN", 115, 121], ["tissues", "TISSUE", 126, 133], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["human cloning", "TREATMENT", 60, 73], ["transplantation of organs and tissues", "TREATMENT", 96, 133], ["genetic testing", "TEST", 139, 154], ["organs", "ANATOMY", 115, 121], ["tissues", "ANATOMY", 126, 133]]], ["For example, the European Union adopted a directive on clinical practice in the conduct of clinical trials on medicinal products for human use in 2001 and investigational medicinal products in 2005.Health and Human Rights ::: The Evolution of Global Health LawThe biotechnology revolution is putting continuing pressure on the international community to develop international law, including human rights law, to effectively govern this realm, and we are likely to see further developments in the future.", [["human", "ORGANISM", 133, 138], ["Human", "ORGANISM", 209, 214], ["human", "ORGANISM", 391, 396], ["human", "SPECIES", 133, 138], ["Human", "SPECIES", 209, 214], ["human", "SPECIES", 391, 396], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 391, 396], ["clinical practice", "TREATMENT", 55, 72], ["medicinal products", "TREATMENT", 110, 128], ["investigational medicinal products", "TREATMENT", 155, 189], ["Global", "OBSERVATION_MODIFIER", 243, 249], ["Health Law", "OBSERVATION", 250, 260]]], ["Rather than codifying a comprehensive instrument in this realm, existing international agreements on biotechnology have been adopted in a piecemeal and, at times, incoherent fashion and today consist of different instruments, including guidelines, code of conduct, resolutions, and treaties adopted under the auspices different international organizations.Linkage and the Scope of Global Health Law ::: The Evolution of Global Health LawThe expanding domain of global health law can be understood, in part, as a product of enhanced appreciation of the interconnectedness of contemporary global concerns and, concomitantly, the linkage of health to other legal issues.", [["Global", "OBSERVATION_MODIFIER", 420, 426], ["Health Law", "OBSERVATION", 427, 437]]], ["International legal scholars traditionally compartmentalized and treated substantive subject matters such as human rights, environmental protection, arms control, and public health as discrete self-contained areas with limited connections.", [["human", "ORGANISM", 109, 114], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["environmental protection", "TREATMENT", 123, 147], ["arms control", "TREATMENT", 149, 161]]], ["Rapid global integration propelled by contemporary globalization has contributed to the recognition of the nexus among different realms of international law.Linkage and the Scope of Global Health Law ::: The Evolution of Global Health LawAs a consequence of issue linkage, international law and global health is increasingly understood to be a central component of other international legal regimes, including labor law, human rights, arms control, and international trade.", [["human", "ORGANISM", 421, 426], ["human", "SPECIES", 421, 426], ["human", "SPECIES", 421, 426], ["Rapid global integration", "PROBLEM", 0, 24], ["labor law", "TREATMENT", 410, 419], ["arms control", "TREATMENT", 435, 447], ["global", "OBSERVATION_MODIFIER", 6, 12], ["integration", "OBSERVATION", 13, 24], ["Global", "OBSERVATION_MODIFIER", 221, 227], ["Health LawAs", "OBSERVATION", 228, 240]]], ["The recent connection between health and human rights in contemporary international law and practice discussed in the preceding section is an important example of the linkage of two traditionally distinct realms of international law.Linkage and the Scope of Global Health Law ::: The Evolution of Global Health LawThe evolution of the concept of human security provides another interesting example of this development.", [["human", "ORGANISM", 41, 46], ["human", "ORGANISM", 346, 351], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 346, 351], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 346, 351], ["Global", "OBSERVATION_MODIFIER", 297, 303], ["Health Law", "OBSERVATION", 304, 314]]], ["The traditional understanding of human security has come under increasing pressure in recent years, with growing support for a comprehensive approach to human security that addresses the wide-ranging factors that impact upon the vulnerability of people.", [["human", "ORGANISM", 33, 38], ["human", "ORGANISM", 153, 158], ["people", "ORGANISM", 246, 252], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 153, 158], ["people", "SPECIES", 246, 252], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 153, 158], ["growing support", "TREATMENT", 105, 120]]], ["In 2003, the UN Commission on Human Security released a report proposing a new security framework and recognizing the linkage between health and human security (United Nations Commission on Human Security, 2003).Linkage and the Scope of Global Health Law ::: The Evolution of Global Health LawWHO's 2005 IHRs described further herein have been at the center of discussion of the linkage between global health and security.", [["Human", "ORGANISM", 30, 35], ["human", "ORGANISM", 145, 150], ["Human", "ORGANISM", 190, 195], ["Human", "SPECIES", 30, 35], ["human", "SPECIES", 145, 150], ["Human", "SPECIES", 190, 195], ["human", "SPECIES", 145, 150], ["Global", "OBSERVATION_MODIFIER", 276, 282]]], ["For example, at the time of the drafting of the revised IHRs expanding global concern with weapons of mass destruction and terrorism underscored the strong interconnection between public health and security and legal commitments established under the Regulations are clearly designed to apply to releases of biological, chemical, and radiological events, accidental and deliberate.", [["mass destruction", "PROBLEM", 102, 118], ["terrorism", "PROBLEM", 123, 132], ["mass", "OBSERVATION", 102, 106], ["strong", "OBSERVATION_MODIFIER", 149, 155]]], ["Recent disease outbreaks, epidemics, natural disasters, and other health emergencies have reinforced the linkage between global health and security.", [["Recent disease outbreaks", "PROBLEM", 0, 24], ["epidemics", "PROBLEM", 26, 35], ["disease", "OBSERVATION", 7, 14]]], ["For example, the recent Ebola outbreak discussed further herein has revitalized discussions of global health security, including a range of proposals for reframing the global health governance to strengthen the global health security regime (Kickbush, 2016).Linkage and the Scope of Global Health Law ::: The Evolution of Global Health LawThe linkage between health, security, and other traditionally defined legal realms is also exemplified in the contemporary global threat of counterfeit medicines.", [["Ebola", "DISEASE", 24, 29], ["Ebola", "ORGANISM", 24, 29], ["counterfeit medicines", "TREATMENT", 479, 500], ["Ebola", "OBSERVATION", 24, 29], ["Global", "OBSERVATION_MODIFIER", 322, 328], ["Health Law", "OBSERVATION", 329, 339]]], ["Expanding international community concern with the global challenge of international trafficking in counterfeit medicines, including substandard, defective or adulterated medicines has underscored the interconnections among global health law, international customs law, international criminal law, and international trade law and led to expanding support for the adoption of an international legal instrument in this realm (Attaran, 2012).Linkage and the Scope of Global Health Law ::: The Evolution of Global Health LawThe nexus between global health law and other traditionally distinct realms of international law is further exemplified by the rapidly evolving field of biotechnology described in the preceding section.", [["international trafficking in counterfeit medicines", "TREATMENT", 71, 121], ["adulterated medicines", "TREATMENT", 159, 180], ["Global", "OBSERVATION_MODIFIER", 503, 509], ["Health Law", "OBSERVATION", 510, 520]]], ["Biotechnology closely interlinks many quarters of the law including, global health, human rights, intellectual property, trade regulation, and environmental law.", [["human", "ORGANISM", 84, 89], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89]]], ["International trade law, particularly the General Agreement on Tariffs and Trade, the Agreement on the Application of Sanitary and Phytosanitary Measures (SPS Agreement), and the Technical Barriers to Trade Agreement (TBT Agreement), functions to discipline or restrict the authority of member states of the WTO to take food, safety, health, environmental and food security considerations into account in making regulatory decisions on the import and use of GMOs.", [["Sanitary and Phytosanitary Measures", "TREATMENT", 118, 153]]], ["Among regional instruments, the European Union regulatory framework in this realm is one of the most extensive, covering issues including import, cultivation, monitoring, and labeling of GMOs and GMO-derived material.", [["cultivation", "TEST", 146, 157], ["monitoring", "TEST", 159, 169], ["regional", "OBSERVATION_MODIFIER", 6, 14], ["instruments", "OBSERVATION", 15, 26]]], ["The main piece of European legislation regarding GMO food is EU Directive 2001/18/EC, which was amended in 2008 by Directive 2008/27/EC and again in 2015 by Directive (EU) 2015/412.", [["EC", "CELL", 82, 84], ["EC", "CELL", 133, 135], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["For example, much of private international law concerns the transactions of public entities.", [["public entities", "OBSERVATION", 76, 91]]], ["International organizations and, through the development of international human rights law, individuals, are also considered subjects of public international law.The Nature and Sources of International Law ::: An Introduction to Public International LawIn international law, the sources of legal rules are very different than in most domestic legal systems because the global political system of sovereign states differs fundamentally from domestic political systems.", [["human", "ORGANISM", 74, 79], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 74, 79], ["legal rules", "OBSERVATION", 290, 301]]], ["In contrast to domestic political systems, there is generally no supranational authority within the global system to develop and enforce law against sovereign states.", [["no", "UNCERTAINTY", 62, 64], ["supranational", "OBSERVATION_MODIFIER", 65, 78], ["authority", "OBSERVATION", 79, 88]]], ["The Vienna Convention, the so-called law of treaties, provides general rules of treaty implementation and interpretation.", [["treaty implementation", "TREATMENT", 80, 101]]], ["The Vienna Convention confirms the generic use of the term treaty by defining a treaty as \u201dan international agreement concluded between States in written form and governed by international law, whether embodied in a single instrument or in two or more related instruments and whatever its particular designation.\u201d", [["a single instrument", "TREATMENT", 214, 233]]], ["Article 19 of the Vienna Convention sets forth the basic legal principle concerning the observance of treaties, pacta sunt servanda: \u201cEvery treaty in force is binding upon the parties to it and must be performed in good faith.\u201dThe Nature and Sources of International Law ::: An Introduction to Public International LawA second important source of international law is customary international law.", [["treaties", "PROBLEM", 102, 110]]], ["The determination of whether or not a particular practice constitutes customary international law is a complex analysis that is more like an art than a science.", [["a complex analysis", "TEST", 101, 119]]], ["Significantly, these nonbinding international legal instruments are not comparable to voluntary instruments adopted at the national level or by industry.", [["legal instruments", "OBSERVATION", 46, 63]]], ["Although generally nonbinding, such instruments are not without legal or political significance.", [["nonbinding", "OBSERVATION", 19, 29]]], ["There are prominent examples of nonbinding instruments in public health with important policy impacts developed under the auspices of different international organization.", [["nonbinding instruments in public health", "PROBLEM", 32, 71], ["prominent", "OBSERVATION_MODIFIER", 10, 19], ["nonbinding instruments", "OBSERVATION", 32, 54], ["different", "OBSERVATION_MODIFIER", 134, 143], ["international organization", "OBSERVATION", 144, 170]]], ["For example, the WTO Doha Declaration on Trade and Public Health, discussed below, is widely considered to have advanced global understanding and, perhaps, action on trade and health matters, particularly in relation to access to essential medicines, even though the legal significance of the declaratory instrument is unclear.", [["essential medicines", "TREATMENT", 230, 249], ["the declaratory instrument", "PROBLEM", 289, 315]]], ["Another well-known example of a nonbinding international code with a significant public health impact is the 1981 WHO Code of Marketing Breastmilk Substitutes that was designed to protect and promote breastfeeding through the provision of adequate information on appropriate infant feeding and the regulation of the marketing of breastmilk substitutes, bottles, and teats.", [["breastmilk", "ORGANISM", 329, 339], ["teats", "ORGANISM_SUBDIVISION", 366, 371], ["appropriate infant feeding", "TREATMENT", 263, 289], ["breastmilk substitutes", "TREATMENT", 329, 351], ["significant", "OBSERVATION_MODIFIER", 69, 80]]], ["Another example of a nonbinding legal regime that has had an impact on state practice is the legal framework established by 2001 United Nations General Assembly Special Session (UNGASS) Declaration of Commitment on HIV/AIDS and the monitoring mechanism mandated under its auspices and under two other subsequent UN General Assembly resolutions.The Nature and Sources of International Law ::: An Introduction to Public International LawAt times, nonbinding intergovernmental resolutions have been highly persuasive, and the conduct of states has tended to follow the principles embodied in these resolutions.", [["HIV/AIDS", "DISEASE", 215, 223], ["HIV", "SPECIES", 215, 218], ["a nonbinding legal regime", "TREATMENT", 19, 44], ["HIV/AIDS", "TREATMENT", 215, 223]]], ["The effectiveness of some nonbinding intergovernmental resolutions in promoting international cooperation has led some commentators to refer to them as soft-law, although the term is highly controversial.", [["nonbinding", "OBSERVATION_MODIFIER", 26, 36], ["intergovernmental resolutions", "OBSERVATION", 37, 66]]], ["Nonbinding legal instruments, at times, have also paved the way for the evolution of treaty law by generating an ongoing diplomatic forum.The Nature and Sources of International Law ::: An Introduction to Public International LawNot all resolutions lead to the development of formalized treaty obligations or are a significant factor in state practice.", [["legal instruments", "OBSERVATION", 11, 28]]], ["The innate weakness of international law stems in large part from the core principle of state sovereignty.", [["The innate weakness", "PROBLEM", 0, 19], ["innate", "OBSERVATION_MODIFIER", 4, 10], ["weakness", "OBSERVATION", 11, 19], ["law stems", "OBSERVATION", 37, 46], ["large", "OBSERVATION_MODIFIER", 50, 55]]], ["In the treaty-making process, states are explicitly agreeing to make rules to govern and, thereby, limit their own conduct and that of their nationals through the development and implementation of legislation and other policies, depending upon the terms of the treaty, which are consistent with their international commitments.", [["treaty", "OBSERVATION", 261, 267], ["consistent with", "UNCERTAINTY", 279, 294]]], ["The concept of sovereignty looms large in the international system, and states are generally loath to sacrifice their freedom of action through the development of binding international obligations.", [["sovereignty looms large in the international system", "PROBLEM", 15, 66], ["sovereignty", "OBSERVATION_MODIFIER", 15, 26], ["looms", "OBSERVATION_MODIFIER", 27, 32], ["large", "OBSERVATION_MODIFIER", 33, 38]]], ["A related weakness stemming from the principle of sovereignty is the general lack of formal enforcement mechanisms in most contemporary economic and social agreements.", [["A related weakness", "PROBLEM", 0, 18], ["weakness", "OBSERVATION", 10, 18]]], ["In addition, there is increasing awareness that the failure of states at times to implement international commitments may reflect more a lack of capacity than political will.", [["increasing awareness", "PROBLEM", 22, 42], ["increasing", "OBSERVATION_MODIFIER", 22, 32], ["awareness", "OBSERVATION", 33, 42]]], ["Many states, particularly developing countries, face acute problems of limitations of resources and capacity in implementing contemporary treaties.", [["face acute problems", "PROBLEM", 48, 67], ["acute", "OBSERVATION_MODIFIER", 53, 58]]], ["Recent advances in the international legislative process have expanded mechanisms to address these problems of domestic capacity through international technical and financial assistance programs incorporated in the texts of relevant conventions.The Limitations of Global Health Lawmaking in International Health Policy ::: An Introduction to Public International LawInternational law and the international legislative process suffer from other important difficulties.", [["domestic capacity", "PROBLEM", 111, 128], ["financial assistance programs", "TREATMENT", 165, 194]]], ["Notably, the international legislative process itself is characterized by numerous challenges and limitations \u2013 including challenges to timely national commitment by states through timely treaty ratification and implementation \u2013 although considerable advances have been made in the last few decades.The Limitations of Global Health Lawmaking in International Health Policy ::: An Introduction to Public International LawAn emerging challenge in international health lawmaking is the limited scope of entities that are subjects of international law and thereby entitled to participate in international agreements and hold rights and duties thereunder.", [["legislative process", "OBSERVATION", 27, 46], ["numerous", "OBSERVATION_MODIFIER", 74, 82], ["challenges", "OBSERVATION", 83, 93]]], ["However, the nature of global health and the major actors in health policy are changing in such a way that challenges this restricted approach to international legal cooperation.", [["global", "OBSERVATION_MODIFIER", 23, 29]]], ["Nonstates ranging from Taiwan to Palestine are excluded from a range of international agreements because of lack of statehood.", [["lack of statehood", "PROBLEM", 108, 125]]], ["In addition, the major actors in global health policy today, including foundations, most notably the Bill and Melinda Gates Foundation, and a wide range of significant public\u2013private partnerships, such as the Global Alliance for Vaccines and Immunizations and the Global Fund for AIDS, Tuberculosis and Malaria, or civil society organizations, such as Medicines sans Frontiers, are also excluded from the international lawmaking process.", [["AIDS", "DISEASE", 280, 284], ["Tuberculosis", "DISEASE", 286, 298], ["Malaria", "DISEASE", 303, 310], ["Vaccines", "TREATMENT", 229, 237], ["Immunizations", "TREATMENT", 242, 255], ["AIDS", "PROBLEM", 280, 284], ["Tuberculosis", "PROBLEM", 286, 298], ["Malaria", "PROBLEM", 303, 310], ["Tuberculosis", "OBSERVATION", 286, 298], ["Malaria", "OBSERVATION", 303, 310]]], ["Recognition of the limitations of treaty making is contributing to growing interest in nonbinding legal mechanisms for global governance in health and other realms of international concern.The Limitations of Global Health Lawmaking in International Health Policy ::: An Introduction to Public International LawDespite the conspicuous limitations of the formal international lawmaking process and the inherent challenges of using treaties to promote collective action, treaties can be useful for raising global awareness and stimulating international commitment and national action.", [["treaties", "TREATMENT", 429, 437]]], ["As an increasing number of health threats are global in scope or have the potential to become so, international legal agreements, including treaties, are likely to become of increasing importance and an essential component of global health governance.", [["increasing", "OBSERVATION_MODIFIER", 6, 16], ["number", "OBSERVATION_MODIFIER", 17, 23]]], ["Beyond these few basic requirements, the Vienna Convention does not mandate any particular methods of negotiation or ratification.The Process of International Lawmaking ::: The International Lawmaking Process and the Role of\u00a0International OrganizationsIn the absence of binding international rules, international organizations have adopted a wide variety of strategies to initiate, negotiate, and conclude international agreements.", [["few", "OBSERVATION_MODIFIER", 13, 16], ["basic", "OBSERVATION_MODIFIER", 17, 22], ["requirements", "OBSERVATION_MODIFIER", 23, 35]]], ["Negotiations are the most difficult and generally the longest substage of the treaty process.", [["treaty", "OBSERVATION", 78, 84]]], ["Initiated in the early 1990s by Taylor and Roemer, the WHO FCTC was envisioned as a mechanism to promote national public health interventions and multilateral cooperation on aspects of tobacco control that transcend national boundaries.", [["tobacco", "ORGANISM", 185, 192], ["tobacco", "SPECIES", 185, 192], ["national public health interventions", "TREATMENT", 105, 141], ["tobacco control", "TREATMENT", 185, 200]]], ["The final text of the Convention cuts across a wide range of tobacco control topics, including advertising, production, smuggling and counterfeit cigarettes, warning labels, clean indoor air policies, and health education (Roemer et al., 2005).", [["tobacco", "ORGANISM", 61, 68]]], ["In 2012 the State Parties to the FCTC adopted the first protocol to the treaty \u2013 the Protocol to Eliminate Illicit Trade in Tobacco Products.Framework Convention on Tobacco Control ::: The World Health Organization ::: Examples of International Organizations and\u00a0International LawmakingAs of October 2015, 180 countries have ratified the FCTC making it one of the most widely subscribed to treaties in the history of the United Nations.", [["Tobacco", "ORGANISM", 124, 131], ["the FCTC", "TREATMENT", 334, 342]]], ["I have described this phenomenon elsewhere as the \u2018power of the process.\u2019", [["this phenomenon", "PROBLEM", 17, 32]]], ["It is widely recognized that WHO's efforts to achieve global public support for an international regulatory framework for tobacco control, stimulated national policy change in a number of countries and thus made an important, albeit limited, contribution to curtailing the epidemic well before global consensus on binding tobacco control norms was secured.", [["tobacco", "ORGANISM", 122, 129], ["tobacco", "ORGANISM", 322, 329], ["tobacco", "SPECIES", 122, 129], ["tobacco", "SPECIES", 322, 329], ["global public support", "TREATMENT", 54, 75], ["tobacco control", "TREATMENT", 122, 137]]], ["The FCTC negotiations were also the raison d'\u00eatre for the establishment of the first global alliance of tobacco control activists, the Framework Convention Alliance \u2013 a coalition of over 300 nongovernmental organizations worldwide \u2013 and thus further influenced the strengthening and deepening of tobacco control legislation in many states around the world.", [["tobacco", "ORGANISM", 104, 111], ["tobacco", "ORGANISM", 296, 303], ["tobacco", "SPECIES", 104, 111], ["tobacco", "SPECIES", 296, 303]]], ["The treaty has some key weaknesses that limit its effectiveness.", [["some key weaknesses", "PROBLEM", 15, 34], ["some", "OBSERVATION_MODIFIER", 15, 19], ["key", "OBSERVATION_MODIFIER", 20, 23], ["weaknesses", "OBSERVATION", 24, 34]]], ["Finally, the tobacco industry and state interests that support it have pushed back against strong tobacco control measures in national and international fora, including disputes brought to the WTO and pursuant to investment treaties against Australia and Uruguay for their use of plain packaging of tobacco products.", [["tobacco", "ORGANISM", 13, 20], ["tobacco", "ORGANISM", 98, 105], ["tobacco", "ORGANISM", 299, 306], ["tobacco", "SPECIES", 13, 20], ["tobacco", "SPECIES", 299, 306], ["tobacco products", "OBSERVATION", 299, 315]]], ["As described above in the \u2018Evolution of International Public Health Law\u2019 section, virulent infectious diseases have a long history in civilization, and international disease control was one of the earliest areas of international cooperation.", [["infectious diseases", "DISEASE", 91, 110], ["virulent infectious diseases", "PROBLEM", 82, 110], ["international disease control", "PROBLEM", 152, 181], ["virulent", "OBSERVATION_MODIFIER", 82, 90], ["infectious", "OBSERVATION", 91, 101]]], ["WHO, upon its founding, inherited the responsibility for the management of the international legal regime for the control of the international spread of diseases.", [["the management", "TREATMENT", 57, 71], ["the international legal regime", "TREATMENT", 75, 105], ["diseases", "PROBLEM", 153, 161], ["diseases", "OBSERVATION", 153, 161]]], ["The IHRs, first adopted by the Health Assembly in 1951 and last modified in 1981, were designed to provide an effective framework for addressing the international spread of disease while ensuring minimum interference with world traffic.", [["disease", "PROBLEM", 173, 180]]], ["However, the IHRs were ineffective in ensuring national action and global cooperation to stop the spread of disease.", [["the IHRs", "TEST", 9, 17], ["disease", "PROBLEM", 108, 115]]], ["The IHRs only applied to a highly narrow subset of infectious diseases and were routinely ignored by states.", [["infectious diseases", "DISEASE", 51, 70], ["The IHRs", "TEST", 0, 8], ["infectious diseases", "PROBLEM", 51, 70], ["highly narrow", "OBSERVATION_MODIFIER", 27, 40], ["infectious", "OBSERVATION", 51, 61]]], ["The magnitude of the global impact of catastrophic appearances of new infectious diseases and the virulent reemergence of old contagions during the 1980s and 1990s underscored the irrelevancy of the old IHRs in global health initiatives and initiated global interest in securing more effective international cooperation to control infectious diseases.International Health Regulations ::: The World Health Organization ::: Examples of International Organizations and\u00a0International LawmakingAlthough the IHR revision process had been underway since 1995, the negotiations were galvanized by the well-publicized global threats of severe acute respiratory syndrome (SARS) in late 2002 and 2003 and outbreaks of both human (H3N2) and avian (H5N1) influenza less than a year later.", [["infectious diseases", "DISEASE", 70, 89], ["infectious diseases", "DISEASE", 331, 350], ["acute respiratory syndrome", "DISEASE", 634, 660], ["SARS", "DISEASE", 662, 666], ["human (H3N2) and avian (H5N1) influenza", "DISEASE", 712, 751], ["human", "ORGANISM", 712, 717], ["avian (H5N1) influenza", "ORGANISM", 729, 751], ["human", "SPECIES", 712, 717], ["avian (H5N1", "SPECIES", 729, 740], ["human", "SPECIES", 712, 717], ["new infectious diseases", "PROBLEM", 66, 89], ["control infectious diseases", "PROBLEM", 323, 350], ["International Lawmaking", "TREATMENT", 466, 489], ["the IHR revision process", "TREATMENT", 498, 522], ["severe acute respiratory syndrome", "PROBLEM", 627, 660], ["influenza", "PROBLEM", 742, 751], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["global", "OBSERVATION_MODIFIER", 21, 27], ["catastrophic", "OBSERVATION_MODIFIER", 38, 50], ["new", "OBSERVATION_MODIFIER", 66, 69], ["infectious", "OBSERVATION", 70, 80], ["virulent", "OBSERVATION_MODIFIER", 98, 106], ["reemergence", "OBSERVATION_MODIFIER", 107, 118], ["revision", "OBSERVATION", 506, 514], ["severe", "OBSERVATION_MODIFIER", 627, 633], ["acute", "OBSERVATION_MODIFIER", 634, 639], ["respiratory syndrome", "OBSERVATION", 640, 660]]], ["The SARS epidemic spread rapidly from its origins in Southern China until it had reached more than 25 countries within a matter of months.", [["SARS", "DISEASE", 4, 8], ["The SARS epidemic spread", "PROBLEM", 0, 24], ["SARS", "OBSERVATION_MODIFIER", 4, 8], ["epidemic", "OBSERVATION_MODIFIER", 9, 17], ["spread", "OBSERVATION_MODIFIER", 18, 24], ["rapidly", "OBSERVATION_MODIFIER", 25, 32]]], ["The magnified public attention to these recent epidemics jolted global awareness of the global vulnerability spurred by the rapid spread of disease in this era of globalization as well as the necessity of international cooperation in halting the spread of deadly agents.", [["the rapid spread of disease", "PROBLEM", 120, 147], ["global", "OBSERVATION_MODIFIER", 88, 94], ["vulnerability", "OBSERVATION_MODIFIER", 95, 108], ["rapid", "OBSERVATION_MODIFIER", 124, 129], ["spread", "OBSERVATION_MODIFIER", 130, 136], ["disease", "OBSERVATION", 140, 147]]], ["As such, the SARS epidemic provided a mobilizing vision for coordinated health action.", [["SARS", "DISEASE", 13, 17], ["the SARS epidemic", "PROBLEM", 9, 26]]], ["Consequently, the IHR revision process provides an important lesson in the significant role played by a galvanizing event, and associated global public and media attention, in bringing states to the table in contemporary international law negotiations.International Health Regulations ::: The World Health Organization ::: Examples of International Organizations and\u00a0International LawmakingThe new IHRs are also an important example of the linkage of traditionally distinct subject matters for the protection of global public health.", [["the IHR revision process", "TREATMENT", 14, 38], ["revision", "OBSERVATION", 22, 30]]], ["The new Regulations bring together under one treaty intertwined concerns of public health, security, international trade, and human rights.", [["human", "ORGANISM", 126, 131], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["The new IHRs expand the scope of disease coverage, incorporate human rights principles, and institute demanding obligations for state surveillance and response.International Health Regulations ::: The World Health Organization ::: Examples of International Organizations and\u00a0International LawmakingThe IHRs were adopted pursuant to Article 21 of WHO's Constitution, a fairly unique lawmaking device in the international system.", [["human", "ORGANISM", 63, 68], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["disease coverage", "TREATMENT", 33, 49], ["human rights principles", "TREATMENT", 63, 86], ["state surveillance", "TEST", 128, 146], ["a fairly unique lawmaking device", "TREATMENT", 366, 398], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["Article 22 of the WHO Constitution provides that regulations adopted under Article 21 are adopted pursuant to a contracting-out procedure designed to simplify and expedite the lawmaking process.", [["procedure", "TREATMENT", 128, 137]]], ["Regulations come into force automatically for all WHO Member States, except for those states that notify WHO's Director-General, the Organization's executive head, of any rejection or reservations.", [["head", "ORGANISM_SUBDIVISION", 158, 162], ["any rejection", "PROBLEM", 167, 180], ["rejection", "OBSERVATION", 171, 180]]], ["The drafters of the WHO Constitution severely circumscribed the scope of this simplified lawmaking process, however, by limiting the scope of the regulatory authority under Article 21 to traditional public health concerns (Table 3).", [["severely circumscribed", "PROBLEM", 37, 59], ["this simplified lawmaking process", "PROBLEM", 73, 106]]], ["Significantly, the IHRs do not include any financial mechanism to assist states that lack capacity to implement the broad public health system and reporting obligations of the instrument.International Health Regulations ::: The World Health Organization ::: Examples of International Organizations and\u00a0International LawmakingThe emergency provisions of the new IHRs have been invoked four times since the entry into force of the agreement, each time raising criticisms both of the instrument and WHO.", [["lack capacity", "PROBLEM", 85, 98]]], ["Recently, the Organization, Member States, and the Regulations themselves faced considerable criticism in the context of the outbreak of Ebola in 2013 in West Africa and, ultimately, the United Nations led the global response to this epidemic.", [["Ebola", "DISEASE", 137, 142], ["Ebola", "ORGANISM", 137, 142], ["Ebola", "OBSERVATION", 137, 142]]], ["The Ebola outbreak, such as the HIN1 2009 outbreak, evidence that the global community is not prepared to respond to global health emergencies.", [["Ebola", "DISEASE", 4, 9], ["The Ebola outbreak", "PROBLEM", 0, 18], ["Ebola", "OBSERVATION_MODIFIER", 4, 9]]], ["In the wake of the flawed response to Ebola, commentators have called for major reforms to prevent future disasters and repair the global system for outbreak prevention and response (Moon, 2015).", [["Ebola", "DISEASE", 38, 43], ["Ebola", "ORGANISM", 38, 43], ["repair", "TREATMENT", 120, 126]]], ["WHO solicited an independent assessment of its efforts during the Ebola crisis and agreed to major reforms at the 2015 World Health Assembly, including an overhaul of the IHR.", [["Ebola", "DISEASE", 66, 71], ["Ebola", "ORGANISM", 66, 71]]], ["Most recently, in February 2016 the WHO Director-General declared a public health emergency of international concern in the context of the outbreak of the Zika virus in order to institute a coordinated international response.Global Code of Practice on the International Recruitment of Health Personnel ::: The World Health Organization ::: Examples of International Organizations and\u00a0International LawmakingThe loss of highly skilled personnel, colloquially referred to as \u2018brain drain,\u2019 has been a central concern of low-income countries for the last half century.", [["brain", "ANATOMY", 474, 479], ["Zika virus", "ORGANISM", 155, 165], ["brain", "ORGAN", 474, 479], ["Zika virus", "SPECIES", 155, 165], ["the Zika virus", "PROBLEM", 151, 165], ["brain drain", "TREATMENT", 474, 485], ["brain", "ANATOMY", 474, 479], ["drain", "OBSERVATION", 480, 485]]], ["The WHO Global Code, adopted by consensus by the World Health Assembly in 2010, marks the first time that the world community has considered and sought to respect critical and, at times, conflicting issues in this realm, including human rights issues.", [["human", "ORGANISM", 231, 236], ["human", "SPECIES", 231, 236], ["human", "SPECIES", 231, 236]]], ["Such policy concerns incorporated in the Code include honoring the right to health of all persons, the right of low-income countries to strengthen their health systems and the right of health workers to migrate to countries that wish to admit and employ them (Taylor and Dhillon, 2011).", [["persons", "ORGANISM", 90, 97], ["persons", "SPECIES", 90, 97], ["right", "ANATOMY_MODIFIER", 67, 72], ["right", "ANATOMY_MODIFIER", 103, 108], ["right", "ANATOMY_MODIFIER", 176, 181]]], ["The WHO Global Code of Practice on the International Recruitment of Health Personnel also reflects the increasing significance of nonbinding instruments in contemporary global health governance.", [["nonbinding instruments", "PROBLEM", 130, 152]]], ["In 2015 WHO held its first formal review of the nature and significance of the Global Code, finding that while the Code was highly relevant for global health, it was not yet widely significant in global practice due, in part, to a lack of national and international resources devoted to its implementation.PIP Framework ::: The World Health Organization ::: Examples of International Organizations and\u00a0International LawmakingAn interesting example of a recent nonbinding international legal instrument in communicable disease control is the PIP Framework adopted as a resolution by the World Health Assembly in 2011.", [["communicable disease", "DISEASE", 505, 525], ["communicable disease control", "TREATMENT", 505, 533]]], ["The PIP Framework was designed to address the controversy that erupted in 2007 when Indonesia reused to share samples of influenza A (H5N1) with WHO collaborating centers.", [["influenza A", "DISEASE", 121, 132], ["H5N1", "DISEASE", 134, 138], ["influenza A", "ORGANISM", 121, 132], ["influenza A", "PROBLEM", 121, 132]]], ["Indonesian officials claimed sovereignty over a virus that was identified within its jurisdiction in part because of concerns that the country's population would not receive a fair share of the benefits of any vaccine developed.", [["a virus", "PROBLEM", 46, 53], ["any vaccine", "TREATMENT", 206, 217]]], ["Notably, the IHRs do not address the thorny issue of access to vaccines and other medications in the context of influenza pandemics.", [["influenza pandemics", "DISEASE", 112, 131], ["vaccines", "TREATMENT", 63, 71], ["other medications", "TREATMENT", 76, 93], ["influenza pandemics", "PROBLEM", 112, 131]]], ["The PIP Framework attempts to resolve the controversy.", [["The PIP Framework attempts", "TREATMENT", 0, 26], ["PIP Framework", "OBSERVATION", 4, 17]]], ["Article 2 of the Framework sets forth the objective to improve pandemic preparedness and response systems with a benefit sharing system for influenza viruses that have human pandemic potential, and access to vaccines and other benefits including antiviral medications.", [["influenza viruses", "DISEASE", 140, 157], ["human", "ORGANISM", 168, 173], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["influenza viruses", "PROBLEM", 140, 157], ["vaccines", "TREATMENT", 208, 216], ["antiviral medications", "TREATMENT", 246, 267]]], ["In particular, although adopted as a resolution of the World Health Assembly, the framework is a hybrid instrument that includes contractual instruments, designated as Standard Material Transfer Agreements, and other mechanisms designed to legally bind members of WHO's Global Influenza Sharing Network and pharmaceutical companies involved in the production of vaccines.Trade-Related Aspects of Intellectual Property Agreement ::: The World Trade Organization ::: Examples of International Organizations and\u00a0International LawmakingThe impact of the WTO's TRIPS in impeding drug development capacity and access to medicines in developing countries has received the most public attention during the last decade.", [["Influenza", "DISEASE", 277, 286], ["TRIPS", "CHEMICAL", 556, 561], ["a hybrid instrument", "TREATMENT", 95, 114], ["contractual instruments", "TREATMENT", 129, 152], ["the production of vaccines", "TREATMENT", 344, 370], ["the WTO's TRIPS", "TREATMENT", 546, 561], ["medicines", "TREATMENT", 614, 623]]], ["As discussed above in the \u2018Health and Human Rights\u2019 section, the concern about TRIPS has arisen particularly in the context of global access to HIV/AIDS antiretrovirals in poor nations.", [["HIV/AIDS", "DISEASE", 144, 152], ["Human", "ORGANISM", 38, 43], ["TRIPS", "CANCER", 79, 84], ["HIV", "ORGANISM", 144, 147], ["Human", "SPECIES", 38, 43], ["HIV", "SPECIES", 144, 147], ["HIV/AIDS antiretrovirals", "TREATMENT", 144, 168]]], ["It is estimated that the vast majority of the world's population of 36 million people living with HIV live in low- and middle-income countries, particularly in sub-Saharan Africa.", [["HIV", "DISEASE", 98, 101], ["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85], ["HIV", "SPECIES", 98, 101], ["HIV", "SPECIES", 98, 101]]], ["Despite important accomplishments over the last decade, according to UNAIDS as of 2013, only one in three persons with HIV/AIDS in sub-Saharan Africa who was eligible for treatment under WHO guidelines had access to prevention, care, or treatment with life-saving antiretrovirals.Trade-Related Aspects of Intellectual Property Agreement ::: The World Trade Organization ::: Examples of International Organizations and\u00a0International LawmakingThe 1994 TRIPS Agreement brought intellectual property rights under one common set of international rules for the first time and established minimum levels of protection that all members of the WTO must accord to the intellectual property of fellow members.", [["HIV/AIDS", "DISEASE", 119, 127], ["persons", "ORGANISM", 106, 113], ["persons", "SPECIES", 106, 113], ["HIV", "SPECIES", 119, 122], ["HIV", "SPECIES", 119, 122], ["HIV/AIDS", "PROBLEM", 119, 127], ["treatment", "TREATMENT", 171, 180], ["care", "TREATMENT", 228, 232], ["treatment", "TREATMENT", 237, 246], ["life", "TREATMENT", 252, 256], ["antiretrovirals", "TREATMENT", 264, 279], ["protection", "TREATMENT", 600, 610]]], ["According to the WTO, TRIPS attempts to balance long-term social objectives of providing incentives for future inventions with short-term access to such inventions.", [["future inventions", "TREATMENT", 104, 121], ["short-term access", "TREATMENT", 127, 144]]], ["By 2005, all member states of the WTO, except for the poorest, were required to be TRIPS compliant.Trade-Related Aspects of Intellectual Property Agreement ::: The World Trade Organization ::: Examples of International Organizations and\u00a0International LawmakingThe most significant aspect of TRIPS, for public health purposes, is that it strengthened international protection of pharmaceutical patents.", [["pharmaceutical patents", "OBSERVATION", 378, 400]]], ["Prior to TRIPS, most developing countries did not recognize patents on pharmaceuticals in order to promote widespread and cost-effective access to medicines through generic competition and to strengthen the development of the local pharmaceutical industry.", [["pharmaceuticals", "TREATMENT", 71, 86], ["medicines", "TREATMENT", 147, 156]]], ["TRIPS requires patent protection of pharmaceuticals for 20 years.", [["patent protection of pharmaceuticals", "TREATMENT", 15, 51], ["patent", "OBSERVATION", 15, 21]]], ["The patent monopolies established by TRIPS are a significant concern to many countries because such monopolies tend to increase the price of medicines and restrict generic competition.Trade-Related Aspects of Intellectual Property Agreement ::: The World Trade Organization ::: Examples of International Organizations and\u00a0International LawmakingThe TRIPS Agreement contains a wide range of safeguards that can be used to protect public health at the national level, including the possibility of overriding patents through compulsory licensing or parallel imports.", [["The patent monopolies", "TREATMENT", 0, 21], ["medicines", "TREATMENT", 141, 150], ["a wide range of safeguards", "TREATMENT", 374, 400], ["patent", "OBSERVATION", 4, 10]]], ["A large part of the concern was settled in November 2001 in the Declaration on the TRIPS Agreement and Public Health, the so-called Doha Declaration, discussed above, in which WTO members reaffirmed the right of states to use TRIPS flexibilities to protect public health and, in particular, promote universal access to essential medications.", [["TRIPS flexibilities", "TREATMENT", 226, 245], ["essential medications", "TREATMENT", 319, 340], ["large", "OBSERVATION_MODIFIER", 2, 7], ["right", "ANATOMY_MODIFIER", 203, 208]]], ["Although it is beyond the scope of this article to provide a detailed analysis of TRIPS, it should be noted that the Doha Declaration did not solve all of the problems associated with intellectual property protection and public health.", [["a detailed analysis", "TEST", 59, 78], ["the problems", "PROBLEM", 155, 167], ["intellectual property protection", "TREATMENT", 184, 216]]], ["Most significantly, are the \u2018TRIPS-plus\u2019 bilateral and multilateral agreements that establish intellectual property rights and obligations that are more stringent than required under TRIPS, including the recently adopted 2015 Trans-Pacific Partnership Agreement that has not entered into force at the time of this writing.Trade-Related Aspects of Intellectual Property Agreement ::: The World Trade Organization ::: Examples of International Organizations and\u00a0International LawmakingThe conflict between the imperatives of ensuring access to essential medications, particularly in the poorest countries and providing incentives to industry to develop new products through the TRIPS framework continues to dominate international public health law discourse.", [["essential medications", "TREATMENT", 542, 563], ["bilateral", "ANATOMY_MODIFIER", 41, 50]]], ["Despite the Doha Declaration and a subsequent, related WTO decision for countries that lack domestic generic capacity, few countries have instituted TRIPS flexibilities to expand access to essential medicines and many have come under pressure from industrialized countries to provide broader intellectual property protection than that required by TRIPS, particularly through the use of bilateral agreements.", [["lack domestic generic capacity", "PROBLEM", 87, 117], ["TRIPS flexibilities", "TREATMENT", 149, 168], ["essential medicines", "TREATMENT", 189, 208], ["broader intellectual property protection", "TREATMENT", 284, 324]]], ["In addition, the transition period for most developing countries to become TRIPS-compliant has recently come to an end in 2005, meaning that all new medicines are patentable in export-capable countries.", [["TRIPS", "CHEMICAL", 75, 80], ["all new medicines", "TREATMENT", 141, 158]]], ["The deadline for TRIPS-compliance has been extended several times for the poorest members, and in November 2015 the TRIPS Council agreed to an extension until 2033 for the least developed country members of the WTO allowing such members to maintain flexibility in their approach to pharmaceutical patents.Trade-Related Aspects of Intellectual Property Agreement ::: The World Trade Organization ::: Examples of International Organizations and\u00a0International LawmakingThe battle over universal access to antiretroviral therapy is symptomatic of the overall challenge of securing access to essential medicines for developing nations.", [["TRIPS", "CHEMICAL", 17, 22], ["International Lawmaking", "TREATMENT", 443, 466], ["universal access", "TREATMENT", 482, 498], ["antiretroviral therapy", "TREATMENT", 502, 524], ["symptomatic", "PROBLEM", 528, 539], ["essential medicines", "TREATMENT", 587, 606]]], ["One-third of the world's population lacks access to basic medicines.", [["basic medicines", "TREATMENT", 52, 67]]], ["The introduction of patent protection for drugs has made efforts to promote universal access more difficult by raising prices and reducing access.", [["patent protection", "TREATMENT", 20, 37], ["drugs", "TREATMENT", 42, 47], ["universal access", "TREATMENT", 76, 92], ["reducing access", "TREATMENT", 130, 145], ["patent", "OBSERVATION", 20, 26]]], ["Moreover, it is estimated that, between 2000 and 2011, only 4% of new drugs or vaccines developed were designed for neglected diseases.", [["new drugs", "TREATMENT", 66, 75], ["vaccines", "TREATMENT", 79, 87], ["neglected diseases", "PROBLEM", 116, 134]]], ["An increasingly significant related legal challenge is the issue of patent protection for repurposed medicines.", [["patent protection", "TREATMENT", 68, 85], ["repurposed medicines", "TREATMENT", 90, 110], ["increasingly", "OBSERVATION_MODIFIER", 3, 15], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["legal challenge", "OBSERVATION", 36, 51], ["patent", "OBSERVATION", 68, 74]]], ["Whether called repurposing, reusing, reprofiling, or rescuing, the process of reusing previously patented medicines is expanding as an avenue for providing cost-effective and timely access to drugs in low- and middle-income countries.", [["reusing previously patented medicines", "TREATMENT", 78, 115], ["drugs", "TREATMENT", 192, 197]]], ["Granting another patent on a known product for a newly discovered use or form adds an additional layer of exclusive rights on the same chemical entity, although only for the new use.", [["patent", "OBSERVATION", 17, 23]]], ["Opponents of patentability, such as MSF, have argued that granting such a new patent is a classic example of \u2018ever-greening\u2019 that considerably extends the period of patent protection for a known substance.", [["patent protection", "TREATMENT", 165, 182], ["new", "OBSERVATION_MODIFIER", 74, 77], ["patent", "OBSERVATION", 78, 84], ["patent", "OBSERVATION", 165, 171]]], ["Notably, TRIPS is silent on the issue of providing patents on new uses for old medicines.", [["TRIPS", "PROTEIN", 9, 14], ["old medicines", "TREATMENT", 75, 88]]], ["Debate on the issue of patentability of repurposed drugs is being taken up in other national and international venues, and there is no commonly accepted international legal practice.", [["repurposed drugs", "TREATMENT", 40, 56]]], ["However, the Trans-Pacific Partnership Agreement, which was adopted in 2015 by 12 states and has been designed as a platform agreement for other states to join, explicitly requires patentability for new uses, new forms, and new methods of use subject to some exceptions.Trade-Related Aspects of Intellectual Property Agreement ::: The World Trade Organization ::: Examples of International Organizations and\u00a0International LawmakingFinding the right balance between health, trade, and intellectual property policies to sustain innovation and ensure widespread access to life-saving technologies is one of the primary public policy challenges of our time.", [["right", "ANATOMY_MODIFIER", 443, 448]]], ["The failure of the international community to secure an effective mechanism under TRIPS to ensure the production and export of essential medicines to meet the health needs of developing states as well as growing recognition of the link between access to medicines and human rights has led to proposals for a radical shift in the way in which pharmaceutical research and development is undertaken, including proposals for a new research and development treaty described above.The WTO SPS and TBT Agreements ::: The World Trade Organization ::: Examples of International Organizations and\u00a0International LawmakingThe need to find an appropriate balance between free trade rules and the rights of states to implement measures to protect public health is a continuing challenge of the WTO regime.", [["TBT", "CHEMICAL", 491, 494], ["human", "ORGANISM", 268, 273], ["human", "SPECIES", 268, 273], ["human", "SPECIES", 268, 273], ["essential medicines", "TREATMENT", 127, 146], ["medicines", "TREATMENT", 254, 263], ["a radical shift", "TREATMENT", 306, 321], ["the WTO regime", "TREATMENT", 776, 790], ["failure", "OBSERVATION", 4, 11], ["radical shift", "OBSERVATION", 308, 321]]], ["WTO law includes an array of constraints on domestic measures that go beyond its basic principle of nondiscrimination.", [["domestic measures", "TREATMENT", 44, 61]]], ["In particular, the WTO codified the SPS Agreement and the TBT Agreement to address the emerging debate over the use of standards, including public health standards, in international trade.", [["TBT", "CHEMICAL", 58, 61]]], ["These agreements are designed to balance the competing demands for domestic regulatory autonomy and the global harmonization of product standards as well as prevent imposition of protectionist policies.", [["domestic regulatory autonomy", "TREATMENT", 67, 95], ["protectionist policies", "TREATMENT", 179, 201]]], ["Some critics contend that the harmonization provisions of these global agreements interfere with the sovereign authority of states to implement domestic public health standards and stop nations from taking preventive measures against health risks in the absence of scientific certainty.", [["preventive measures", "TREATMENT", 206, 225]]], ["Others favor the harmonization provisions arguing that higher and more costly safety standards in high-income states can be protectionist measures that act as barrier to access to the markets of high-income states.", [["protectionist measures", "TREATMENT", 124, 146], ["higher", "OBSERVATION_MODIFIER", 55, 61]]], ["This issue has been hotly contested, particularly in the realms of environmental health and of product standards for food safety.The WTO SPS and TBT Agreements ::: The World Trade Organization ::: Examples of International Organizations and\u00a0International LawmakingThe SPS Agreement defines SPS measures basically as all measures instituted by states to (1) protect animal or plant life or health in its territory from the spread of pests or disease; (2) protect human or animal life or health in its territory from the risk arising from the presence of an additive, contaminant, or disease-causing organism in a food, beverage, or foodstuff; (3) protect human life or health in its territory from the risk arising from a disease-causing organisms carried by an animal or plant; and (4) prevent or limit other damage in its territory from the spread of a pest.", [["TBT", "CHEMICAL", 145, 148], ["human", "ORGANISM", 462, 467], ["human", "ORGANISM", 654, 659], ["human", "SPECIES", 462, 467], ["human", "SPECIES", 654, 659], ["human", "SPECIES", 462, 467], ["human", "SPECIES", 654, 659], ["SPS measures", "TREATMENT", 290, 302], ["disease", "PROBLEM", 441, 448], ["disease", "PROBLEM", 582, 589], ["a disease", "PROBLEM", 719, 728], ["organisms", "PROBLEM", 737, 746], ["other damage in its territory", "PROBLEM", 803, 832], ["disease", "OBSERVATION", 721, 728], ["damage", "OBSERVATION", 809, 815]]], ["The SPS Agreement prohibits states from imposing measures that \u201carbitrarily or unjustifiably discriminate between Member where identical conditions prevail\u201d and authorizes WTO members to impose SPS measures to protect public health that may impact international if such measures are based upon internationally established guidelines and risk assessment procedures and scientific justification.", [["SPS measures", "TREATMENT", 194, 206], ["risk assessment procedures", "TEST", 337, 363]]], ["When existing scientific evidence is insufficient to determine risk, states are authorized under the agreement to adopt SPS measures on the basis of available information as an interim measure, but must objectively ground their assessment of risk within a reasonable period of time.The WTO SPS and TBT Agreements ::: The World Trade Organization ::: Examples of International Organizations and\u00a0International LawmakingThe WTO divided the issue of technical standards or barriers between the SPS and the TBT agreement, and the scope of these two treaties are mutually exclusive with the TBT Agreement applicable to all regulations not covered by the SPS Agreement.", [["TBT", "CHEMICAL", 298, 301], ["TBT", "CHEMICAL", 585, 588], ["SPS measures", "TREATMENT", 120, 132], ["technical standards", "TREATMENT", 446, 465], ["the TBT", "TREATMENT", 581, 588]]], ["Like the SPS Agreement, the TBT Agreement is designed to balance the policy goals of national autonomy in technical regulations and free trade by obligating states to ensure their technical regulations, including product standards, do not unreasonably restrict international trade.", [["TBT", "CHEMICAL", 28, 31]]], ["Public health and environmental health national standards have been the subject of dispute in a number of recent TBT cases, including cases involving a ban on clove cigarettes, regulations on labeling tuna as dolphin-safe and a country-of-origin labeling scheme for meat.", [["meat", "ANATOMY", 266, 270], ["TBT", "CHEMICAL", 113, 116], ["meat", "ORGANISM_SUBDIVISION", 266, 270]]], ["Most recently, Cuba and others challenged Australia's tobacco plain packaging standards under the WTO dispute resolution mechanism primarily based on allegation that the plain packaging regulation violates TBT obligations.ConclusionThis article has provided a broad overview of the rapidly expanding field of global health law.", [["TBT", "CHEMICAL", 206, 209], ["tobacco", "ORGANISM", 54, 61], ["tobacco", "SPECIES", 54, 61], ["the plain packaging regulation", "TREATMENT", 166, 196]]], ["This is an era of significant change in health policy.", [["significant", "OBSERVATION_MODIFIER", 18, 29], ["change", "OBSERVATION", 30, 36]]], ["Over the last decade and a half, public health has emerged as an issue central to virtually all areas of multilateralism, ranging from arms control to security to human rights to trade.", [["multilateralism", "DISEASE", 105, 120], ["human", "ORGANISM", 163, 168], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["all", "OBSERVATION_MODIFIER", 92, 95], ["areas", "OBSERVATION_MODIFIER", 96, 101], ["multilateralism", "OBSERVATION", 105, 120]]], ["At the same time, the global dimensions of public health are transforming traditional approaches to public health.", [["global", "OBSERVATION_MODIFIER", 22, 28], ["dimensions", "OBSERVATION_MODIFIER", 29, 39]]], ["In addition, the idea that governments have human rights responsibilities to protect and promote public health and can and should be held accountable domestically and internationally for their actions is gaining widespread acceptance.", [["human", "ORGANISM", 44, 49], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49]]], ["Through the establishment of international health commitments, states legally bind themselves to establish, implement and, at times, coordinate national health laws and national health policy.ConclusionThe effective design and management of international health law will be one of the major challenges for global health governance in this century.", [["effective", "OBSERVATION_MODIFIER", 206, 215]]], ["Recent developments in international health law and diplomacy have led to increasing calls for international lawmaking in an expanding number of areas related to public health.", [["international lawmaking", "PROBLEM", 95, 118]]], ["It is important to recognize that international law is not an appropriate policy instrument for all global health problems.", [["all global health problems", "PROBLEM", 96, 122]]], ["Given the substantial limitations of international law and the international legislative process, careful consideration should be given to the selection of global health concerns and the construction of legal regimes in future international health lawmaking enterprises.", [["legal regimes", "TREATMENT", 203, 216]]], ["It is hoped that increased attention to the impact of international law, most notably international trade law, will open up critical avenues for advancing human health.See also", [["human", "ORGANISM", 155, 160], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 155, 160], ["increased", "OBSERVATION_MODIFIER", 17, 26]]]], "f9204b33cf8c143de59154ff2c226ddfe3a14840": [["TCID50 or 10 5 TCID50, the SARS-CoV-2 infection resulted in rapid weight loss in both groups and 23 uniform lethality in the 10 5 TCID50 group.", [["infection", "DISEASE", 38, 47], ["weight loss", "DISEASE", 66, 77], ["SARS-CoV-2", "ORGANISM", 27, 37], ["SARS-CoV", "SPECIES", 27, 35], ["the SARS", "TEST", 23, 31], ["CoV", "TEST", 32, 35], ["2 infection", "PROBLEM", 36, 47], ["rapid weight loss in both groups and 23 uniform lethality", "PROBLEM", 60, 117], ["infection", "OBSERVATION", 38, 47], ["rapid", "OBSERVATION_MODIFIER", 60, 65], ["weight loss", "OBSERVATION", 66, 77], ["uniform", "OBSERVATION_MODIFIER", 100, 107], ["lethality", "OBSERVATION", 108, 117]]], ["High levels of viral RNA shedding were observed from 24 the upper and lower respiratory tract and intermittent shedding was observed from the intestinal 25 tract.", [["lower respiratory tract", "ANATOMY", 70, 93], ["intestinal 25 tract", "ANATOMY", 142, 161], ["upper", "ORGANISM_SUBDIVISION", 60, 65], ["lower", "ORGANISM_SUBDIVISION", 70, 75], ["respiratory tract", "ORGANISM_SUBDIVISION", 76, 93], ["intestinal 25 tract", "ORGANISM_SUBDIVISION", 142, 161], ["viral RNA shedding", "PROBLEM", 15, 33], ["intermittent shedding", "PROBLEM", 98, 119], ["viral RNA", "OBSERVATION", 15, 24], ["upper", "ANATOMY_MODIFIER", 60, 65], ["lower", "ANATOMY_MODIFIER", 70, 75], ["respiratory tract", "ANATOMY", 76, 93], ["intermittent", "OBSERVATION_MODIFIER", 98, 110], ["shedding", "OBSERVATION", 111, 119], ["intestinal 25 tract", "ANATOMY", 142, 161]]], ["Inoculation with SARS-CoV-2 resulted in upper and lower respiratory tract infection with 26 high infectious virus titers in nasal turbinates, trachea and lungs.", [["lower respiratory tract", "ANATOMY", 50, 73], ["nasal turbinates", "ANATOMY", 124, 140], ["trachea", "ANATOMY", 142, 149], ["lungs", "ANATOMY", 154, 159], ["SARS-CoV-2", "CHEMICAL", 17, 27], ["respiratory tract infection", "DISEASE", 56, 83], ["SARS-CoV-2", "ORGANISM", 17, 27], ["upper", "ORGANISM_SUBDIVISION", 40, 45], ["lower", "ORGANISM_SUBDIVISION", 50, 55], ["respiratory tract", "ORGANISM_SUBDIVISION", 56, 73], ["nasal turbinates", "MULTI-TISSUE_STRUCTURE", 124, 140], ["trachea", "MULTI-TISSUE_STRUCTURE", 142, 149], ["lungs", "ORGAN", 154, 159], ["SARS-CoV", "SPECIES", 17, 25], ["SARS", "PROBLEM", 17, 21], ["CoV", "TEST", 22, 25], ["upper and lower respiratory tract infection", "PROBLEM", 40, 83], ["high infectious virus titers in nasal turbinates, trachea and lungs", "PROBLEM", 92, 159], ["upper", "ANATOMY_MODIFIER", 40, 45], ["lower", "ANATOMY_MODIFIER", 50, 55], ["respiratory tract", "ANATOMY", 56, 73], ["infection", "OBSERVATION", 74, 83], ["26 high", "OBSERVATION_MODIFIER", 89, 96], ["infectious virus", "OBSERVATION", 97, 113], ["nasal turbinates", "ANATOMY", 124, 140], ["trachea", "ANATOMY", 142, 149], ["lungs", "ANATOMY", 154, 159]]], ["The observed interstitial 27 pneumonia and pulmonary pathology, with SARS-CoV-2 replication evident in pneumocytes, 28 were similar to that reported in severe cases of COVID-19.", [["interstitial", "ANATOMY", 13, 25], ["pulmonary", "ANATOMY", 43, 52], ["pneumocytes", "ANATOMY", 103, 114], ["pneumonia", "DISEASE", 29, 38], ["pulmonary", "ORGAN", 43, 52], ["pneumocytes", "CELL", 103, 114], ["pneumocytes", "CELL_TYPE", 103, 114], ["The observed interstitial 27 pneumonia", "PROBLEM", 0, 38], ["pulmonary pathology", "PROBLEM", 43, 62], ["SARS", "PROBLEM", 69, 73], ["CoV", "TEST", 74, 77], ["pneumocytes", "PROBLEM", 103, 114], ["COVID", "TEST", 168, 173], ["interstitial", "OBSERVATION_MODIFIER", 13, 25], ["27", "OBSERVATION_MODIFIER", 26, 28], ["pneumonia", "OBSERVATION", 29, 38], ["pulmonary", "ANATOMY", 43, 52], ["pathology", "OBSERVATION", 53, 62], ["pneumocytes", "ANATOMY", 103, 114], ["severe", "OBSERVATION_MODIFIER", 152, 158]]], ["SARS-CoV-2 infection resulted in 29 macrophage and lymphocyte infiltration in the lungs and upregulation of Th1 and proinflammatory 30 cytokines/chemokines.", [["macrophage", "ANATOMY", 36, 46], ["lymphocyte", "ANATOMY", 51, 61], ["lungs", "ANATOMY", 82, 87], ["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 11, 20], ["SARS-CoV-2", "ORGANISM", 0, 10], ["macrophage", "CELL", 36, 46], ["lymphocyte", "CELL", 51, 61], ["lungs", "ORGAN", 82, 87], ["Th1", "GENE_OR_GENE_PRODUCT", 108, 111], ["Th1 and proinflammatory 30 cytokines", "PROTEIN", 108, 144], ["chemokines", "PROTEIN", 145, 155], ["SARS-CoV-2", "SPECIES", 0, 10], ["SARS", "TEST", 0, 4], ["CoV-2 infection", "PROBLEM", 5, 20], ["29 macrophage", "PROBLEM", 33, 46], ["lymphocyte infiltration in the lungs", "PROBLEM", 51, 87], ["proinflammatory 30 cytokines/chemokines", "TREATMENT", 116, 155], ["infection", "OBSERVATION", 11, 20], ["29 macrophage", "OBSERVATION_MODIFIER", 33, 46], ["lymphocyte infiltration", "OBSERVATION", 51, 74], ["lungs", "ANATOMY", 82, 87], ["upregulation", "OBSERVATION_MODIFIER", 92, 104], ["Th1", "OBSERVATION_MODIFIER", 108, 111], ["proinflammatory", "OBSERVATION_MODIFIER", 116, 131]]], ["Extrapulmonary replication of SARS-CoV-2 was observed in the cerebral 31 cortex and hippocampus of several animals at 7 DPI but not at 3 DPI.", [["cerebral 31 cortex", "ANATOMY", 61, 79], ["hippocampus", "ANATOMY", 84, 95], ["SARS", "DISEASE", 30, 34], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["cerebral 31 cortex", "CANCER", 61, 79], ["hippocampus", "ORGAN", 84, 95], ["SARS-CoV", "SPECIES", 30, 38], ["SARS", "PROBLEM", 30, 34], ["CoV", "TEST", 35, 38], ["SARS", "OBSERVATION", 30, 34], ["cerebral 31 cortex", "ANATOMY", 61, 79], ["hippocampus", "ANATOMY", 84, 95]]], ["The rapid inflammatory 32 response and observed pathology bears resemblance to .", [["The rapid inflammatory 32 response", "PROBLEM", 0, 34], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["inflammatory", "OBSERVATION_MODIFIER", 10, 22], ["32 response", "OBSERVATION_MODIFIER", 23, 34]]], ["Taken together, this suggests 33 that this mouse model can be useful for studies of pathogenesis and medical countermeasure 34 development.", [["mouse", "ORGANISM", 43, 48], ["mouse", "SPECIES", 43, 48], ["mouse", "SPECIES", 43, 48], ["pathogenesis", "PROBLEM", 84, 96]]]], "24ef46ecfbe22b27e816ea4c747f1de24477ab98": [["RSV (94% swabs and 84% tissues).", [["swabs", "ANATOMY", 9, 14], ["tissues", "ANATOMY", 23, 30], ["RSV", "ORGANISM", 0, 3], ["tissues", "TISSUE", 23, 30], ["RSV", "SPECIES", 0, 3], ["RSV", "TEST", 0, 3], ["swabs", "TEST", 9, 14]]], ["Specificity was \u2265 95% for all viruses except HRV for both collection methods.", [["Specificity", "TEST", 0, 11], ["all viruses", "PROBLEM", 26, 37], ["HRV", "PROBLEM", 45, 48], ["both collection methods", "TREATMENT", 53, 76]]]], "a6188f0cc737d00575ce20486a53007188d75193": [["Severe cases of coronavirus disease 2019 (COVID-19) cannot be adequately managed with mechanical ventilation alone.", [["coronavirus disease", "DISEASE", 16, 35], ["coronavirus disease", "PROBLEM", 16, 35], ["COVID", "TEST", 42, 47], ["mechanical ventilation", "TREATMENT", 86, 108], ["coronavirus disease", "OBSERVATION", 16, 35], ["mechanical ventilation", "OBSERVATION", 86, 108]]], ["The role and outcome of extracorporeal membrane oxygenation (ECMO) in the management of COVID-19 is currently unclear.", [["extracorporeal membrane", "ANATOMY", 24, 47], ["COVID-19", "CHEMICAL", 88, 96], ["COVID-19", "CHEMICAL", 88, 96], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 24, 47], ["extracorporeal membrane oxygenation", "TREATMENT", 24, 59], ["ECMO", "TREATMENT", 61, 65], ["COVID", "TEST", 88, 93]]], ["Eight COVID-19 patients have received ECMO support in Shanghai with seven with venovenous (VV) ECMO support and one veno arterial (VA) ECMO during cardiopulmonary resuscitation.", [["veno arterial", "ANATOMY", 116, 129], ["cardiopulmonary", "ANATOMY", 147, 162], ["patients", "ORGANISM", 15, 23], ["veno arterial", "MULTI-TISSUE_STRUCTURE", 116, 129], ["patients", "SPECIES", 15, 23], ["VV", "SPECIES", 91, 93], ["ECMO support", "TREATMENT", 38, 50], ["venovenous (VV) ECMO support", "TREATMENT", 79, 107], ["one veno arterial (VA) ECMO", "TREATMENT", 112, 139], ["cardiopulmonary resuscitation", "TREATMENT", 147, 176], ["cardiopulmonary", "ANATOMY", 147, 162]]], ["As of March 25, 2020, four patients died (50% mortality), three patients (37.5%) were successfully weaned off ECMO after 22, 40, and 47 days support, respectively, but remain on mechanical ventilation.", [["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 64, 72], ["ECMO", "TREATMENT", 110, 114], ["mechanical ventilation", "TREATMENT", 178, 200], ["mechanical ventilation", "OBSERVATION", 178, 200]]], ["One patient is still on VV ECMO with mechanical ventilation.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["VV", "SPECIES", 24, 26], ["VV ECMO", "TREATMENT", 24, 31], ["mechanical ventilation", "TREATMENT", 37, 59], ["mechanical ventilation", "OBSERVATION", 37, 59]]], ["The partial pressure of oxygen/fractional of inspired oxygen ratio before ECMO initiation was between 54 and 76, and all were well below 100.", [["oxygen", "CHEMICAL", 24, 30], ["oxygen", "CHEMICAL", 54, 60], ["oxygen", "CHEMICAL", 24, 30], ["oxygen", "CHEMICAL", 54, 60], ["oxygen", "SIMPLE_CHEMICAL", 24, 30], ["oxygen", "SIMPLE_CHEMICAL", 54, 60], ["The partial pressure of oxygen", "TREATMENT", 0, 30], ["inspired oxygen ratio", "TREATMENT", 45, 66], ["partial", "OBSERVATION_MODIFIER", 4, 11], ["pressure", "OBSERVATION_MODIFIER", 12, 20], ["oxygen", "OBSERVATION_MODIFIER", 24, 30], ["fractional", "OBSERVATION_MODIFIER", 31, 41]]], ["The duration of mechanical ventilation before ECMO ranged from 4 to 21 days.", [["mechanical ventilation", "TREATMENT", 16, 38], ["ECMO", "TREATMENT", 46, 50], ["mechanical ventilation", "OBSERVATION", 16, 38]]], ["Except the one emergent VA ECMO during cardiopulmonary resuscitation, other patients were on ECMO support for between 18 and 47 days.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["cardiopulmonary resuscitation", "TREATMENT", 39, 68], ["ECMO support", "TREATMENT", 93, 105]]], ["In conclusion, ensuring effective, timely, and safe ECMO support in COVID-19 is key to improving clinical outcomes.", [["safe ECMO support", "TREATMENT", 47, 64]]], ["Extracorporeal membrane oxygenation support might be an integral part of the critical care provided for COVID-19 patients in centers with advanced ECMO expertise.", [["Extracorporeal membrane", "ANATOMY", 0, 23], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 0, 23], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["Extracorporeal membrane oxygenation support", "TREATMENT", 0, 43], ["advanced ECMO expertise", "TREATMENT", 138, 161], ["membrane oxygenation", "OBSERVATION", 15, 35]]], ["ASAIO Journal 2020; 66:475-481.Key Words: coronavirus disease 2019, extracorporeal membrane oxygenation, ChinaCoronavirus disease 2019 (COVID-19) has spread rapidly in China and many other countries since its outbreak due to its person-to-person transmission and its highly contagious nature.", [["extracorporeal membrane", "ANATOMY", 68, 91], ["coronavirus disease", "DISEASE", 42, 61], ["ChinaCoronavirus disease", "DISEASE", 105, 129], ["COVID-19", "CHEMICAL", 136, 144], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 68, 91], ["person", "SPECIES", 229, 235], ["person", "SPECIES", 239, 245], ["coronavirus disease", "PROBLEM", 42, 61], ["extracorporeal membrane oxygenation", "TREATMENT", 68, 103], ["ChinaCoronavirus disease", "PROBLEM", 105, 129], ["COVID", "TEST", 136, 141], ["coronavirus disease", "OBSERVATION", 42, 61], ["extracorporeal membrane oxygenation", "OBSERVATION", 68, 103]]], ["The majority of COVID-19 patients suffer mild symptoms and recover completely.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["COVID", "TEST", 16, 21], ["mild symptoms", "PROBLEM", 41, 54], ["mild", "OBSERVATION_MODIFIER", 41, 45], ["symptoms", "OBSERVATION", 46, 54]]], ["However, approximately 14% of cases are severe and 5% are critical with mortality estimates of 2.3%-3.83%.", [["mortality estimates", "TEST", 72, 91], ["severe", "OBSERVATION_MODIFIER", 40, 46]]], ["[1] [2] [3] The role of extracorporeal membrane oxygenation (ECMO) in the management of COVID-19 is unclear at this point.", [["extracorporeal membrane", "ANATOMY", 24, 47], ["COVID-19", "CHEMICAL", 88, 96], ["COVID-19", "CHEMICAL", 88, 96], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 24, 47], ["extracorporeal membrane oxygenation", "TREATMENT", 24, 59], ["ECMO", "TREATMENT", 61, 65], ["COVID", "TEST", 88, 93], ["extracorporeal", "ANATOMY_MODIFIER", 24, 38]]], ["It has been used in some patients with COVID-19 in China, but detailed information is unavailable.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["[4] [5] [6] [7] Extracorporeal membrane oxygenation may have a role in the management of some patients with COVID-19 who have refractory hypoxemic respiratory failure.", [["Extracorporeal membrane", "ANATOMY", 16, 39], ["respiratory", "ANATOMY", 147, 158], ["hypoxemic respiratory failure", "DISEASE", 137, 166], ["[4] [5] [6] [7", "SIMPLE_CHEMICAL", 0, 14], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["Extracorporeal membrane oxygenation", "TREATMENT", 16, 51], ["COVID", "TEST", 108, 113], ["refractory hypoxemic respiratory failure", "PROBLEM", 126, 166], ["refractory", "OBSERVATION_MODIFIER", 126, 136], ["hypoxemic", "OBSERVATION_MODIFIER", 137, 146], ["respiratory failure", "OBSERVATION", 147, 166]]], ["However, much about the virus is unknown, including the natural history, incidence of late complications, viral persistence, or the prognoses in different subsets of patients.", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["the virus", "PROBLEM", 20, 29], ["late complications", "PROBLEM", 86, 104], ["viral persistence", "PROBLEM", 106, 123], ["virus", "OBSERVATION", 24, 29], ["late", "OBSERVATION_MODIFIER", 86, 90], ["complications", "OBSERVATION", 91, 104], ["viral persistence", "OBSERVATION", 106, 123]]], ["8 The World Health Organization (WHO) guidance document includes a statement to consider referring patients with refractory hypoxemia despite lung-protective ventilation in settings with access to expertise in ECMO support.", [["lung", "ANATOMY", 142, 146], ["hypoxemia", "DISEASE", 124, 133], ["patients", "ORGANISM", 99, 107], ["lung", "ORGAN", 142, 146], ["patients", "SPECIES", 99, 107], ["refractory hypoxemia", "PROBLEM", 113, 133], ["lung-protective ventilation", "TREATMENT", 142, 169], ["ECMO support", "TREATMENT", 210, 222], ["hypoxemia", "OBSERVATION", 124, 133], ["lung", "ANATOMY", 142, 146], ["protective ventilation", "OBSERVATION", 147, 169]]], ["9 Similarly, the United States Center for Disease Control provides interim guidance (https://www.cdc.gov/coronavirus/2019-ncov/hcp/ clinical-guidance-management-patients.html) for clinical management of COVID-19 patients with and without acute respiratory distress syndrome (ARDS).", [["respiratory", "ANATOMY", 244, 255], ["acute respiratory distress syndrome", "DISEASE", 238, 273], ["ARDS", "DISEASE", 275, 279], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 212, 220], ["Disease Control", "TREATMENT", 42, 57], ["clinical management", "TREATMENT", 180, 199], ["COVID", "TEST", 203, 208], ["acute respiratory distress syndrome", "PROBLEM", 238, 273], ["ARDS", "PROBLEM", 275, 279], ["without", "UNCERTAINTY", 230, 237], ["acute", "OBSERVATION_MODIFIER", 238, 243], ["respiratory", "ANATOMY", 244, 255], ["distress", "OBSERVATION", 256, 264], ["ARDS", "OBSERVATION", 275, 279]]], ["10 Where ECMO expertise is available, ECMO should be considered according to the standard management algorithm for ARDS in supporting patients with viral lower respiratory tract infection.", [["lower respiratory tract", "ANATOMY", 154, 177], ["ARDS", "DISEASE", 115, 119], ["viral lower respiratory tract infection", "DISEASE", 148, 187], ["patients", "ORGANISM", 134, 142], ["tract", "ORGANISM_SUBDIVISION", 172, 177], ["patients", "SPECIES", 134, 142], ["ECMO", "TREATMENT", 38, 42], ["the standard management algorithm", "TEST", 77, 110], ["ARDS", "PROBLEM", 115, 119], ["viral lower respiratory tract infection", "PROBLEM", 148, 187], ["respiratory tract", "ANATOMY", 160, 177], ["infection", "OBSERVATION", 178, 187]]], ["However, there is little worldwide experience with using ECMO to support COVID-19 patients.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["ECMO", "TREATMENT", 57, 61], ["little", "OBSERVATION_MODIFIER", 18, 24], ["worldwide", "OBSERVATION_MODIFIER", 25, 34]]], ["A recent Euro Extracorporeal Life-Support Organization adult ECMO-COVID-19 patients survey verified the use of ECMO for COVID-19 in Europe: nine in England, two in German, three in Belgium, 18 in France, 10 in Spain, one in Sweden, one in Poland, one in Czech, and 14 in Italy.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["A recent Euro Extracorporeal Life", "TREATMENT", 0, 33], ["COVID", "TEST", 66, 71], ["ECMO", "TREATMENT", 111, 115], ["COVID", "TEST", 120, 125]]], ["11 As of March 22, 2020, 404 COVID-19 cases have been confirmed in Shanghai, China, because the first patient was confirmed on January 20, 2020.", [["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["COVID", "TEST", 29, 34]]], ["4 All patients were admitted to a COVID-19-designated hospital, Shanghai Public Health Clinical Center.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["Extracorporeal membrane oxygenation support has been integrated in the comprehensive COVID-19 management by multidisciplinary teams led by critical care physicians.", [["Extracorporeal membrane", "ANATOMY", 0, 23], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 0, 23], ["Extracorporeal membrane oxygenation support", "TREATMENT", 0, 43], ["membrane oxygenation", "OBSERVATION", 15, 35]]], ["We aim to share our experiences, core principles, outcomes, and pitfalls in establishing and managing ECMO in critically ill COVID-19 patients and provide guidance on this technique and the resources and expertise required from our initial experience in Shanghai, China.Extracorporeal Membrane Oxygenation for CoronavirusDisease 2019 in Shanghai, ChinaMaterials and MethodsShanghai has extensive experience in epidemic prevention and control following the H7N9 crisis in 2013.", [["critically ill", "DISEASE", 110, 124], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["ECMO", "TREATMENT", 102, 106], ["this technique", "TREATMENT", 167, 181], ["Extracorporeal Membrane Oxygenation", "TREATMENT", 270, 305], ["CoronavirusDisease", "PROBLEM", 310, 328], ["epidemic prevention", "TREATMENT", 410, 429], ["the H7N9 crisis", "PROBLEM", 452, 467], ["Membrane Oxygenation", "OBSERVATION", 285, 305]]], ["All confirmed COVID-19 patients were admitted to negative pressure patient units at Shanghai Public Health Clinical Center and managed according to the severity of disease.Materials and MethodsTo maintain the highest quality of ECMO management, a three member ECMO team with one physician perfusionist, one critical care physician, and one pulmonologist, are available at all times to oversee ECMO management, participate in clinical evaluation and treatment, and communicate with the Shanghai COVID-19 ECMO Expert Team for guidance.", [["patients", "ORGANISM", 23, 31], ["patient", "ORGANISM", 67, 74], ["patients", "SPECIES", 23, 31], ["patient", "SPECIES", 67, 74], ["COVID", "TEST", 14, 19], ["disease", "PROBLEM", 164, 171], ["Methods", "TREATMENT", 186, 193], ["ECMO management", "TREATMENT", 228, 243], ["ECMO management", "TREATMENT", 393, 408], ["clinical evaluation", "TEST", 425, 444], ["treatment", "TREATMENT", 449, 458], ["disease", "OBSERVATION", 164, 171]]], ["A total of 12 ECMO units from Shanghai's major hospitals were enlisted to ensure the needs of critically ill COVID-19 patients, with four units stored outside the hospital as backup.", [["critically ill", "DISEASE", 94, 108], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["critically ill COVID", "TREATMENT", 94, 114]]], ["To ensure consistency and standardization among ECMO team members, the ECMO team developed the \"Shanghai ECMO Support for COVID-19 Guideline\" which was incorporated into the \"Shanghai Expert Consensus on Comprehensive Treatment of Coronavirus Disease 2019.\" 13Extracorporeal Membrane Oxygenation Environmental RequirementAll COVID-19 ECMO patients should be placed in a single negative pressure intensive care unit room.", [["Coronavirus Disease", "DISEASE", 231, 250], ["patients", "ORGANISM", 339, 347], ["patients", "SPECIES", 339, 347], ["COVID", "TREATMENT", 122, 127], ["Coronavirus Disease", "PROBLEM", 231, 250], ["13Extracorporeal Membrane Oxygenation", "TREATMENT", 258, 295], ["ECMO", "TREATMENT", 334, 338], ["Membrane Oxygenation", "OBSERVATION", 275, 295]]], ["Pipeline oxygen and air supply must be available.", [["oxygen", "CHEMICAL", 9, 15], ["oxygen", "CHEMICAL", 9, 15], ["oxygen", "SIMPLE_CHEMICAL", 9, 15], ["Pipeline oxygen", "TREATMENT", 0, 15], ["air supply", "TREATMENT", 20, 30]]], ["There should be at least two power outlets dedicated to ECMO and equipped with uninterruptible power supply (UPS), which can support ECMO at full capacity for at least 30 minutes in the case of power failure.", [["ECMO", "TREATMENT", 56, 60], ["uninterruptible power supply", "TREATMENT", 79, 107], ["ECMO", "TREATMENT", 133, 137], ["power failure", "PROBLEM", 194, 207], ["power failure", "OBSERVATION", 194, 207]]], ["Extracorporeal membrane oxygenation equipment should be plugged into the UPS and should not be shared with any other electronic devices.", [["Extracorporeal membrane", "ANATOMY", 0, 23], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 0, 23], ["Extracorporeal membrane oxygenation equipment", "TREATMENT", 0, 45], ["membrane oxygenation", "OBSERVATION", 15, 35]]], ["The ECMO water tank and monitors may share a power outlet with other equipment.Extracorporeal Membrane Oxygenation Equipment and DisposablesThe same brand ECMO machine and disposables should be utilized to ensure consistency and safety.", [["The ECMO water tank", "TREATMENT", 0, 19], ["Extracorporeal Membrane Oxygenation Equipment", "TREATMENT", 79, 124], ["The same brand ECMO machine", "TREATMENT", 140, 167], ["disposables", "TREATMENT", 172, 183], ["Membrane", "OBSERVATION", 94, 102], ["Oxygenation Equipment", "OBSERVATION", 103, 124]]], ["The number of ECMO equipment should be maintained at the current number of critically ill COVID-19 patients in the hospital + 2.", [["critically ill", "DISEASE", 75, 89], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["ECMO equipment", "TREATMENT", 14, 28], ["ECMO", "OBSERVATION", 14, 18]]], ["The number of ECMO kits and cannulas should be maintained at the current number of critically ill COVID-19 patients in the hospital + 4.", [["critically ill", "DISEASE", 83, 97], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["ECMO kits", "TREATMENT", 14, 23], ["cannulas", "TREATMENT", 28, 36], ["ECMO", "OBSERVATION", 14, 18]]], ["Activated coagulation time (ACT) cartridges should be calculated based on every 4 hours monitoring per patient and at least 1 week's supply should be available.Extracorporeal Membrane Oxygenation Equipment and DisposablesTransferred ECMO equipment from other hospitals should be tested for the air and oxygen connections before use.", [["oxygen", "CHEMICAL", 302, 308], ["oxygen", "CHEMICAL", 302, 308], ["patient", "ORGANISM", 103, 110], ["oxygen", "SIMPLE_CHEMICAL", 302, 308], ["patient", "SPECIES", 103, 110], ["Activated coagulation time (ACT) cartridges", "TREATMENT", 0, 43], ["Extracorporeal Membrane Oxygenation Equipment", "TREATMENT", 160, 205], ["ECMO equipment", "TREATMENT", 233, 247], ["the air and oxygen connections", "TREATMENT", 290, 320], ["Membrane Oxygenation", "OBSERVATION", 175, 195]]], ["The ECMO centrifugal pump should be examined to ensure that it is able to operate for at least 30 minutes after power loss.", [["The ECMO centrifugal pump", "TREATMENT", 0, 25], ["power loss", "PROBLEM", 112, 122]]], ["The ECMO cart should have a full oxygen cylinder tank with adjustable flow meters (provides continuous oxygen supply for 2 hours at 5 L/ minute).", [["oxygen", "CHEMICAL", 33, 39], ["oxygen", "CHEMICAL", 103, 109], ["oxygen", "CHEMICAL", 33, 39], ["oxygen", "CHEMICAL", 103, 109], ["oxygen", "SIMPLE_CHEMICAL", 33, 39], ["oxygen", "SIMPLE_CHEMICAL", 103, 109], ["The ECMO cart", "TREATMENT", 0, 13], ["a full oxygen cylinder tank", "TREATMENT", 26, 53], ["adjustable flow meters", "TREATMENT", 59, 81], ["continuous oxygen supply", "TREATMENT", 92, 116]]], ["Each ECMO unit should have a manual hand crank, four metal pipeline clamps, four plastic pipeline clamps, a tube of ultrasonic coupling agent, a flashlight, and pipeline straps.", [["hand", "ANATOMY", 36, 40], ["hand", "ORGANISM_SUBDIVISION", 36, 40], ["tube", "TISSUE", 108, 112], ["a manual hand crank", "TREATMENT", 27, 46], ["four metal pipeline clamps", "TREATMENT", 48, 74], ["four plastic pipeline clamps", "TREATMENT", 76, 104], ["a tube of ultrasonic coupling agent", "TREATMENT", 106, 141], ["a flashlight", "TREATMENT", 143, 155], ["pipeline straps", "TREATMENT", 161, 176]]], ["All ECMO disposables, equipment, and disinfectant kits should be placed in the ECMO cart and placed within 50 meters of ECMO patients.", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["All ECMO disposables", "TREATMENT", 0, 20], ["disinfectant kits", "TREATMENT", 37, 54], ["the ECMO cart", "TREATMENT", 75, 88], ["ECMO", "TREATMENT", 120, 124]]], ["Disposables should be replaced immediately.Extracorporeal Membrane Oxygenation Indications and TimingTo avoid organ damage by prolonged hypoxia, standard ARDS treatment should include protective lung ventilation, optimal positive end expiratory pressure, pharmaceutical paralysis, lung recruitment, and prone positioning.", [["organ", "ANATOMY", 110, 115], ["lung", "ANATOMY", 195, 199], ["lung", "ANATOMY", 281, 285], ["organ damage", "DISEASE", 110, 122], ["hypoxia", "DISEASE", 136, 143], ["ARDS", "DISEASE", 154, 158], ["paralysis", "DISEASE", 270, 279], ["organ", "ORGAN", 110, 115], ["lung", "ORGAN", 195, 199], ["lung", "ORGAN", 281, 285], ["Extracorporeal Membrane Oxygenation Indications", "TREATMENT", 43, 90], ["organ damage", "PROBLEM", 110, 122], ["prolonged hypoxia", "PROBLEM", 126, 143], ["standard ARDS treatment", "TREATMENT", 145, 168], ["protective lung ventilation", "TREATMENT", 184, 211], ["optimal positive end expiratory pressure", "TREATMENT", 213, 253], ["pharmaceutical paralysis", "TREATMENT", 255, 279], ["lung recruitment", "TREATMENT", 281, 297], ["Membrane Oxygenation", "OBSERVATION", 58, 78], ["prolonged", "OBSERVATION_MODIFIER", 126, 135], ["hypoxia", "OBSERVATION", 136, 143], ["lung", "ANATOMY", 195, 199], ["ventilation", "OBSERVATION", 200, 211], ["expiratory pressure", "OBSERVATION", 234, 253], ["paralysis", "OBSERVATION", 270, 279], ["lung", "ANATOMY", 281, 285], ["recruitment", "OBSERVATION", 286, 297]]], ["If the patient does not improve as indicated by either partial pressure of oxygen (PaO 2 )/fractional of inspired oxygen (FiO 2 ) <100 mmHg or power of hydrogen (PH) <7.25 and partial pressure of carbon dioxide >60 mmHg over 6 hours despite optimal mechanical ventilation, ECMO should be considered.", [["oxygen", "CHEMICAL", 75, 81], ["oxygen", "CHEMICAL", 114, 120], ["hydrogen", "CHEMICAL", 152, 160], ["carbon dioxide", "CHEMICAL", 196, 210], ["oxygen", "CHEMICAL", 75, 81], ["PaO 2", "CHEMICAL", 83, 88], ["oxygen", "CHEMICAL", 114, 120], ["FiO 2", "CHEMICAL", 122, 127], ["hydrogen", "CHEMICAL", 152, 160], ["carbon dioxide", "CHEMICAL", 196, 210], ["patient", "ORGANISM", 7, 14], ["oxygen", "SIMPLE_CHEMICAL", 75, 81], ["oxygen", "SIMPLE_CHEMICAL", 114, 120], ["hydrogen", "SIMPLE_CHEMICAL", 152, 160], ["carbon dioxide", "SIMPLE_CHEMICAL", 196, 210], ["patient", "SPECIES", 7, 14], ["partial pressure of oxygen (PaO", "TREATMENT", 55, 86], ["inspired oxygen (FiO", "TREATMENT", 105, 125], ["hydrogen (PH)", "TEST", 152, 165], ["carbon dioxide", "TEST", 196, 210], ["optimal mechanical ventilation", "TREATMENT", 241, 271], ["ECMO", "TREATMENT", 273, 277], ["mechanical ventilation", "OBSERVATION", 249, 271]]], ["Because some severe COVID-19 patients progress very quickly, ECMO should be immediately established if any of the following criteria are met after failure of aggressive ventilation management and worsening clinical condition: 1) PaO 2 /FiO 2 <50 mmHg for more than 1 hour.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["some severe COVID", "PROBLEM", 8, 25], ["ECMO", "TREATMENT", 61, 65], ["aggressive ventilation management", "TREATMENT", 158, 191], ["PaO", "TEST", 229, 232], ["FiO", "TEST", 236, 239], ["severe", "OBSERVATION_MODIFIER", 13, 19]]], ["2) PaO 2 /FiO 2 <80 mmHg for more than 2 hours, and 3) existence of uncompensated respiratory acidosis with PH <7.2 for more than 1 hour.Infection Control in Extracorporeal Membrane Oxygenation ManagementDuring ECMO cannulation, replacement of oxygenators, and other invasive procedures, level 3 infection control precautions should be exercised including the use of Powered Air-Purifying Respirators (PAPR), protective suites, disposable sterile surgical gowns, and three layers of sterile gloves.", [["respiratory", "ANATOMY", 82, 93], ["respiratory acidosis", "DISEASE", 82, 102], ["infection", "DISEASE", 296, 305], ["PaO", "TEST", 3, 6], ["FiO", "TEST", 10, 13], ["uncompensated respiratory acidosis", "PROBLEM", 68, 102], ["PH", "TEST", 108, 110], ["Infection Control", "TREATMENT", 137, 154], ["Extracorporeal Membrane Oxygenation", "TREATMENT", 158, 193], ["ECMO cannulation", "TREATMENT", 211, 227], ["replacement of oxygenators", "TREATMENT", 229, 255], ["other invasive procedures", "TREATMENT", 261, 286], ["level 3 infection control precautions", "TREATMENT", 288, 325], ["Powered Air-", "TREATMENT", 367, 379], ["protective suites", "TREATMENT", 409, 426], ["disposable sterile surgical gowns", "TREATMENT", 428, 461], ["sterile gloves", "TREATMENT", 483, 497], ["uncompensated", "OBSERVATION_MODIFIER", 68, 81], ["respiratory acidosis", "OBSERVATION", 82, 102], ["Extracorporeal Membrane", "OBSERVATION", 158, 181], ["oxygenators", "OBSERVATION_MODIFIER", 244, 255], ["surgical gowns", "OBSERVATION", 447, 461]]], ["During routine ECMO rounding, invasive procedures and airway exposure should be avoided.", [["airway", "ANATOMY", 54, 60], ["airway", "MULTI-TISSUE_STRUCTURE", 54, 60], ["routine ECMO rounding", "TREATMENT", 7, 28], ["invasive procedures", "TREATMENT", 30, 49], ["airway exposure", "TREATMENT", 54, 69], ["airway", "ANATOMY", 54, 60]]], ["Routine ECMO rounding generally does not require PAPR usage.Extracorporeal Membrane Oxygenation EstablishmentExcept for emergency veno arterial (VA) ECMO cannulation during cardiopulmonary resuscitation, all patients should be placed on venovenous (VV) ECMO for the purpose of correcting hypoxia.", [["veno arterial", "ANATOMY", 130, 143], ["cardiopulmonary", "ANATOMY", 173, 188], ["hypoxia", "DISEASE", 288, 295], ["veno arterial", "MULTI-TISSUE_STRUCTURE", 130, 143], ["patients", "ORGANISM", 208, 216], ["PAPR", "PROTEIN", 49, 53], ["patients", "SPECIES", 208, 216], ["VV", "SPECIES", 249, 251], ["Routine ECMO rounding", "TREATMENT", 0, 21], ["PAPR usage", "TREATMENT", 49, 59], ["Extracorporeal Membrane Oxygenation", "TREATMENT", 60, 95], ["emergency veno arterial (VA) ECMO cannulation", "TREATMENT", 120, 165], ["cardiopulmonary resuscitation", "TREATMENT", 173, 202], ["venovenous (VV) ECMO", "TREATMENT", 237, 257], ["correcting hypoxia", "PROBLEM", 277, 295], ["ECMO", "OBSERVATION", 8, 12], ["Membrane Oxygenation", "OBSERVATION", 75, 95], ["hypoxia", "OBSERVATION", 288, 295]]], ["Before instituting VV ECMO, hemodynamics should be evaluated with point-of-care ultrasound and treated with positive inotropes and vasopressors to maintain hemodynamic stability.", [["VV", "SPECIES", 19, 21], ["VV ECMO", "TREATMENT", 19, 26], ["ultrasound", "TEST", 80, 90], ["positive inotropes", "TREATMENT", 108, 126], ["vasopressors", "TREATMENT", 131, 143], ["hemodynamic stability", "OBSERVATION", 156, 177]]], ["The internal jugular vein should be cannulated with a 17Fr arterial cannula, and the femoral vein should be accessed with a 21Fr venous cannula under real-time ultrasound guidance with the Seldinger technique.", [["internal jugular vein", "ANATOMY", 4, 25], ["arterial", "ANATOMY", 59, 67], ["femoral vein", "ANATOMY", 85, 97], ["venous", "ANATOMY", 129, 135], ["internal jugular vein", "MULTI-TISSUE_STRUCTURE", 4, 25], ["arterial cannula", "MULTI-TISSUE_STRUCTURE", 59, 75], ["femoral vein", "MULTI-TISSUE_STRUCTURE", 85, 97], ["venous cannula", "MULTI-TISSUE_STRUCTURE", 129, 143], ["a 17Fr arterial cannula", "TREATMENT", 52, 75], ["the femoral vein", "TREATMENT", 81, 97], ["a 21Fr venous cannula", "TREATMENT", 122, 143], ["the Seldinger technique", "TREATMENT", 185, 208], ["internal jugular vein", "ANATOMY", 4, 25], ["cannulated", "OBSERVATION", 36, 46], ["arterial cannula", "OBSERVATION", 59, 75], ["femoral vein", "ANATOMY", 85, 97]]], ["The tip of the internal jugular vein cannula (Perfusion Cannula; Maquet Cardiopulmonary GmbH, Antalya, Turkey) should be positioned at the junction between right atrium and superior vena cava.", [["internal jugular vein", "ANATOMY", 15, 36], ["right atrium", "ANATOMY", 156, 168], ["superior vena cava", "ANATOMY", 173, 191], ["internal jugular vein", "MULTI-TISSUE_STRUCTURE", 15, 36], ["right atrium", "MULTI-TISSUE_STRUCTURE", 156, 168], ["superior vena cava", "MULTI-TISSUE_STRUCTURE", 173, 191], ["the internal jugular vein cannula (Perfusion Cannula", "TREATMENT", 11, 63], ["Maquet Cardiopulmonary GmbH, Antalya, Turkey)", "TREATMENT", 65, 110], ["tip", "OBSERVATION_MODIFIER", 4, 7], ["internal jugular vein", "ANATOMY", 15, 36], ["cannula", "ANATOMY_MODIFIER", 37, 44], ["Perfusion Cannula", "OBSERVATION", 46, 63], ["right atrium", "ANATOMY", 156, 168], ["superior vena cava", "ANATOMY", 173, 191]]], ["The tip of the femoral vein cannula (Drainage Cannula; Maquet Cardiopulmonary GmbH, Antalya, Turkey) should be advanced into the right atrium approximately 1 cm beyond the inferior vena cava junction and avoid cannula tip contacting the interatrial septum using echocardiographic guidance.Extracorporeal Membrane Oxygenation EstablishmentThe ECMO circuit is prefilled with crystalloid, and the oxygen saturation probe should be routinely placed on the drainage and perfusion cannulas.", [["femoral vein", "ANATOMY", 15, 27], ["right atrium", "ANATOMY", 129, 141], ["inferior vena cava junction", "ANATOMY", 172, 199], ["cannula", "ANATOMY", 210, 217], ["interatrial septum", "ANATOMY", 237, 255], ["oxygen", "CHEMICAL", 394, 400], ["oxygen", "CHEMICAL", 394, 400], ["femoral vein", "MULTI-TISSUE_STRUCTURE", 15, 27], ["right atrium", "MULTI-TISSUE_STRUCTURE", 129, 141], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 172, 190], ["interatrial septum", "MULTI-TISSUE_STRUCTURE", 237, 255], ["oxygen", "SIMPLE_CHEMICAL", 394, 400], ["the femoral vein cannula (Drainage Cannula", "TREATMENT", 11, 53], ["Maquet Cardiopulmonary GmbH, Antalya, Turkey)", "TREATMENT", 55, 100], ["cannula tip", "TREATMENT", 210, 221], ["echocardiographic guidance", "TEST", 262, 288], ["Extracorporeal Membrane Oxygenation", "TREATMENT", 289, 324], ["The ECMO circuit", "TREATMENT", 338, 354], ["crystalloid", "TREATMENT", 373, 384], ["the oxygen saturation probe", "TREATMENT", 390, 417], ["the drainage", "TREATMENT", 448, 460], ["perfusion cannulas", "TREATMENT", 465, 483], ["tip", "OBSERVATION_MODIFIER", 4, 7], ["femoral vein", "ANATOMY", 15, 27], ["cannula", "ANATOMY_MODIFIER", 28, 35], ["Drainage Cannula", "OBSERVATION", 37, 53], ["right atrium", "ANATOMY", 129, 141], ["1 cm", "OBSERVATION", 156, 160], ["inferior vena cava", "ANATOMY", 172, 190], ["junction", "ANATOMY_MODIFIER", 191, 199], ["cannula tip", "OBSERVATION", 210, 221], ["interatrial septum", "ANATOMY", 237, 255], ["Membrane Oxygenation", "OBSERVATION", 304, 324], ["ECMO circuit", "OBSERVATION", 342, 354], ["drainage", "OBSERVATION", 452, 460]]], ["FiO 2 is initially set to 100%.", [["FiO", "TEST", 0, 3]]], ["Extracorporeal membrane oxygenation (Maquet Cardiopulmonary GmbH, Rastatt, Germany) starts from 1 L/minute blood flow and increases 1 L/minute every 30 seconds until the maximum flow is achieved.", [["Extracorporeal membrane", "ANATOMY", 0, 23], ["blood", "ANATOMY", 107, 112], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["Extracorporeal membrane oxygenation", "TREATMENT", 0, 35], ["blood flow", "TEST", 107, 117], ["the maximum flow", "TEST", 166, 182], ["membrane oxygenation", "OBSERVATION", 15, 35]]], ["Peripheral pulse oxygen saturation and mixed venous oxygen saturation are monitored.", [["Peripheral", "ANATOMY", 0, 10], ["venous", "ANATOMY", 45, 51], ["oxygen", "CHEMICAL", 17, 23], ["oxygen", "CHEMICAL", 52, 58], ["oxygen", "CHEMICAL", 17, 23], ["oxygen", "CHEMICAL", 52, 58], ["oxygen", "SIMPLE_CHEMICAL", 17, 23], ["venous", "MULTI-TISSUE_STRUCTURE", 45, 51], ["oxygen", "SIMPLE_CHEMICAL", 52, 58], ["Peripheral pulse oxygen saturation", "TEST", 0, 34], ["mixed venous oxygen saturation", "TEST", 39, 69], ["pulse", "OBSERVATION_MODIFIER", 11, 16], ["oxygen saturation", "OBSERVATION", 17, 34], ["mixed", "OBSERVATION_MODIFIER", 39, 44], ["venous", "ANATOMY", 45, 51], ["oxygen saturation", "OBSERVATION", 52, 69]]], ["Cannulas are secured after verification by echocardiography and surface markers are identified.", [["surface", "ANATOMY", 64, 71], ["Cannulas", "TREATMENT", 0, 8], ["echocardiography", "TEST", 43, 59], ["surface markers", "TEST", 64, 79]]], ["Then the ECMO flow and sweep rate should be adjusted to maintain peripheral capillary oxygen saturation >90% and mixed venous oxygen saturation >70%.", [["peripheral capillary", "ANATOMY", 65, 85], ["venous", "ANATOMY", 119, 125], ["oxygen", "CHEMICAL", 86, 92], ["oxygen", "CHEMICAL", 126, 132], ["oxygen", "CHEMICAL", 86, 92], ["oxygen", "CHEMICAL", 126, 132], ["peripheral capillary", "TISSUE", 65, 85], ["oxygen", "SIMPLE_CHEMICAL", 86, 92], ["venous", "MULTI-TISSUE_STRUCTURE", 119, 125], ["oxygen", "SIMPLE_CHEMICAL", 126, 132], ["the ECMO flow", "TREATMENT", 5, 18], ["sweep rate", "TEST", 23, 33], ["peripheral capillary oxygen saturation", "TEST", 65, 103], ["mixed venous oxygen saturation", "TEST", 113, 143], ["peripheral", "ANATOMY_MODIFIER", 65, 75], ["capillary", "ANATOMY_MODIFIER", 76, 85], ["venous", "ANATOMY", 119, 125]]], ["If ECMO flow is inadequate and cannula position seems appropriate per echocardiography imaging, volume should be given ( figure 1) .Extracorporeal Membrane Oxygenation Management GoalThe patient's hemoglobin level should be maintained above 11 g/dl throughout the ECMO support.", [["patient", "ORGANISM", 187, 194], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 197, 207], ["hemoglobin", "PROTEIN", 197, 207], ["patient", "SPECIES", 187, 194], ["ECMO flow", "TEST", 3, 12], ["cannula position", "TREATMENT", 31, 47], ["echocardiography imaging", "TEST", 70, 94], ["volume", "TREATMENT", 96, 102], ["Extracorporeal Membrane Oxygenation Management", "TREATMENT", 132, 178], ["The patient's hemoglobin level", "TEST", 183, 213], ["the ECMO support", "TREATMENT", 260, 276], ["Membrane Oxygenation", "OBSERVATION", 147, 167]]], ["Indices including peripheral arterial oxygenation, ECMO premembrane oxygenation, postmembrane oxygenation, percutaneous oxygenation, and mixed venous oxygenation should be used to determine the patient's oxygen supply and demand balance.", [["peripheral arterial", "ANATOMY", 18, 37], ["premembrane", "ANATOMY", 56, 67], ["postmembrane", "ANATOMY", 81, 93], ["percutaneous", "ANATOMY", 107, 119], ["venous", "ANATOMY", 143, 149], ["oxygen", "CHEMICAL", 204, 210], ["oxygen", "CHEMICAL", 204, 210], ["peripheral arterial", "MULTI-TISSUE_STRUCTURE", 18, 37], ["venous", "MULTI-TISSUE_STRUCTURE", 143, 149], ["patient", "ORGANISM", 194, 201], ["oxygen", "SIMPLE_CHEMICAL", 204, 210], ["patient", "SPECIES", 194, 201], ["Indices", "TEST", 0, 7], ["peripheral arterial oxygenation", "TEST", 18, 49], ["ECMO premembrane oxygenation", "TREATMENT", 51, 79], ["postmembrane oxygenation", "TREATMENT", 81, 105], ["percutaneous oxygenation", "TREATMENT", 107, 131], ["mixed venous oxygenation", "TREATMENT", 137, 161], ["the patient's oxygen supply", "TREATMENT", 190, 217], ["peripheral", "ANATOMY_MODIFIER", 18, 28], ["arterial", "ANATOMY", 29, 37], ["oxygenation", "OBSERVATION_MODIFIER", 38, 49], ["oxygenation", "OBSERVATION_MODIFIER", 94, 105], ["percutaneous oxygenation", "OBSERVATION", 107, 131], ["venous", "ANATOMY", 143, 149], ["oxygenation", "OBSERVATION", 150, 161]]], ["Gastrointestinal dysfunction and increased abdominal pressure in COVID-19 patients may directly affect ECMO flow and cause instability.Extracorporeal Membrane Oxygenation Anticoagulation ManagementExtracorporeal membrane oxygenation patients should be anticoagulated using regular heparin followed by a maintenance infusion titrated between 2 and 20 unit/kg/hour to target ACT 180-200 seconds and partial thromboplastin time 50-80 seconds.", [["Gastrointestinal", "ANATOMY", 0, 16], ["abdominal", "ANATOMY", 43, 52], ["Membrane", "ANATOMY", 150, 158], ["Extracorporeal membrane", "ANATOMY", 197, 220], ["Gastrointestinal dysfunction", "DISEASE", 0, 28], ["heparin", "CHEMICAL", 281, 288], ["Gastrointestinal", "ORGAN", 0, 16], ["abdominal", "ORGANISM_SUBDIVISION", 43, 52], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 233, 241], ["heparin", "SIMPLE_CHEMICAL", 281, 288], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 405, 419], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 233, 241], ["Gastrointestinal dysfunction", "PROBLEM", 0, 28], ["increased abdominal pressure in COVID", "PROBLEM", 33, 70], ["ECMO flow", "TEST", 103, 112], ["instability", "PROBLEM", 123, 134], ["Extracorporeal Membrane Oxygenation Anticoagulation Management", "TREATMENT", 135, 197], ["Extracorporeal membrane oxygenation", "TREATMENT", 197, 232], ["regular heparin", "TREATMENT", 273, 288], ["a maintenance infusion", "TREATMENT", 301, 323], ["partial thromboplastin time", "TEST", 397, 424], ["dysfunction", "OBSERVATION", 17, 28], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["abdominal", "ANATOMY", 43, 52], ["pressure", "OBSERVATION_MODIFIER", 53, 61], ["Membrane Oxygenation", "OBSERVATION", 150, 170]]], ["If heparin resistance is suspected and antithrombin deficiency III activity is low, fresh frozen plasma should be given.", [["plasma", "ANATOMY", 97, 103], ["heparin", "CHEMICAL", 3, 10], ["heparin", "SIMPLE_CHEMICAL", 3, 10], ["antithrombin deficiency III", "GENE_OR_GENE_PRODUCT", 39, 66], ["plasma", "ORGANISM_SUBSTANCE", 97, 103], ["antithrombin", "PROTEIN", 39, 51], ["heparin resistance", "TREATMENT", 3, 21], ["antithrombin deficiency III activity", "PROBLEM", 39, 75], ["fresh frozen plasma", "TREATMENT", 84, 103], ["heparin resistance", "OBSERVATION", 3, 21], ["antithrombin deficiency", "OBSERVATION", 39, 62]]], ["In addition, heparin-induced thrombocytopenia (HIT) should be monitored and treated accordingly.", [["heparin", "CHEMICAL", 13, 20], ["thrombocytopenia", "DISEASE", 29, 45], ["HIT", "DISEASE", 47, 50], ["heparin", "SIMPLE_CHEMICAL", 13, 20], ["heparin", "TREATMENT", 13, 20], ["induced thrombocytopenia", "PROBLEM", 21, 45], ["HIT", "TEST", 47, 50], ["thrombocytopenia", "OBSERVATION", 29, 45]]], ["When there is significant thrombosis on the ECMO oxygenator, increase in fibrinolysis (D dimer > 10 \u00b5g/ml), decrease in fibrinogen (FIB < 1.5 g/L), and thromboelastogram (TEG) signs of hyperfibrinolysis, the ECMO circuit should be replaced.", [["thrombosis", "DISEASE", 26, 36], ["hyperfibrinolysis", "DISEASE", 185, 202], ["D dimer", "GENE_OR_GENE_PRODUCT", 87, 94], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 120, 130], ["fibrinogen", "PROTEIN", 120, 130], ["FIB", "PROTEIN", 132, 135], ["significant thrombosis", "PROBLEM", 14, 36], ["the ECMO oxygenator", "TREATMENT", 40, 59], ["fibrinolysis (D dimer", "TEST", 73, 94], ["fibrinogen", "TEST", 120, 130], ["FIB", "TEST", 132, 135], ["thromboelastogram", "TEST", 152, 169], ["TEG", "TEST", 171, 174], ["hyperfibrinolysis", "PROBLEM", 185, 202], ["the ECMO circuit", "TREATMENT", 204, 220], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["thrombosis", "OBSERVATION", 26, 36], ["ECMO oxygenator", "OBSERVATION", 44, 59], ["increase", "OBSERVATION_MODIFIER", 61, 69], ["fibrinolysis", "OBSERVATION", 73, 85], ["decrease", "OBSERVATION_MODIFIER", 108, 116], ["hyperfibrinolysis", "OBSERVATION", 185, 202]]], ["In addition, tranexamic acid should be started (10-20 mg/kg over 3 hours followed by a 1,000 mg, 1-2 mg/kg/hour daily infusion for 2-3 days) and FIB replaced at 1-2 g/days until FIB >1.5 g/L. If there is significant bleeding or need of invasive procedures, heparin may be reduced or suspended for a maximum period of 24 hours.Point-of-Care Ultrasound During Extracorporeal Membrane OxygenationPoint-of-care ultrasound should be performed daily.", [["tranexamic acid", "CHEMICAL", 13, 28], ["bleeding", "DISEASE", 216, 224], ["heparin", "CHEMICAL", 257, 264], ["tranexamic acid", "CHEMICAL", 13, 28], ["tranexamic acid", "SIMPLE_CHEMICAL", 13, 28], ["heparin", "SIMPLE_CHEMICAL", 257, 264], ["tranexamic acid", "TREATMENT", 13, 28], ["FIB", "TREATMENT", 145, 148], ["FIB", "TREATMENT", 178, 181], ["significant bleeding", "PROBLEM", 204, 224], ["invasive procedures", "TREATMENT", 236, 255], ["heparin", "TREATMENT", 257, 264], ["Ultrasound", "TEST", 340, 350], ["Extracorporeal Membrane", "TREATMENT", 358, 381], ["ultrasound", "TEST", 407, 417], ["significant", "OBSERVATION_MODIFIER", 204, 215], ["bleeding", "OBSERVATION", 216, 224]]], ["Ultrasonography of the lungs, heart, abdomen, and vasculature is extremely valuable in this patient population for a multitude of purposes.", [["lungs", "ANATOMY", 23, 28], ["heart", "ANATOMY", 30, 35], ["abdomen", "ANATOMY", 37, 44], ["vasculature", "ANATOMY", 50, 61], ["lungs", "ORGAN", 23, 28], ["heart", "ORGAN", 30, 35], ["abdomen", "ORGAN", 37, 44], ["vasculature", "MULTI-TISSUE_STRUCTURE", 50, 61], ["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99], ["Ultrasonography of the lungs, heart, abdomen", "TEST", 0, 44], ["lungs", "ANATOMY", 23, 28], ["heart", "ANATOMY", 30, 35], ["abdomen", "ANATOMY", 37, 44], ["vasculature", "ANATOMY", 50, 61]]], ["Lung ultrasound is used to assess indicators of pneumothorax, pleural effusion, lung consolidation, and interstitial changes.", [["Lung", "ANATOMY", 0, 4], ["pleural", "ANATOMY", 62, 69], ["lung", "ANATOMY", 80, 84], ["interstitial", "ANATOMY", 104, 116], ["pneumothorax", "DISEASE", 48, 60], ["pleural effusion", "DISEASE", 62, 78], ["Lung", "ORGAN", 0, 4], ["pleural", "PATHOLOGICAL_FORMATION", 62, 69], ["lung", "ORGAN", 80, 84], ["Lung ultrasound", "TEST", 0, 15], ["pneumothorax", "PROBLEM", 48, 60], ["pleural effusion", "PROBLEM", 62, 78], ["lung consolidation", "PROBLEM", 80, 98], ["interstitial changes", "PROBLEM", 104, 124], ["pneumothorax", "OBSERVATION", 48, 60], ["pleural", "ANATOMY", 62, 69], ["effusion", "OBSERVATION", 70, 78], ["lung", "ANATOMY", 80, 84], ["consolidation", "OBSERVATION", 85, 98], ["interstitial", "ANATOMY_MODIFIER", 104, 116]]], ["Cardiac ultrasound is used to evaluate ejection fraction, pulmonary artery pressure, chamber size, right ventricular/left ventricular function, pericardial effusion, and inferior vena cava diameter.", [["Cardiac", "ANATOMY", 0, 7], ["pulmonary artery", "ANATOMY", 58, 74], ["right ventricular", "ANATOMY", 99, 116], ["left ventricular", "ANATOMY", 117, 133], ["pericardial", "ANATOMY", 144, 155], ["inferior vena cava", "ANATOMY", 170, 188], ["pericardial effusion", "DISEASE", 144, 164], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 58, 74], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 99, 116], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 117, 133], ["pericardial", "ORGAN", 144, 155], ["inferior", "MULTI-TISSUE_STRUCTURE", 170, 178], ["vena cava", "MULTI-TISSUE_STRUCTURE", 179, 188], ["Cardiac ultrasound", "TEST", 0, 18], ["ejection fraction", "TEST", 39, 56], ["pulmonary artery pressure", "TEST", 58, 83], ["right ventricular/left ventricular function", "TEST", 99, 142], ["pericardial effusion", "PROBLEM", 144, 164], ["pulmonary artery", "ANATOMY", 58, 74], ["pressure", "OBSERVATION_MODIFIER", 75, 83], ["chamber", "OBSERVATION_MODIFIER", 85, 92], ["size", "OBSERVATION_MODIFIER", 93, 97], ["right ventricular", "ANATOMY", 99, 116], ["left ventricular", "ANATOMY", 117, 133], ["pericardial", "ANATOMY", 144, 155], ["effusion", "OBSERVATION", 156, 164], ["inferior vena cava", "ANATOMY", 170, 188], ["diameter", "OBSERVATION_MODIFIER", 189, 197]]], ["Abdominal ultrasound can help assess bowel peristalsis as well as obstruction, and vascular ultrasound can detect deep venous thrombosis.Protective Lung Ventilation on Extracorporeal Membrane OxygenationThe main purpose of mechanical ventilation on ECMO is to protect the lungs and avoid damage to the right heart.", [["Abdominal", "ANATOMY", 0, 9], ["bowel", "ANATOMY", 37, 42], ["vascular", "ANATOMY", 83, 91], ["venous", "ANATOMY", 119, 125], ["Lung", "ANATOMY", 148, 152], ["lungs", "ANATOMY", 272, 277], ["right heart", "ANATOMY", 302, 313], ["obstruction", "DISEASE", 66, 77], ["venous thrombosis", "DISEASE", 119, 136], ["damage to the right heart", "DISEASE", 288, 313], ["bowel", "ORGAN", 37, 42], ["vascular", "MULTI-TISSUE_STRUCTURE", 83, 91], ["venous thrombosis", "PATHOLOGICAL_FORMATION", 119, 136], ["Lung", "ORGAN", 148, 152], ["lungs", "ORGAN", 272, 277], ["heart", "ORGAN", 308, 313], ["Abdominal ultrasound", "TEST", 0, 20], ["bowel peristalsis", "PROBLEM", 37, 54], ["obstruction", "PROBLEM", 66, 77], ["vascular ultrasound", "TEST", 83, 102], ["deep venous thrombosis", "PROBLEM", 114, 136], ["Protective Lung Ventilation", "TREATMENT", 137, 164], ["Extracorporeal Membrane Oxygenation", "TREATMENT", 168, 203], ["mechanical ventilation", "TREATMENT", 223, 245], ["ECMO", "TREATMENT", 249, 253], ["damage to the right heart", "PROBLEM", 288, 313], ["bowel", "ANATOMY", 37, 42], ["peristalsis", "OBSERVATION", 43, 54], ["obstruction", "OBSERVATION", 66, 77], ["vascular", "ANATOMY", 83, 91], ["deep", "ANATOMY_MODIFIER", 114, 118], ["venous", "ANATOMY", 119, 125], ["thrombosis", "OBSERVATION", 126, 136], ["Lung", "ANATOMY", 148, 152], ["Ventilation", "OBSERVATION", 153, 164], ["Extracorporeal Membrane", "OBSERVATION", 168, 191], ["Oxygenation", "OBSERVATION_MODIFIER", 192, 203], ["main", "OBSERVATION_MODIFIER", 207, 211], ["mechanical ventilation", "OBSERVATION", 223, 245], ["lungs", "ANATOMY", 272, 277], ["right", "ANATOMY_MODIFIER", 302, 307], ["heart", "ANATOMY", 308, 313]]], ["An aggressive strategy of protective lung ventilation sets FiO 2 <40%, tidal volume (Vt) 2-4 ml/kg (ideal body weight), plateau pressure <25 cm H 2 O, and respiratory rate (RR) 8-10 times/ minute.", [["lung", "ANATOMY", 37, 41], ["body", "ANATOMY", 106, 110], ["lung", "ORGAN", 37, 41], ["body", "ORGANISM_SUBDIVISION", 106, 110], ["protective lung ventilation", "TREATMENT", 26, 53], ["FiO", "TEST", 59, 62], ["tidal volume", "TEST", 71, 83], ["Vt", "TEST", 85, 87], ["ideal body weight", "TEST", 100, 117], ["plateau pressure", "TEST", 120, 136], ["respiratory rate", "TEST", 155, 171], ["RR", "TEST", 173, 175], ["aggressive", "OBSERVATION_MODIFIER", 3, 13], ["lung", "ANATOMY", 37, 41], ["ventilation", "OBSERVATION", 42, 53], ["respiratory", "ANATOMY", 155, 166]]], ["If the plateau pressure exceeds 25 cm H 2 O, Vt should be reduced by 1 ml/kg.", [["the plateau pressure", "TEST", 3, 23], ["Vt", "TREATMENT", 45, 47]]], ["Pressure control mechanical ventilation is the most commonly used ventilator mode before weaning ECMO.", [["Pressure control mechanical ventilation", "TREATMENT", 0, 39], ["ventilator mode", "TREATMENT", 66, 81], ["weaning ECMO", "TREATMENT", 89, 101], ["mechanical ventilation", "OBSERVATION", 17, 39]]], ["If patient's oxygenation is inadequate, ECMO malfunction should be considered before adjusting ventilator parameters.", [["patient", "ORGANISM", 3, 10], ["patient", "SPECIES", 3, 10], ["ECMO malfunction", "TREATMENT", 40, 56], ["ventilator parameters", "TEST", 95, 116]]], ["Sedation and paralysis should be considered in COVID-19 patients with anxiety and high oxygen demand status.Protective Lung Ventilation on Extracorporeal Membrane OxygenationChest computed tomography (CT) is not routinely performed as transport is considered a patient safety issue.", [["Lung", "ANATOMY", 119, 123], ["paralysis", "DISEASE", 13, 22], ["anxiety", "DISEASE", 70, 77], ["oxygen", "CHEMICAL", 87, 93], ["oxygen", "CHEMICAL", 87, 93], ["patients", "ORGANISM", 56, 64], ["oxygen", "SIMPLE_CHEMICAL", 87, 93], ["Lung", "ORGAN", 119, 123], ["patient", "ORGANISM", 261, 268], ["patients", "SPECIES", 56, 64], ["patient", "SPECIES", 261, 268], ["Sedation", "TREATMENT", 0, 8], ["paralysis", "TREATMENT", 13, 22], ["anxiety", "PROBLEM", 70, 77], ["high oxygen demand status", "PROBLEM", 82, 107], ["Protective Lung Ventilation", "TREATMENT", 108, 135], ["Extracorporeal Membrane OxygenationChest computed tomography (CT)", "TEST", 139, 204], ["Lung", "ANATOMY", 119, 123], ["Ventilation", "OBSERVATION", 124, 135]]], ["Respiratory mechanics, lung ultrasound, and electrical impedance imaging (electrical impedance tomography [EIT]) are alternative monitoring methods for lung mechanics.", [["Respiratory", "ANATOMY", 0, 11], ["lung", "ANATOMY", 23, 27], ["lung", "ANATOMY", 152, 156], ["lung", "ORGAN", 23, 27], ["lung", "ORGAN", 152, 156], ["Respiratory mechanics", "TEST", 0, 21], ["lung ultrasound", "TEST", 23, 38], ["electrical impedance imaging", "TEST", 44, 72], ["electrical impedance tomography", "TEST", 74, 105], ["alternative monitoring methods", "TREATMENT", 117, 147], ["lung mechanics", "PROBLEM", 152, 166], ["lung", "ANATOMY", 23, 27], ["lung", "ANATOMY", 152, 156], ["mechanics", "OBSERVATION", 157, 166]]], ["Hypercapnia should be initially managed by increasing the VV ECMO sweep rate.", [["Hypercapnia", "DISEASE", 0, 11], ["Hypercapnia", "PROBLEM", 0, 11], ["the VV ECMO sweep rate", "TREATMENT", 54, 76]]], ["During weaning, the RR should be adjusted accordingly, but RR should generally be less than 14.Awake Extracorporeal Membrane OxygenationCoronavirus disease 2019 patients usually develop refractory hyperthermia and other high oxygen consumption states even with effective support.", [["hyperthermia", "DISEASE", 197, 209], ["oxygen", "CHEMICAL", 225, 231], ["oxygen", "CHEMICAL", 225, 231], ["patients", "ORGANISM", 161, 169], ["oxygen", "SIMPLE_CHEMICAL", 225, 231], ["patients", "SPECIES", 161, 169], ["the RR", "TREATMENT", 16, 22], ["RR", "TEST", 59, 61], ["Extracorporeal Membrane OxygenationCoronavirus disease", "PROBLEM", 101, 155], ["refractory hyperthermia", "PROBLEM", 186, 209], ["other high oxygen consumption", "PROBLEM", 214, 243], ["effective support", "TREATMENT", 261, 278], ["refractory", "OBSERVATION_MODIFIER", 186, 196], ["hyperthermia", "OBSERVATION", 197, 209], ["high", "OBSERVATION_MODIFIER", 220, 224], ["oxygen consumption", "OBSERVATION", 225, 243]]], ["Considering the great difficulty with infection control and unstable pulmonary status in COVID-19 patients, we do not recommend ECMO support without endotracheal intubation.Continuous Renal Replacement Therapy While on Extracorporeal Membrane OxygenationIndications for continuous renal replacement therapy (CRRT) during ECMO are as follows: serum creatinine \u2265354 \u03bcmol/L; urine volume <0.3 ml/kg/hour >24 hours; refractory metabolic acidosis with PH <7.2 or HCO 3 \u2212 <15 mmol/L; severe electrolyte disturbances including K \u22656.5 mmol/L; volume overload, such as conjunctival edema, pulmonary edema, congestive heart failure, pleural, and abdominal effusion; sepsis; and multiple organ failure.", [["pulmonary", "ANATOMY", 69, 78], ["endotracheal", "ANATOMY", 149, 161], ["Renal", "ANATOMY", 184, 189], ["renal", "ANATOMY", 281, 286], ["serum", "ANATOMY", 342, 347], ["urine", "ANATOMY", 372, 377], ["conjunctival", "ANATOMY", 560, 572], ["pulmonary", "ANATOMY", 580, 589], ["heart", "ANATOMY", 608, 613], ["pleural", "ANATOMY", 623, 630], ["abdominal effusion", "ANATOMY", 636, 654], ["organ", "ANATOMY", 677, 682], ["infection", "DISEASE", 38, 47], ["creatinine", "CHEMICAL", 348, 358], ["metabolic acidosis", "DISEASE", 423, 441], ["electrolyte disturbances", "DISEASE", 485, 509], ["K", "CHEMICAL", 520, 521], ["volume overload", "DISEASE", 535, 550], ["conjunctival edema", "DISEASE", 560, 578], ["pulmonary edema", "DISEASE", 580, 595], ["congestive heart failure", "DISEASE", 597, 621], ["abdominal effusion", "DISEASE", 636, 654], ["sepsis", "DISEASE", 656, 662], ["multiple organ failure", "DISEASE", 668, 690], ["creatinine", "CHEMICAL", 348, 358], ["HCO 3 \u2212", "CHEMICAL", 458, 465], ["pulmonary", "ORGAN", 69, 78], ["patients", "ORGANISM", 98, 106], ["Renal", "ORGAN", 184, 189], ["renal", "ORGAN", 281, 286], ["serum", "ORGANISM_SUBSTANCE", 342, 347], ["creatinine", "SIMPLE_CHEMICAL", 348, 358], ["urine", "ORGANISM_SUBSTANCE", 372, 377], ["pulmonary", "ORGAN", 580, 589], ["heart", "ORGAN", 608, 613], ["pleural", "MULTI-TISSUE_STRUCTURE", 623, 630], ["abdominal", "ORGANISM_SUBDIVISION", 636, 645], ["organ", "ORGAN", 677, 682], ["patients", "SPECIES", 98, 106], ["infection control", "TREATMENT", 38, 55], ["unstable pulmonary status", "PROBLEM", 60, 85], ["ECMO support", "TREATMENT", 128, 140], ["endotracheal intubation", "TREATMENT", 149, 172], ["Continuous Renal Replacement Therapy", "TREATMENT", 173, 209], ["Extracorporeal Membrane OxygenationIndications", "TREATMENT", 219, 265], ["continuous renal replacement therapy", "TREATMENT", 270, 306], ["CRRT", "TREATMENT", 308, 312], ["ECMO", "TREATMENT", 321, 325], ["serum creatinine", "TEST", 342, 358], ["urine volume", "TEST", 372, 384], ["refractory metabolic acidosis", "PROBLEM", 412, 441], ["PH", "TEST", 447, 449], ["HCO", "TEST", 458, 461], ["severe electrolyte disturbances", "PROBLEM", 478, 509], ["K", "TEST", 520, 521], ["\u2265", "TEST", 522, 523], ["mmol/L", "TEST", 527, 533], ["volume overload", "PROBLEM", 535, 550], ["conjunctival edema", "PROBLEM", 560, 578], ["pulmonary edema", "PROBLEM", 580, 595], ["congestive heart failure", "PROBLEM", 597, 621], ["pleural, and abdominal effusion", "PROBLEM", 623, 654], ["sepsis", "PROBLEM", 656, 662], ["multiple organ failure", "PROBLEM", 668, 690], ["great", "OBSERVATION_MODIFIER", 16, 21], ["infection", "OBSERVATION", 38, 47], ["pulmonary", "ANATOMY", 69, 78], ["Renal", "ANATOMY", 184, 189], ["Replacement", "OBSERVATION", 190, 201], ["renal", "ANATOMY", 281, 286], ["replacement", "OBSERVATION", 287, 298], ["metabolic acidosis", "OBSERVATION", 423, 441], ["severe", "OBSERVATION_MODIFIER", 478, 484], ["electrolyte disturbances", "OBSERVATION", 485, 509], ["volume overload", "OBSERVATION", 535, 550], ["conjunctival", "ANATOMY", 560, 572], ["edema", "OBSERVATION", 573, 578], ["pulmonary", "ANATOMY", 580, 589], ["edema", "OBSERVATION", 590, 595], ["congestive", "OBSERVATION_MODIFIER", 597, 607], ["heart", "ANATOMY", 608, 613], ["failure", "OBSERVATION", 614, 621], ["pleural", "ANATOMY", 623, 630], ["abdominal", "ANATOMY", 636, 645], ["effusion", "OBSERVATION", 646, 654], ["sepsis", "OBSERVATION", 656, 662], ["multiple", "OBSERVATION_MODIFIER", 668, 676], ["organ", "ANATOMY", 677, 682], ["failure", "OBSERVATION", 683, 690]]], ["The above indications could be expanded depending on the severity of COVID-19, and early intervention is advocated.", [["COVID", "TEST", 69, 74]]], ["If CRRT equipment is capable of recognizing the ECMO pressure range, the CRRT access line is connected to the port on the ECMO oxygenator, and the CRRT return line is connected to the port between the pump and the oxygenator.", [["CRRT equipment", "TREATMENT", 3, 17], ["the ECMO pressure range", "TREATMENT", 44, 67], ["the CRRT access line", "TREATMENT", 69, 89], ["the ECMO oxygenator", "TREATMENT", 118, 137], ["the CRRT return line", "TREATMENT", 143, 163], ["the port", "TREATMENT", 180, 188], ["the pump", "TREATMENT", 197, 205], ["the oxygenator", "TREATMENT", 210, 224], ["ECMO oxygenator", "OBSERVATION", 122, 137], ["oxygenator", "OBSERVATION_MODIFIER", 214, 224]]], ["Two modes of CRRT are used, continuous venous to venous hemodiafiltration (CVVHDF) and continuous venous to venous hemofiltration (CVVH).", [["venous", "ANATOMY", 39, 45], ["venous", "ANATOMY", 49, 55], ["venous", "ANATOMY", 98, 104], ["venous", "ANATOMY", 108, 114], ["venous", "MULTI-TISSUE_STRUCTURE", 39, 45], ["venous", "MULTI-TISSUE_STRUCTURE", 49, 55], ["venous", "MULTI-TISSUE_STRUCTURE", 98, 104], ["venous", "MULTI-TISSUE_STRUCTURE", 108, 114], ["CRRT", "TREATMENT", 13, 17], ["continuous venous to venous hemodiafiltration", "TREATMENT", 28, 73], ["CVVHDF", "TREATMENT", 75, 81], ["continuous venous to venous hemofiltration", "TREATMENT", 87, 129], ["CVVH", "TREATMENT", 131, 135], ["venous", "ANATOMY", 39, 45], ["venous", "ANATOMY", 49, 55], ["hemodiafiltration", "OBSERVATION", 56, 73], ["venous", "ANATOMY", 98, 104], ["venous", "ANATOMY", 108, 114], ["hemofiltration", "OBSERVATION", 115, 129]]], ["To improve dialysis efficiency, CVVH is preferred.", [["dialysis efficiency", "TREATMENT", 11, 30], ["CVVH", "TREATMENT", 32, 36], ["dialysis efficiency", "OBSERVATION", 11, 30]]], ["If the patient is hypercoagulable or not on anticoagulation, CVVHDF or CVVH combined with CVVHDF could be used.", [["hypercoagulable", "DISEASE", 18, 33], ["CVVHDF", "CHEMICAL", 90, 96], ["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["hypercoagulable", "PROBLEM", 18, 33], ["anticoagulation", "TREATMENT", 44, 59], ["CVVHDF", "TREATMENT", 61, 67], ["CVVH", "TREATMENT", 71, 75], ["CVVHDF", "TREATMENT", 90, 96], ["hypercoagulable", "OBSERVATION", 18, 33]]], ["The CRRT dose is usually 28-32 ml/kg/hour for 10-12 hours.Extracorporeal Membrane Oxygenation ComplicationsMouth, nose, and throat bleeding should be controlled by decreasing anticoagulation in addition to ear nose throat consultation.", [["nose", "ANATOMY", 114, 118], ["throat", "ANATOMY", 124, 130], ["ear", "ANATOMY", 206, 209], ["bleeding", "DISEASE", 131, 139], ["nose", "ORGANISM_SUBDIVISION", 114, 118], ["throat", "ORGANISM_SUBDIVISION", 124, 130], ["ear", "ORGAN", 206, 209], ["The CRRT dose", "TREATMENT", 0, 13], ["Extracorporeal Membrane Oxygenation ComplicationsMouth, nose", "PROBLEM", 58, 118], ["throat bleeding", "PROBLEM", 124, 139], ["decreasing anticoagulation", "TREATMENT", 164, 190], ["ear nose throat consultation", "TEST", 206, 234], ["Membrane Oxygenation", "OBSERVATION", 73, 93], ["nose", "ANATOMY", 114, 118], ["throat", "ANATOMY", 124, 130], ["bleeding", "OBSERVATION", 131, 139], ["ear", "ANATOMY", 206, 209], ["nose throat", "ANATOMY", 210, 221]]], ["To reduce infections, laboratory testing and blood draws should be minimized.", [["blood", "ANATOMY", 45, 50], ["infections", "DISEASE", 10, 20], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["infections", "PROBLEM", 10, 20], ["laboratory testing", "TEST", 22, 40], ["blood draws", "TEST", 45, 56], ["infections", "OBSERVATION", 10, 20]]], ["Extracorporeal membrane oxygenation cannulation components need covering with anti-infection transparent dressing with daily inspection and regular disinfection.Extracorporeal Membrane Oxygenation ComplicationsCoronavirus disease 2019 patients commonly suffer from flatulence.", [["Extracorporeal membrane", "ANATOMY", 0, 23], ["Coronavirus disease", "DISEASE", 210, 229], ["flatulence", "DISEASE", 265, 275], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 0, 23], ["patients", "ORGANISM", 235, 243], ["patients", "SPECIES", 235, 243], ["Extracorporeal membrane oxygenation cannulation components", "TREATMENT", 0, 58], ["anti-infection transparent dressing", "TREATMENT", 78, 113], ["daily inspection", "TEST", 119, 135], ["regular disinfection", "TREATMENT", 140, 160], ["Extracorporeal Membrane Oxygenation ComplicationsCoronavirus disease", "PROBLEM", 161, 229], ["flatulence", "PROBLEM", 265, 275], ["membrane", "OBSERVATION_MODIFIER", 15, 23], ["oxygenation cannulation", "OBSERVATION", 24, 47], ["Membrane", "OBSERVATION_MODIFIER", 176, 184], ["Oxygenation Complications", "OBSERVATION", 185, 210], ["flatulence", "OBSERVATION", 265, 275]]], ["If abdominal flatulence results in elevated abdominal pressure, the femoral vein drainage can be seriously reduced during ECMO support.", [["abdominal", "ANATOMY", 3, 12], ["abdominal", "ANATOMY", 44, 53], ["femoral vein", "ANATOMY", 68, 80], ["abdominal flatulence", "DISEASE", 3, 23], ["abdominal", "ORGANISM_SUBDIVISION", 3, 12], ["abdominal", "ORGANISM_SUBDIVISION", 44, 53], ["femoral vein", "MULTI-TISSUE_STRUCTURE", 68, 80], ["abdominal flatulence", "PROBLEM", 3, 23], ["elevated abdominal pressure", "PROBLEM", 35, 62], ["the femoral vein drainage", "TREATMENT", 64, 89], ["ECMO support", "TREATMENT", 122, 134], ["abdominal", "ANATOMY", 3, 12], ["flatulence", "OBSERVATION", 13, 23], ["elevated", "OBSERVATION_MODIFIER", 35, 43], ["abdominal", "ANATOMY", 44, 53], ["pressure", "OBSERVATION_MODIFIER", 54, 62], ["femoral vein", "ANATOMY", 68, 80], ["drainage", "OBSERVATION", 81, 89]]], ["If nasal lactulose and enema are ineffective in treatment, traditional Chinese medicine may be considered including nasal administration of 50 ml dachengqi decoction twice a day.Extracorporeal Membrane Oxygenation ComplicationsCaution must be taken to avoid ECMO cannula displacement and accidental decannulation.", [["nasal", "ANATOMY", 3, 8], ["nasal", "ANATOMY", 116, 121], ["lactulose", "CHEMICAL", 9, 18], ["dachengqi decoction", "CHEMICAL", 146, 165], ["lactulose", "CHEMICAL", 9, 18], ["lactulose", "SIMPLE_CHEMICAL", 9, 18], ["nasal", "ORGANISM_SUBDIVISION", 116, 121], ["nasal lactulose", "TREATMENT", 3, 18], ["enema", "TREATMENT", 23, 28], ["treatment", "TREATMENT", 48, 57], ["traditional Chinese medicine", "TREATMENT", 59, 87], ["nasal administration", "TREATMENT", 116, 136], ["Extracorporeal Membrane Oxygenation", "TREATMENT", 178, 213], ["ECMO cannula displacement", "TREATMENT", 258, 283], ["accidental decannulation", "TREATMENT", 288, 312], ["Membrane Oxygenation", "OBSERVATION", 193, 213], ["accidental decannulation", "OBSERVATION", 288, 312]]], ["The ECMO circuit should be properly secured to the bedside with avoidance of dropping the equipment to the ground.", [["The ECMO circuit", "TREATMENT", 0, 16], ["ECMO", "OBSERVATION", 4, 8]]], ["Bedside nursing staff must be trained to manage ECMO emergencies such as power loss and air/oxygen loss.Extracorporeal Membrane Oxygenation Weaning Procedures and StandardsPatients with improved chest x-rays, chest CT, arterial blood gas, and respiratory mechanics may attempt ECMO weaning.", [["chest", "ANATOMY", 195, 200], ["chest", "ANATOMY", 209, 214], ["arterial blood", "ANATOMY", 219, 233], ["respiratory", "ANATOMY", 243, 254], ["oxygen", "CHEMICAL", 92, 98], ["oxygen", "CHEMICAL", 92, 98], ["oxygen", "SIMPLE_CHEMICAL", 92, 98], ["arterial", "MULTI-TISSUE_STRUCTURE", 219, 227], ["blood", "ORGANISM_SUBSTANCE", 228, 233], ["ECMO emergencies", "TREATMENT", 48, 64], ["power loss", "PROBLEM", 73, 83], ["air/oxygen loss", "PROBLEM", 88, 103], ["Extracorporeal Membrane Oxygenation", "TREATMENT", 104, 139], ["Weaning Procedures", "TREATMENT", 140, 158], ["improved chest x-rays", "TEST", 186, 207], ["chest CT", "TEST", 209, 217], ["arterial blood gas", "TEST", 219, 237], ["respiratory mechanics", "TREATMENT", 243, 264], ["ECMO weaning", "TREATMENT", 277, 289], ["oxygen loss", "OBSERVATION", 92, 103], ["Membrane", "OBSERVATION", 119, 127], ["Oxygenation Weaning", "OBSERVATION", 128, 147], ["chest", "ANATOMY", 195, 200], ["chest", "ANATOMY", 209, 214], ["arterial", "ANATOMY", 219, 227]]], ["The sweep to flow ratio is maintained at 1:1, and ECMO flow gradually reduced to 2.5 L/minute while continuing the same mechanical ventilation parameters.", [["The sweep to flow ratio", "TEST", 0, 23], ["ECMO flow", "TEST", 50, 59], ["the same mechanical ventilation parameters", "TREATMENT", 111, 153], ["mechanical ventilation", "OBSERVATION", 120, 142]]], ["With the ECMO flow maintained at 2.5 L/minute, the ECMO sweep is gradually reduced until there is complete cessation of the sweep.", [["the ECMO flow", "TEST", 5, 18], ["the ECMO sweep", "TREATMENT", 47, 61]]], ["We observe the patient for 6-12 hours after each adjustment.", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22]]], ["If the patient condition worsens or oxygenation levels are not sustained during the weaning, ECMO parameters are restored to previous settings.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["the patient condition worsens", "PROBLEM", 3, 32], ["oxygenation levels", "TEST", 36, 54], ["the weaning", "TREATMENT", 80, 91], ["ECMO parameters", "TEST", 93, 108]]], ["To take patients off ECMO, the following criteria must be maintained for 24-48 hours at ECMO flow rates of 2.5 L/minute without sweep: hemodynamic stability; improvements in chest x-ray, chest CT, EIT, or lung ultrasonography; PaO 2 /FiO 2 >150 mmHg, PCO 2 \u226450 mmHg, and RR \u226420; body temperature <38\u00b0C; Murray index: 2-3; hematocrit >35% (figure 2).resultsExtracorporeal membrane oxygenation was necessary for 8 out of the 16 critically ill COVID-19 patients in whom severe hypoxia could not be reversed with optimized mechanical ventilation.resultsOn January 30, 2020, the first VV ECMO for a COVID-19 patient with severe hypoxia that could not be reversed by aggressive mechanical ventilation was established.", [["lung", "ANATOMY", 205, 209], ["body", "ANATOMY", 279, 283], ["Extracorporeal membrane", "ANATOMY", 356, 379], ["critically ill", "DISEASE", 426, 440], ["hypoxia", "DISEASE", 474, 481], ["hypoxia", "DISEASE", 623, 630], ["patients", "ORGANISM", 8, 16], ["lung", "ORGAN", 205, 209], ["body", "ORGANISM_SUBDIVISION", 279, 283], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 356, 379], ["patients", "ORGANISM", 450, 458], ["patient", "ORGANISM", 603, 610], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 450, 458], ["patient", "SPECIES", 603, 610], ["VV", "SPECIES", 580, 582], ["ECMO", "TREATMENT", 21, 25], ["ECMO flow rates", "TEST", 88, 103], ["chest x-ray", "TEST", 174, 185], ["chest CT", "TEST", 187, 195], ["EIT, or lung ultrasonography", "TEST", 197, 225], ["PaO", "TEST", 227, 230], ["FiO", "TEST", 234, 237], ["PCO", "TEST", 251, 254], ["RR", "TEST", 271, 273], ["body temperature", "TEST", 279, 295], ["Murray index", "TEST", 303, 315], ["hematocrit", "TEST", 322, 332], ["Extracorporeal membrane oxygenation", "TREATMENT", 356, 391], ["severe hypoxia", "PROBLEM", 467, 481], ["optimized mechanical ventilation", "TREATMENT", 509, 541], ["the first VV ECMO", "TREATMENT", 570, 587], ["a COVID", "TEST", 592, 599], ["severe hypoxia", "PROBLEM", 616, 630], ["aggressive mechanical ventilation", "TREATMENT", 661, 694], ["hemodynamic stability", "OBSERVATION", 135, 156], ["chest", "ANATOMY", 174, 179], ["chest", "ANATOMY", 187, 192], ["lung", "ANATOMY", 205, 209], ["hypoxia", "OBSERVATION", 474, 481], ["mechanical ventilation", "OBSERVATION", 519, 541], ["severe", "OBSERVATION_MODIFIER", 616, 622], ["hypoxia", "OBSERVATION", 623, 630]]], ["To date, eight COVID-19 patients have received ECMO: seven with VV ECMO support and one patient was emergently placed on VA ECMO during cardiopulmonary resuscitation.", [["cardiopulmonary", "ANATOMY", 136, 151], ["patients", "ORGANISM", 24, 32], ["patient", "ORGANISM", 88, 95], ["patients", "SPECIES", 24, 32], ["patient", "SPECIES", 88, 95], ["VV", "SPECIES", 64, 66], ["ECMO", "TREATMENT", 47, 51], ["VV ECMO support", "TREATMENT", 64, 79], ["VA ECMO", "TREATMENT", 121, 128], ["cardiopulmonary resuscitation", "TREATMENT", 136, 165], ["cardiopulmonary", "ANATOMY", 136, 151]]], ["As of March 25, 2020, four patients died (50% mortality).", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35]]], ["Three patients were successfully (37.5%) weaned off ECMO after 22, 40, and 47 days support, respectively, but remain on mechanical ventilation.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["ECMO", "TREATMENT", 52, 56], ["mechanical ventilation", "TREATMENT", 120, 142], ["mechanical ventilation", "OBSERVATION", 120, 142]]], ["One patient is still on VV ECMO with mechanical ventilation.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["VV", "SPECIES", 24, 26], ["VV ECMO", "TREATMENT", 24, 31], ["mechanical ventilation", "TREATMENT", 37, 59], ["mechanical ventilation", "OBSERVATION", 37, 59]]], ["Patient 7 received ECMO initially on January 30, 2020, for 8 days and weaned off.", [["Patient", "SPECIES", 0, 7], ["ECMO", "TREATMENT", 19, 23]]], ["His condition deteriorated on February 12, 2020, and ECMO had to be restarted again.", [["ECMO", "TREATMENT", 53, 57]]], ["He died after 10 days of ECMO support the second time.resultsTwo patients were female, and six were male.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["ECMO support", "TREATMENT", 25, 37]]], ["Four patients had hypertension, and two patients had cerebral infarct medical history.", [["cerebral", "ANATOMY", 53, 61], ["hypertension", "DISEASE", 18, 30], ["cerebral infarct", "DISEASE", 53, 69], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 40, 48], ["cerebral", "ORGAN", 53, 61], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 40, 48], ["hypertension", "PROBLEM", 18, 30], ["cerebral infarct medical history", "PROBLEM", 53, 85], ["hypertension", "OBSERVATION", 18, 30], ["cerebral", "ANATOMY", 53, 61], ["infarct", "OBSERVATION", 62, 69]]], ["The PaO 2 /FiO 2 ratio before ECMO initiation were between 54 and 76, and all were well below 100.", [["FiO 2", "CHEMICAL", 11, 16], ["PaO 2", "GENE_OR_GENE_PRODUCT", 4, 9], ["FiO 2", "GENE_OR_GENE_PRODUCT", 11, 16], ["The PaO", "TEST", 0, 7], ["FiO", "TEST", 11, 14], ["ECMO initiation", "TEST", 30, 45]]], ["The duration of mechanical ventilation before ECMO ranged from 4 to 21 days.", [["mechanical ventilation", "TREATMENT", 16, 38], ["ECMO", "TREATMENT", 46, 50], ["mechanical ventilation", "OBSERVATION", 16, 38]]], ["Except the one emergent VA ECMO during cardiopulmonary resuscitation, other patients were on ECMO support for between 18 and 47 days ( Table 1) .DiscussionExtracorporeal membrane oxygenation has been used clinically in Shanghai for nearly 19 years.", [["Extracorporeal membrane", "ANATOMY", 155, 178], ["patients", "ORGANISM", 76, 84], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 155, 178], ["patients", "SPECIES", 76, 84], ["cardiopulmonary resuscitation", "TREATMENT", 39, 68], ["ECMO support", "TREATMENT", 93, 105], ["Extracorporeal membrane oxygenation", "TREATMENT", 155, 190]]], ["Cross-training, academic exchange, as well mutual support among perfusionists, critical care physicians, pulmonologists, cardiologists, and emergency medicine physicians have created a solid foundation for the successful implementation of ECMO programs in this area during crises.", [["academic exchange", "TREATMENT", 16, 33], ["ECMO programs", "TREATMENT", 239, 252], ["crises", "PROBLEM", 273, 279]]], ["Extracorporeal membrane oxygenation support in the prevention and control of the highly pathogenic avian influenza H7N8 in 2013 provided our team valuable experience.", [["Extracorporeal membrane", "ANATOMY", 0, 23], ["avian influenza H7N8", "DISEASE", 99, 119], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 0, 23], ["avian influenza H7N8", "ORGANISM", 99, 119], ["avian influenza H7N8", "SPECIES", 99, 119], ["Extracorporeal membrane oxygenation support", "TREATMENT", 0, 43], ["membrane", "OBSERVATION", 15, 23], ["oxygenation support", "OBSERVATION", 24, 43]]], ["The Shanghai ECMO Clinical Quality Control Registry in 2018 properly prepared ECMO-capable hospitals and departments for the timely enlisting of equipment and ECMO experts during the COVID-19 crisis.", [["ECMO", "TREATMENT", 159, 163], ["the COVID", "TEST", 179, 188]]], ["14 Diffuse pulmonary edema and hyaline membrane formation are the main pathologic features in COVID-19 patients.", [["pulmonary", "ANATOMY", 11, 20], ["hyaline membrane", "ANATOMY", 31, 47], ["pulmonary edema", "DISEASE", 11, 26], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 11, 26], ["hyaline membrane", "MULTI-TISSUE_STRUCTURE", 31, 47], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["Diffuse pulmonary edema", "PROBLEM", 3, 26], ["hyaline membrane formation", "PROBLEM", 31, 57], ["Diffuse", "OBSERVATION_MODIFIER", 3, 10], ["pulmonary", "ANATOMY", 11, 20], ["edema", "OBSERVATION", 21, 26], ["hyaline membrane formation", "OBSERVATION", 31, 57], ["main", "OBSERVATION_MODIFIER", 66, 70], ["pathologic", "OBSERVATION_MODIFIER", 71, 81]]], ["15 Hypoxia can progress rapidly, and optimal mechanical ventilation might not be enough to correct for patients in critical status.", [["Hypoxia", "DISEASE", 3, 10], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["Hypoxia", "PROBLEM", 3, 10], ["optimal mechanical ventilation", "TREATMENT", 37, 67]]], ["Traditional ECMO indications, or the standards as adopted in the extracorporeal membrane oxygenation for severe acute respiratory distress syndrome study, 16 may lead to prolonged hypoxia and multiple organ failure in these patients.", [["extracorporeal membrane", "ANATOMY", 65, 88], ["respiratory", "ANATOMY", 118, 129], ["organ", "ANATOMY", 201, 206], ["acute respiratory distress syndrome", "DISEASE", 112, 147], ["hypoxia", "DISEASE", 180, 187], ["organ failure", "DISEASE", 201, 214], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 65, 88], ["organ", "ORGAN", 201, 206], ["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 224, 232], ["Traditional ECMO indications", "TREATMENT", 0, 28], ["the extracorporeal membrane oxygenation", "TREATMENT", 61, 100], ["severe acute respiratory distress syndrome study", "PROBLEM", 105, 153], ["prolonged hypoxia", "PROBLEM", 170, 187], ["multiple organ failure", "PROBLEM", 192, 214], ["extracorporeal membrane", "ANATOMY", 65, 88], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["respiratory distress", "OBSERVATION", 118, 138], ["hypoxia", "OBSERVATION", 180, 187], ["multiple", "OBSERVATION_MODIFIER", 192, 200], ["organ", "ANATOMY", 201, 206], ["failure", "OBSERVATION", 207, 214]]], ["Therefore, we recommend early establishment of ECMO when mechanical ventilation is insufficient to correct hypoxia in COVID-19 patients.", [["hypoxia", "DISEASE", 107, 114], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["ECMO", "TREATMENT", 47, 51], ["mechanical ventilation", "TREATMENT", 57, 79], ["hypoxia", "PROBLEM", 107, 114], ["COVID", "TEST", 118, 123]]], ["Our indications are consistent with the latest version of the COVID-19 Diagnosis and Treatment Guidelines (Version 7).", [["the COVID", "TREATMENT", 58, 67], ["consistent with", "UNCERTAINTY", 20, 35]]], ["17 The safety and success of ECMO in the Shanghai Public Health Clinical Center were challenged by many factors including, but not limited to, strict infection control requirements, unfamiliar team members in new environments, and slow communication and feedback in isolation wards.", [["infection", "DISEASE", 150, 159], ["ECMO", "TREATMENT", 29, 33], ["strict infection control requirements", "PROBLEM", 143, 180], ["infection", "OBSERVATION", 150, 159]]], ["Lessons learned from prior crisis experiences including equipment check before use, management of gas and electrical emergency hazards, availability and location of ECMO disposables, and proactive alarm management to avoid disturbances to unfamiliar healthcare providers were invaluable for our team and the hospital.DiscussionIt is understood that ECMO does not provide direct support for organs other than the lungs or heart beyond increasing systemic oxygen delivery and mitigating ventilator-induced lung injury.", [["organs", "ANATOMY", 390, 396], ["lungs", "ANATOMY", 412, 417], ["heart", "ANATOMY", 421, 426], ["lung", "ANATOMY", 504, 508], ["oxygen", "CHEMICAL", 454, 460], ["lung injury", "DISEASE", 504, 515], ["ECMO", "CHEMICAL", 349, 353], ["oxygen", "CHEMICAL", 454, 460], ["organs", "ORGAN", 390, 396], ["lungs", "ORGAN", 412, 417], ["heart", "ORGAN", 421, 426], ["oxygen", "SIMPLE_CHEMICAL", 454, 460], ["lung", "ORGAN", 504, 508], ["prior crisis experiences", "PROBLEM", 21, 45], ["equipment check", "TEST", 56, 71], ["management", "TREATMENT", 84, 94], ["ECMO disposables", "TREATMENT", 165, 181], ["proactive alarm management", "TREATMENT", 187, 213], ["disturbances", "PROBLEM", 223, 235], ["ECMO", "TREATMENT", 349, 353], ["direct support", "TREATMENT", 371, 385], ["increasing systemic oxygen delivery", "TREATMENT", 434, 469], ["mitigating ventilator", "TREATMENT", 474, 495], ["induced lung injury", "PROBLEM", 496, 515], ["lungs", "ANATOMY", 412, 417], ["heart", "ANATOMY", 421, 426], ["systemic", "OBSERVATION_MODIFIER", 445, 453], ["oxygen delivery", "OBSERVATION", 454, 469], ["lung", "ANATOMY", 504, 508], ["injury", "OBSERVATION", 509, 515]]], ["A substantial proportion of critically ill patients with COVID-19 appear to have developed cardiac arrhythmias or shock, but it is unknown how many have or will develop refractory multiorgan failure, for which ECMO may be of more limited use.", [["cardiac", "ANATOMY", 91, 98], ["multiorgan", "ANATOMY", 180, 190], ["critically ill", "DISEASE", 28, 42], ["cardiac arrhythmias", "DISEASE", 91, 110], ["shock", "DISEASE", 114, 119], ["multiorgan failure", "DISEASE", 180, 198], ["patients", "ORGANISM", 43, 51], ["cardiac", "ORGAN", 91, 98], ["multiorgan", "ORGAN", 180, 190], ["patients", "SPECIES", 43, 51], ["COVID", "TEST", 57, 62], ["cardiac arrhythmias", "PROBLEM", 91, 110], ["shock", "PROBLEM", 114, 119], ["refractory multiorgan failure", "PROBLEM", 169, 198], ["ECMO", "TREATMENT", 210, 214], ["substantial", "OBSERVATION_MODIFIER", 2, 13], ["proportion", "OBSERVATION_MODIFIER", 14, 24], ["critically", "OBSERVATION_MODIFIER", 28, 38], ["ill", "OBSERVATION_MODIFIER", 39, 42], ["cardiac", "ANATOMY", 91, 98], ["arrhythmias", "OBSERVATION", 99, 110], ["shock", "OBSERVATION", 114, 119], ["failure", "OBSERVATION", 191, 198]]], ["8 More data on the mechanism of death and disease are required to determine whether ECMO is appropriate to offer to COVID-19 patients.", [["death", "DISEASE", 32, 37], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["death", "PROBLEM", 32, 37], ["disease", "PROBLEM", 42, 49], ["ECMO", "TREATMENT", 84, 88]]], ["However, it appears that the damage and duration of lung injuries in COVID-19 are extensive, and prolonged ECMO support might be required as shown in our study.", [["lung", "ANATOMY", 52, 56], ["lung injuries", "DISEASE", 52, 65], ["lung", "ORGAN", 52, 56], ["the damage", "PROBLEM", 25, 35], ["lung injuries", "PROBLEM", 52, 65], ["COVID", "TEST", 69, 74], ["prolonged ECMO support", "TREATMENT", 97, 119], ["our study", "TEST", 150, 159], ["damage", "OBSERVATION", 29, 35], ["lung", "ANATOMY", 52, 56], ["injuries", "OBSERVATION", 57, 65], ["extensive", "OBSERVATION_MODIFIER", 82, 91]]], ["Extracorporeal membrane oxygenation is highly resource consumptive, and many COVID-19 affected countries might not be able to afford this expensive technology.", [["Extracorporeal membrane", "ANATOMY", 0, 23], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 0, 23], ["Extracorporeal membrane oxygenation", "TREATMENT", 0, 35], ["membrane oxygenation", "OBSERVATION", 15, 35]]], ["In less wellresourced countries, many more lives will be saved by ensuring that oxygen and pulse oximetry are widely available.", [["oxygen", "CHEMICAL", 80, 86], ["oxygen", "CHEMICAL", 80, 86], ["oxygen", "SIMPLE_CHEMICAL", 80, 86], ["pulse oximetry", "TEST", 91, 105], ["less wellresourced", "OBSERVATION_MODIFIER", 3, 21]]], ["Confirmation of the diagnosis, appropriate quarantine and oxygen therapy alone might save many lives with minimal cost.", [["oxygen", "CHEMICAL", 58, 64], ["oxygen", "CHEMICAL", 58, 64], ["oxygen", "SIMPLE_CHEMICAL", 58, 64], ["appropriate quarantine", "TREATMENT", 31, 53], ["oxygen therapy", "TREATMENT", 58, 72]]], ["Mechanical ventilation or, for those most likely to benefit, ECMO needs to be evaluated for benefits/risks on a case-bycase basis.", [["Mechanical ventilation", "TREATMENT", 0, 22], ["ECMO", "TREATMENT", 61, 65], ["ventilation", "OBSERVATION", 11, 22]]], ["8 In conclusion, ensuring effective, timely, and safe ECMO support in COVID-19 is key to improving clinical outcomes.", [["safe ECMO support", "TREATMENT", 49, 66]]], ["Extracorporeal membrane oxygenation support might be an integral part of the critical care provided for COVID-19 patients in centers with advanced ECMO expertise.", [["Extracorporeal membrane", "ANATOMY", 0, 23], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 0, 23], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["Extracorporeal membrane oxygenation support", "TREATMENT", 0, 43], ["advanced ECMO expertise", "TREATMENT", 138, 161], ["membrane oxygenation", "OBSERVATION", 15, 35]]], ["BC, bladder cancer; BMI, body mass index; CI, cerebral infarction; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; ECPR-VA, extracorporeal cardiopulmonary resuscitation-veno-arterial; FA, femoral artery; FV, femoral vein; IJV, internal jugular vein; MN, membranous nephropathy; NA, not available; P/F, partial pressure of oxygen (PaO 2 ) divided by fractional of inspired oxygen (FiO 2 ); RASS, Richmond Agitation-Sedation Score; VV, venovenous.", [["BC", "ANATOMY", 0, 2], ["bladder cancer", "ANATOMY", 4, 18], ["body", "ANATOMY", 25, 29], ["cerebral", "ANATOMY", 46, 54], ["pulmonary", "ANATOMY", 93, 102], ["extracorporeal membrane", "ANATOMY", 154, 177], ["extracorporeal", "ANATOMY", 200, 214], ["arterial", "ANATOMY", 250, 258], ["femoral artery", "ANATOMY", 264, 278], ["FV", "ANATOMY", 280, 282], ["femoral vein", "ANATOMY", 284, 296], ["IJV", "ANATOMY", 298, 301], ["internal jugular vein", "ANATOMY", 303, 324], ["MN", "ANATOMY", 326, 328], ["bladder cancer", "DISEASE", 4, 18], ["cerebral infarction", "DISEASE", 46, 65], ["COPD", "DISEASE", 67, 71], ["chronic obstructive pulmonary disease", "DISEASE", 73, 110], ["coronavirus disease", "DISEASE", 122, 141], ["nephropathy", "DISEASE", 341, 352], ["oxygen", "CHEMICAL", 398, 404], ["oxygen", "CHEMICAL", 448, 454], ["oxygen", "CHEMICAL", 398, 404], ["PaO 2 )", "CHEMICAL", 406, 413], ["oxygen", "CHEMICAL", 448, 454], ["FiO 2", "CHEMICAL", 456, 461], ["bladder cancer", "CANCER", 4, 18], ["body", "ORGANISM_SUBDIVISION", 25, 29], ["cerebral", "ORGAN", 46, 54], ["pulmonary", "ORGAN", 93, 102], ["arterial", "MULTI-TISSUE_STRUCTURE", 250, 258], ["FA", "SIMPLE_CHEMICAL", 260, 262], ["femoral artery", "MULTI-TISSUE_STRUCTURE", 264, 278], ["FV", "MULTI-TISSUE_STRUCTURE", 280, 282], ["femoral vein", "MULTI-TISSUE_STRUCTURE", 284, 296], ["IJV", "MULTI-TISSUE_STRUCTURE", 298, 301], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 312, 324], ["oxygen", "SIMPLE_CHEMICAL", 398, 404], ["oxygen", "SIMPLE_CHEMICAL", 448, 454], ["BC", "TEST", 0, 2], ["bladder cancer", "PROBLEM", 4, 18], ["BMI", "PROBLEM", 20, 23], ["body mass index", "PROBLEM", 25, 40], ["CI", "PROBLEM", 42, 44], ["cerebral infarction", "PROBLEM", 46, 65], ["COPD", "PROBLEM", 67, 71], ["chronic obstructive pulmonary disease", "PROBLEM", 73, 110], ["COVID", "TEST", 112, 117], ["coronavirus disease", "PROBLEM", 122, 141], ["ECMO", "TREATMENT", 148, 152], ["extracorporeal membrane oxygenation", "TREATMENT", 154, 189], ["ECPR", "TEST", 191, 195], ["extracorporeal cardiopulmonary resuscitation", "TREATMENT", 200, 244], ["IJV, internal jugular vein", "PROBLEM", 298, 324], ["membranous nephropathy", "PROBLEM", 330, 352], ["partial pressure of oxygen (PaO", "TREATMENT", 378, 409], ["inspired oxygen (FiO", "TREATMENT", 439, 459], ["Richmond Agitation", "PROBLEM", 471, 489], ["Sedation Score", "TEST", 490, 504], ["venovenous", "TREATMENT", 510, 520], ["bladder", "ANATOMY", 4, 11], ["cancer", "OBSERVATION", 12, 18], ["body", "ANATOMY", 25, 29], ["mass", "OBSERVATION", 30, 34], ["cerebral", "ANATOMY", 46, 54], ["infarction", "OBSERVATION", 55, 65], ["COPD", "OBSERVATION", 67, 71], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["obstructive", "OBSERVATION_MODIFIER", 81, 92], ["pulmonary", "ANATOMY", 93, 102], ["disease", "OBSERVATION", 103, 110], ["extracorporeal", "ANATOMY_MODIFIER", 200, 214], ["cardiopulmonary", "ANATOMY", 215, 230], ["arterial", "ANATOMY", 250, 258], ["femoral artery", "ANATOMY", 264, 278], ["femoral vein", "ANATOMY", 284, 296], ["IJV", "ANATOMY", 298, 301], ["internal jugular vein", "ANATOMY", 303, 324], ["membranous", "OBSERVATION_MODIFIER", 330, 340], ["nephropathy", "OBSERVATION", 341, 352], ["pressure", "OBSERVATION_MODIFIER", 386, 394], ["venovenous", "ANATOMY", 510, 520]]]], "PMC7370900": [["IntroductionThe 2019 Coronavirus Disease (COVID-19) pandemic will likely be looked back upon as a testament to the rapid and voracious nature of evidence-based medicine in the 21st century.", [["Coronavirus Disease", "DISEASE", 21, 40], ["The 2019 Coronavirus Disease", "PROBLEM", 12, 40], ["COVID", "TEST", 42, 47], ["pandemic", "PROBLEM", 52, 60], ["Coronavirus Disease", "OBSERVATION", 21, 40]]], ["For comparison, Kawasaki Disease (KD) is one of the most recognized pediatric inflammatory syndromes and took 6 years to be identified and reported by Dr. Tomisaku Kawasaki [1].", [["Kawasaki Disease", "DISEASE", 16, 32], ["KD", "DISEASE", 34, 36], ["Kawasaki Disease", "PROBLEM", 16, 32], ["pediatric inflammatory syndromes", "PROBLEM", 68, 100], ["inflammatory syndromes", "OBSERVATION", 78, 100]]], ["Meanwhile, the COVID-19 pandemic has generated more than 19,000 publications of case reports, molecular studies, and clinical trials in less than 3 months\u2019 time.IntroductionMost have focused on COVID-19 in adults, as early data suggested that children were spared from severe disease [2].", [["adults", "ORGANISM", 206, 212], ["children", "ORGANISM", 243, 251], ["children", "SPECIES", 243, 251], ["the COVID", "TEST", 11, 20], ["molecular studies", "TEST", 94, 111], ["severe disease", "PROBLEM", 269, 283], ["severe", "OBSERVATION_MODIFIER", 269, 275], ["disease", "OBSERVATION", 276, 283]]], ["However, since May 2020, multiple American and European institutions have brought attention to an enigmatic phenomenon known as multisystem inflammatory syndrome in children (MIS-C) with seeming connections and/or overlapping phenotype to KD [3], [4], [5].", [["multisystem inflammatory syndrome", "DISEASE", 128, 161], ["children", "ORGANISM", 165, 173], ["[4]", "SIMPLE_CHEMICAL", 247, 250], ["children", "SPECIES", 165, 173], ["an enigmatic phenomenon", "PROBLEM", 95, 118], ["multisystem inflammatory syndrome", "PROBLEM", 128, 161], ["multisystem", "OBSERVATION_MODIFIER", 128, 139], ["inflammatory syndrome", "OBSERVATION", 140, 161]]], ["This current review paper will discuss about KD and its potential connection to pediatric COVID-19 and MIS-C.The History of Kawasaki DiseaseIn 1967, Dr. Kawasaki published his detailed case series of 50 children that developed a condition he termed as \u201cacute febrile mucocutaneous lymph node syndrome\u201d [1].", [["lymph node", "ANATOMY", 281, 291], ["Kawasaki DiseaseIn", "DISEASE", 124, 142], ["mucocutaneous lymph node syndrome", "DISEASE", 267, 300], ["children", "ORGANISM", 203, 211], ["lymph node", "MULTI-TISSUE_STRUCTURE", 281, 291], ["children", "SPECIES", 203, 211], ["pediatric COVID", "TEST", 80, 95], ["acute febrile mucocutaneous lymph node syndrome", "PROBLEM", 253, 300], ["acute", "OBSERVATION_MODIFIER", 253, 258], ["febrile", "OBSERVATION_MODIFIER", 259, 266], ["mucocutaneous", "OBSERVATION_MODIFIER", 267, 280], ["lymph node syndrome", "OBSERVATION", 281, 300]]], ["The long term sequel of KD was not recognized until the 1970s, when surveys demonstrated a significant number of fatal cases secondary to coronary artery (CA) aneurysm (CAA) formation, with subsequent thrombosis and stenosis [6].The History of Kawasaki DiseaseNowadays, KD is recognized as the leading cause of acquired CA disease in the pediatric population [7].", [["coronary artery", "ANATOMY", 138, 153], ["coronary artery (CA) aneurysm", "DISEASE", 138, 167], ["CAA", "DISEASE", 169, 172], ["thrombosis", "DISEASE", 201, 211], ["stenosis", "DISEASE", 216, 224], ["Kawasaki DiseaseNowadays", "DISEASE", 244, 268], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 138, 153], ["CA", "MULTI-TISSUE_STRUCTURE", 155, 157], ["CAA", "PATHOLOGICAL_FORMATION", 169, 172], ["fatal cases", "PROBLEM", 113, 124], ["coronary artery (CA) aneurysm (CAA) formation", "PROBLEM", 138, 183], ["subsequent thrombosis", "PROBLEM", 190, 211], ["stenosis", "PROBLEM", 216, 224], ["Kawasaki DiseaseNowadays", "PROBLEM", 244, 268], ["acquired CA disease", "PROBLEM", 311, 330], ["long term", "OBSERVATION_MODIFIER", 4, 13], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["fatal cases", "OBSERVATION", 113, 124], ["coronary artery", "ANATOMY", 138, 153], ["aneurysm", "OBSERVATION", 159, 167], ["thrombosis", "OBSERVATION", 201, 211], ["stenosis", "OBSERVATION", 216, 224], ["CA", "OBSERVATION", 320, 322]]], ["Standards of care were established in 1984, following the introduction of high-dose intravenous immunoglobulin (IVIG) to reduce the prevalence of CA abnormalities [8].", [["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 95], ["immunoglobulin", "SIMPLE_CHEMICAL", 96, 110], ["IVIG", "SIMPLE_CHEMICAL", 112, 116], ["CA", "GENE_OR_GENE_PRODUCT", 146, 148], ["immunoglobulin", "PROTEIN", 96, 110], ["high-dose intravenous immunoglobulin (IVIG", "TREATMENT", 74, 116], ["CA abnormalities", "PROBLEM", 146, 162]]], ["Since 2004, the American Heart Association (AHA) has published guidelines describing the management, treatment and long-term management of KD [7].", [["the management", "TREATMENT", 85, 99], ["treatment", "TREATMENT", 101, 110], ["long-term management", "TREATMENT", 115, 135], ["Heart", "ANATOMY", 25, 30]]], ["To date, over 300,000 children have been diagnosed and treated for KD [9].", [["children", "ORGANISM", 22, 30], ["children", "SPECIES", 22, 30]]], ["However, despite emerging treatment options, the precise etiology of KD has remained elusive.", [["KD", "DISEASE", 69, 71], ["emerging treatment options", "TREATMENT", 17, 43], ["KD", "PROBLEM", 69, 71]]], ["KD remains a clinical diagnosis - all diagnostic findings are non-specific.Cardiac Complications of Kawasaki DiseaseThe most concerning complication of KD is CAAs that can be detected within 2 weeks during the convalescent stage of KD [10].", [["Cardiac", "ANATOMY", 75, 82], ["Kawasaki Disease", "DISEASE", 100, 116], ["CAAs", "DISEASE", 158, 162], ["Cardiac", "ORGAN", 75, 82], ["CAAs", "CANCER", 158, 162], ["Kawasaki Disease", "PROBLEM", 100, 116], ["non-specific", "OBSERVATION_MODIFIER", 62, 74], ["Complications", "OBSERVATION", 83, 96], ["Kawasaki Disease", "OBSERVATION", 100, 116]]], ["These abnormalities are typically identified by echocardiography.", [["These abnormalities", "PROBLEM", 0, 19], ["echocardiography", "TEST", 48, 64], ["abnormalities", "OBSERVATION", 6, 19]]], ["CAAs can be seen in 25% of untreated KD patients, and is reduced to 4% after the introduction of IVIG [7].", [["CAAs", "DISEASE", 0, 4], ["KD", "DISEASE", 37, 39], ["CAAs", "SIMPLE_CHEMICAL", 0, 4], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["IVIG", "TREATMENT", 97, 101]]], ["Current standard of care involves administering IVIG, along with high-dose oral aspirin, within 10 days (ideally 7 days) from onset of fever [7,11].Cardiac Complications of Kawasaki DiseaseThe pathology of CA abnormalities involves three phases [12] - #1) necrotizing arteritis in the acute phase, with neutrophils destroying the wall (tunica media to tunica adventitia) leading to aneurysmal formation; #2) subacute/chronic vasculitis involving T cell lymphocytes, plasma B cells and macrophages infiltrating the vessel wall; and #3) luminal myofibroblastic proliferation, involving myofibroblasts and matrix deposition over months and years that contributes to arterial stenosis.", [["oral", "ANATOMY", 75, 79], ["Cardiac", "ANATOMY", 148, 155], ["neutrophils", "ANATOMY", 303, 314], ["wall", "ANATOMY", 330, 334], ["tunica adventitia", "ANATOMY", 352, 369], ["aneurysmal", "ANATOMY", 382, 392], ["T cell lymphocytes", "ANATOMY", 446, 464], ["plasma B cells", "ANATOMY", 466, 480], ["macrophages", "ANATOMY", 485, 496], ["vessel wall", "ANATOMY", 514, 525], ["luminal myofibroblastic", "ANATOMY", 535, 558], ["myofibroblasts", "ANATOMY", 584, 598], ["matrix", "ANATOMY", 603, 609], ["arterial", "ANATOMY", 663, 671], ["aspirin", "CHEMICAL", 80, 87], ["fever", "DISEASE", 135, 140], ["Kawasaki Disease", "DISEASE", 173, 189], ["necrotizing arteritis", "DISEASE", 256, 277], ["aneurysmal", "DISEASE", 382, 392], ["vasculitis", "DISEASE", 425, 435], ["luminal", "CHEMICAL", 535, 542], ["arterial stenosis", "DISEASE", 663, 680], ["aspirin", "CHEMICAL", 80, 87], ["IVIG", "SIMPLE_CHEMICAL", 48, 52], ["oral", "ORGANISM_SUBDIVISION", 75, 79], ["aspirin", "SIMPLE_CHEMICAL", 80, 87], ["Cardiac", "ORGAN", 148, 155], ["neutrophils", "CELL", 303, 314], ["wall", "TISSUE", 330, 334], ["tunica media", "TISSUE", 336, 348], ["tunica adventitia", "TISSUE", 352, 369], ["T cell lymphocytes", "CELL", 446, 464], ["plasma B cells", "CELL", 466, 480], ["macrophages", "CELL", 485, 496], ["vessel wall", "MULTI-TISSUE_STRUCTURE", 514, 525], ["myofibroblasts", "CELL", 584, 598], ["matrix", "CELLULAR_COMPONENT", 603, 609], ["arterial", "MULTI-TISSUE_STRUCTURE", 663, 671], ["neutrophils", "CELL_TYPE", 303, 314], ["T cell lymphocytes", "CELL_TYPE", 446, 464], ["plasma B cells", "CELL_TYPE", 466, 480], ["macrophages", "CELL_TYPE", 485, 496], ["myofibroblasts", "CELL_TYPE", 584, 598], ["IVIG", "TREATMENT", 48, 52], ["high-dose oral aspirin", "TREATMENT", 65, 87], ["fever", "PROBLEM", 135, 140], ["Kawasaki Disease", "PROBLEM", 173, 189], ["CA abnormalities", "PROBLEM", 206, 222], ["necrotizing arteritis", "PROBLEM", 256, 277], ["neutrophils", "PROBLEM", 303, 314], ["aneurysmal formation", "PROBLEM", 382, 402], ["subacute/chronic vasculitis", "PROBLEM", 408, 435], ["T cell lymphocytes", "PROBLEM", 446, 464], ["plasma B cells", "PROBLEM", 466, 480], ["macrophages infiltrating the vessel wall", "PROBLEM", 485, 525], ["luminal myofibroblastic proliferation", "PROBLEM", 535, 572], ["myofibroblasts and matrix deposition", "PROBLEM", 584, 620], ["arterial stenosis", "PROBLEM", 663, 680], ["fever", "OBSERVATION", 135, 140], ["Complications", "OBSERVATION", 156, 169], ["Kawasaki Disease", "OBSERVATION", 173, 189], ["necrotizing", "OBSERVATION_MODIFIER", 256, 267], ["arteritis", "OBSERVATION", 268, 277], ["acute phase", "OBSERVATION_MODIFIER", 285, 296], ["neutrophils", "OBSERVATION", 303, 314], ["wall", "ANATOMY_MODIFIER", 330, 334], ["tunica", "ANATOMY", 336, 342], ["tunica adventitia", "ANATOMY", 352, 369], ["aneurysmal", "OBSERVATION", 382, 392], ["subacute", "OBSERVATION_MODIFIER", 408, 416], ["chronic", "OBSERVATION_MODIFIER", 417, 424], ["vasculitis", "OBSERVATION", 425, 435], ["cell lymphocytes", "OBSERVATION", 448, 464], ["plasma B cells", "OBSERVATION", 466, 480], ["macrophages", "OBSERVATION_MODIFIER", 485, 496], ["vessel", "ANATOMY", 514, 520], ["wall", "ANATOMY_MODIFIER", 521, 525], ["luminal", "ANATOMY_MODIFIER", 535, 542], ["myofibroblastic proliferation", "OBSERVATION", 543, 572], ["myofibroblasts", "OBSERVATION", 584, 598], ["matrix", "OBSERVATION_MODIFIER", 603, 609], ["deposition", "OBSERVATION_MODIFIER", 610, 620], ["arterial", "ANATOMY", 663, 671], ["stenosis", "OBSERVATION", 672, 680]]], ["Thus, untreated KD patients with severe CAAs (i.e. large/giant aneurysms) typically do not have any cardiac symptoms in the acute phase, and may present with late manifestations of myocardial ischemia and/or sudden cardiac death secondary to severe CA flow disturbance and/or thrombosis [12].", [["giant aneurysms", "ANATOMY", 57, 72], ["cardiac", "ANATOMY", 100, 107], ["myocardial", "ANATOMY", 181, 191], ["cardiac", "ANATOMY", 215, 222], ["CAAs", "DISEASE", 40, 44], ["aneurysms", "DISEASE", 63, 72], ["cardiac symptoms", "DISEASE", 100, 116], ["myocardial ischemia", "DISEASE", 181, 200], ["sudden cardiac death", "DISEASE", 208, 228], ["thrombosis", "DISEASE", 276, 286], ["patients", "ORGANISM", 19, 27], ["cardiac", "ORGAN", 100, 107], ["myocardial", "MULTI-TISSUE_STRUCTURE", 181, 191], ["cardiac", "ORGAN", 215, 222], ["patients", "SPECIES", 19, 27], ["severe CAAs", "PROBLEM", 33, 44], ["large/giant aneurysms", "PROBLEM", 51, 72], ["any cardiac symptoms", "PROBLEM", 96, 116], ["myocardial ischemia", "PROBLEM", 181, 200], ["sudden cardiac death", "PROBLEM", 208, 228], ["severe CA flow disturbance", "PROBLEM", 242, 268], ["thrombosis", "PROBLEM", 276, 286], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["CAAs", "OBSERVATION", 40, 44], ["large", "OBSERVATION_MODIFIER", 51, 56], ["giant", "OBSERVATION_MODIFIER", 57, 62], ["aneurysms", "OBSERVATION", 63, 72], ["cardiac", "ANATOMY", 100, 107], ["symptoms", "OBSERVATION", 108, 116], ["acute phase", "OBSERVATION_MODIFIER", 124, 135], ["myocardial", "ANATOMY", 181, 191], ["ischemia", "OBSERVATION", 192, 200], ["cardiac", "ANATOMY", 215, 222], ["death", "OBSERVATION", 223, 228], ["severe", "OBSERVATION_MODIFIER", 242, 248], ["CA", "OBSERVATION", 249, 251], ["flow disturbance", "OBSERVATION", 252, 268], ["thrombosis", "OBSERVATION", 276, 286]]], ["Some of these patients are missed in the acute phase and are not diagnosed until the therapeutic window has passed, presenting with findings of severe CAAs.Cardiac Complications of Kawasaki DiseaseMyocarditis can also occur in the acute phase of KD.", [["Cardiac", "ANATOMY", 156, 163], ["CAAs", "DISEASE", 151, 155], ["Kawasaki DiseaseMyocarditis", "DISEASE", 181, 208], ["KD", "DISEASE", 246, 248], ["patients", "ORGANISM", 14, 22], ["CAAs", "PATHOLOGICAL_FORMATION", 151, 155], ["Cardiac", "ORGAN", 156, 163], ["patients", "SPECIES", 14, 22], ["severe CAAs", "PROBLEM", 144, 155], ["Kawasaki DiseaseMyocarditis", "PROBLEM", 181, 208], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["CAAs", "OBSERVATION", 151, 155], ["Complications", "OBSERVATION", 164, 177], ["Kawasaki", "OBSERVATION", 181, 189]]], ["Myocardial edema has been found in KD patients before CAA develop [13].", [["Myocardial", "ANATOMY", 0, 10], ["Myocardial edema", "DISEASE", 0, 16], ["CAA", "CHEMICAL", 54, 57], ["CAA", "CHEMICAL", 54, 57], ["Myocardial edema", "PATHOLOGICAL_FORMATION", 0, 16], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["Myocardial edema", "PROBLEM", 0, 16], ["edema", "OBSERVATION", 11, 16]]], ["Rarely, true myocardial cell necrosis or permanent cellular loss can develop [14].", [["myocardial cell", "ANATOMY", 13, 28], ["cellular", "ANATOMY", 51, 59], ["myocardial cell necrosis", "DISEASE", 13, 37], ["cellular loss", "DISEASE", 51, 64], ["myocardial cell", "CELL", 13, 28], ["cellular", "CELL", 51, 59], ["true myocardial cell necrosis", "PROBLEM", 8, 37], ["permanent cellular loss", "PROBLEM", 41, 64], ["myocardial", "ANATOMY", 13, 23], ["cell necrosis", "OBSERVATION", 24, 37], ["permanent", "OBSERVATION_MODIFIER", 41, 50], ["cellular loss", "OBSERVATION", 51, 64]]], ["Oftentimes there is transient left ventricular (LV) dysfunction and ventricular ectopy [15].", [["left ventricular", "ANATOMY", 30, 46], ["LV", "ANATOMY", 48, 50], ["ventricular", "ANATOMY", 68, 79], ["left ventricular (LV) dysfunction", "DISEASE", 30, 63], ["ventricular ectopy", "DISEASE", 68, 86], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 30, 46], ["LV", "MULTI-TISSUE_STRUCTURE", 48, 50], ["ventricular", "MULTI-TISSUE_STRUCTURE", 68, 79], ["transient left ventricular (LV) dysfunction", "PROBLEM", 20, 63], ["ventricular ectopy", "PROBLEM", 68, 86], ["transient", "OBSERVATION_MODIFIER", 20, 29], ["left ventricular", "ANATOMY", 30, 46], ["LV", "ANATOMY", 48, 50], ["dysfunction", "OBSERVATION", 52, 63], ["ventricular", "ANATOMY", 68, 79], ["ectopy", "OBSERVATION", 80, 86]]], ["In a small subset of KD patients, this will manifest as cardiovascular shock and hypotension requiring the use of intravascular volume boluses and vasoactive medications, KD shock syndrome [16].Laboratory Findings of Kawasaki DiseaseKD patients have characteristic serum lab findings of inflammation, albeit non-specific to other inflammatory disease [17].", [["cardiovascular", "ANATOMY", 56, 70], ["intravascular", "ANATOMY", 114, 127], ["serum", "ANATOMY", 265, 270], ["cardiovascular shock", "DISEASE", 56, 76], ["hypotension", "DISEASE", 81, 92], ["KD shock syndrome", "DISEASE", 171, 188], ["Kawasaki DiseaseKD", "DISEASE", 217, 235], ["inflammation", "DISEASE", 287, 299], ["patients", "ORGANISM", 24, 32], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["patients", "ORGANISM", 236, 244], ["serum", "ORGANISM_SUBSTANCE", 265, 270], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 236, 244], ["cardiovascular shock", "PROBLEM", 56, 76], ["hypotension", "PROBLEM", 81, 92], ["intravascular volume boluses", "TREATMENT", 114, 142], ["vasoactive medications", "TREATMENT", 147, 169], ["KD shock syndrome", "PROBLEM", 171, 188], ["inflammation", "PROBLEM", 287, 299], ["other inflammatory disease", "PROBLEM", 324, 350], ["small", "OBSERVATION_MODIFIER", 5, 10], ["inflammation", "OBSERVATION", 287, 299], ["inflammatory", "OBSERVATION_MODIFIER", 330, 342]]], ["Patients in acute phase of KD typically have leukocytosis with a predominance of neutrophils.", [["neutrophils", "ANATOMY", 81, 92], ["KD", "DISEASE", 27, 29], ["leukocytosis", "DISEASE", 45, 57], ["Patients", "ORGANISM", 0, 8], ["neutrophils", "CELL", 81, 92], ["neutrophils", "CELL_TYPE", 81, 92], ["Patients", "SPECIES", 0, 8], ["leukocytosis", "PROBLEM", 45, 57], ["neutrophils", "PROBLEM", 81, 92], ["acute phase", "OBSERVATION_MODIFIER", 12, 23], ["leukocytosis", "OBSERVATION", 45, 57], ["predominance", "OBSERVATION_MODIFIER", 65, 77], ["neutrophils", "OBSERVATION", 81, 92]]], ["Elevation of acute-phase reactants such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) is always present and considered a key criterion particularly in cases of \u201cincomplete\u201d KD [7].", [["erythrocyte", "ANATOMY", 43, 54], ["erythrocyte", "CELL", 43, 54], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 84, 102], ["CRP", "GENE_OR_GENE_PRODUCT", 104, 107], ["C-reactive protein", "PROTEIN", 84, 102], ["CRP", "PROTEIN", 104, 107], ["Elevation of acute-phase reactants", "PROBLEM", 0, 34], ["erythrocyte sedimentation rate", "TEST", 43, 73], ["ESR", "TEST", 75, 78], ["C-reactive protein", "TEST", 84, 102], ["CRP", "TEST", 104, 107], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["-phase", "OBSERVATION_MODIFIER", 18, 24]]], ["Thrombocytosis can be impressive and occur with peaks as high as 700 \u00d7 103/mL.", [["Thrombocytosis", "DISEASE", 0, 14], ["Thrombocytosis", "PROBLEM", 0, 14]]], ["Sterile pyuria is also common.", [["pyuria", "DISEASE", 8, 14], ["Sterile pyuria", "PROBLEM", 0, 14], ["pyuria", "OBSERVATION", 8, 14]]], ["N-terminal pro hormone B-type natriuretic peptide (NT-proBNP) is commonly elevated in KD patients [7] and is useful in diagnosis with a pooled sensitivity of 80 \u2013 89% and positive likelihood ratio of 3.2 [18,19].", [["NT-proBNP", "CHEMICAL", 51, 60], ["N", "CHEMICAL", 0, 1], ["B-type natriuretic peptide", "GENE_OR_GENE_PRODUCT", 23, 49], ["NT-proBNP", "GENE_OR_GENE_PRODUCT", 51, 60], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["terminal pro hormone", "TEST", 2, 22], ["type natriuretic peptide", "TREATMENT", 25, 49], ["NT-proBNP)", "TEST", 51, 61], ["a pooled sensitivity", "TEST", 134, 154], ["positive likelihood ratio", "TEST", 171, 196], ["elevated", "OBSERVATION_MODIFIER", 74, 82]]], ["NT-proBNP may also potentially serve as a prognostic marker for IVIG resistance [19].Etiologies and Epidemiology of Kawasaki DiseaseThe etiology, immunology and pathophysiology of KD are still not fully understood, although elements of the immune system clearly play a role [20,21].", [["NT-proBNP", "CHEMICAL", 0, 9], ["Kawasaki Disease", "DISEASE", 116, 132], ["KD", "DISEASE", 180, 182], ["NT-proBNP", "GENE_OR_GENE_PRODUCT", 0, 9], ["IVIG", "SIMPLE_CHEMICAL", 64, 68], ["NT-proBNP", "TEST", 0, 9], ["IVIG resistance", "TREATMENT", 64, 79], ["Kawasaki Disease", "PROBLEM", 116, 132], ["Kawasaki Disease", "OBSERVATION", 116, 132]]], ["There are several proposed components, best summarized by Marrani et al [22] -#1) Response to a pathogen: KD is self-limited with low recurrence rate [23], in addition to having seasonal variation in North America [24].", [["several proposed components", "PROBLEM", 10, 37], ["low recurrence rate", "PROBLEM", 130, 149], ["seasonal variation", "PROBLEM", 178, 196], ["several", "OBSERVATION_MODIFIER", 10, 17], ["components", "OBSERVATION_MODIFIER", 27, 37]]], ["Additionally, RNA-containing intracytoplasmic inclusion bodies [25] and IgA antibodies [26] can also be found in the bronchial epithelium of KD patients.", [["bronchial epithelium", "ANATOMY", 117, 137], ["IgA", "GENE_OR_GENE_PRODUCT", 72, 75], ["bronchial epithelium", "TISSUE", 117, 137], ["patients", "ORGANISM", 144, 152], ["IgA antibodies", "PROTEIN", 72, 86], ["patients", "SPECIES", 144, 152], ["RNA", "TEST", 14, 17], ["intracytoplasmic inclusion bodies", "PROBLEM", 29, 62], ["IgA antibodies", "TEST", 72, 86], ["intracytoplasmic", "OBSERVATION_MODIFIER", 29, 45], ["inclusion bodies", "OBSERVATION", 46, 62], ["bronchial epithelium", "ANATOMY", 117, 137]]], ["These studies suggest a viral pathogen activating the immune response via molecular mimicry [22], and subsequent immunity against re-exposure.", [["These studies", "TEST", 0, 13], ["a viral pathogen", "PROBLEM", 22, 38], ["viral", "OBSERVATION_MODIFIER", 24, 29]]], ["However, genetic profile has also identified that patients with acute KD have clear differences from other patients with viral disease [27].Etiologies and Epidemiology of Kawasaki Disease#2) T-cell driven autoimmune process: Anti-endothelial antibodies can be found in KD patients [28], resembling other forms of vasculitis such as lupus or anti-phospholipid syndrome.", [["viral disease", "DISEASE", 121, 134], ["Kawasaki Disease", "DISEASE", 171, 187], ["vasculitis", "DISEASE", 313, 323], ["lupus or anti-phospholipid syndrome", "DISEASE", 332, 367], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 107, 115], ["T-cell", "CELL", 191, 197], ["Anti-endothelial antibodies", "GENE_OR_GENE_PRODUCT", 225, 252], ["patients", "ORGANISM", 272, 280], ["Anti-endothelial antibodies", "PROTEIN", 225, 252], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 272, 280], ["acute KD", "PROBLEM", 64, 72], ["viral disease", "PROBLEM", 121, 134], ["Kawasaki Disease", "PROBLEM", 171, 187], ["T-cell driven autoimmune process", "PROBLEM", 191, 223], ["Anti-endothelial antibodies", "PROBLEM", 225, 252], ["vasculitis", "PROBLEM", 313, 323], ["lupus", "PROBLEM", 332, 337], ["anti-phospholipid syndrome", "PROBLEM", 341, 367], ["Kawasaki Disease", "OBSERVATION", 171, 187], ["vasculitis", "OBSERVATION", 313, 323], ["lupus", "OBSERVATION", 332, 337], ["anti-phospholipid syndrome", "OBSERVATION", 341, 367]]], ["KD patients after IVIG appear to have increased regulatory T cells that affect immunomodulation [21].", [["T cells", "ANATOMY", 59, 66], ["patients", "ORGANISM", 3, 11], ["IVIG", "SIMPLE_CHEMICAL", 18, 22], ["T cells", "CELL", 59, 66], ["regulatory T cells", "CELL_TYPE", 48, 66], ["patients", "SPECIES", 3, 11], ["IVIG", "TREATMENT", 18, 22], ["increased regulatory T cells", "PROBLEM", 38, 66]]], ["However, few studies show association of KD patients with other forms of autoimmune disease.Etiologies and Epidemiology of Kawasaki Disease#3) Aberrant activation of proinflammatory cytokines: During the acute phase, KD patients demonstrate massive release of interleukin-1 (IL-1), IL-6, and tumor necrosis factor (TNF) [29].", [["autoimmune disease", "DISEASE", 73, 91], ["Kawasaki Disease", "DISEASE", 123, 139], ["necrosis", "DISEASE", 298, 306], ["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 220, 228], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 260, 273], ["IL-1", "GENE_OR_GENE_PRODUCT", 275, 279], ["IL-6", "GENE_OR_GENE_PRODUCT", 282, 286], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 292, 313], ["TNF", "GENE_OR_GENE_PRODUCT", 315, 318], ["proinflammatory cytokines", "PROTEIN", 166, 191], ["interleukin-1 (IL-1", "PROTEIN", 260, 279], ["IL-6", "PROTEIN", 282, 286], ["tumor necrosis factor", "PROTEIN", 292, 313], ["TNF", "PROTEIN", 315, 318], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 220, 228], ["few studies", "TEST", 9, 20], ["autoimmune disease", "PROBLEM", 73, 91], ["Kawasaki Disease", "PROBLEM", 123, 139], ["Aberrant activation of proinflammatory cytokines", "PROBLEM", 143, 191], ["interleukin", "TEST", 260, 271], ["IL", "TEST", 275, 277], ["IL", "TEST", 282, 284], ["tumor necrosis factor", "PROBLEM", 292, 313], ["autoimmune", "OBSERVATION", 73, 83], ["Kawasaki Disease", "OBSERVATION", 123, 139], ["proinflammatory cytokines", "OBSERVATION", 166, 191], ["massive", "OBSERVATION_MODIFIER", 241, 248], ["tumor", "OBSERVATION_MODIFIER", 292, 297], ["necrosis", "OBSERVATION", 298, 306]]], ["IL-1 in particular has been implicated in CAA formation, leading to current trials investigating the use of IL-1 antagonists (Anakinra) to treat IVIG resistant CAAs [30].", [["CAA", "CHEMICAL", 42, 45], ["Anakinra", "CHEMICAL", 126, 134], ["CAAs", "DISEASE", 160, 164], ["CAA", "CHEMICAL", 42, 45], ["Anakinra", "CHEMICAL", 126, 134], ["IL-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["CAA", "SIMPLE_CHEMICAL", 42, 45], ["IL-1 antagonists", "GENE_OR_GENE_PRODUCT", 108, 124], ["Anakinra", "SIMPLE_CHEMICAL", 126, 134], ["IVIG", "SIMPLE_CHEMICAL", 145, 149], ["IL-1", "PROTEIN", 0, 4], ["IL-1 antagonists", "TREATMENT", 108, 124], ["Anakinra", "TREATMENT", 126, 134], ["IVIG resistant CAAs", "TREATMENT", 145, 164], ["CAA", "OBSERVATION", 42, 45]]], ["However, autoimmune diseases involving cytokines are usually associated with single gene defects, whereas the KD profile suggests more polygenic influence [31].Etiologies and Epidemiology of Kawasaki DiseaseUltimately, KD can be recognized as a complex inflammatory syndrome that occasionally affects the CAs of patients with genetic predisposition and a trigger.", [["autoimmune diseases", "DISEASE", 9, 28], ["Kawasaki DiseaseUltimately", "DISEASE", 191, 217], ["patients", "ORGANISM", 312, 320], ["cytokines", "PROTEIN", 39, 48], ["patients", "SPECIES", 312, 320], ["autoimmune diseases", "PROBLEM", 9, 28], ["cytokines", "PROBLEM", 39, 48], ["single gene defects", "PROBLEM", 77, 96], ["the KD profile", "TEST", 106, 120], ["a complex inflammatory syndrome", "PROBLEM", 243, 274], ["genetic predisposition", "PROBLEM", 326, 348], ["autoimmune diseases", "OBSERVATION", 9, 28], ["defects", "OBSERVATION", 89, 96], ["complex", "OBSERVATION_MODIFIER", 245, 252], ["inflammatory", "OBSERVATION", 253, 265]]], ["(Figure 1) Children of Asian and Pacific Islander descent are at highest risk \u2013 in Japan, the annual incidence is \u223c 260 per 100,000.", [["Children", "ORGANISM", 11, 19], ["Children", "SPECIES", 11, 19]]], ["Despite decades of research and hundreds of suggested pathogens, ranging from superantigens to shampoo rugs [33,34], no clear-cut antigen has been definitely linked to KD.", [["superantigens", "PROTEIN", 78, 91], ["pathogens", "PROBLEM", 54, 63], ["shampoo rugs", "TEST", 95, 107], ["clear-cut antigen", "PROBLEM", 120, 137]]], ["The rise of COVID-19 and MIS-C has now further challenged our understanding of KD.COVID-19 in Pediatric populationAlthough children of all ages are susceptible to COVID-19, the impact and clinical manifestations have been less severe compared to the adult population.", [["COVID-19", "CHEMICAL", 12, 20], ["COVID-19", "GENE_OR_GENE_PRODUCT", 12, 20], ["MIS-C", "GENE_OR_GENE_PRODUCT", 25, 30], ["children", "ORGANISM", 123, 131], ["children", "SPECIES", 123, 131], ["COVID", "TEST", 12, 17], ["COVID", "TEST", 163, 168], ["clinical manifestations", "PROBLEM", 188, 211], ["rise", "OBSERVATION_MODIFIER", 4, 8], ["less severe", "OBSERVATION_MODIFIER", 222, 233]]], ["As of June 5th 2020, the US had 66,376 cases of COVID-19 in children <18 years old.", [["children", "ORGANISM", 60, 68], ["children", "SPECIES", 60, 68], ["the US", "TEST", 21, 27], ["COVID", "TEST", 48, 53]]], ["The hospitalized rate is low with an estimated rate of 5.7%; the mortality rate is even lower in the US [35].", [["The hospitalized rate", "TEST", 0, 21], ["an estimated rate", "TEST", 34, 51], ["the mortality rate", "TEST", 61, 79], ["low", "OBSERVATION_MODIFIER", 25, 28]]], ["Proposed mechanisms include a stronger innate immune response compared to adults, and higher angiotensin converting enzyme (ACE)-2 expression which reduces the presence of angiotensin-2, known to correlate with COVID-19 viral load and clinical course [36,37].COVID-19 in Pediatric populationIn a cross-sectional study of North American pediatric intensive care units (PICUs), between March and April 2020, 48 children were admitted to 14 PICUs in the US [38].", [["angiotensin", "CHEMICAL", 93, 104], ["angiotensin-2", "CHEMICAL", 172, 185], ["angiotensin converting enzyme (ACE)-2", "GENE_OR_GENE_PRODUCT", 93, 130], ["angiotensin-2", "GENE_OR_GENE_PRODUCT", 172, 185], ["COVID-19", "GENE_OR_GENE_PRODUCT", 211, 219], ["children", "ORGANISM", 409, 417], ["angiotensin converting enzyme", "PROTEIN", 93, 122], ["ACE", "PROTEIN", 124, 127], ["children", "SPECIES", 409, 417], ["higher angiotensin converting enzyme (ACE)", "PROBLEM", 86, 128], ["angiotensin", "TEST", 172, 183], ["COVID", "TEST", 211, 216], ["viral load", "TEST", 220, 230]]], ["73% presented with respiratory symptoms, and 38% required invasive ventilation.", [["respiratory", "ANATOMY", 19, 30], ["respiratory symptoms", "DISEASE", 19, 39], ["respiratory symptoms", "PROBLEM", 19, 39], ["invasive ventilation", "TREATMENT", 58, 78], ["respiratory", "ANATOMY", 19, 30], ["invasive ventilation", "OBSERVATION", 58, 78]]], ["At our institution, which covers the District of Columbia (DC) metropolitan region (DC, Maryland, and Virginia), we have observed a steady increase of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) circulation in the 6 weeks since March 15, 2020 [39].", [["DC", "ANATOMY", 59, 61], ["DC", "ANATOMY", 84, 86], ["acute respiratory syndrome coronavirus", "DISEASE", 158, 196], ["severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2", "SPECIES", 151, 210], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 151, 196], ["SARS", "TEST", 200, 204], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["acute", "OBSERVATION_MODIFIER", 158, 163], ["respiratory syndrome coronavirus", "OBSERVATION", 164, 196]]], ["In our cohort, there was an association between other underlying comorbidities and hospitalization.First report and case definitions for MIS-CThe \u201cstay-at-home\u201d self-quarantine orders, a necessity for controlling the COVID-19 pandemic, initially raised concern amongst pediatric cardiologists that the reduced contact with health care providers and over-emphasis of COVID-19 by Bayesian thinking would potentially lead to under recognition of KD [11].", [["COVID-19", "DNA", 366, 374], ["other underlying comorbidities", "PROBLEM", 48, 78], ["MIS", "PROBLEM", 137, 140], ["COVID", "TREATMENT", 366, 371], ["comorbidities", "OBSERVATION", 65, 78]]], ["A concerning surge in presence of CAAs was somewhat anticipated, although there was also speculation that social distancing would reduce exposure of plausible trigger agents for KD.First report and case definitions for MIS-CThus, it was of great surprise to observe reports of pediatric patients treated for both COVID-19 and KD-like illness (Figure 2) [40].", [["CAAs", "DISEASE", 34, 38], ["KD-like illness", "DISEASE", 326, 341], ["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 287, 295], ["CAAs", "PROBLEM", 34, 38], ["plausible trigger agents", "TREATMENT", 149, 173], ["MIS", "PROBLEM", 219, 222], ["COVID", "TEST", 313, 318], ["CAAs", "OBSERVATION", 34, 38]]], ["The first case report was published in early April 2020 [41], but the first major call to attention was on April 26, 2020 when National Health Service in the United Kingdom (NHS UK) issued an alert to highlight a rise in cases of critically ill children with overlapping features of toxic shock syndrome, atypical KD and severe COVID-19 infection [42].", [["critically ill", "DISEASE", 230, 244], ["toxic shock syndrome", "DISEASE", 283, 303], ["KD", "DISEASE", 314, 316], ["COVID-19", "CHEMICAL", 328, 336], ["infection", "DISEASE", 337, 346], ["children", "ORGANISM", 245, 253], ["children", "SPECIES", 245, 253], ["toxic shock syndrome", "PROBLEM", 283, 303], ["atypical KD", "PROBLEM", 305, 316], ["severe COVID-19 infection", "PROBLEM", 321, 346], ["toxic shock syndrome", "OBSERVATION", 283, 303], ["severe", "OBSERVATION_MODIFIER", 321, 327]]], ["This was subsequently highlighted by Royal College of Paediatrics and Child Health (RCPCH), US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) [43], [44], [45].", [["Disease Control", "TREATMENT", 107, 122]]], ["There have been multiple descriptions and names, including Pediatric Multisystem Inflammatory Syndrome (PMIS) and MIS-C.", [["Multisystem Inflammatory Syndrome", "DISEASE", 69, 102], ["PMIS", "DISEASE", 104, 108], ["Pediatric Multisystem Inflammatory Syndrome", "PROBLEM", 59, 102], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["Multisystem", "OBSERVATION_MODIFIER", 69, 80], ["Inflammatory Syndrome", "OBSERVATION", 81, 102]]], ["For consistency we will use the CDC's definition \u201cMIS-C\u201d.MIS-C clinical dataTo date, the clinical data related to MIS-C are mainly collected from COVID-19 epicenters in Europe and the US.", [["MIS-C", "GENE_OR_GENE_PRODUCT", 114, 119], ["the clinical data", "TEST", 85, 102], ["MIS", "TEST", 114, 117], ["COVID", "TEST", 146, 151], ["the US", "TEST", 180, 186]]], ["Multiple case series have been published in eastern United States, Italy, UK and France [3,4,[46], [47], [48], [49], [50], [51], [52]].", [["3,4,[46], [47], [48], [49], [50], [51], [52]]", "SIMPLE_CHEMICAL", 89, 134]]], ["As of 6/16/2020, at least 130 patients have been reported in publications.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["The New York State Department of Health also identified 211 patients with similar presentations [53].MIS-C clinical dataSymptoms included fever with variable degree of respiratory symptoms and chest X-ray findings.", [["respiratory", "ANATOMY", 168, 179], ["dataSymptoms", "DISEASE", 116, 128], ["fever", "DISEASE", 138, 143], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["MIS-C clinical dataSymptoms", "PROBLEM", 101, 128], ["fever", "PROBLEM", 138, 143], ["respiratory symptoms", "PROBLEM", 168, 188], ["chest X-ray findings", "TEST", 193, 213], ["respiratory", "ANATOMY", 168, 179], ["chest", "ANATOMY", 193, 198]]], ["70% of patients had abdominal pain/diarrhea as presenting symptom.", [["abdominal", "ANATOMY", 20, 29], ["abdominal pain", "DISEASE", 20, 34], ["diarrhea", "DISEASE", 35, 43], ["patients", "ORGANISM", 7, 15], ["abdominal", "ORGANISM_SUBDIVISION", 20, 29], ["patients", "SPECIES", 7, 15], ["abdominal pain", "PROBLEM", 20, 34], ["diarrhea", "PROBLEM", 35, 43], ["presenting symptom", "PROBLEM", 47, 65], ["abdominal", "ANATOMY", 20, 29], ["pain", "OBSERVATION", 30, 34], ["diarrhea", "OBSERVATION", 35, 43]]], ["Regarding COVID-19 exposure, 74% had positive antibody test and 32% had positive PCR test.", [["COVID", "TEST", 10, 15], ["positive antibody test", "PROBLEM", 37, 59], ["positive PCR test", "PROBLEM", 72, 89]]], ["Most of the affected children received IVIG (75%), with 57% requiring vasoactive support and 13 patients (10%) requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO) as part of mechanical circulatory assistance.", [["veno-arterial extracorporeal membrane", "ANATOMY", 121, 158], ["children", "ORGANISM", 21, 29], ["patients", "ORGANISM", 96, 104], ["children", "SPECIES", 21, 29], ["patients", "SPECIES", 96, 104], ["IVIG", "TREATMENT", 39, 43], ["vasoactive support", "TREATMENT", 70, 88], ["veno-arterial extracorporeal membrane oxygenation", "TREATMENT", 121, 170], ["VA-ECMO", "TREATMENT", 172, 179], ["mechanical circulatory assistance", "TREATMENT", 192, 225], ["circulatory assistance", "OBSERVATION", 203, 225]]], ["In France, all patients were weaned off VA-ECMO.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["ECMO", "TREATMENT", 43, 47]]], ["There was one death reported in the UK (secondary to cerebral ischemic infarction).", [["cerebral", "ANATOMY", 53, 61], ["death", "DISEASE", 14, 19], ["cerebral ischemic infarction", "DISEASE", 53, 81], ["cerebral", "ORGAN", 53, 61], ["one death", "PROBLEM", 10, 19], ["cerebral ischemic infarction", "PROBLEM", 53, 81], ["one", "OBSERVATION_MODIFIER", 10, 13], ["death", "OBSERVATION", 14, 19], ["cerebral", "ANATOMY", 53, 61], ["ischemic", "OBSERVATION_MODIFIER", 62, 70], ["infarction", "OBSERVATION", 71, 81]]], ["None of the US case series reported any deaths, however 2 deaths were reported by the New York State Department of Health [49,53].MIS-C clinical dataThe overall MIS-C presentation appears to overlap KD with noticeable differences.", [["deaths", "DISEASE", 40, 46], ["deaths", "DISEASE", 58, 64], ["clinical data", "TEST", 136, 149]]], ["A significant portion of patients had findings consistent with KD including rash, conjunctivitis, lymphadenopathy, extremity edema and fissured lips.", [["extremity", "ANATOMY", 115, 124], ["lips", "ANATOMY", 144, 148], ["KD", "DISEASE", 63, 65], ["rash", "DISEASE", 76, 80], ["conjunctivitis", "DISEASE", 82, 96], ["lymphadenopathy", "DISEASE", 98, 113], ["extremity edema", "DISEASE", 115, 130], ["patients", "ORGANISM", 25, 33], ["edema", "PATHOLOGICAL_FORMATION", 125, 130], ["lips", "ORGANISM_SUBDIVISION", 144, 148], ["patients", "SPECIES", 25, 33], ["KD", "PROBLEM", 63, 65], ["rash", "PROBLEM", 76, 80], ["conjunctivitis", "PROBLEM", 82, 96], ["lymphadenopathy", "PROBLEM", 98, 113], ["extremity edema", "PROBLEM", 115, 130], ["fissured lips", "PROBLEM", 135, 148], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["consistent with", "UNCERTAINTY", 47, 62], ["KD", "OBSERVATION_MODIFIER", 63, 65], ["rash", "OBSERVATION", 76, 80], ["conjunctivitis", "OBSERVATION", 82, 96], ["lymphadenopathy", "OBSERVATION", 98, 113], ["extremity", "ANATOMY", 115, 124], ["edema", "OBSERVATION", 125, 130], ["fissured", "OBSERVATION_MODIFIER", 135, 143], ["lips", "ANATOMY", 144, 148]]], ["56% had evidence of decreased LV function by echocardiography.", [["LV", "ANATOMY", 30, 32], ["LV", "MULTI-TISSUE_STRUCTURE", 30, 32], ["decreased LV function", "PROBLEM", 20, 41], ["echocardiography", "TEST", 45, 61], ["decreased", "OBSERVATION", 20, 29], ["LV function", "OBSERVATION", 30, 41]]], ["Cardiac magnetic resonance imaging in several of these patients demonstrated increased signal intensity on T1 and T2-weighted imaging, consistent with diffuse myocardial edema, with no enhancement on late gadolinium imaging to suggest fibrosis [52].", [["Cardiac", "ANATOMY", 0, 7], ["myocardial", "ANATOMY", 159, 169], ["myocardial edema", "DISEASE", 159, 175], ["gadolinium", "CHEMICAL", 205, 215], ["fibrosis", "DISEASE", 235, 243], ["gadolinium", "CHEMICAL", 205, 215], ["patients", "ORGANISM", 55, 63], ["myocardial edema", "PATHOLOGICAL_FORMATION", 159, 175], ["patients", "SPECIES", 55, 63], ["Cardiac magnetic resonance imaging", "TEST", 0, 34], ["increased signal intensity", "PROBLEM", 77, 103], ["T1", "TEST", 107, 109], ["T2-weighted imaging", "TEST", 114, 133], ["diffuse myocardial edema", "PROBLEM", 151, 175], ["enhancement", "PROBLEM", 185, 196], ["late gadolinium imaging", "TEST", 200, 223], ["fibrosis", "PROBLEM", 235, 243], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["signal", "OBSERVATION_MODIFIER", 87, 93], ["intensity", "OBSERVATION_MODIFIER", 94, 103], ["consistent with", "UNCERTAINTY", 135, 150], ["diffuse", "OBSERVATION_MODIFIER", 151, 158], ["myocardial", "ANATOMY", 159, 169], ["edema", "OBSERVATION", 170, 175], ["no", "UNCERTAINTY", 182, 184], ["enhancement", "OBSERVATION_MODIFIER", 185, 196], ["suggest", "UNCERTAINTY", 227, 234], ["fibrosis", "OBSERVATION", 235, 243]]], ["Interestingly, only 15% had documented CA dilation, although the interpretation of CAA is affected by variations in image interpretation (i.e. absolute measurement vs. use of pediatric normative standards) and timing of echocardiography (i.e. whether echocardiography was performed before, during, or after immune modulation therapy).", [["CAA", "CHEMICAL", 83, 86], ["CAA", "CHEMICAL", 83, 86], ["CA", "GENE_OR_GENE_PRODUCT", 39, 41], ["documented CA dilation", "PROBLEM", 28, 50], ["CAA", "PROBLEM", 83, 86], ["image interpretation", "TEST", 116, 136], ["echocardiography", "TEST", 220, 236], ["echocardiography", "TEST", 251, 267], ["immune modulation therapy", "TREATMENT", 307, 332], ["dilation", "OBSERVATION", 42, 50], ["CAA", "OBSERVATION", 83, 86]]], ["Laboratory findings include elevated troponin, NT-proBNP, inflammatory markers, as well as lymphopenia and thrombocytopenia (Table 3).Is MIS-C a form of KD?Proponents of a connection between MIS-C and KD would argue that both conditions have a common trigger that provokes a cascade reaction in genetically susceptible children leading to the phenotype described above.", [["lymphopenia", "DISEASE", 91, 102], ["thrombocytopenia", "DISEASE", 107, 123], ["troponin", "GENE_OR_GENE_PRODUCT", 37, 45], ["NT-proBNP", "GENE_OR_GENE_PRODUCT", 47, 56], ["MIS-C", "GENE_OR_GENE_PRODUCT", 191, 196], ["children", "ORGANISM", 319, 327], ["troponin", "PROTEIN", 37, 45], ["inflammatory markers", "PROTEIN", 58, 78], ["children", "SPECIES", 319, 327], ["Laboratory findings", "TEST", 0, 19], ["elevated troponin", "PROBLEM", 28, 45], ["NT", "TEST", 47, 49], ["proBNP", "TEST", 50, 56], ["inflammatory markers", "PROBLEM", 58, 78], ["lymphopenia", "PROBLEM", 91, 102], ["thrombocytopenia", "PROBLEM", 107, 123], ["KD", "PROBLEM", 153, 155], ["a connection between MIS", "TREATMENT", 170, 194], ["a cascade reaction", "PROBLEM", 273, 291], ["elevated troponin", "OBSERVATION", 28, 45], ["inflammatory markers", "OBSERVATION", 58, 78], ["lymphopenia", "OBSERVATION", 91, 102], ["thrombocytopenia", "OBSERVATION", 107, 123]]], ["(Figure 1)Is MIS-C a form of KD?Opponents would argue that MIS-C children present with (1) older age of presentation, (2) more profound form of inflammation than that of KD or KD shock syndrome, (3) more gastrointestinal manifestation, (4) different laboratory findings including lymphopenia, thrombocytopenia, elevated troponin, elevated NT-proBNP, elevated D-Dimer, and elevated ferritin, and (5) and have higher propensity towards LV dysfunction and shock compared to KD patients.", [["gastrointestinal", "ANATOMY", 204, 220], ["LV", "ANATOMY", 434, 436], ["inflammation", "DISEASE", 144, 156], ["KD", "DISEASE", 170, 172], ["KD shock", "DISEASE", 176, 184], ["lymphopenia", "DISEASE", 280, 291], ["thrombocytopenia", "DISEASE", 293, 309], ["LV dysfunction", "DISEASE", 434, 448], ["shock", "DISEASE", 453, 458], ["MIS-C", "ORGANISM", 59, 64], ["children", "ORGANISM", 65, 73], ["gastrointestinal", "ORGAN", 204, 220], ["troponin", "GENE_OR_GENE_PRODUCT", 320, 328], ["NT-proBNP", "GENE_OR_GENE_PRODUCT", 339, 348], ["D-Dimer", "GENE_OR_GENE_PRODUCT", 359, 366], ["ferritin", "GENE_OR_GENE_PRODUCT", 381, 389], ["LV", "MULTI-TISSUE_STRUCTURE", 434, 436], ["patients", "ORGANISM", 474, 482], ["troponin", "PROTEIN", 320, 328], ["NT-proBNP", "PROTEIN", 339, 348], ["D-Dimer", "PROTEIN", 359, 366], ["ferritin", "PROTEIN", 381, 389], ["children", "SPECIES", 65, 73], ["patients", "SPECIES", 474, 482], ["KD", "PROBLEM", 29, 31], ["inflammation", "PROBLEM", 144, 156], ["KD", "PROBLEM", 170, 172], ["KD shock syndrome", "PROBLEM", 176, 193], ["more gastrointestinal manifestation", "PROBLEM", 199, 234], ["different laboratory findings", "PROBLEM", 240, 269], ["lymphopenia", "PROBLEM", 280, 291], ["thrombocytopenia", "PROBLEM", 293, 309], ["elevated troponin", "PROBLEM", 311, 328], ["elevated NT", "PROBLEM", 330, 341], ["proBNP", "TEST", 342, 348], ["elevated D-Dimer", "PROBLEM", 350, 366], ["elevated ferritin", "PROBLEM", 372, 389], ["LV dysfunction", "PROBLEM", 434, 448], ["shock", "PROBLEM", 453, 458], ["inflammation", "OBSERVATION", 144, 156], ["shock syndrome", "OBSERVATION", 179, 193], ["gastrointestinal", "ANATOMY", 204, 220], ["lymphopenia", "OBSERVATION", 280, 291], ["thrombocytopenia", "OBSERVATION", 293, 309], ["elevated", "OBSERVATION_MODIFIER", 372, 380], ["ferritin", "OBSERVATION", 381, 389], ["LV", "ANATOMY", 434, 436], ["dysfunction", "OBSERVATION", 437, 448], ["shock", "OBSERVATION", 453, 458]]], ["They would also highlight how MIS-C seem to have less propensity towards children of Asian and Pacific Islander descent [49,54].", [["MIS-C", "GENE_OR_GENE_PRODUCT", 30, 35], ["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81]]], ["The clinical patterns resemble that of toxic shock syndrome, typically the result of massive cytokine production, leading to capillary leak and subsequent hypotension [55].Is MIS-C a form of KD?Proponents of the MIS-C and KD connection would counter-argue that laboratory values difference noted in the Whittaker et al comparison might be in part explained by the different genetic compositions of the cohorts that were compared.", [["capillary", "ANATOMY", 125, 134], ["toxic shock syndrome", "DISEASE", 39, 59], ["hypotension", "DISEASE", 155, 166], ["capillary", "TISSUE", 125, 134], ["cytokine", "PROTEIN", 93, 101], ["toxic shock syndrome", "PROBLEM", 39, 59], ["massive cytokine production", "PROBLEM", 85, 112], ["capillary leak", "PROBLEM", 125, 139], ["subsequent hypotension", "PROBLEM", 144, 166], ["KD", "PROBLEM", 191, 193], ["the MIS", "TREATMENT", 208, 215], ["laboratory values", "TEST", 261, 278], ["toxic", "OBSERVATION_MODIFIER", 39, 44], ["shock syndrome", "OBSERVATION", 45, 59], ["massive", "OBSERVATION_MODIFIER", 85, 92], ["cytokine production", "OBSERVATION", 93, 112], ["capillary leak", "OBSERVATION", 125, 139], ["hypotension", "OBSERVATION", 155, 166]]], ["The UK series showed that 37% of the patients were of African descent whereas the KD San Diego cohort contains a large Hispanic portion [49,56].", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["The UK series", "TEST", 0, 13], ["African descent", "PROBLEM", 54, 69], ["a large Hispanic portion", "TREATMENT", 111, 135], ["large", "OBSERVATION_MODIFIER", 113, 118]]], ["They would also highlight that the geographic variation may be related to the differences in the sequences of SARS-CoV-2 [57].", [["SARS", "DISEASE", 110, 114], ["SARS-CoV", "ORGANISM", 110, 118], ["SARS-CoV", "SPECIES", 110, 118], ["SARS", "TEST", 110, 114], ["CoV", "TEST", 115, 118], ["may be related to", "UNCERTAINTY", 56, 73]]], ["The COVID-19 genomic data from GISAID [58] demonstrates that several variants (spike protein) have occurred more frequently in European countries and the eastern US, correlating with regions that produced the case series for MIS-C.", [["COVID-19", "DNA", 4, 12], ["spike protein", "PROTEIN", 79, 92], ["The COVID", "TEST", 0, 9], ["genomic data", "TEST", 13, 25], ["GISAID", "TEST", 31, 37], ["several variants (spike protein)", "PROBLEM", 61, 93], ["the eastern US", "TEST", 150, 164], ["MIS", "TEST", 225, 228]]], ["Meanwhile, in regions where other variants of SARS-CoV-2 are more prevalent [59,60], such as East Asian countries and the Western US, there has been a paucity of reports despite being historically prevalent for KD.", [["SARS", "DISEASE", 46, 50], ["SARS-CoV-2", "ORGANISM", 46, 56], ["SARS-CoV", "SPECIES", 46, 54], ["SARS", "PROBLEM", 46, 50], ["CoV", "TEST", 51, 54], ["the Western US", "TEST", 118, 132]]], ["One recent computer model has suggested that the spike mutations create a structure motif similar to those of bacterial superantigens, directly binding to T cell receptors and potentially activating the cytokine storm observed in MIS-C [61].", [["T cell", "ANATOMY", 155, 161], ["T cell receptors", "GENE_OR_GENE_PRODUCT", 155, 171], ["bacterial superantigens", "PROTEIN", 110, 133], ["T cell receptors", "PROTEIN", 155, 171], ["cytokine", "PROTEIN", 203, 211], ["the spike mutations", "PROBLEM", 45, 64], ["a structure motif", "PROBLEM", 72, 89], ["bacterial superantigens", "PROBLEM", 110, 133], ["T cell receptors", "TREATMENT", 155, 171], ["the cytokine storm", "PROBLEM", 199, 217], ["bacterial superantigens", "OBSERVATION", 110, 133], ["cytokine storm", "OBSERVATION", 203, 217]]], ["The difference in race/ethnicity suggests that MIS-C is activated by a trigger (possibly a virus) in a population with different genetic susceptibility compared to KD.Coronavirus as a trigger ::: The Cytokine StormThe role of coronavirus as a potential trigger for KD has been previously proposed with mixed results.", [["MIS-C", "GENE_OR_GENE_PRODUCT", 47, 52], ["coronavirus", "ORGANISM", 226, 237], ["Cytokine", "PROTEIN", 200, 208], ["The difference in race/ethnicity", "PROBLEM", 0, 32], ["MIS", "PROBLEM", 47, 50], ["a virus)", "PROBLEM", 89, 97], ["different genetic susceptibility", "PROBLEM", 119, 151], ["Coronavirus", "PROBLEM", 167, 178], ["coronavirus", "PROBLEM", 226, 237], ["KD", "PROBLEM", 265, 267], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["Cytokine Storm", "OBSERVATION", 200, 214]]], ["Coronavirus has been noted in KD patients but not in exclusive fashion (i.e. concurrent viral illness) [66].", [["Coronavirus", "CHEMICAL", 0, 11], ["viral illness", "DISEASE", 88, 101], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["Coronavirus", "PROBLEM", 0, 11]]], ["Specific strains of coronavirus have also been associated with KD in small case series [67] that could not be reproduced in other locations [68].", [["coronavirus", "ORGANISM", 20, 31], ["coronavirus", "SPECIES", 20, 31], ["Specific strains of coronavirus", "PROBLEM", 0, 31], ["coronavirus", "OBSERVATION", 20, 31], ["small", "OBSERVATION_MODIFIER", 69, 74]]], ["The viral genomics of coronavirus challenges the identification of any triggers for KD, as coronavirus is a positive sense RNA virus [69] and its genome is prone to mutation and genetic drift [59].", [["coronavirus", "DISEASE", 91, 102], ["coronavirus", "ORGANISM", 22, 33], ["coronavirus challenges", "PROBLEM", 22, 44], ["KD", "PROBLEM", 84, 86], ["coronavirus", "PROBLEM", 91, 102], ["a positive sense RNA virus", "PROBLEM", 106, 132], ["viral genomics", "OBSERVATION", 4, 18]]], ["Still, the absence of preceding symptoms, the 3 \u2013 6 week lag between virus prevalence and MIS-C prevalence, and higher frequency of positive antibody results suggests that SARS-CoV-2 acts as a trigger [5].\u201cGOK\u201d ::: The Cytokine StormIt is poignant and bittersweet to note that the quick recognition of MIS-C is only possible because of meticulous research conducted by Dr. Tomisaku Kawasaki, who recently passed away on June 5th 2020.", [["SARS", "DISEASE", 172, 176], ["MIS-C", "GENE_OR_GENE_PRODUCT", 90, 95], ["SARS-CoV-2", "ORGANISM", 172, 182], ["Cytokine", "GENE_OR_GENE_PRODUCT", 219, 227], ["MIS-C", "SIMPLE_CHEMICAL", 302, 307], ["Cytokine StormIt", "PROTEIN", 219, 235], ["SARS-CoV", "SPECIES", 172, 180], ["preceding symptoms", "PROBLEM", 22, 40], ["virus prevalence", "TEST", 69, 85], ["MIS", "TEST", 90, 93], ["positive antibody results", "PROBLEM", 132, 157], ["SARS", "PROBLEM", 172, 176]]], ["Dr. Kawasaki observed an unusual sickness not referenced in literature; as he saw more cases, he kept detailed observations in a folder labeled as \u201cGOK\u201d [70] - \u201cGod Only Knows.\u201d\u201cGOK\u201d ::: The Cytokine StormIn the six weeks since the first NHS UK Alert, pediatricians and cardiologists now recognize the significance of MIS-C and a \u201ccall to action\u201d [5,11,40,71,72] to prevent CAAs.", [["Kawasaki", "DISEASE", 4, 12], ["CAAs", "DISEASE", 374, 378], ["CAAs", "PATHOLOGICAL_FORMATION", 374, 378], ["Cytokine", "PROTEIN", 191, 199], ["The Cytokine StormIn", "TREATMENT", 187, 207], ["CAAs", "PROBLEM", 374, 378], ["CAAs", "OBSERVATION", 374, 378]]], ["Should we consider MIS-C as the same as KD?", [["MIS", "TREATMENT", 19, 22]]], ["If one were to consider KD as part of an inflammatory syndrome[22], it is reasonable to consider MIS-C as a unique and ubiquitous form [5] along its spectrum.\u201cGOK\u201d ::: The Cytokine StormNonetheless, the presentation of CAAs in a small but significant portion of MIS-C patients warrants caution and continued surveillance.", [["CAAs", "DISEASE", 219, 223], ["MIS-C", "SIMPLE_CHEMICAL", 97, 102], ["CAAs", "CANCER", 219, 223], ["patients", "ORGANISM", 268, 276], ["Cytokine", "PROTEIN", 172, 180], ["patients", "SPECIES", 268, 276], ["an inflammatory syndrome", "PROBLEM", 38, 62], ["CAAs", "PROBLEM", 219, 223], ["continued surveillance", "TEST", 298, 320], ["inflammatory", "OBSERVATION", 41, 53], ["Cytokine StormNonetheless", "OBSERVATION", 172, 197], ["CAAs", "OBSERVATION", 219, 223], ["small", "OBSERVATION_MODIFIER", 229, 234], ["significant", "OBSERVATION_MODIFIER", 239, 250], ["portion", "OBSERVATION_MODIFIER", 251, 258]]], ["Cardiologists will continue to have a role in providing accurate assessment of CAs and myocardial function to guide management [7].", [["myocardial", "ANATOMY", 87, 97], ["myocardial", "MULTI-TISSUE_STRUCTURE", 87, 97], ["accurate assessment", "TEST", 56, 75]]], ["Long-term studies are essential for MIS-C and COVID-19 patients, in the form of registry data and genomics [59,[73], [74], [75]].", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["Long-term studies", "TEST", 0, 17], ["MIS", "TEST", 36, 39], ["COVID", "TEST", 46, 51]]], ["These studies will help define the clinical course, epidemiology, mechanism of MIS-C \u2013 and potentially even KD itself.", [["MIS-C", "GENE_OR_GENE_PRODUCT", 79, 84], ["These studies", "TEST", 0, 13], ["MIS", "PROBLEM", 79, 82]]], ["The COVID-19 pandemic may serve as both challenge and opportunity for us to understand an inflammatory syndrome that \u201cGod Only Knows.\u201dDeclaration of Competing InterestNone.", [["The COVID", "TREATMENT", 0, 9], ["an inflammatory syndrome", "PROBLEM", 87, 111], ["inflammatory", "OBSERVATION", 90, 102]]]], "PMC7451224": [["IntroductionUrological service provision has changed dramatically in every country with the advent of COVID-19.", [["COVID", "TEST", 102, 107]]], ["Additional measures to ensure patient safety and protect staff are required, compelling us to re-prioritize waiting lists and rethink service provision and structure.", [["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["Additional measures", "TREATMENT", 0, 19]]], ["However, until a vaccination for COVID-19 is widely available, we need to continue to provide a safe and workable service, in parallel with the virus.IntroductionIn Ireland, the first case of SARS-CoV-2 was detected on 29 February 2020 [1].", [["SARS", "DISEASE", 192, 196], ["SARS-CoV-2", "ORGANISM", 192, 202], ["SARS-CoV", "SPECIES", 192, 200], ["COVID", "TEST", 33, 38], ["the virus", "PROBLEM", 140, 149]]], ["Following initial restrictions on large gatherings, the Irish government imposed stringent restrictions on movement from 27 March.", [["large", "OBSERVATION_MODIFIER", 34, 39]]], ["Time-sensitive elective surgery was outsourced to these hospitals, which, in the absence of emergency admissions, were deemed \u2018COVID-free\u2019.IntroductionDuring this time, we experienced a paradigm change in every aspect of our urological service.", [["elective surgery", "TREATMENT", 15, 31], ["a paradigm change", "PROBLEM", 184, 201]]], ["Elective surgery was performed at 2 sites, with mandatory pre-operative COVID-19 testing for all patients.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["Elective surgery", "TREATMENT", 0, 16], ["mandatory pre-operative COVID", "TEST", 48, 77]]], ["Patients with urgent conditions who were required to attend in person were separated in space and time, and we could not provide the same volume of diagnostic procedures as previously.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["person", "SPECIES", 63, 69], ["diagnostic procedures", "TREATMENT", 148, 169]]], ["Nevertheless, the hyper-stratification of patients for procedures and investigations has also forced us to reflect on our practice and review our criteria for accepting, investigating and discharging patients.IntroductionThe aim of this study is to provide an insight into the measures taken to restructure the urology service in our unit.", [["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 200, 208], ["procedures", "TEST", 55, 65], ["investigations", "TEST", 70, 84], ["this study", "TEST", 232, 242], ["urology", "ANATOMY", 311, 318]]], ["We compare the current work volume to the equivalent period last year and explain the rationale and methods used to triage care provision.", [["triage care provision", "TREATMENT", 116, 137]]], ["Although our initial reaction may be to mourn the loss of high-volume operating lists, and our previous structure, attention must turn to how we will provide a safe and workable service until, and perhaps beyond, the introduction of COVID-19 vaccination.Patient selection and study design ::: MethodsDepartmental activities for April and May 2020 (the study period) and 2019 were analysed.", [["COVID-19", "CHEMICAL", 233, 241], ["Patient", "SPECIES", 254, 261], ["COVID-19 vaccination", "TREATMENT", 233, 253]]], ["Details of admissions, diagnostic procedures, outpatient reviews, operations, morbidities and mortalities were recorded.", [["diagnostic procedures", "TEST", 23, 44]]], ["Following the government initiative to provide access for elective operation in offsite non-COVID hospitals, we prospectively recorded the outsourcing of these cases.", [["elective operation", "TREATMENT", 58, 76]]], ["All robotic prostate surgery was performed offsite prior to COVID-19\u2014access for robotic-assisted radical prostatectomy (RARP) was retained in the offsite COVID-free hospital for this period.Inpatient care ::: Management protocol ::: MethodsTo avoid potential infection of the entire urological team at once, the service was divided, with 2 consultants and 4 non-consultant hospital doctors (NCHDs) per team.", [["prostate", "ANATOMY", 12, 20], ["infection", "DISEASE", 259, 268], ["prostate", "ORGAN", 12, 20], ["All robotic prostate surgery", "TREATMENT", 0, 28], ["COVID-19\u2014access", "TREATMENT", 60, 75], ["robotic-assisted radical prostatectomy", "TREATMENT", 80, 118], ["RARP", "TREATMENT", 120, 124], ["Methods", "TREATMENT", 233, 240], ["potential infection", "PROBLEM", 249, 268], ["prostate", "ANATOMY", 12, 20], ["radical prostatectomy", "OBSERVATION", 97, 118], ["infection", "OBSERVATION", 259, 268]]], ["To map the change in urological emergency referrals, consecutive emergency admissions during matched 16-day pre-COVID and intra-COVID periods were evaluated.", [["intra-COVID periods", "TREATMENT", 122, 141]]], ["Diagnosis, intervention, length of stay (LOS), and alteration in management due to COVID-19 were recorded.", [["intervention", "TREATMENT", 11, 23], ["alteration in management", "TREATMENT", 51, 75], ["COVID", "TEST", 83, 88]]], ["Statistical analysis was performed using Mann-Whitney U test.Testing for COVID-19 ::: Management protocol ::: MethodsIn the initial study period, all patients were questionnaire screened, and those with fever, respiratory symptoms, or feeling generally unwell were tested.", [["respiratory", "ANATOMY", 210, 221], ["fever", "DISEASE", 203, 208], ["respiratory symptoms", "DISEASE", 210, 230], ["COVID-19", "CHEMICAL", 73, 81], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["Statistical analysis", "TEST", 0, 20], ["Mann-Whitney U test", "TEST", 41, 60], ["COVID", "TEST", 73, 78], ["Methods", "TREATMENT", 110, 117], ["fever", "PROBLEM", 203, 208], ["respiratory symptoms", "PROBLEM", 210, 230], ["feeling generally unwell", "PROBLEM", 235, 259]]], ["Sigma Virocult\u00ae nasopharyngeal swab was used and run on a standard reverse transcriptase polymerase chain reaction (RT-PCR) assay.", [["nasopharyngeal swab", "ANATOMY", 16, 35], ["Sigma", "GENE_OR_GENE_PRODUCT", 0, 5], ["reverse transcriptase", "PROTEIN", 67, 88], ["Sigma Virocult\u00ae nasopharyngeal swab", "TEST", 0, 35], ["a standard reverse transcriptase polymerase chain reaction", "TREATMENT", 56, 114], ["RT-PCR", "TEST", 116, 122]]], ["All patients who required operative intervention were tested.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["operative intervention", "TREATMENT", 26, 48]]], ["From May onwards, all patients were tested on admission, even if asymptomatic.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["asymptomatic", "PROBLEM", 65, 77]]], ["All patients for elective procedures are tested in pre-assessment clinic 1\u20133 days before surgery.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["elective procedures", "TREATMENT", 17, 36], ["surgery", "TREATMENT", 89, 96]]], ["In select, high-risk cases, the GeneXpert\u24c7 test was used, with a result available within an hour.Diagnostic procedures ::: Management protocol ::: MethodsIn the initial period, no prostate biopsies were performed.", [["prostate biopsies", "ANATOMY", 180, 197], ["prostate biopsies", "CANCER", 180, 197], ["the GeneXpert\u24c7 test", "TEST", 28, 47], ["Diagnostic procedures", "TEST", 97, 118], ["Methods", "TREATMENT", 147, 154], ["prostate biopsies", "TEST", 180, 197], ["no", "UNCERTAINTY", 177, 179], ["prostate", "ANATOMY", 180, 188], ["biopsies", "OBSERVATION", 189, 197]]], ["Following this, high-risk patients were selected, and their biopsies prioritized.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["their biopsies", "TEST", 54, 68]]], ["Each planned list of flexible cystoscopies was reviewed and risk stratified.", [["flexible cystoscopies", "TREATMENT", 21, 42]]], ["Haematuria clinic capacity was halved, with patients receiving cystoscopy, phlebotomy and same-day CT urogram.", [["Haematuria", "DISEASE", 0, 10], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["Haematuria clinic capacity", "PROBLEM", 0, 26], ["cystoscopy", "TEST", 63, 73], ["phlebotomy", "TREATMENT", 75, 85], ["same-day CT urogram", "TEST", 90, 109]]], ["CT replaced renal ultrasound, to avoid close contact between sonographer and patient.Outpatient clinic ::: Management protocol ::: MethodsAll outpatient clinics were conducted by telephone.", [["renal", "ANATOMY", 12, 17], ["renal", "ORGAN", 12, 17], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["CT", "TEST", 0, 2], ["renal ultrasound", "TEST", 12, 28], ["Methods", "TREATMENT", 131, 138], ["renal", "ANATOMY", 12, 17]]], ["Only patients with a new cancer diagnosis, or those requiring urgent, nondeferrable attention, were asked to attend in person and met with the consultant and cancer nurse specialist.", [["cancer", "ANATOMY", 25, 31], ["cancer", "ANATOMY", 158, 164], ["cancer", "DISEASE", 25, 31], ["cancer", "DISEASE", 158, 164], ["patients", "ORGANISM", 5, 13], ["cancer", "CANCER", 25, 31], ["cancer", "CANCER", 158, 164], ["patients", "SPECIES", 5, 13], ["person", "SPECIES", 119, 125], ["a new cancer diagnosis", "PROBLEM", 19, 41], ["new", "OBSERVATION_MODIFIER", 21, 24], ["cancer", "OBSERVATION", 25, 31]]], ["Appointments for these patients were spaced 30 min apart, to minimize and ideally avoid contact with other patients.Virtual clinic ::: Management protocol ::: MethodsWith increasing volume of referrals and many outpatient appointments deferred, virtual models of care are essential.", [["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 107, 115]]], ["A proportion of less urgent return patients were cohorted.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["less", "OBSERVATION_MODIFIER", 16, 20]]], ["These patients were assessed by a consultant in a \u2018virtual\u2019 clinic using electronic records (letters, imaging, blood results) and chart review if required.Virtual clinic ::: Management protocol ::: MethodsPatients were either discharged, were discharged for GP testing with specified re-referral criteria, received a phone call or follow-up letter by a clinical nurse specialist, were investigated and reviewed by phone/letter or were booked in for face-to-face consultation.Multidisciplinary meetings ::: Management protocol ::: MethodsThe weekly multidisciplinary meeting was curtailed with attendance limited to essential members.", [["blood", "ANATOMY", 111, 116], ["patients", "ORGANISM", 6, 14], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["patients", "SPECIES", 6, 14], ["imaging", "TEST", 102, 109], ["GP testing", "TEST", 258, 268], ["Methods", "TREATMENT", 530, 537]]], ["Two urologists, one radiation and one medical oncologist, one pathologist, one radiologist and the cancer coordinator met weekly, in a physically distanced setting.", [["cancer", "ANATOMY", 99, 105], ["cancer", "DISEASE", 99, 105], ["cancer", "CANCER", 99, 105], ["cancer", "OBSERVATION", 99, 105]]], ["Additional participants could join via teleconference.Emergency operating ::: Management protocol ::: MethodsPatients presenting to the emergency department who required operative intervention were managed surgically as in the pre-COVID period.", [["participants", "SPECIES", 11, 23], ["operative intervention", "TREATMENT", 170, 192]]], ["Where possible, surgery was delayed until confirmation of a negative COVID test.", [["surgery", "TREATMENT", 16, 23], ["a negative COVID test", "TEST", 58, 79]]], ["However, the absence of a negative test did not preclude time-sensitive surgery, which was then performed with additional precautions.", [["additional precautions", "TREATMENT", 111, 133]]], ["We performed an analysis of volume of emergency referrals and time to operative intervention in matched 16-day periods in the pre- and intra-COVID periods.Outsourcing of surgery ::: Management protocol ::: MethodsUrgent elective cases were identified and outsourced to the non-COVID private hospital, temporarily seconded to the public healthcare system and operated on by their own consultants [4].", [["an analysis", "TEST", 13, 24], ["operative intervention", "TREATMENT", 70, 92], ["the pre- and intra-COVID periods", "TREATMENT", 122, 154]]], ["Each consultant and their senior NCHD reviewed their waiting list and selected these patients.", [["NCHD", "CANCER", 33, 37], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93]]], ["Patients were tested for COVID-19 the day before their procedure and deferred if positive.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 25, 30], ["their procedure", "TREATMENT", 49, 64], ["positive", "PROBLEM", 81, 89]]], ["On the day of surgery, patients completed a symptom questionnaire and were temperature-screened.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["surgery", "TREATMENT", 14, 21], ["a symptom questionnaire", "TEST", 42, 65], ["temperature", "TEST", 75, 86]]], ["Patients were asked to self-isolate for 14 days before their surgery.Analysis ::: MethodsData were collated and analysed, to determine the effect of COVID-19 restrictions on volume and outcome.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["their surgery", "TREATMENT", 55, 68], ["MethodsData", "TEST", 82, 93], ["COVID", "TREATMENT", 149, 154]]], ["The number of positive cases for COVID-19 was measured, to determine if the system of separate-site elective operation facilitated urgent intervention without iatrogenic coronavirus infections.Operating ::: ResultsDuring the study period, 74 emergency operations were performed onsite in the COVID hospital, with 85 elective operations outsourced to the COVID-free hospital.", [["coronavirus infections", "DISEASE", 170, 192], ["coronavirus", "ORGANISM", 170, 181], ["COVID", "TEST", 33, 38], ["separate-site elective operation", "TREATMENT", 86, 118], ["urgent intervention", "TREATMENT", 131, 150], ["iatrogenic coronavirus infections", "PROBLEM", 159, 192], ["85 elective operations", "TREATMENT", 313, 335], ["positive", "OBSERVATION_MODIFIER", 14, 22], ["coronavirus infections", "OBSERVATION", 170, 192]]], ["Of cases performed in the primary centre, 78.4% (n = 58) were for urolithiasis.", [["urolithiasis", "DISEASE", 66, 78], ["urolithiasis", "PROBLEM", 66, 78], ["urolithiasis", "OBSERVATION", 66, 78]]], ["Two (2.7%) cases performed onsite were oncological resections, both of which were deemed unsuitable for outsourcing.", [["oncological resections", "TREATMENT", 39, 61], ["oncological resections", "OBSERVATION", 39, 61]]], ["Fifty-three oncological resections were performed in the same period in 2019.", [["three oncological resections", "TREATMENT", 6, 34], ["oncological resections", "OBSERVATION", 12, 34]]], ["Details of operations performed in each period are displayed in Table 1.COVID-19 infection rates ::: ResultsOf the 101 patients admitted to the primary centre, 5 (5.0%) tested positive for COVID-19 during their admission.", [["infection", "DISEASE", 81, 90], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["COVID", "TEST", 72, 77], ["COVID", "TEST", 189, 194], ["infection", "OBSERVATION", 81, 90]]], ["A further patient was transferred directly from a regional hospital to the non-COVID centre for planned major cancer surgery.", [["cancer", "ANATOMY", 110, 116], ["cancer", "DISEASE", 110, 116], ["patient", "ORGANISM", 10, 17], ["cancer", "CANCER", 110, 116], ["patient", "SPECIES", 10, 17], ["planned major cancer surgery", "TREATMENT", 96, 124], ["cancer", "OBSERVATION", 110, 116]]], ["This patient tested positive on arrival and required admission and ICU care.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["ICU care", "TREATMENT", 67, 75], ["positive", "OBSERVATION", 20, 28]]], ["Of these six inpatients who had COVID-19, two (33.3%) died, 1 (16.7%) required prolonged high-flow oxygen and 3 (50%) had mild symptoms.", [["oxygen", "CHEMICAL", 99, 105], ["oxygen", "CHEMICAL", 99, 105], ["oxygen", "SIMPLE_CHEMICAL", 99, 105], ["COVID", "TEST", 32, 37], ["prolonged high-flow oxygen", "TREATMENT", 79, 105], ["mild symptoms", "PROBLEM", 122, 135]]], ["All patients had been an inpatient in a hospital for a minimum of 10 days prior to testing positive.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["testing", "TEST", 83, 90]]], ["One was admitted with epididymo-orchitis and had a negative screening questionnaire and therefore was not initially tested.", [["epididymo-orchitis", "DISEASE", 22, 40], ["epididymo-orchitis", "PROBLEM", 22, 40], ["epididymo-orchitis", "OBSERVATION", 22, 40]]], ["None of the COVID-19 positive patients had undergone a procedure under general anaesthetic.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["the COVID", "TEST", 8, 17], ["a procedure", "TREATMENT", 53, 64], ["general anaesthetic", "TREATMENT", 71, 90]]], ["Three (50.0%) had tested negative at admission and underwent nephrostomy insertion for infected and obstructed kidneys but subsequently contracted COVID-19 in the hospital.Staff COVID-19 rates ::: ResultsFollowing the segregation of the two urology teams, two members of one team contracted COVID-19, 3 weeks apart.", [["kidneys", "ANATOMY", 111, 118], ["COVID-19", "CHEMICAL", 147, 155], ["kidneys", "ORGAN", 111, 118], ["nephrostomy insertion", "TREATMENT", 61, 82], ["infected and obstructed kidneys", "PROBLEM", 87, 118], ["nephrostomy", "OBSERVATION", 61, 72], ["infected", "OBSERVATION", 87, 95], ["obstructed", "OBSERVATION", 100, 110], ["kidneys", "ANATOMY", 111, 118], ["contracted", "OBSERVATION", 136, 146]]], ["On the urology ward, 12 (44.4%) of 27 nurses tested positive for coronavirus in the study period.Inpatient workload ::: ResultsThere were 91 and 107 emergency admissions, and 10 and 87 elective admissions in the 2020 and 2019 study periods, respectively.", [["coronavirus", "DISEASE", 65, 76], ["coronavirus", "ORGANISM", 65, 76], ["coronavirus", "PROBLEM", 65, 76]]], ["To assess the change in urological emergency referrals, we performed a separate evaluation of matched 16-day pre-COVID and intra-COVID periods.", [["a separate evaluation", "TEST", 69, 90], ["intra-COVID periods", "TREATMENT", 123, 142]]], ["Mean admissions, consults and phone calls per 24 h decreased significantly from 2.6 to 1.5 (P = 0.03), 3.1 to 1.6 (P = 0.01) and 18 to 12 (P = 0.005). respectively.", [["P", "TEST", 92, 93], ["P", "TEST", 115, 116]]], ["Urolithiasis accounted for 53.7% (n = 22) of pre-COVID and 41.7% (n = 10) of intra-COVID admissions.", [["Urolithiasis", "DISEASE", 0, 12], ["pre-COVID", "DISEASE", 45, 54], ["Urolithiasis", "PROBLEM", 0, 12], ["pre-COVID", "TEST", 45, 54]]], ["Operative intervention was required in 78.1% (n = 32) and 50.0% (n = 12) of patients in each cohort.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Operative intervention", "TREATMENT", 0, 22]]], ["However, there was no significant difference in mean time to intervention or median length of stay (LOS) between groups.", [["intervention", "TREATMENT", 61, 73], ["no", "UNCERTAINTY", 19, 21], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["difference", "OBSERVATION_MODIFIER", 34, 44]]], ["Of patients presenting with urolithiasis, there was no change in proportion of presentations with concomitant acute kidney injury (P = 0.78).", [["kidney", "ANATOMY", 116, 122], ["urolithiasis", "DISEASE", 28, 40], ["acute kidney injury", "DISEASE", 110, 129], ["patients", "ORGANISM", 3, 11], ["kidney", "ORGAN", 116, 122], ["patients", "SPECIES", 3, 11], ["urolithiasis", "PROBLEM", 28, 40], ["concomitant acute kidney injury", "PROBLEM", 98, 129], ["urolithiasis", "OBSERVATION", 28, 40], ["no", "UNCERTAINTY", 52, 54], ["change", "OBSERVATION_MODIFIER", 55, 61], ["concomitant", "OBSERVATION_MODIFIER", 98, 109], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["kidney", "ANATOMY", 116, 122], ["injury", "OBSERVATION", 123, 129]]], ["Among the intra-COVID group, 12.5% (n = 3) of patients reported delaying their presentation (median 7 days) due to COVID-19.Outpatient clinic ::: ResultsMore patients (n = 972) were reviewed through phone clinic than were seen in person previously in the pre-COVID clinic setting (n = 895).", [["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 158, 166], ["person", "SPECIES", 230, 236], ["the intra-COVID group", "TEST", 6, 27], ["COVID", "TEST", 115, 120]]], ["There were considerably fewer flexible cystoscopies, prostate biopsies and ESWL sessions performed in the 2020 period than the 2019 period (Table 2).", [["prostate biopsies", "ANATOMY", 53, 70], ["prostate biopsies", "MULTI-TISSUE_STRUCTURE", 53, 70], ["flexible cystoscopies", "TREATMENT", 30, 51], ["prostate biopsies", "TEST", 53, 70], ["ESWL sessions", "TEST", 75, 88], ["prostate", "ANATOMY", 53, 61]]], ["The urodynamics advanced nurse practitioner was re-deployed\u2014no urodynamics were performed during this time.", [["urodynamics", "PROBLEM", 63, 74]]], ["Four hundred patients were assessed by a consultant through this medium.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["One hundred sixty (40%) patients were discharged directly with a letter and advice sent to the patient and their primary care physician.", [["patients", "ORGANISM", 24, 32], ["patient", "ORGANISM", 95, 102], ["patients", "SPECIES", 24, 32], ["patient", "SPECIES", 95, 102]]], ["One hundred twenty-one (30%) required further imaging.", [["further imaging", "TEST", 38, 53]]], ["Seventy-nine (20%) were suitable for phone or formal review by the LUTS clinical nurse specialist.", [["LUTS", "DISEASE", 67, 71]]], ["Forty (10%) necessitated face-to-face review for assessment or investigation.", [["assessment or investigation", "TEST", 49, 76]]], ["In 47 patients, there was insufficient information available in the electronic platforms, thus requiring formal chart review.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["Overall, 360 patients could be managed via \u2018virtual\u2019 means.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["The potential outpatient cost savings were estimated at \u20ac27,000.New cancer diagnoses ::: ResultsThere were 16 new cancer diagnoses, compared with 47 in the same period last year.", [["cancer", "ANATOMY", 68, 74], ["cancer", "ANATOMY", 114, 120], ["cancer", "DISEASE", 68, 74], ["cancer", "DISEASE", 114, 120], ["cancer", "CANCER", 68, 74], ["cancer", "CANCER", 114, 120], ["16 new cancer diagnoses", "PROBLEM", 107, 130], ["cancer", "OBSERVATION", 68, 74], ["new", "OBSERVATION_MODIFIER", 110, 113], ["cancer", "OBSERVATION", 114, 120]]], ["New renal tumour diagnoses fell from 10 to 4, and prostate cancer diagnoses from 26 to 4.New cancer diagnoses ::: ResultsWith careful prioritization of high-risk patients, there was no decrease in the number of new bladder cancer diagnoses.", [["renal tumour", "ANATOMY", 4, 16], ["prostate cancer", "ANATOMY", 50, 65], ["cancer", "ANATOMY", 93, 99], ["bladder cancer", "ANATOMY", 215, 229], ["renal tumour", "DISEASE", 4, 16], ["prostate cancer", "DISEASE", 50, 65], ["cancer", "DISEASE", 93, 99], ["bladder cancer", "DISEASE", 215, 229], ["renal tumour", "CANCER", 4, 16], ["prostate cancer", "CANCER", 50, 65], ["cancer", "CANCER", 93, 99], ["patients", "ORGANISM", 162, 170], ["bladder cancer", "CANCER", 215, 229], ["patients", "SPECIES", 162, 170], ["New renal tumour diagnoses", "PROBLEM", 0, 26], ["prostate cancer", "PROBLEM", 50, 65], ["new bladder cancer diagnoses", "PROBLEM", 211, 239], ["renal", "ANATOMY", 4, 9], ["tumour", "OBSERVATION", 10, 16], ["prostate", "ANATOMY", 50, 58], ["cancer", "OBSERVATION", 59, 65], ["cancer", "OBSERVATION", 93, 99], ["no", "UNCERTAINTY", 182, 184], ["decrease", "OBSERVATION_MODIFIER", 185, 193], ["new", "OBSERVATION_MODIFIER", 211, 214], ["bladder", "ANATOMY", 215, 222], ["cancer", "OBSERVATION", 223, 229]]], ["Cancer diagnosis numbers are displayed in Table 2.Teaching/training ::: ResultsThree national urology training days and all weekly educational meetings were cancelled.", [["Cancer", "ANATOMY", 0, 6], ["Cancer", "DISEASE", 0, 6], ["Cancer", "CANCER", 0, 6]]], ["Across the two senior training programme NCHDs, the mean number of operations per trainee fell from 50 cases per month to 7.DiscussionCompared with the same period in 2019, we performed fewer operations and fewer outpatient procedures, had fewer admissions, diagnosed fewer cancers, and reviewed most outpatients by phone rather than in person.", [["cancers", "ANATOMY", 274, 281], ["cancers", "DISEASE", 274, 281], ["cancers", "CANCER", 274, 281], ["person", "SPECIES", 337, 343], ["cancers", "OBSERVATION", 274, 281]]], ["We were reasonably successful in preventing our patients contracting COVID-19.", [["COVID-19", "CHEMICAL", 69, 77], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["our patients contracting COVID", "TEST", 44, 74]]], ["For patients who became infected, outcomes were poor, with 33% of cases culminating in death.", [["death", "DISEASE", 87, 92], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["infected", "PROBLEM", 24, 32], ["death", "PROBLEM", 87, 92], ["infected", "OBSERVATION", 24, 32]]], ["An increased length of stay leads to an increased risk of contracting COVID-19.", [["COVID-19", "CHEMICAL", 70, 78], ["contracting COVID", "TEST", 58, 75], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["length", "OBSERVATION_MODIFIER", 13, 19], ["increased", "OBSERVATION_MODIFIER", 40, 49]]], ["As cases in Ireland drop, the greater risk to patients is not in the community, but in the hospital.DiscussionSimilar to other centres, there were fewer emergency admissions and fewer average calls per 24 h in the COVID period compared with pre-COVID [5, 6].", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54]]], ["However, patients admitted emergently requiring operative intervention continued to have timely surgery, with no difference in time to intervention or LOS.DiscussionWith a return to elective onsite operating lists, requirements for pre-operative testing and physical distancing preclude a return to pre-COVID volume.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["operative intervention", "TREATMENT", 48, 70], ["timely surgery", "TREATMENT", 89, 103], ["pre-operative testing", "TEST", 232, 253]]], ["Therefore, although neither our catchment area nor our population has decreased, our ability to offer operative management has markedly declined.", [["operative management", "TREATMENT", 102, 122], ["decreased", "OBSERVATION_MODIFIER", 70, 79]]], ["This will require re-triaging of waiting lists, with a predilection for oncology and for urgent renal function-preserving operations.", [["renal", "ANATOMY", 96, 101], ["renal", "ORGAN", 96, 101], ["urgent renal function", "TEST", 89, 110], ["preserving operations", "TREATMENT", 111, 132], ["renal", "ANATOMY", 96, 101]]], ["For urological cancer surgery, moving elective operation offsite during the study period was successful.", [["urological cancer", "ANATOMY", 4, 21], ["urological cancer", "DISEASE", 4, 21], ["urological cancer", "CANCER", 4, 21], ["urological cancer surgery", "TREATMENT", 4, 29], ["moving elective operation", "TREATMENT", 31, 56], ["the study", "TEST", 72, 81], ["cancer", "OBSERVATION", 15, 21]]], ["No patients contracted the virus in the post-operative period.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["patients contracted the virus", "PROBLEM", 3, 32], ["contracted", "OBSERVATION", 12, 22], ["virus", "OBSERVATION", 27, 32]]], ["Other cases suited for outsourcing included those where intensive post-operative monitoring was not required.", [["intensive post-operative monitoring", "TEST", 56, 91]]], ["It was ideal for most day case work including flexible ureterorenoscopy.", [["flexible ureterorenoscopy", "TEST", 46, 71]]], ["We were highly selective on outsourcing patients requiring cystectomy and did not outsource RPLND, percutaneous renal surgery or major reconstructive surgery.", [["renal", "ANATOMY", 112, 117], ["RPLND", "DISEASE", 92, 97], ["patients", "ORGANISM", 40, 48], ["renal", "ORGAN", 112, 117], ["patients", "SPECIES", 40, 48], ["cystectomy", "TREATMENT", 59, 69], ["RPLND", "TREATMENT", 92, 97], ["percutaneous renal surgery", "TREATMENT", 99, 125], ["major reconstructive surgery", "TREATMENT", 129, 157], ["selective", "OBSERVATION_MODIFIER", 15, 24], ["cystectomy", "OBSERVATION", 59, 69], ["renal", "ANATOMY", 112, 117], ["surgery", "OBSERVATION", 118, 125], ["reconstructive surgery", "OBSERVATION", 135, 157]]], ["Tackling the mounting list of patients for benign surgery will require diversification from our previous systems.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["benign surgery", "TREATMENT", 43, 57]]], ["Additional elective lists at weekends, in model 2 and 3 hospitals (smaller regional hospitals), or by purchasing additional access in private hospitals, offer potential options to alleviate waiting lists [7].DiscussionStringent triage of patients for diagnostic procedures has led to higher cancer diagnosis ratio.", [["cancer", "ANATOMY", 291, 297], ["cancer", "DISEASE", 291, 297], ["patients", "ORGANISM", 238, 246], ["cancer", "CANCER", 291, 297], ["patients", "SPECIES", 238, 246], ["diagnostic procedures", "TEST", 251, 272], ["cancer", "OBSERVATION", 291, 297]]], ["However, it is difficult to gauge how many other cancers and other pathologies await diagnosis.", [["cancers", "ANATOMY", 49, 56], ["cancers", "DISEASE", 49, 56], ["cancers", "CANCER", 49, 56], ["many other cancers", "PROBLEM", 38, 56], ["other pathologies", "PROBLEM", 61, 78], ["cancers", "OBSERVATION", 49, 56]]], ["Continued deferral of lower-risk investigation is not a viable long-term strategy.DiscussionThere was a 66% decrease in new cancer diagnoses in the study period compared with the previous year, predominantly prostate and renal tumours.", [["cancer", "ANATOMY", 124, 130], ["prostate", "ANATOMY", 208, 216], ["renal tumours", "ANATOMY", 221, 234], ["cancer", "DISEASE", 124, 130], ["prostate and renal tumours", "DISEASE", 208, 234], ["cancer", "CANCER", 124, 130], ["prostate", "CANCER", 208, 216], ["renal tumours", "CANCER", 221, 234], ["a viable long-term strategy", "TREATMENT", 54, 81], ["a 66% decrease in new cancer", "PROBLEM", 102, 130], ["predominantly prostate and renal tumours", "PROBLEM", 194, 234], ["decrease", "OBSERVATION_MODIFIER", 108, 116], ["new", "OBSERVATION_MODIFIER", 120, 123], ["cancer", "OBSERVATION", 124, 130], ["prostate", "ANATOMY", 208, 216], ["renal", "ANATOMY", 221, 226], ["tumours", "OBSERVATION", 227, 234]]], ["This was due to the temporary cessation and then cautious reintroduction of prostate biopsies as well as decreased primary care referrals.", [["prostate biopsies", "ANATOMY", 76, 93], ["prostate biopsies", "CANCER", 76, 93], ["the temporary cessation", "TREATMENT", 16, 39], ["prostate biopsies", "TREATMENT", 76, 93], ["prostate", "ANATOMY", 76, 84]]], ["There was also a 52% decrease in new referrals to the outpatient clinic.", [["decrease", "OBSERVATION_MODIFIER", 21, 29]]], ["A rebound increase in diagnoses is therefore inevitable in the coming months.", [["A rebound increase", "PROBLEM", 0, 18], ["rebound", "OBSERVATION_MODIFIER", 2, 9], ["increase", "OBSERVATION_MODIFIER", 10, 18]]], ["The combination of smaller-volume operating lists with this reciprocal surge in oncological cases will undoubtedly present challenges.DiscussionSimilar to other institutions, innovative models such as a \u2018virtual\u2019 outpatient clinic allows reliable review of outpatients with fewer face-to-face follow-up attendances [8, 9].", [["this reciprocal surge", "TREATMENT", 55, 76], ["smaller", "OBSERVATION_MODIFIER", 19, 26]]], ["We will review many nephrolithiasis patients in this way, as well as those requiring surveillance investigations (e.g. blood tests or scans) post-cancer treatment.", [["blood", "ANATOMY", 119, 124], ["cancer", "ANATOMY", 146, 152], ["nephrolithiasis", "DISEASE", 20, 35], ["cancer", "DISEASE", 146, 152], ["patients", "ORGANISM", 36, 44], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["cancer", "CANCER", 146, 152], ["patients", "SPECIES", 36, 44], ["many nephrolithiasis", "PROBLEM", 15, 35], ["surveillance investigations", "TEST", 85, 112], ["blood tests", "TEST", 119, 130], ["scans", "TEST", 134, 139], ["post-cancer treatment", "TREATMENT", 141, 162], ["nephrolithiasis", "OBSERVATION", 20, 35], ["cancer", "OBSERVATION", 146, 152]]], ["The traditional outpatient model will be reserved for patients requiring clinical examination, uroflowmetry, discussion of a new cancer diagnosis or consultation for major surgery.", [["cancer", "ANATOMY", 129, 135], ["cancer", "DISEASE", 129, 135], ["patients", "ORGANISM", 54, 62], ["cancer", "CANCER", 129, 135], ["patients", "SPECIES", 54, 62], ["clinical examination", "TEST", 73, 93], ["uroflowmetry", "TEST", 95, 107], ["major surgery", "TREATMENT", 166, 179], ["cancer", "OBSERVATION", 129, 135]]], ["The remaining patients will be contacted by phone or virtual telehealth platform, in a hybrid clinic model.DiscussionWith any closely working team, many members could conceivably be simultaneously infected, eliminating the entire specialty service.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["We found the short-term division of the team an effective model in preventing potential cross-infection.", [["potential cross-infection", "PROBLEM", 78, 103], ["preventing potential", "UNCERTAINTY", 67, 87], ["cross-infection", "OBSERVATION", 88, 103]]], ["We feel that if any doctor or nurse on the urology ward tests positive, it is prudent to test all other team members at that time.DiscussionDespite initial frustration with upheaval of the long-established and efficient delivery of care, we have learned much in restructuring our service.", [["the urology ward tests", "TEST", 39, 61]]], ["Through the measures outlined, we have been reasonably successful in preventing the spread of COVID-19 among patients attending the hospital.", [["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117]]], ["There has undoubtedly been an opportunity cost, with significant effects on training and operative experience.", [["operative experience", "TREATMENT", 89, 109]]], ["There are several challenges facing the provision of high-quality urological care in 2020.", [["several", "OBSERVATION_MODIFIER", 10, 17], ["challenges", "OBSERVATION", 18, 28]]], ["Although the impact of SARS-CoV-19 on Irish healthcare and society has been profound, we have not been as intensely affected as some of our European and American counterparts.", [["SARS", "DISEASE", 23, 27], ["SARS-CoV-19", "ORGANISM", 23, 34]]], ["As society continues to re-open, we look to safely navigate the parallel agendas of coronavirus prevention and adequate service provision for our community and catchment area.", [["coronavirus", "DISEASE", 84, 95], ["coronavirus", "ORGANISM", 84, 95], ["coronavirus prevention", "TREATMENT", 84, 106]]]], "021fba0f252408868fa29b65686dedb3b3d6bf02": [["IntroductionGlobal pesticide production should be highly effective, confer low toxicity and high safety coefficient, and exhibit satisfactory selectivity and environmental compatibility.", [["toxicity", "DISEASE", 79, 87], ["Global pesticide production", "PROBLEM", 12, 39], ["low toxicity", "PROBLEM", 75, 87]]], ["Botanical pesticides have been widely investigated and applied because of their desirable properties [1] .", [["Botanical pesticides", "TREATMENT", 0, 20]]], ["As such, the use of biological active ingredients [3] or action targets [4] as guides is an important aspect in research and development of botanical pesticides.IntroductionPeriploca sepium Bunge, a traditional Chinese herbal medicinal plant belonging to the Asclepiadaceae family, exhibits medicinal and insecticidal properties [5, 6] .", [["Periploca sepium Bunge", "CHEMICAL", 173, 195], ["[4]", "SIMPLE_CHEMICAL", 72, 75], ["Periploca sepium Bunge", "ORGANISM", 173, 195], ["Asclepiadaceae", "ORGANISM", 259, 273], ["biological active ingredients", "TREATMENT", 20, 49], ["IntroductionPeriploca sepium Bunge", "TREATMENT", 161, 195], ["a traditional Chinese herbal medicinal plant", "TREATMENT", 197, 241], ["botanical pesticides", "OBSERVATION", 140, 160]]], ["P. sepium secondary metabolites contain periplocosides, which are pregnane glycosides with evident insecticidal activity against several insect species [7] .", [["periplocosides", "CHEMICAL", 40, 54], ["periplocosides", "CHEMICAL", 40, 54], ["pregnane glycosides", "CHEMICAL", 66, 85], ["periplocosides", "SIMPLE_CHEMICAL", 40, 54], ["pregnane glycosides", "SIMPLE_CHEMICAL", 66, 85], ["P. sepium", "SPECIES", 0, 9], ["P. sepium secondary metabolites contain periplocosides", "PROBLEM", 0, 54], ["pregnane glycosides", "TREATMENT", 66, 85], ["several insect species", "PROBLEM", 129, 151]]], ["These compounds possess a special mode of action that involves metabolites contain periplocosides, which are pregnane glycosides with evident insecticidal activity against several insect species [7] .", [["periplocosides", "CHEMICAL", 83, 97], ["periplocosides", "CHEMICAL", 83, 97], ["pregnane glycosides", "CHEMICAL", 109, 128], ["periplocosides", "SIMPLE_CHEMICAL", 83, 97], ["pregnane glycosides", "SIMPLE_CHEMICAL", 109, 128], ["periplocosides", "PROBLEM", 83, 97], ["pregnane glycosides", "TREATMENT", 109, 128], ["several insect species", "PROBLEM", 172, 194]]], ["These compounds possess a special mode of action that involves obvious swelling of the abdomen, and, thus far, no other modes of insecticidal action have been recorded [8] .", [["abdomen", "ANATOMY", 87, 94], ["abdomen", "ORGAN", 87, 94], ["obvious swelling of the abdomen", "PROBLEM", 63, 94], ["swelling", "OBSERVATION", 71, 79], ["abdomen", "ANATOMY", 87, 94]]], ["Fluorescence localization analysis indicated that periplocoside NW (PSNW) can bind to the midgut cells of Mythimna separata larvae [9] .", [["midgut cells", "ANATOMY", 90, 102], ["periplocoside", "CHEMICAL", 50, 63], ["PSNW", "CHEMICAL", 68, 72], ["PSNW", "CHEMICAL", 68, 72], ["periplocoside NW", "SIMPLE_CHEMICAL", 50, 66], ["PSNW", "SIMPLE_CHEMICAL", 68, 72], ["midgut cells", "CELL", 90, 102], ["Mythimna separata", "ORGANISM", 106, 123], ["PSNW", "PROTEIN", 68, 72], ["midgut cells", "CELL_TYPE", 90, 102], ["Mythimna separata", "SPECIES", 106, 123], ["Mythimna separata", "SPECIES", 106, 123], ["Fluorescence localization analysis", "TEST", 0, 34], ["periplocoside NW (PSNW)", "TREATMENT", 50, 73]]], ["Ultrastructural observations showed that microvilli, organelle, and cytomembrane are destructed in the midgut cells of M. separata larvae [10] .", [["microvilli", "ANATOMY", 41, 51], ["organelle", "ANATOMY", 53, 62], ["cytomembrane", "ANATOMY", 68, 80], ["midgut cells", "ANATOMY", 103, 115], ["microvilli", "CELLULAR_COMPONENT", 41, 51], ["organelle", "CELLULAR_COMPONENT", 53, 62], ["cytomembrane", "CELLULAR_COMPONENT", 68, 80], ["midgut cells", "CELL", 103, 115], ["M. separata larvae", "ORGANISM", 119, 137], ["midgut cells", "CELL_TYPE", 103, 115], ["M. separata", "SPECIES", 119, 130], ["M. separata", "SPECIES", 119, 130], ["Ultrastructural observations", "TEST", 0, 28], ["microvilli, organelle", "PROBLEM", 41, 62], ["cytomembrane", "PROBLEM", 68, 80], ["microvilli", "OBSERVATION_MODIFIER", 41, 51], ["midgut cells", "ANATOMY", 103, 115]]], ["Research on histopathological effects indicated that brush-border membrane vesicles (BBMVs) from the midgut epithelium cells of M. separata larvae are the initial action site; one or more binding sites may also exist in the larvae [11] .", [["brush-border membrane vesicles", "ANATOMY", 53, 83], ["BBMVs", "ANATOMY", 85, 90], ["midgut epithelium cells", "ANATOMY", 101, 124], ["brush-border membrane vesicles", "CELLULAR_COMPONENT", 53, 83], ["BBMVs", "CELLULAR_COMPONENT", 85, 90], ["midgut epithelium cells", "CELL", 101, 124], ["M. separata larvae", "ORGANISM", 128, 146], ["midgut epithelium cells", "CELL_TYPE", 101, 124], ["M. separata", "SPECIES", 128, 139], ["M. separata", "SPECIES", 128, 139], ["histopathological effects", "TEST", 12, 37], ["brush-border membrane vesicles", "PROBLEM", 53, 83], ["midgut epithelium", "ANATOMY", 101, 118]]], ["However, the specific binding sites and insecticidal mechanism of periplocosides in M. separata larval midgut cells remain unclear.IntroductionThe cellular targets of bioactive compounds can be identified using several approaches.", [["midgut cells", "ANATOMY", 103, 115], ["cellular", "ANATOMY", 147, 155], ["periplocosides", "CHEMICAL", 66, 80], ["periplocosides", "SIMPLE_CHEMICAL", 66, 80], ["M. separata", "ORGANISM", 84, 95], ["midgut cells", "CELL", 103, 115], ["cellular", "CELL", 147, 155], ["M. separata larval midgut cells", "CELL_TYPE", 84, 115], ["M. separata", "SPECIES", 84, 95], ["M. separata", "SPECIES", 84, 95], ["the specific binding sites", "PROBLEM", 9, 35], ["periplocosides", "PROBLEM", 66, 80], ["bioactive compounds", "TREATMENT", 167, 186], ["cellular", "OBSERVATION_MODIFIER", 147, 155], ["targets", "OBSERVATION_MODIFIER", 156, 163], ["bioactive compounds", "OBSERVATION", 167, 186]]], ["In contrast to other approaches, affinity-based approaches are employed to identify directly small-molecule binding proteins.IntroductionIn this research, although periplocoside E has relatively low insecticidal activity or is inactive compared with periplocoside P and T [13] , periplocoside E was selected based on the structure and high consumption of experimental materials to determine the binding protein of periplocosides compounds.", [["periplocoside E", "CHEMICAL", 164, 179], ["periplocoside E", "CHEMICAL", 279, 294], ["periplocoside E", "CHEMICAL", 164, 179], ["periplocoside P and T [13] , periplocoside E", "CHEMICAL", 250, 294], ["periplocoside E", "SIMPLE_CHEMICAL", 164, 179], ["periplocoside P", "SIMPLE_CHEMICAL", 250, 265], ["T [13]", "SIMPLE_CHEMICAL", 270, 276], ["periplocoside E", "SIMPLE_CHEMICAL", 279, 294], ["periplocosides compounds", "SIMPLE_CHEMICAL", 414, 438], ["small-molecule binding proteins", "PROTEIN", 93, 124], ["binding protein", "PROTEIN", 395, 410], ["directly small-molecule binding proteins", "PROBLEM", 84, 124], ["relatively low insecticidal activity", "PROBLEM", 184, 220], ["periplocoside E", "TREATMENT", 279, 294], ["experimental materials", "TREATMENT", 355, 377], ["the binding protein of periplocosides compounds", "PROBLEM", 391, 438], ["small", "OBSERVATION_MODIFIER", 93, 98]]], ["The chemical structure of periplocoside E is similar to those of periplocoside P and T in terms of the common features except for one or two substituents ( Figure 1 ).", [["periplocoside", "CHEMICAL", 26, 39], ["periplocoside E", "CHEMICAL", 26, 41], ["periplocoside P", "CHEMICAL", 65, 80], ["periplocoside E", "SIMPLE_CHEMICAL", 26, 41], ["periplocoside", "SIMPLE_CHEMICAL", 65, 78], ["chemical structure", "OBSERVATION", 4, 22]]], ["Thus, we separated the binding protein of periplocoside E from the BBMVs from the midgut epithelium of M. separata larvae through affinity chromatography to elucidate the mode of action of the compound.Identification of the Ligand (Periplocoside E-Semi-Succinic Acid Ester)The ligand, periplocoside E-semi-succinic acid ester, was synthesized ( Figure 2 ) and identified by electrospray ionization-mass spectrometry (ESI-MS) and nuclear magnetic resonance (NMR) analysis.Identification of the Ligand (Periplocoside E-Semi-Succinic Acid Ester)The ligand, periplocoside E-semi-succinic acid ester, was synthesized ( Figure 2 ) and identified by electrospray ionization-mass spectrometry (ESI-MS) and nuclear magnetic resonance (NMR) analysis. metabolites contain periplocosides, which are pregnane glycosides with evident insecticidal activity against several insect species [7] .", [["BBMVs", "ANATOMY", 67, 72], ["midgut epithelium", "ANATOMY", 82, 99], ["Periplocoside E-Semi-Succinic Acid Ester", "CHEMICAL", 232, 272], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 285, 325], ["Periplocoside E-Semi-Succinic Acid Ester", "CHEMICAL", 501, 541], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 554, 594], ["periplocosides", "CHEMICAL", 761, 775], ["periplocoside E", "CHEMICAL", 42, 57], ["Succinic Acid Ester", "CHEMICAL", 253, 272], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 285, 325], ["Succinic Acid Ester", "CHEMICAL", 522, 541], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 554, 594], ["periplocosides", "CHEMICAL", 761, 775], ["pregnane glycosides", "CHEMICAL", 787, 806], ["periplocoside E", "GENE_OR_GENE_PRODUCT", 42, 57], ["BBMVs", "GENE_OR_GENE_PRODUCT", 67, 72], ["midgut epithelium", "TISSUE", 82, 99], ["M. separata larvae", "ORGANISM", 103, 121], ["Periplocoside E-Semi-Succinic Acid Ester", "SIMPLE_CHEMICAL", 232, 272], ["periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 285, 325], ["Periplocoside E-Semi-Succinic Acid Ester", "SIMPLE_CHEMICAL", 501, 541], ["periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 554, 594], ["periplocosides", "SIMPLE_CHEMICAL", 761, 775], ["pregnane glycosides", "SIMPLE_CHEMICAL", 787, 806], ["binding protein", "PROTEIN", 23, 38], ["periplocoside E", "PROTEIN", 42, 57], ["M. separata", "SPECIES", 103, 114], ["M. separata", "SPECIES", 103, 114], ["affinity chromatography", "TEST", 130, 153], ["the Ligand", "TEST", 220, 230], ["Periplocoside E-Semi-Succinic Acid Ester", "TEST", 232, 272], ["The ligand", "TEST", 273, 283], ["periplocoside E", "TEST", 285, 300], ["semi-succinic acid ester", "TEST", 301, 325], ["electrospray ionization", "TEST", 374, 397], ["mass spectrometry", "TEST", 398, 415], ["nuclear magnetic resonance", "TEST", 429, 455], ["the Ligand", "TEST", 489, 499], ["Periplocoside E-Semi-Succinic Acid Ester", "TEST", 501, 541], ["The ligand", "TEST", 542, 552], ["periplocoside E", "TEST", 554, 569], ["semi-succinic acid ester", "TEST", 570, 594], ["electrospray ionization", "TEST", 643, 666], ["mass spectrometry", "TEST", 667, 684], ["nuclear magnetic resonance", "TEST", 698, 724], ["periplocosides", "PROBLEM", 761, 775], ["pregnane glycosides", "TREATMENT", 787, 806], ["several insect species", "PROBLEM", 850, 872], ["midgut epithelium", "ANATOMY", 82, 99], ["Ligand", "ANATOMY", 224, 230], ["Ligand", "ANATOMY", 493, 499]]], ["These compounds possess a special mode of action that involves obvious swelling of the abdomen, and, thus far, no other modes of insecticidal action have been recorded [8] .", [["abdomen", "ANATOMY", 87, 94], ["abdomen", "ORGAN", 87, 94], ["obvious swelling of the abdomen", "PROBLEM", 63, 94], ["swelling", "OBSERVATION", 71, 79], ["abdomen", "ANATOMY", 87, 94]]], ["Fluorescence localization analysis indicated that periplocoside NW (PSNW) can bind to the midgut cells of Mythimna separata larvae [9] .", [["midgut cells", "ANATOMY", 90, 102], ["periplocoside", "CHEMICAL", 50, 63], ["PSNW", "CHEMICAL", 68, 72], ["PSNW", "CHEMICAL", 68, 72], ["periplocoside NW", "SIMPLE_CHEMICAL", 50, 66], ["PSNW", "SIMPLE_CHEMICAL", 68, 72], ["midgut cells", "CELL", 90, 102], ["Mythimna separata", "ORGANISM", 106, 123], ["PSNW", "PROTEIN", 68, 72], ["midgut cells", "CELL_TYPE", 90, 102], ["Mythimna separata", "SPECIES", 106, 123], ["Mythimna separata", "SPECIES", 106, 123], ["Fluorescence localization analysis", "TEST", 0, 34], ["periplocoside NW (PSNW)", "TREATMENT", 50, 73]]], ["Ultrastructural observations showed that microvilli, organelle, and cytomembrane are destructed in the midgut cells of M. separata larvae [10] .", [["microvilli", "ANATOMY", 41, 51], ["organelle", "ANATOMY", 53, 62], ["cytomembrane", "ANATOMY", 68, 80], ["midgut cells", "ANATOMY", 103, 115], ["microvilli", "CELLULAR_COMPONENT", 41, 51], ["organelle", "CELLULAR_COMPONENT", 53, 62], ["cytomembrane", "CELLULAR_COMPONENT", 68, 80], ["midgut cells", "CELL", 103, 115], ["M. separata larvae", "ORGANISM", 119, 137], ["midgut cells", "CELL_TYPE", 103, 115], ["M. separata", "SPECIES", 119, 130], ["M. separata", "SPECIES", 119, 130], ["Ultrastructural observations", "TEST", 0, 28], ["microvilli, organelle", "PROBLEM", 41, 62], ["cytomembrane", "PROBLEM", 68, 80], ["microvilli", "OBSERVATION_MODIFIER", 41, 51], ["midgut cells", "ANATOMY", 103, 115]]], ["Research on histopathological effects indicated that brush-border membrane vesicles (BBMVs) from the midgut epithelium cells of M. separata larvae are the initial action site; one or more binding sites may also exist in the larvae [11] .", [["brush-border membrane vesicles", "ANATOMY", 53, 83], ["BBMVs", "ANATOMY", 85, 90], ["midgut epithelium cells", "ANATOMY", 101, 124], ["brush-border membrane vesicles", "CELLULAR_COMPONENT", 53, 83], ["BBMVs", "CELLULAR_COMPONENT", 85, 90], ["midgut epithelium cells", "CELL", 101, 124], ["M. separata larvae", "ORGANISM", 128, 146], ["midgut epithelium cells", "CELL_TYPE", 101, 124], ["M. separata", "SPECIES", 128, 139], ["M. separata", "SPECIES", 128, 139], ["histopathological effects", "TEST", 12, 37], ["brush-border membrane vesicles", "PROBLEM", 53, 83], ["midgut epithelium", "ANATOMY", 101, 118]]], ["However, the specific binding sites and insecticidal mechanism of periplocosides in M. separata larval midgut cells remain unclear.Identification of the Ligand (Periplocoside E-Semi-Succinic Acid Ester)The cellular targets of bioactive compounds can be identified using several approaches.", [["midgut cells", "ANATOMY", 103, 115], ["cellular", "ANATOMY", 206, 214], ["periplocosides", "CHEMICAL", 66, 80], ["Succinic Acid Ester", "CHEMICAL", 182, 201], ["Succinic Acid Ester", "CHEMICAL", 182, 201], ["periplocosides", "SIMPLE_CHEMICAL", 66, 80], ["M. separata", "ORGANISM", 84, 95], ["midgut cells", "CELL", 103, 115], ["Periplocoside E-Semi-Succinic Acid Ester", "SIMPLE_CHEMICAL", 161, 201], ["cellular", "CELL", 206, 214], ["M. separata larval midgut cells", "CELL_TYPE", 84, 115], ["M. separata", "SPECIES", 84, 95], ["M. separata", "SPECIES", 84, 95], ["the specific binding sites", "PROBLEM", 9, 35], ["periplocosides", "PROBLEM", 66, 80], ["the Ligand (Periplocoside E-Semi-Succinic Acid Ester", "TREATMENT", 149, 201], ["bioactive compounds", "TREATMENT", 226, 245], ["Ligand", "ANATOMY", 153, 159], ["bioactive compounds", "OBSERVATION", 226, 245]]], ["In contrast to other approaches, affinity-based approaches are employed to identify directly small-molecule binding proteins.Identification of the Ligand (Periplocoside E-Semi-Succinic Acid Ester)In this research, although periplocoside E has relatively low insecticidal activity or is inactive compared with periplocoside P and T [13] , periplocoside E was selected based on the structure and high consumption of experimental materials to determine the binding protein of periplocosides compounds.", [["Periplocoside E-Semi-Succinic Acid Ester", "CHEMICAL", 155, 195], ["periplocoside E", "CHEMICAL", 223, 238], ["periplocoside E", "CHEMICAL", 338, 353], ["Succinic Acid Ester", "CHEMICAL", 176, 195], ["periplocoside E", "CHEMICAL", 223, 238], ["periplocoside P and T [13] , periplocoside E", "CHEMICAL", 309, 353], ["periplocoside E", "SIMPLE_CHEMICAL", 223, 238], ["periplocoside P", "SIMPLE_CHEMICAL", 309, 324], ["T [13]", "SIMPLE_CHEMICAL", 329, 335], ["periplocoside E", "SIMPLE_CHEMICAL", 338, 353], ["periplocosides compounds", "SIMPLE_CHEMICAL", 473, 497], ["small-molecule binding proteins", "PROTEIN", 93, 124], ["binding protein", "PROTEIN", 454, 469], ["directly small-molecule binding proteins", "PROBLEM", 84, 124], ["the Ligand (Periplocoside E-Semi-Succinic Acid Ester)", "TREATMENT", 143, 196], ["relatively low insecticidal activity", "PROBLEM", 243, 279], ["periplocoside E", "TREATMENT", 338, 353], ["experimental materials", "TREATMENT", 414, 436], ["the binding protein of periplocosides compounds", "PROBLEM", 450, 497], ["small", "OBSERVATION_MODIFIER", 93, 98], ["Ligand", "ANATOMY", 147, 153]]], ["The chemical structure of periplocoside E is similar to those of periplocoside P and T in terms of the common features except for one or two substituents ( Figure 1 ).", [["periplocoside", "CHEMICAL", 26, 39], ["periplocoside E", "CHEMICAL", 26, 41], ["periplocoside P", "CHEMICAL", 65, 80], ["periplocoside E", "SIMPLE_CHEMICAL", 26, 41], ["periplocoside", "SIMPLE_CHEMICAL", 65, 78], ["chemical structure", "OBSERVATION", 4, 22]]], ["Thus, we separated the binding protein of periplocoside E from the BBMVs from the midgut epithelium of M. separata larvae through affinity chromatography to elucidate the mode of action of the compound.Identification of the Ligand (Periplocoside E-Semi-Succinic Acid Ester)The ligand, periplocoside E-semi-succinic acid ester, was synthesized ( Figure 2 ) and identified by electrospray ionization-mass spectrometry (ESI-MS) and nuclear magnetic resonance (NMR) analysis.", [["BBMVs", "ANATOMY", 67, 72], ["midgut epithelium", "ANATOMY", 82, 99], ["Periplocoside E-Semi-Succinic Acid Ester", "CHEMICAL", 232, 272], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 285, 325], ["periplocoside E", "CHEMICAL", 42, 57], ["Succinic Acid Ester", "CHEMICAL", 253, 272], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 285, 325], ["periplocoside E", "GENE_OR_GENE_PRODUCT", 42, 57], ["BBMVs", "GENE_OR_GENE_PRODUCT", 67, 72], ["midgut epithelium", "TISSUE", 82, 99], ["M. separata larvae", "ORGANISM", 103, 121], ["Periplocoside E-Semi-Succinic Acid Ester", "SIMPLE_CHEMICAL", 232, 272], ["periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 285, 325], ["binding protein", "PROTEIN", 23, 38], ["periplocoside E", "PROTEIN", 42, 57], ["M. separata", "SPECIES", 103, 114], ["M. separata", "SPECIES", 103, 114], ["affinity chromatography", "TEST", 130, 153], ["the Ligand", "TEST", 220, 230], ["Periplocoside E-Semi-Succinic Acid Ester", "TEST", 232, 272], ["The ligand", "TEST", 273, 283], ["periplocoside E", "TEST", 285, 300], ["semi-succinic acid ester", "TEST", 301, 325], ["electrospray ionization", "TEST", 374, 397], ["mass spectrometry", "TEST", 398, 415], ["nuclear magnetic resonance", "TEST", 429, 455], ["midgut epithelium", "ANATOMY", 82, 99], ["Ligand", "ANATOMY", 224, 230]]], ["According to ESI-MS identification, the quasi-molecular ion peaks [M + Na] + of periplocoside E was located at m/z 1293.48 ( Figure 3A ), and the quasi-molecular ion peak [M + Na] + of periplocoside E-semi-succinic acid ester was found at m/z 1393.56 ( Figure 3B ).", [["Na", "CHEMICAL", 71, 73], ["periplocoside", "CHEMICAL", 80, 93], ["Na", "CHEMICAL", 176, 178], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 185, 225], ["Na", "CHEMICAL", 71, 73], ["periplocoside E", "CHEMICAL", 80, 95], ["Na", "CHEMICAL", 176, 178], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 185, 225], ["M + Na] +", "SIMPLE_CHEMICAL", 67, 76], ["periplocoside E", "SIMPLE_CHEMICAL", 80, 95], ["M + Na] +", "SIMPLE_CHEMICAL", 172, 181], ["periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 185, 225], ["the quasi-molecular ion peaks", "TEST", 36, 65], ["Na", "TEST", 71, 73], ["periplocoside E", "TEST", 80, 95], ["the quasi-molecular ion peak", "TEST", 142, 170], ["Na", "TEST", 176, 178], ["periplocoside E", "TEST", 185, 200], ["semi-succinic acid ester", "TEST", 201, 225]]], ["The ESI-MS value of periplocoside E-semi-succinic acid ester is consistent with the theoretical value.", [["periplocoside E-semi-succinic acid ester", "CHEMICAL", 20, 60], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 20, 60], ["periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 20, 60], ["The ESI", "TEST", 0, 7], ["MS value", "TEST", 8, 16], ["periplocoside E-semi-succinic acid ester", "TEST", 20, 60], ["consistent with", "UNCERTAINTY", 64, 79]]], ["Further analysis by NMR identification showed that periplocoside E-semi-succinic acid ester ( Figure 4B ) contains four more lines than that of periplcoside E ( Figure 4A ).", [["periplocoside E-semi-succinic acid ester", "CHEMICAL", 51, 91], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 51, 91], ["periplcoside E", "CHEMICAL", 144, 158], ["periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 51, 91], ["periplcoside E", "SIMPLE_CHEMICAL", 144, 158], ["Further analysis", "TEST", 0, 16], ["NMR identification", "TEST", 20, 38], ["periplocoside E", "TEST", 51, 66], ["semi-succinic acid ester", "TEST", 67, 91], ["more lines", "OBSERVATION_MODIFIER", 120, 130]]], ["The NMR spectra of these lines are \u03b4C 174.59, 173.35, 28.39, and 28.34, respectively.", [["lines", "CELL", 25, 30], ["these lines", "TEST", 19, 30], ["\u03b4C", "TEST", 35, 37]]], ["Among these lines, \u03b4C 174.59 and 173.35 represent two carbonyl carbon atoms in the succinic anhydride structure, and \u03b4C 28.39 and 28.34 are assigned to two methylene carbon atoms.", [["carbonyl carbon", "CHEMICAL", 54, 69], ["succinic anhydride", "CHEMICAL", 83, 101], ["methylene", "CHEMICAL", 156, 165], ["carbonyl", "CHEMICAL", 54, 62], ["carbon", "CHEMICAL", 63, 69], ["succinic anhydride", "CHEMICAL", 83, 101], ["methylene carbon", "CHEMICAL", 156, 172], ["lines", "CELL", 12, 17], ["carbonyl carbon atoms", "SIMPLE_CHEMICAL", 54, 75], ["succinic anhydride", "SIMPLE_CHEMICAL", 83, 101], ["methylene carbon atoms", "SIMPLE_CHEMICAL", 156, 178], ["\u03b4C", "TEST", 19, 21], ["two carbonyl carbon atoms", "PROBLEM", 50, 75], ["\u03b4C", "TEST", 117, 119], ["two methylene carbon atoms", "TREATMENT", 152, 178], ["lines", "OBSERVATION", 12, 17], ["two", "OBSERVATION_MODIFIER", 50, 53], ["carbonyl", "OBSERVATION", 54, 62], ["carbon atoms", "OBSERVATION", 63, 75]]], ["Hence, periplocoside E-semi-succinic acid ester was successfully synthesized.", [["periplocoside E-semi-succinic acid ester", "CHEMICAL", 7, 47], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 7, 47], ["periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 7, 47], ["periplocoside E-semi-succinic acid ester", "TREATMENT", 7, 47]]], ["According to ESI-MS identification, the quasi-molecular ion peaks [M + Na] + of periplocoside E was located at m/z 1293.48 ( Figure 3A ), and the quasi-molecular ion peak [M + Na] + of periplocoside E-semi-succinic acid ester was found at m/z 1393.56 ( Figure 3B ).", [["Na", "CHEMICAL", 71, 73], ["periplocoside", "CHEMICAL", 80, 93], ["Na", "CHEMICAL", 176, 178], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 185, 225], ["Na", "CHEMICAL", 71, 73], ["periplocoside E", "CHEMICAL", 80, 95], ["Na", "CHEMICAL", 176, 178], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 185, 225], ["M + Na] +", "SIMPLE_CHEMICAL", 67, 76], ["periplocoside E", "SIMPLE_CHEMICAL", 80, 95], ["M + Na] +", "SIMPLE_CHEMICAL", 172, 181], ["periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 185, 225], ["the quasi-molecular ion peaks", "TEST", 36, 65], ["Na", "TEST", 71, 73], ["periplocoside E", "TEST", 80, 95], ["the quasi-molecular ion peak", "TEST", 142, 170], ["Na", "TEST", 176, 178], ["periplocoside E", "TEST", 185, 200], ["semi-succinic acid ester", "TEST", 201, 225]]], ["The ESI-MS value of periplocoside E-semi-succinic acid ester is consistent with the theoretical value.", [["periplocoside E-semi-succinic acid ester", "CHEMICAL", 20, 60], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 20, 60], ["periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 20, 60], ["The ESI", "TEST", 0, 7], ["MS value", "TEST", 8, 16], ["periplocoside E-semi-succinic acid ester", "TEST", 20, 60], ["consistent with", "UNCERTAINTY", 64, 79]]], ["Further analysis by NMR identification showed that periplocoside E-semi-succinic acid ester ( Figure 4B ) contains four more lines than that of periplcoside E ( Figure 4A ).", [["periplocoside E-semi-succinic acid ester", "CHEMICAL", 51, 91], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 51, 91], ["periplcoside E", "CHEMICAL", 144, 158], ["periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 51, 91], ["periplcoside E", "SIMPLE_CHEMICAL", 144, 158], ["Further analysis", "TEST", 0, 16], ["NMR identification", "TEST", 20, 38], ["periplocoside E", "TEST", 51, 66], ["semi-succinic acid ester", "TEST", 67, 91], ["more lines", "OBSERVATION_MODIFIER", 120, 130]]], ["The NMR spectra of these lines are \u03b4C 174.59, 173.35, 28.39, and 28.34, respectively.", [["lines", "CELL", 25, 30], ["these lines", "TEST", 19, 30], ["\u03b4C", "TEST", 35, 37]]], ["Among these lines, \u03b4C 174.59 and 173.35 represent two carbonyl carbon atoms in the succinic anhydride structure, and \u03b4C 28.39 and 28.34 are assigned to two methylene carbon atoms.", [["carbonyl carbon", "CHEMICAL", 54, 69], ["succinic anhydride", "CHEMICAL", 83, 101], ["methylene", "CHEMICAL", 156, 165], ["carbonyl", "CHEMICAL", 54, 62], ["carbon", "CHEMICAL", 63, 69], ["succinic anhydride", "CHEMICAL", 83, 101], ["methylene carbon", "CHEMICAL", 156, 172], ["lines", "CELL", 12, 17], ["carbonyl carbon atoms", "SIMPLE_CHEMICAL", 54, 75], ["succinic anhydride", "SIMPLE_CHEMICAL", 83, 101], ["methylene carbon atoms", "SIMPLE_CHEMICAL", 156, 178], ["\u03b4C", "TEST", 19, 21], ["two carbonyl carbon atoms", "PROBLEM", 50, 75], ["\u03b4C", "TEST", 117, 119], ["two methylene carbon atoms", "TREATMENT", 152, 178], ["lines", "OBSERVATION", 12, 17], ["two", "OBSERVATION_MODIFIER", 50, 53], ["carbonyl", "OBSERVATION", 54, 62], ["carbon atoms", "OBSERVATION", 63, 75]]], ["Hence, periplocoside E-semi-succinic acid ester was successfully synthesized.Isolation of Binding ProteinsOur preliminary results revealed that the BBMVs from the midgut epithelium cells of M. separata larvae possess the initial action site of periplocosides [11] .", [["midgut epithelium cells", "ANATOMY", 163, 186], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 7, 47], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 7, 47], ["periplocosides", "CHEMICAL", 244, 258], ["periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 7, 47], ["BBMVs", "GENE_OR_GENE_PRODUCT", 148, 153], ["midgut epithelium cells", "CELL", 163, 186], ["M. separata larvae", "ORGANISM", 190, 208], ["Binding Proteins", "PROTEIN", 90, 106], ["BBMVs", "PROTEIN", 148, 153], ["midgut epithelium cells", "CELL_TYPE", 163, 186], ["M. separata", "SPECIES", 190, 201], ["M. separata", "SPECIES", 190, 201], ["periplocoside E-semi-succinic acid ester", "TREATMENT", 7, 47], ["the BBMVs", "PROBLEM", 144, 153], ["M. separata larvae", "PROBLEM", 190, 208], ["midgut epithelium", "ANATOMY", 163, 180]]], ["Therefore, the BBMVs of M. separata larvae was isolated and subjected to affinity chromatography to separate the binding proteins of periplocosides.", [["BBMVs", "ORGANISM", 15, 20], ["M. separata larvae", "ORGANISM", 24, 42], ["periplocosides", "SIMPLE_CHEMICAL", 133, 147], ["binding proteins", "PROTEIN", 113, 129], ["M. separata", "SPECIES", 24, 35], ["M. separata", "SPECIES", 24, 35], ["M. separata larvae", "PROBLEM", 24, 42], ["affinity chromatography", "TEST", 73, 96]]], ["Two fractions, namely, Fractions 1 (Phosphate buffer (PB), unbound protein eluted with a binding buffer) and 2 (I, eluted with periplocoside E dissolved in the binding buffer) were collected ( Figure 5A ).Isolation of Binding ProteinsSDS-PAGE ( Figure 5B ) and LC/Q-TOF-MS analysis was conducted to resolve and evaluate proteins eluted by excess periplocoside E. Table 1 shows the binding proteins obtained from the NCBI database.Isolation of Binding ProteinsOur preliminary results revealed that the BBMVs from the midgut epithelium cells of M. separata larvae possess the initial action site of periplocosides [11] .", [["midgut epithelium cells", "ANATOMY", 516, 539], ["Phosphate", "CHEMICAL", 36, 45], ["periplocoside E", "CHEMICAL", 127, 142], ["periplocoside", "CHEMICAL", 346, 359], ["Phosphate", "CHEMICAL", 36, 45], ["periplocoside E", "CHEMICAL", 127, 142], ["periplocosides", "CHEMICAL", 597, 611], ["Phosphate buffer", "SIMPLE_CHEMICAL", 36, 52], ["periplocoside E", "SIMPLE_CHEMICAL", 127, 142], ["BBMVs", "GENE_OR_GENE_PRODUCT", 501, 506], ["midgut epithelium cells", "CELL", 516, 539], ["M. separata larvae", "ORGANISM", 543, 561], ["binding proteins", "PROTEIN", 381, 397], ["Binding Proteins", "PROTEIN", 443, 459], ["BBMVs", "PROTEIN", 501, 506], ["midgut epithelium cells", "CELL_TYPE", 516, 539], ["M. separata", "SPECIES", 543, 554], ["M. separata", "SPECIES", 543, 554], ["Fractions", "TEST", 23, 32], ["Phosphate buffer (PB)", "TREATMENT", 36, 57], ["unbound protein", "TREATMENT", 59, 74], ["a binding buffer", "TREATMENT", 87, 103], ["periplocoside E dissolved", "TREATMENT", 127, 152], ["Binding ProteinsSDS", "TEST", 218, 237], ["LC", "TEST", 261, 263], ["MS analysis", "TEST", 270, 281], ["proteins", "TEST", 320, 328], ["the binding proteins", "TEST", 377, 397], ["the BBMVs", "PROBLEM", 497, 506], ["M. separata larvae", "PROBLEM", 543, 561], ["midgut epithelium", "ANATOMY", 516, 533]]], ["Therefore, the BBMVs of M. separata larvae was isolated and subjected to affinity chromatography to separate the binding proteins of periplocosides.", [["BBMVs", "ORGANISM", 15, 20], ["M. separata larvae", "ORGANISM", 24, 42], ["periplocosides", "SIMPLE_CHEMICAL", 133, 147], ["binding proteins", "PROTEIN", 113, 129], ["M. separata", "SPECIES", 24, 35], ["M. separata", "SPECIES", 24, 35], ["M. separata larvae", "PROBLEM", 24, 42], ["affinity chromatography", "TEST", 73, 96]]], ["Two fractions, namely, Fractions 1 (Phosphate buffer (PB), unbound protein eluted with a binding buffer) and 2 (I, eluted with periplocoside E dissolved in the binding buffer) were collected ( Figure 5A ).Isolation of Binding ProteinsSDS-PAGE ( Figure 5B ) and LC/Q-TOF-MS analysis was conducted to resolve and evaluate proteins eluted by excess periplocoside E. Table 1 shows the binding proteins obtained from the NCBI database.", [["Phosphate", "CHEMICAL", 36, 45], ["periplocoside E", "CHEMICAL", 127, 142], ["periplocoside", "CHEMICAL", 346, 359], ["Phosphate", "CHEMICAL", 36, 45], ["periplocoside E", "CHEMICAL", 127, 142], ["Phosphate buffer", "SIMPLE_CHEMICAL", 36, 52], ["periplocoside E", "SIMPLE_CHEMICAL", 127, 142], ["binding proteins", "PROTEIN", 381, 397], ["Fractions", "TEST", 23, 32], ["Phosphate buffer (PB)", "TREATMENT", 36, 57], ["unbound protein", "TREATMENT", 59, 74], ["a binding buffer", "TREATMENT", 87, 103], ["periplocoside E dissolved", "TREATMENT", 127, 152], ["Binding ProteinsSDS", "TEST", 218, 237], ["LC", "TEST", 261, 263], ["MS analysis", "TEST", 270, 281], ["proteins", "TEST", 320, 328], ["the binding proteins", "TEST", 377, 397]]], ["Table 1 shows that eight binding proteins of periplocoside E (luciferin 4-monooxygenase, aminopeptidase N, aminopeptidase N3, NADH dehydrogenase subunit 5, phosphatidylinositol 3phosphate 3-phosphatase myotubularin, actin, uncharacterized family 31 glucosidase KIAA1161, and 2OG-Fe(2) oxygenase superfamily protein) were obtained from the M. separata midgut through affinity chromatography.", [["midgut", "ANATOMY", 351, 357], ["luciferin", "CHEMICAL", 62, 71], ["periplocoside E", "CHEMICAL", 45, 60], ["luciferin", "CHEMICAL", 62, 71], ["NADH", "CHEMICAL", 126, 130], ["phosphatidylinositol 3phosphate", "CHEMICAL", 156, 187], ["Fe", "CHEMICAL", 279, 281], ["periplocoside E", "SIMPLE_CHEMICAL", 45, 60], ["luciferin 4-monooxygenase", "GENE_OR_GENE_PRODUCT", 62, 87], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 89, 105], ["aminopeptidase N3", "GENE_OR_GENE_PRODUCT", 107, 124], ["NADH dehydrogenase subunit 5", "GENE_OR_GENE_PRODUCT", 126, 154], ["phosphatidylinositol 3phosphate 3-phosphatase myotubularin", "GENE_OR_GENE_PRODUCT", 156, 214], ["actin", "GENE_OR_GENE_PRODUCT", 216, 221], ["family 31 glucosidase", "GENE_OR_GENE_PRODUCT", 239, 260], ["2OG-Fe(2) oxygenase", "GENE_OR_GENE_PRODUCT", 275, 294], ["M. separata", "ORGANISM", 339, 350], ["midgut", "ORGANISM", 351, 357], ["binding proteins", "PROTEIN", 25, 41], ["periplocoside E", "PROTEIN", 45, 60], ["luciferin 4-monooxygenase", "PROTEIN", 62, 87], ["aminopeptidase N", "PROTEIN", 89, 105], ["aminopeptidase N3", "PROTEIN", 107, 124], ["NADH dehydrogenase subunit 5", "PROTEIN", 126, 154], ["phosphatidylinositol 3phosphate 3-phosphatase", "PROTEIN", 156, 201], ["myotubularin", "PROTEIN", 202, 214], ["actin", "PROTEIN", 216, 221], ["uncharacterized family 31 glucosidase KIAA1161, and 2OG-Fe(2) oxygenase superfamily protein", "PROTEIN", 223, 314], ["M. separata", "SPECIES", 339, 350], ["M. separata", "SPECIES", 339, 350], ["periplocoside E (luciferin", "TREATMENT", 45, 71], ["monooxygenase", "TREATMENT", 74, 87], ["aminopeptidase N", "TREATMENT", 89, 105], ["aminopeptidase N3", "TREATMENT", 107, 124], ["NADH dehydrogenase subunit", "TREATMENT", 126, 152], ["phosphatidylinositol 3phosphate", "TREATMENT", 156, 187], ["glucosidase KIAA1161", "TEST", 249, 269], ["2OG-Fe(2) oxygenase superfamily protein", "TREATMENT", 275, 314], ["affinity chromatography", "TEST", 366, 389]]], ["Based on previous observations of symptoms, a preliminary research mechanism, the function of the obtained proteins, and the determination results of enzyme activity (data not published), we speculate that aminopeptidase N and aminopeptidase N3 are likely to be the putative target of periplocosides.Isolation of Binding ProteinsSymptoms of insect poisoning by periplocosides are characterized by a cessation of feeding and apparent abdomen swelling [8] .", [["abdomen", "ANATOMY", 433, 440], ["insect poisoning", "DISEASE", 341, 357], ["periplocosides", "DISEASE", 361, 375], ["abdomen swelling", "DISEASE", 433, 449], ["N", "CHEMICAL", 221, 222], ["periplocosides", "CHEMICAL", 285, 299], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 206, 222], ["aminopeptidase N3", "GENE_OR_GENE_PRODUCT", 227, 244], ["periplocosides", "SIMPLE_CHEMICAL", 285, 299], ["insect", "ORGANISM", 341, 347], ["abdomen", "ORGANISM_SUBDIVISION", 433, 440], ["aminopeptidase N", "PROTEIN", 206, 222], ["aminopeptidase N3", "PROTEIN", 227, 244], ["symptoms", "PROBLEM", 34, 42], ["enzyme activity", "PROBLEM", 150, 165], ["aminopeptidase N and aminopeptidase N3", "TREATMENT", 206, 244], ["periplocosides", "TREATMENT", 285, 299], ["insect poisoning", "PROBLEM", 341, 357], ["apparent abdomen swelling", "PROBLEM", 424, 449], ["abdomen", "ANATOMY", 433, 440], ["swelling", "OBSERVATION", 441, 449]]], ["Further ultrastructural observation showed that microvilli on midgut epithelial cells are severely damaged [10] .", [["microvilli", "ANATOMY", 48, 58], ["midgut epithelial cells", "ANATOMY", 62, 85], ["microvilli", "CELLULAR_COMPONENT", 48, 58], ["midgut epithelial cells", "CELL", 62, 85], ["midgut epithelial cells", "CELL_TYPE", 62, 85], ["Further ultrastructural observation", "TEST", 0, 35], ["microvilli on midgut epithelial cells", "PROBLEM", 48, 85], ["severely damaged", "PROBLEM", 90, 106], ["epithelial cells", "OBSERVATION", 69, 85]]], ["We hypothesized that periplocosides may disrupt microvilli on the epithelial cells of the midgut of insects by interacting with proteins on the microvillar membrane or those associated with the membrane; these interactions may affect the normal functions of insects.", [["microvilli", "ANATOMY", 48, 58], ["epithelial cells", "ANATOMY", 66, 82], ["midgut", "ANATOMY", 90, 96], ["microvillar membrane", "ANATOMY", 144, 164], ["membrane", "ANATOMY", 194, 202], ["periplocosides", "CHEMICAL", 21, 35], ["periplocosides", "CHEMICAL", 21, 35], ["periplocosides", "SIMPLE_CHEMICAL", 21, 35], ["microvilli", "CELLULAR_COMPONENT", 48, 58], ["epithelial cells", "CELL", 66, 82], ["midgut", "ORGAN", 90, 96], ["microvillar membrane", "CELLULAR_COMPONENT", 144, 164], ["membrane", "CELLULAR_COMPONENT", 194, 202], ["epithelial cells", "CELL_TYPE", 66, 82], ["the microvillar membrane", "TREATMENT", 140, 164], ["epithelial cells", "OBSERVATION", 66, 82], ["microvillar membrane", "OBSERVATION_MODIFIER", 144, 164]]], ["Similar to periplocosides, the Bt toxin [14] and celangulins [15] act on the midgut of insects.", [["midgut", "ANATOMY", 77, 83], ["periplocosides", "CHEMICAL", 11, 25], ["Bt toxin [14] and celangulins [15]", "CHEMICAL", 31, 65], ["celangulins", "CHEMICAL", 49, 60], ["periplocosides", "SIMPLE_CHEMICAL", 11, 25], ["Bt toxin [14]", "SIMPLE_CHEMICAL", 31, 44], ["celangulins [15]", "SIMPLE_CHEMICAL", 49, 65], ["midgut", "ORGAN", 77, 83], ["Bt", "SPECIES", 31, 33], ["periplocosides", "TEST", 11, 25], ["the Bt toxin", "TEST", 27, 39], ["celangulins", "TEST", 49, 60]]], ["Thus, periplocosides may have the same target protein as that of the Bt toxin and celangulins.Isolation of Binding ProteinsResearch on the Bt toxin indicated that aminopeptidase N (APN) [16] , cadherin-like protein [17] , alkaline phosphatase (ALP) [18] , and actin [19] are the receptors of the detoxification function.", [["periplocosides", "CHEMICAL", 6, 20], ["periplocosides", "SIMPLE_CHEMICAL", 6, 20], ["Bt toxin", "GENE_OR_GENE_PRODUCT", 69, 77], ["celangulins", "GENE_OR_GENE_PRODUCT", 82, 93], ["Bt toxin", "GENE_OR_GENE_PRODUCT", 139, 147], ["aminopeptidase N (APN) [16]", "GENE_OR_GENE_PRODUCT", 163, 190], ["cadherin-like protein [17", "GENE_OR_GENE_PRODUCT", 193, 218], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 222, 242], ["ALP", "GENE_OR_GENE_PRODUCT", 244, 247], ["actin [19]", "SIMPLE_CHEMICAL", 260, 270], ["Bt toxin", "PROTEIN", 69, 77], ["celangulins", "PROTEIN", 82, 93], ["Binding Proteins", "PROTEIN", 107, 123], ["Bt toxin", "PROTEIN", 139, 147], ["aminopeptidase N (APN) [16] , cadherin-like protein [17]", "PROTEIN", 163, 219], ["alkaline phosphatase", "PROTEIN", 222, 242], ["ALP", "PROTEIN", 244, 247], ["actin", "PROTEIN", 260, 265], ["Bt", "SPECIES", 69, 71], ["Bt", "SPECIES", 139, 141], ["periplocosides", "TREATMENT", 6, 20], ["the Bt toxin", "TEST", 65, 77], ["celangulins", "TREATMENT", 82, 93], ["Binding Proteins", "PROBLEM", 107, 123], ["the Bt toxin", "TEST", 135, 147], ["aminopeptidase N (APN)", "TEST", 163, 185], ["cadherin-like protein", "TEST", 193, 214], ["alkaline phosphatase (ALP)", "TEST", 222, 248], ["actin", "TEST", 260, 265], ["Binding Proteins", "OBSERVATION", 107, 123]]], ["V-ATPase is a potential putative target protein of celangulins [20] .", [["V-ATPase", "GENE_OR_GENE_PRODUCT", 0, 8], ["celangulins [20]", "GENE_OR_GENE_PRODUCT", 51, 67], ["V-ATPase", "PROTEIN", 0, 8], ["celangulins", "PROTEIN", 51, 62]]], ["Through comparison with the receptors of the Bt toxin and celangulins, we found actin and aminopeptidase N (APN) in the present Table 1 shows that eight binding proteins of periplocoside E (luciferin 4-monooxygenase, aminopeptidase N, aminopeptidase N3, NADH dehydrogenase subunit 5, phosphatidylinositol 3-phosphate 3-phosphatase myotubularin, actin, uncharacterized family 31 glucosidase KIAA1161, and 2OG-Fe(2) oxygenase superfamily protein) were obtained from the M. separata midgut through affinity chromatography.", [["midgut", "ANATOMY", 480, 486], ["luciferin", "CHEMICAL", 190, 199], ["phosphatidylinositol 3-phosphate", "CHEMICAL", 284, 316], ["periplocoside E", "CHEMICAL", 173, 188], ["luciferin", "CHEMICAL", 190, 199], ["NADH", "CHEMICAL", 254, 258], ["phosphatidylinositol 3-phosphate", "CHEMICAL", 284, 316], ["Fe", "CHEMICAL", 408, 410], ["Bt toxin", "GENE_OR_GENE_PRODUCT", 45, 53], ["celangulins", "GENE_OR_GENE_PRODUCT", 58, 69], ["actin", "GENE_OR_GENE_PRODUCT", 80, 85], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 90, 106], ["APN", "GENE_OR_GENE_PRODUCT", 108, 111], ["periplocoside E", "SIMPLE_CHEMICAL", 173, 188], ["luciferin 4-monooxygenase", "GENE_OR_GENE_PRODUCT", 190, 215], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 217, 233], ["aminopeptidase N3", "GENE_OR_GENE_PRODUCT", 235, 252], ["NADH dehydrogenase subunit 5", "GENE_OR_GENE_PRODUCT", 254, 282], ["phosphatidylinositol 3-phosphate 3-phosphatase myotubularin", "GENE_OR_GENE_PRODUCT", 284, 343], ["actin", "GENE_OR_GENE_PRODUCT", 345, 350], ["family 31 glucosidase", "GENE_OR_GENE_PRODUCT", 368, 389], ["2OG-Fe(2) oxygenase", "GENE_OR_GENE_PRODUCT", 404, 423], ["M. separata", "ORGANISM", 468, 479], ["midgut", "ORGANISM", 480, 486], ["Bt toxin", "PROTEIN", 45, 53], ["celangulins", "PROTEIN", 58, 69], ["actin", "PROTEIN", 80, 85], ["aminopeptidase N", "PROTEIN", 90, 106], ["APN", "PROTEIN", 108, 111], ["binding proteins", "PROTEIN", 153, 169], ["periplocoside E", "PROTEIN", 173, 188], ["luciferin 4-monooxygenase", "PROTEIN", 190, 215], ["aminopeptidase N", "PROTEIN", 217, 233], ["aminopeptidase N3, NADH dehydrogenase subunit 5", "PROTEIN", 235, 282], ["phosphatidylinositol 3-phosphate 3-phosphatase", "PROTEIN", 284, 330], ["myotubularin", "PROTEIN", 331, 343], ["actin", "PROTEIN", 345, 350], ["uncharacterized family 31 glucosidase KIAA1161, and 2OG-Fe(2) oxygenase superfamily protein", "PROTEIN", 352, 443], ["M. separata", "SPECIES", 468, 479], ["Bt", "SPECIES", 45, 47], ["M. separata", "SPECIES", 468, 479], ["the Bt toxin", "TEST", 41, 53], ["actin and aminopeptidase N (APN", "TREATMENT", 80, 111], ["periplocoside E", "TREATMENT", 173, 188], ["luciferin", "TEST", 190, 199], ["monooxygenase", "TREATMENT", 202, 215], ["aminopeptidase N", "TREATMENT", 217, 233], ["aminopeptidase N3", "TREATMENT", 235, 252], ["NADH dehydrogenase subunit", "TREATMENT", 254, 280], ["phosphatidylinositol", "TEST", 284, 304], ["phosphate", "TEST", 307, 316], ["glucosidase", "TEST", 378, 389], ["2OG-Fe(2) oxygenase superfamily protein", "TREATMENT", 404, 443], ["affinity chromatography", "TEST", 495, 518]]], ["Based on previous observations of symptoms, a preliminary research mechanism, the function of the obtained proteins, and the determination results of enzyme activity (data not published), we speculate that aminopeptidase N and aminopeptidase N3 are likely to be the putative target of periplocosides.Isolation of Binding ProteinsSymptoms of insect poisoning by periplocosides are characterized by a cessation of feeding and apparent abdomen swelling [8] .", [["abdomen", "ANATOMY", 433, 440], ["insect poisoning", "DISEASE", 341, 357], ["periplocosides", "DISEASE", 361, 375], ["abdomen swelling", "DISEASE", 433, 449], ["N", "CHEMICAL", 221, 222], ["periplocosides", "CHEMICAL", 285, 299], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 206, 222], ["aminopeptidase N3", "GENE_OR_GENE_PRODUCT", 227, 244], ["periplocosides", "SIMPLE_CHEMICAL", 285, 299], ["insect", "ORGANISM", 341, 347], ["abdomen", "ORGANISM_SUBDIVISION", 433, 440], ["aminopeptidase N", "PROTEIN", 206, 222], ["aminopeptidase N3", "PROTEIN", 227, 244], ["symptoms", "PROBLEM", 34, 42], ["enzyme activity", "PROBLEM", 150, 165], ["aminopeptidase N and aminopeptidase N3", "TREATMENT", 206, 244], ["periplocosides", "TREATMENT", 285, 299], ["insect poisoning", "PROBLEM", 341, 357], ["apparent abdomen swelling", "PROBLEM", 424, 449], ["abdomen", "ANATOMY", 433, 440], ["swelling", "OBSERVATION", 441, 449]]], ["Further ultrastructural observation showed that microvilli on midgut epithelial cells are severely damaged [10] .", [["microvilli", "ANATOMY", 48, 58], ["midgut epithelial cells", "ANATOMY", 62, 85], ["microvilli", "CELLULAR_COMPONENT", 48, 58], ["midgut epithelial cells", "CELL", 62, 85], ["midgut epithelial cells", "CELL_TYPE", 62, 85], ["Further ultrastructural observation", "TEST", 0, 35], ["microvilli on midgut epithelial cells", "PROBLEM", 48, 85], ["severely damaged", "PROBLEM", 90, 106], ["epithelial cells", "OBSERVATION", 69, 85]]], ["We hypothesized that periplocosides may disrupt microvilli on the epithelial cells of the midgut of insects by interacting with proteins on the microvillar membrane or those associated with the membrane; these interactions may affect the normal functions of insects.", [["microvilli", "ANATOMY", 48, 58], ["epithelial cells", "ANATOMY", 66, 82], ["midgut", "ANATOMY", 90, 96], ["microvillar membrane", "ANATOMY", 144, 164], ["membrane", "ANATOMY", 194, 202], ["periplocosides", "CHEMICAL", 21, 35], ["periplocosides", "CHEMICAL", 21, 35], ["periplocosides", "SIMPLE_CHEMICAL", 21, 35], ["microvilli", "CELLULAR_COMPONENT", 48, 58], ["epithelial cells", "CELL", 66, 82], ["midgut", "ORGAN", 90, 96], ["microvillar membrane", "CELLULAR_COMPONENT", 144, 164], ["membrane", "CELLULAR_COMPONENT", 194, 202], ["epithelial cells", "CELL_TYPE", 66, 82], ["the microvillar membrane", "TREATMENT", 140, 164], ["epithelial cells", "OBSERVATION", 66, 82], ["microvillar membrane", "OBSERVATION_MODIFIER", 144, 164]]], ["Similar to periplocosides, the Bt toxin [14] and celangulins [15] act on the midgut of insects.", [["midgut", "ANATOMY", 77, 83], ["periplocosides", "CHEMICAL", 11, 25], ["Bt toxin [14] and celangulins [15]", "CHEMICAL", 31, 65], ["celangulins", "CHEMICAL", 49, 60], ["periplocosides", "SIMPLE_CHEMICAL", 11, 25], ["Bt toxin [14]", "SIMPLE_CHEMICAL", 31, 44], ["celangulins [15]", "SIMPLE_CHEMICAL", 49, 65], ["midgut", "ORGAN", 77, 83], ["Bt", "SPECIES", 31, 33], ["periplocosides", "TEST", 11, 25], ["the Bt toxin", "TEST", 27, 39], ["celangulins", "TEST", 49, 60]]], ["Thus, periplocosides may have the same target protein as that of the Bt toxin and celangulins.Isolation of Binding ProteinsResearch on the Bt toxin indicated that aminopeptidase N (APN) [16] , cadherin-like protein [17] , alkaline phosphatase (ALP) [18] , and actin [19] are the receptors of the detoxification function.", [["periplocosides", "CHEMICAL", 6, 20], ["periplocosides", "SIMPLE_CHEMICAL", 6, 20], ["Bt toxin", "GENE_OR_GENE_PRODUCT", 69, 77], ["celangulins", "GENE_OR_GENE_PRODUCT", 82, 93], ["Bt toxin", "GENE_OR_GENE_PRODUCT", 139, 147], ["aminopeptidase N (APN) [16]", "GENE_OR_GENE_PRODUCT", 163, 190], ["cadherin-like protein [17", "GENE_OR_GENE_PRODUCT", 193, 218], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 222, 242], ["ALP", "GENE_OR_GENE_PRODUCT", 244, 247], ["actin [19]", "SIMPLE_CHEMICAL", 260, 270], ["Bt toxin", "PROTEIN", 69, 77], ["celangulins", "PROTEIN", 82, 93], ["Binding Proteins", "PROTEIN", 107, 123], ["Bt toxin", "PROTEIN", 139, 147], ["aminopeptidase N (APN) [16] , cadherin-like protein [17]", "PROTEIN", 163, 219], ["alkaline phosphatase", "PROTEIN", 222, 242], ["ALP", "PROTEIN", 244, 247], ["actin", "PROTEIN", 260, 265], ["Bt", "SPECIES", 69, 71], ["Bt", "SPECIES", 139, 141], ["periplocosides", "TREATMENT", 6, 20], ["the Bt toxin", "TEST", 65, 77], ["celangulins", "TREATMENT", 82, 93], ["Binding Proteins", "PROBLEM", 107, 123], ["the Bt toxin", "TEST", 135, 147], ["aminopeptidase N (APN)", "TEST", 163, 185], ["cadherin-like protein", "TEST", 193, 214], ["alkaline phosphatase (ALP)", "TEST", 222, 248], ["actin", "TEST", 260, 265], ["Binding Proteins", "OBSERVATION", 107, 123]]], ["V-ATPase is a potential putative target protein of celangulins [20] .", [["V-ATPase", "GENE_OR_GENE_PRODUCT", 0, 8], ["celangulins [20]", "GENE_OR_GENE_PRODUCT", 51, 67], ["V-ATPase", "PROTEIN", 0, 8], ["celangulins", "PROTEIN", 51, 62]]], ["Through comparison with the receptors of the Bt toxin and celangulins, we found actin and aminopeptidase N (APN) in the present research.", [["Bt toxin", "GENE_OR_GENE_PRODUCT", 45, 53], ["celangulins", "GENE_OR_GENE_PRODUCT", 58, 69], ["actin", "GENE_OR_GENE_PRODUCT", 80, 85], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 90, 106], ["APN", "GENE_OR_GENE_PRODUCT", 108, 111], ["Bt toxin", "PROTEIN", 45, 53], ["celangulins", "PROTEIN", 58, 69], ["actin", "PROTEIN", 80, 85], ["aminopeptidase N", "PROTEIN", 90, 106], ["APN", "PROTEIN", 108, 111], ["Bt", "SPECIES", 45, 47], ["the Bt toxin", "TEST", 41, 53], ["actin and aminopeptidase N (APN", "TREATMENT", 80, 111]]], ["Actin is an abundant protein in eukaryotic cells [21] .", [["cells", "ANATOMY", 43, 48], ["Actin", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 43, 48], ["Actin", "PROTEIN", 0, 5], ["eukaryotic cells", "CELL_TYPE", 32, 48], ["eukaryotic cells", "OBSERVATION", 32, 48]]], ["Actin's main function is to form microfilaments to maintain cell morphology; actin also exhibits other multiple functions, such as cell motility, cell division, and organelle movement [22, 23] .", [["microfilaments", "ANATOMY", 33, 47], ["cell", "ANATOMY", 60, 64], ["cell", "ANATOMY", 131, 135], ["cell", "ANATOMY", 146, 150], ["organelle", "ANATOMY", 165, 174], ["Actin", "GENE_OR_GENE_PRODUCT", 0, 5], ["microfilaments", "CELLULAR_COMPONENT", 33, 47], ["cell", "CELL", 60, 64], ["actin", "GENE_OR_GENE_PRODUCT", 77, 82], ["cell", "CELL", 131, 135], ["cell", "CELL", 146, 150], ["organelle", "CELLULAR_COMPONENT", 165, 174], ["Actin", "PROTEIN", 0, 5], ["actin", "PROTEIN", 77, 82], ["organelle movement", "TEST", 165, 183], ["cell morphology", "OBSERVATION", 60, 75]]], ["Many of these processes are mediated by extensive and intimate interactions of actin and cellular membranes [24] .", [["cellular membranes", "ANATOMY", 89, 107], ["actin", "GENE_OR_GENE_PRODUCT", 79, 84], ["cellular membranes", "CELLULAR_COMPONENT", 89, 107], ["actin", "PROTEIN", 79, 84], ["extensive", "OBSERVATION_MODIFIER", 40, 49], ["cellular membranes", "OBSERVATION", 89, 107]]], ["However, in terms of selectivity, actin has less possibility of becoming a target protein of pesticides because of its highly conservative nature in insect cells.", [["cells", "ANATOMY", 156, 161], ["actin", "GENE_OR_GENE_PRODUCT", 34, 39], ["insect cells", "CELL", 149, 161], ["actin", "PROTEIN", 34, 39], ["insect cells", "CELL_TYPE", 149, 161], ["a target protein of pesticides", "PROBLEM", 73, 103], ["highly", "OBSERVATION_MODIFIER", 119, 125], ["conservative", "OBSERVATION", 126, 138], ["insect cells", "OBSERVATION", 149, 161]]], ["Further studies on actin must be performed to exclude and validate this conjecture.Isolation of Binding ProteinsAminopeptidase-N (APN) is an exopeptidase that is abundant in the BBMVs of many lepidopteran and dipteran insects.", [["BBMVs", "ANATOMY", 178, 183], ["actin", "GENE_OR_GENE_PRODUCT", 19, 24], ["Aminopeptidase-N", "GENE_OR_GENE_PRODUCT", 112, 128], ["APN", "GENE_OR_GENE_PRODUCT", 130, 133], ["dipteran insects", "ORGANISM", 209, 225], ["actin", "PROTEIN", 19, 24], ["Binding ProteinsAminopeptidase-N", "PROTEIN", 96, 128], ["APN", "PROTEIN", 130, 133], ["exopeptidase", "PROTEIN", 141, 153], ["Further studies", "TEST", 0, 15], ["Binding ProteinsAminopeptidase-N (APN)", "TREATMENT", 96, 134], ["an exopeptidase", "TREATMENT", 138, 153], ["abundant", "OBSERVATION_MODIFIER", 162, 170]]], ["APN catalyzes the removal of N-terminal neutral amino acids [25] .", [["amino acids", "CHEMICAL", 48, 59], ["N-", "CHEMICAL", 29, 31], ["amino acids", "CHEMICAL", 48, 59], ["APN", "GENE_OR_GENE_PRODUCT", 0, 3], ["amino acids", "AMINO_ACID", 48, 59], ["APN", "PROTEIN", 0, 3], ["the removal", "TREATMENT", 14, 25], ["N-terminal neutral amino acids", "TREATMENT", 29, 59]]], ["APN is a common component of lepidoptera larval midgut and is used as a marker enzyme to assess the purity of BBMVs from insect larval midguts [26] .", [["midgut", "ANATOMY", 48, 54], ["midguts", "ANATOMY", 135, 142], ["APN", "GENE_OR_GENE_PRODUCT", 0, 3], ["lepidoptera", "ORGANISM", 29, 40], ["larval midgut", "ORGAN", 41, 54], ["BBMVs", "GENE_OR_GENE_PRODUCT", 110, 115], ["APN", "PROTEIN", 0, 3], ["lepidoptera larval midgut", "TREATMENT", 29, 54], ["a marker enzyme", "TEST", 70, 85]]], ["APN belongs to the family of zinc-dependent enzyme peptide with the zinc finger structure and N-glycosylation sites (Asn-X-Ser/Thr).", [["zinc", "CHEMICAL", 29, 33], ["zinc", "CHEMICAL", 29, 33], ["zinc", "CHEMICAL", 68, 72], ["N", "CHEMICAL", 94, 95], ["Asn", "CHEMICAL", 117, 120], ["Ser", "CHEMICAL", 123, 126], ["Thr", "CHEMICAL", 127, 130], ["APN", "GENE_OR_GENE_PRODUCT", 0, 3], ["zinc", "SIMPLE_CHEMICAL", 29, 33], ["Ser/Thr", "AMINO_ACID", 123, 130], ["APN", "PROTEIN", 0, 3], ["zinc finger structure", "PROTEIN", 68, 89], ["N-glycosylation sites", "PROTEIN", 94, 115], ["X", "PROTEIN", 121, 122], ["zinc-dependent enzyme peptide", "TREATMENT", 29, 58], ["the zinc finger structure", "PROBLEM", 64, 89], ["glycosylation sites", "TREATMENT", 96, 115], ["Asn", "TEST", 117, 120], ["Ser/Thr)", "TREATMENT", 123, 131]]], ["The phosphatidyl inositol signal sequence is located in the C-terminal, and the signal peptide sequence is situated in the N-terminal.", [["phosphatidyl inositol", "CHEMICAL", 4, 25], ["phosphatidyl inositol", "CHEMICAL", 4, 25], ["C", "CHEMICAL", 60, 61], ["phosphatidyl inositol", "SIMPLE_CHEMICAL", 4, 25], ["phosphatidyl inositol signal sequence", "PROTEIN", 4, 41], ["C-terminal", "PROTEIN", 60, 70], ["N-terminal", "PROTEIN", 123, 133], ["The phosphatidyl inositol signal sequence", "TEST", 0, 41], ["the signal peptide sequence", "TEST", 76, 103], ["terminal", "ANATOMY_MODIFIER", 62, 70], ["N-terminal", "OBSERVATION_MODIFIER", 123, 133]]], ["APN is connected to BBMVs in the insect midgut through the glycosylated phosphatidylinositol [27] .Isolation of Binding ProteinsThe most studied and reported aspect of APN is the Bt toxin.", [["midgut", "ANATOMY", 40, 46], ["phosphatidylinositol", "CHEMICAL", 72, 92], ["phosphatidylinositol", "CHEMICAL", 72, 92], ["APN", "GENE_OR_GENE_PRODUCT", 0, 3], ["BBMVs", "GENE_OR_GENE_PRODUCT", 20, 25], ["insect midgut", "ORGAN", 33, 46], ["phosphatidylinositol", "SIMPLE_CHEMICAL", 72, 92], ["APN", "GENE_OR_GENE_PRODUCT", 168, 171], ["Bt toxin", "SIMPLE_CHEMICAL", 179, 187], ["APN", "PROTEIN", 0, 3], ["BBMVs", "PROTEIN", 20, 25], ["Binding Proteins", "PROTEIN", 112, 128], ["APN", "PROTEIN", 168, 171], ["Bt toxin", "PROTEIN", 179, 187], ["Bt", "SPECIES", 179, 181], ["the glycosylated phosphatidylinositol", "TEST", 55, 92], ["Binding Proteins", "PROBLEM", 112, 128], ["Binding Proteins", "OBSERVATION", 112, 128], ["most studied", "OBSERVATION_MODIFIER", 132, 144]]], ["APN is the first toxin receptor protein that plays a role in the mechanism of the Bt toxin [16] .", [["APN", "GENE_OR_GENE_PRODUCT", 0, 3], ["APN", "PROTEIN", 0, 3], ["toxin receptor protein", "PROTEIN", 17, 39], ["the first toxin receptor protein", "PROBLEM", 7, 39], ["the Bt toxin", "TEST", 78, 90]]], ["Knight et al. [28] and Gill et al. [29] cloned a 120-kD receptor-related protein gene combined with the Cry1Ac of Manduca sexta and Heliothis virescen; these studies applied the method of cDNA library and showed that APN is the encoding protein.", [["Cry1Ac", "GENE_OR_GENE_PRODUCT", 104, 110], ["Manduca sexta", "ORGANISM", 114, 127], ["Heliothis virescen", "ORGANISM", 132, 150], ["APN", "GENE_OR_GENE_PRODUCT", 217, 220], ["120-kD receptor-related protein gene", "DNA", 49, 85], ["Cry1Ac", "PROTEIN", 104, 110], ["cDNA library", "DNA", 188, 200], ["APN", "PROTEIN", 217, 220], ["encoding protein", "PROTEIN", 228, 244], ["Manduca sexta", "SPECIES", 114, 127], ["Heliothis virescen", "SPECIES", 132, 150], ["Manduca sexta", "SPECIES", 114, 127], ["Heliothis virescen", "SPECIES", 132, 150], ["protein gene", "TREATMENT", 73, 85], ["the Cry1Ac of Manduca sexta", "TREATMENT", 100, 127], ["Heliothis virescen", "TREATMENT", 132, 150], ["these studies", "TEST", 152, 165], ["cDNA library", "TEST", 188, 200]]], ["Moreover, binding experiments showed that APN is the receptor of Lymantria dispar, Plutella xylostella, and Trichoplusia ni combined with Cry1Ac [30, 31] .", [["Trichoplusia ni", "CHEMICAL", 108, 123], ["APN", "GENE_OR_GENE_PRODUCT", 42, 45], ["Lymantria dispar", "ORGANISM", 65, 81], ["Plutella xylostella", "ORGANISM", 83, 102], ["Trichoplusia ni", "ORGANISM", 108, 123], ["Cry1Ac", "GENE_OR_GENE_PRODUCT", 138, 144], ["APN", "PROTEIN", 42, 45], ["Cry1Ac", "PROTEIN", 138, 144], ["Lymantria dispar", "SPECIES", 65, 81], ["Plutella xylostella", "SPECIES", 83, 102], ["Lymantria dispar", "SPECIES", 65, 81], ["Plutella xylostella", "SPECIES", 83, 102], ["Trichoplusia ni", "SPECIES", 108, 123], ["binding experiments", "TEST", 10, 29], ["Lymantria dispar", "PROBLEM", 65, 81], ["Plutella xylostella", "PROBLEM", 83, 102], ["Cry1Ac", "TEST", 138, 144]]], ["Gill et al. [32] indicated that the APN of Manduca sexta in the midguts of Drosophila melanogaster larvae is not sensitive to Cry1Ac; they found that this structure led to the presence of D. melanogaster larvae, which is sensitive to Cry1Ac.", [["midguts", "ANATOMY", 64, 71], ["APN", "GENE_OR_GENE_PRODUCT", 36, 39], ["Manduca sexta", "ORGANISM", 43, 56], ["midguts", "ORGANISM_SUBSTANCE", 64, 71], ["Drosophila melanogaster", "ORGANISM", 75, 98], ["larvae", "ORGANISM", 99, 105], ["Cry1Ac", "GENE_OR_GENE_PRODUCT", 126, 132], ["D. melanogaster", "ORGANISM", 188, 203], ["larvae", "ORGANISM", 204, 210], ["Cry1Ac", "GENE_OR_GENE_PRODUCT", 234, 240], ["APN", "PROTEIN", 36, 39], ["Cry1Ac", "PROTEIN", 126, 132], ["Cry1Ac", "PROTEIN", 234, 240], ["Manduca sexta", "SPECIES", 43, 56], ["Drosophila melanogaster", "SPECIES", 75, 98], ["D. melanogaster", "SPECIES", 188, 203], ["Manduca sexta", "SPECIES", 43, 56], ["Drosophila melanogaster", "SPECIES", 75, 98], ["D. melanogaster", "SPECIES", 188, 203], ["the APN of Manduca sexta", "TREATMENT", 32, 56], ["Drosophila melanogaster larvae", "PROBLEM", 75, 105], ["Cry1Ac", "TEST", 126, 132], ["D. melanogaster larvae", "PROBLEM", 188, 210], ["melanogaster larvae", "OBSERVATION", 191, 210]]], ["Furthermore, multiple aminopeptidase-N protein sequence alignments showed that the first 40 residues of human, rat, pig, and mouse enzymes are characterized by signal sequence, which may function as a membrane anchor [33, 34] .", [["membrane", "ANATOMY", 201, 209], ["aminopeptidase-N", "GENE_OR_GENE_PRODUCT", 22, 38], ["human", "ORGANISM", 104, 109], ["rat", "ORGANISM", 111, 114], ["pig", "ORGANISM", 116, 119], ["mouse", "ORGANISM", 125, 130], ["membrane", "CELLULAR_COMPONENT", 201, 209], ["aminopeptidase", "PROTEIN", 22, 36], ["human, rat, pig, and mouse enzymes", "PROTEIN", 104, 138], ["human", "SPECIES", 104, 109], ["rat", "SPECIES", 111, 114], ["pig", "SPECIES", 116, 119], ["mouse", "SPECIES", 125, 130], ["human", "SPECIES", 104, 109], ["rat", "SPECIES", 111, 114], ["pig", "SPECIES", 116, 119], ["mouse", "SPECIES", 125, 130], ["multiple aminopeptidase-N protein sequence alignments", "TEST", 13, 66], ["mouse enzymes", "TEST", 125, 138], ["signal sequence", "TEST", 160, 175]]], ["Some reports showed that human and pig coronaviruses also use aminopeptidase N as receptor in their target tissues [35, 36] .", [["tissues", "ANATOMY", 107, 114], ["human", "ORGANISM", 25, 30], ["pig coronaviruses", "ORGANISM", 35, 52], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 62, 78], ["tissues", "TISSUE", 107, 114], ["aminopeptidase N", "PROTEIN", 62, 78], ["human", "SPECIES", 25, 30], ["pig", "SPECIES", 35, 38], ["human", "SPECIES", 25, 30], ["pig coronaviruses", "SPECIES", 35, 52], ["human and pig coronaviruses", "TREATMENT", 25, 52], ["aminopeptidase N", "TREATMENT", 62, 78]]], ["APN has a long history of existence as a target receptor.Isolation of Binding ProteinsIn conclusion, the eight proteins isolated through affinity chromatography are potential binding proteins that interact with periplocosides.", [["periplocosides", "CHEMICAL", 211, 225], ["APN", "GENE_OR_GENE_PRODUCT", 0, 3], ["periplocosides", "SIMPLE_CHEMICAL", 211, 225], ["APN", "PROTEIN", 0, 3], ["Binding Proteins", "PROTEIN", 70, 86], ["binding proteins", "PROTEIN", 175, 191], ["Binding Proteins", "PROBLEM", 70, 86], ["affinity chromatography", "TEST", 137, 160], ["potential binding proteins", "PROBLEM", 165, 191], ["periplocosides", "TREATMENT", 211, 225], ["Binding Proteins", "OBSERVATION", 70, 86]]], ["Aminopeptidase-N may be the target protein of periplocosides because it induces a series of symptoms to destroy the digestive system.", [["digestive system", "ANATOMY", 116, 132], ["Aminopeptidase-N", "CHEMICAL", 0, 16], ["Aminopeptidase-N", "GENE_OR_GENE_PRODUCT", 0, 16], ["digestive", "ORGAN", 116, 125], ["system", "ANATOMICAL_SYSTEM", 126, 132], ["Aminopeptidase-N", "TREATMENT", 0, 16], ["the target protein of periplocosides", "TREATMENT", 24, 60], ["symptoms", "PROBLEM", 92, 100], ["digestive system", "ANATOMY", 116, 132]]], ["However, further in-depth studies are needed to qualify and validate whether APN is the receptor of periplocosides.", [["periplocosides", "CHEMICAL", 100, 114], ["APN", "GENE_OR_GENE_PRODUCT", 77, 80], ["periplocosides", "GENE_OR_GENE_PRODUCT", 100, 114], ["APN", "PROTEIN", 77, 80], ["further in-depth studies", "TEST", 9, 33], ["periplocosides", "TREATMENT", 100, 114]]], ["The presence of periplocosides in the midgut of insects, which leads to the death of the insect, should be evaluated using the interaction of periplocosides with APN.", [["midgut", "ANATOMY", 38, 44], ["periplocosides", "CHEMICAL", 16, 30], ["death", "DISEASE", 76, 81], ["periplocosides", "CHEMICAL", 16, 30], ["periplocosides", "GENE_OR_GENE_PRODUCT", 16, 30], ["midgut", "ORGAN", 38, 44], ["periplocosides", "GENE_OR_GENE_PRODUCT", 142, 156], ["APN", "GENE_OR_GENE_PRODUCT", 162, 165], ["APN", "PROTEIN", 162, 165], ["periplocosides", "PROBLEM", 16, 30], ["APN", "TREATMENT", 162, 165], ["periplocosides", "OBSERVATION", 16, 30]]], ["This work will serve as an important guide in elucidating the mechanism of periplocosides.ConclusionsEight potential binding proteins of periplocoside E were isolated from the midgut BBMVs of M. separata larvae through affinity chromatography.", [["midgut BBMVs", "ANATOMY", 176, 188], ["periplocosides", "CHEMICAL", 75, 89], ["periplocoside E", "CHEMICAL", 137, 152], ["periplocosides", "SIMPLE_CHEMICAL", 75, 89], ["periplocoside E", "SIMPLE_CHEMICAL", 137, 152], ["midgut BBMVs", "ORGANISM_SUBSTANCE", 176, 188], ["M. separata larvae", "ORGANISM", 192, 210], ["binding proteins", "PROTEIN", 117, 133], ["periplocoside E", "PROTEIN", 137, 152], ["M. separata", "SPECIES", 192, 203], ["M. separata", "SPECIES", 192, 203], ["periplocosides", "TREATMENT", 75, 89], ["periplocoside E", "PROBLEM", 137, 152], ["affinity chromatography", "TEST", 219, 242]]], ["These proteins include luciferin 4-monooxygenase, aminopeptidase N, aminopeptidase N3, NADH dehydrogenase subunit 5, phosphatidylinositol 3-phosphate 3-phosphatase myotubularin, actin, uncharacterized family 31 glucosidase KIAA1161, and 2OG-Fe(2) oxygenase superfamily protein.", [["luciferin", "CHEMICAL", 23, 32], ["NADH", "CHEMICAL", 87, 91], ["phosphatidylinositol 3-phosphate", "CHEMICAL", 117, 149], ["luciferin", "CHEMICAL", 23, 32], ["NADH", "CHEMICAL", 87, 91], ["phosphatidylinositol 3-phosphate", "CHEMICAL", 117, 149], ["Fe", "CHEMICAL", 241, 243], ["luciferin 4-monooxygenase", "GENE_OR_GENE_PRODUCT", 23, 48], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 50, 66], ["aminopeptidase N3", "GENE_OR_GENE_PRODUCT", 68, 85], ["NADH dehydrogenase subunit 5", "GENE_OR_GENE_PRODUCT", 87, 115], ["phosphatidylinositol 3-phosphate 3", "GENE_OR_GENE_PRODUCT", 117, 151], ["myotubularin", "GENE_OR_GENE_PRODUCT", 164, 176], ["actin", "GENE_OR_GENE_PRODUCT", 178, 183], ["family 31 glucosidase", "GENE_OR_GENE_PRODUCT", 201, 222], ["KIAA1161", "GENE_OR_GENE_PRODUCT", 223, 231], ["2OG-Fe(2) oxygenase", "GENE_OR_GENE_PRODUCT", 237, 256], ["luciferin 4-monooxygenase", "PROTEIN", 23, 48], ["aminopeptidase N", "PROTEIN", 50, 66], ["aminopeptidase N3, NADH dehydrogenase subunit 5", "PROTEIN", 68, 115], ["phosphatidylinositol 3-phosphate 3-phosphatase", "PROTEIN", 117, 163], ["myotubularin", "PROTEIN", 164, 176], ["actin", "PROTEIN", 178, 183], ["uncharacterized family 31 glucosidase KIAA1161, and 2OG-Fe(2) oxygenase superfamily protein", "PROTEIN", 185, 276], ["These proteins", "TEST", 0, 14], ["luciferin", "TEST", 23, 32], ["monooxygenase", "TREATMENT", 35, 48], ["aminopeptidase N", "TREATMENT", 50, 66], ["aminopeptidase N3", "TREATMENT", 68, 85], ["NADH dehydrogenase subunit", "TREATMENT", 87, 113], ["phosphatidylinositol", "TREATMENT", 117, 137], ["phosphate", "TREATMENT", 140, 149], ["2OG-Fe(2) oxygenase superfamily protein", "TREATMENT", 237, 276]]], ["The functions of some of the important proteins linked to the symptoms caused by periplocosides were also analyzed.", [["periplocosides", "CHEMICAL", 81, 95], ["periplocosides", "SIMPLE_CHEMICAL", 81, 95], ["the symptoms", "PROBLEM", 58, 70], ["periplocosides", "PROBLEM", 81, 95]]], ["We speculate that aminopeptidase N (APN) is the putative target protein of periplocosides.", [["periplocosides", "CHEMICAL", 75, 89], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 18, 34], ["APN", "GENE_OR_GENE_PRODUCT", 36, 39], ["periplocosides", "GENE_OR_GENE_PRODUCT", 75, 89], ["aminopeptidase N", "PROTEIN", 18, 34], ["APN", "PROTEIN", 36, 39], ["periplocosides", "PROTEIN", 75, 89], ["aminopeptidase N (APN)", "TREATMENT", 18, 40]]], ["However, further studies are needed to verify the accuracy of this assumption.InsectsThe fifth instar larvae of M. separata were provided by the Institute of Pesticide Science, Northwest A & F University (NWAFU) (Yangling, China).", [["M. separata", "ORGANISM", 112, 123], ["M. separata", "SPECIES", 112, 123], ["M. separata", "SPECIES", 112, 123], ["further studies", "TEST", 9, 24]]], ["A colony of M. separata was cultured in the laboratory for 20 years at 25\u02ddC, 70% relative humidity, and a photoperiod of 16 h of light, with 8 h of darkness under periodic introduction of field-collected insects.ChemicalsPeriplocoside E was extracted and purified from P. sepium Bunge (root barks) in the Institute of Pesticide Science, Northwest A & F University (NWAFU, Yangling, China) [37] .", [["colony", "ANATOMY", 2, 8], ["root barks", "ANATOMY", 286, 296], ["Periplocoside E", "CHEMICAL", 221, 236], ["Periplocoside E", "CHEMICAL", 221, 236], ["M. separata", "ORGANISM", 12, 23], ["Periplocoside E", "SIMPLE_CHEMICAL", 221, 236], ["P. sepium Bunge", "ORGANISM", 269, 284], ["root barks", "MULTI-TISSUE_STRUCTURE", 286, 296], ["M. separata", "SPECIES", 12, 23], ["P. sepium", "SPECIES", 269, 278], ["M. separata", "SPECIES", 12, 23], ["P. sepium", "SPECIES", 269, 278], ["A colony of M. separata", "TEST", 0, 23], ["darkness", "PROBLEM", 148, 156], ["ChemicalsPeriplocoside E", "TREATMENT", 212, 236], ["colony", "OBSERVATION_MODIFIER", 2, 8]]], ["The chemical structure of PS-E is shown in Figure 1 .", [["PS-E", "SIMPLE_CHEMICAL", 26, 30]]], ["PS-E has a purity of over 98% based on high performance liquid chromatography (HPLC) analysis.", [["PS-E", "CHEMICAL", 0, 4], ["PS-E", "SIMPLE_CHEMICAL", 0, 4], ["PS", "TEST", 0, 2], ["high performance liquid chromatography", "TEST", 39, 77], ["HPLC) analysis", "TEST", 79, 93]]], ["EAH sepharose 4B was purchased from general electronics (GE) Healthcare (Beijing, China).", [["EAH sepharose 4B", "PROTEIN", 0, 16], ["EAH sepharose 4B", "TREATMENT", 0, 16]]], ["Tris, NaCl, HCl, acetic acid, sodium acetate, and all other chemicals were purchased from Solarbio (Beijing, China).Preparation of Brush Border Membrane Vesicles (BBMV)The fifth instar larvae of M. separata Walker were starved for 12 h before the experiment.", [["Tris, NaCl, HCl, acetic acid", "CHEMICAL", 0, 28], ["sodium acetate", "CHEMICAL", 30, 44], ["Tris", "CHEMICAL", 0, 4], ["NaCl", "CHEMICAL", 6, 10], ["HCl", "CHEMICAL", 12, 15], ["acetic acid", "CHEMICAL", 17, 28], ["sodium acetate", "CHEMICAL", 30, 44], ["Tris", "SIMPLE_CHEMICAL", 0, 4], ["NaCl", "SIMPLE_CHEMICAL", 6, 10], ["HCl", "SIMPLE_CHEMICAL", 12, 15], ["acetic acid", "SIMPLE_CHEMICAL", 17, 28], ["sodium acetate", "SIMPLE_CHEMICAL", 30, 44], ["BBMV", "MULTI-TISSUE_STRUCTURE", 163, 167], ["M. separata Walker", "ORGANISM", 195, 213], ["M. separata", "SPECIES", 195, 206], ["M. separata", "SPECIES", 195, 206], ["Tris", "TREATMENT", 0, 4], ["NaCl", "TREATMENT", 6, 10], ["HCl", "TREATMENT", 12, 15], ["acetic acid", "TREATMENT", 17, 28], ["sodium acetate", "TREATMENT", 30, 44], ["Brush Border Membrane Vesicles", "TREATMENT", 131, 161], ["separata Walker", "TREATMENT", 198, 213], ["Brush", "ANATOMY_MODIFIER", 131, 136]]], ["The midguts were then dissected.", [["midguts", "ANATOMY", 4, 11], ["midguts", "ORGANISM_SUBSTANCE", 4, 11]]], ["Peritrophic matrix and gut contents were removed.", [["Peritrophic matrix", "ANATOMY", 0, 18], ["gut", "ANATOMY", 23, 26], ["Peritrophic matrix", "CELLULAR_COMPONENT", 0, 18], ["gut", "ORGAN", 23, 26], ["Peritrophic matrix and gut contents", "PROBLEM", 0, 35], ["matrix", "OBSERVATION", 12, 18], ["gut", "ANATOMY", 23, 26], ["contents", "OBSERVATION", 27, 35]]], ["The remaining tissues were washed in an ice-cold 0.7% NaCl solution.", [["tissues", "ANATOMY", 14, 21], ["NaCl", "CHEMICAL", 54, 58], ["NaCl", "CHEMICAL", 54, 58], ["tissues", "TISSUE", 14, 21], ["an ice-cold 0.7% NaCl solution", "TREATMENT", 37, 67], ["remaining", "OBSERVATION_MODIFIER", 4, 13], ["tissues", "OBSERVATION", 14, 21]]], ["The cleaned tissue was dried on filter paper, weighed, and used to separate the BBMVs according to the differential magnesium precipitation method with some modifications [38] .", [["tissue", "ANATOMY", 12, 18], ["magnesium", "CHEMICAL", 116, 125], ["magnesium", "CHEMICAL", 116, 125], ["tissue", "TISSUE", 12, 18], ["magnesium", "SIMPLE_CHEMICAL", 116, 125], ["The cleaned tissue", "TREATMENT", 0, 18], ["the differential magnesium precipitation method", "TREATMENT", 99, 146], ["cleaned tissue", "OBSERVATION_MODIFIER", 4, 18]]], ["The final BBMV pellet was dissolved in an ice-cold dissolution buffer (150 mM NaCl, 5 mM EGTA, 1 mM PMSF, 20 mM Tris-HCl, and 1% CHAPS).", [["BBMV pellet", "ANATOMY", 10, 21], ["NaCl", "CHEMICAL", 78, 82], ["EGTA", "CHEMICAL", 89, 93], ["Tris-HCl", "CHEMICAL", 112, 120], ["NaCl", "CHEMICAL", 78, 82], ["EGTA", "CHEMICAL", 89, 93], ["PMSF", "CHEMICAL", 100, 104], ["Tris-HCl", "CHEMICAL", 112, 120], ["CHAPS", "CHEMICAL", 129, 134], ["BBMV", "ORGANISM", 10, 14], ["PMSF", "SIMPLE_CHEMICAL", 100, 104], ["Tris-HCl", "SIMPLE_CHEMICAL", 112, 120], ["BBMV", "SPECIES", 10, 14], ["The final BBMV pellet", "TREATMENT", 0, 21], ["an ice-cold dissolution buffer", "TREATMENT", 39, 69], ["5 mM EGTA", "TREATMENT", 84, 93], ["20 mM Tris-HCl", "TREATMENT", 106, 120], ["1% CHAPS", "TREATMENT", 126, 134]]], ["Protein concentration was quantified by Bradford Assay, and the prepared BBMVs were stored at\u00b480\u02ddC until analysis.Synthesis of LigandThe ligand, periplocoside E-semi-succinic acid ester, was synthesized using periplocoside E and succinic anhydride ( Figure 2) .Synthesis of LigandBriefly, 100 mg of periplocoside E (0.08 mmol) and 100 mg of succinic anhydride (1 mmol) were placed in a reaction vessel and dissolved in 20 mL of anhydrous pyridine.", [["BBMVs", "ANATOMY", 73, 78], ["vessel", "ANATOMY", 395, 401], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 145, 185], ["periplocoside E", "CHEMICAL", 209, 224], ["succinic anhydride", "CHEMICAL", 229, 247], ["LigandBriefly", "CHEMICAL", 274, 287], ["periplocoside E", "CHEMICAL", 299, 314], ["succinic anhydride", "CHEMICAL", 341, 359], ["anhydrous pyridine", "CHEMICAL", 428, 446], ["periplocoside E-semi-succinic acid ester", "CHEMICAL", 145, 185], ["periplocoside E", "CHEMICAL", 209, 224], ["succinic anhydride", "CHEMICAL", 229, 247], ["periplocoside E", "CHEMICAL", 299, 314], ["succinic anhydride", "CHEMICAL", 341, 359], ["anhydrous pyridine", "CHEMICAL", 428, 446], ["BBMVs", "CELL", 73, 78], ["periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 145, 185], ["periplocoside E", "SIMPLE_CHEMICAL", 209, 224], ["succinic anhydride", "SIMPLE_CHEMICAL", 229, 247], ["LigandBriefly", "SIMPLE_CHEMICAL", 274, 287], ["periplocoside E", "SIMPLE_CHEMICAL", 299, 314], ["succinic anhydride", "SIMPLE_CHEMICAL", 341, 359], ["vessel", "MULTI-TISSUE_STRUCTURE", 395, 401], ["anhydrous pyridine", "SIMPLE_CHEMICAL", 428, 446], ["Protein concentration", "TEST", 0, 21], ["analysis", "TEST", 105, 113], ["Synthesis of LigandThe ligand", "TEST", 114, 143], ["periplocoside E-semi-succinic acid ester", "TREATMENT", 145, 185], ["periplocoside E and succinic anhydride", "TREATMENT", 209, 247], ["Synthesis of LigandBriefly", "TREATMENT", 261, 287], ["periplocoside E", "TREATMENT", 299, 314], ["succinic anhydride", "TREATMENT", 341, 359], ["a reaction vessel", "TREATMENT", 384, 401], ["anhydrous pyridine", "TREATMENT", 428, 446], ["vessel", "ANATOMY", 395, 401]]], ["The mixture was reacted at 120\u02ddC through a heating reflux method.", [["C", "SIMPLE_CHEMICAL", 31, 32], ["a heating reflux method", "TREATMENT", 41, 64], ["reflux", "OBSERVATION", 51, 57]]], ["Subsequently, 20 mL of methanol was added to terminate the completed reaction (surveillance by thin layer chromatography (TLC)).", [["methanol", "CHEMICAL", 23, 31], ["methanol", "CHEMICAL", 23, 31], ["methanol", "SIMPLE_CHEMICAL", 23, 31], ["methanol", "TREATMENT", 23, 31], ["thin layer chromatography", "TEST", 95, 120]]], ["The solvent was evaporated at 60\u02ddC by using rotary evaporators (Thermo Fisher, Beijing, China).", [["C", "SIMPLE_CHEMICAL", 33, 34]]], ["The remaining dry powder was dissolved in methyl alcohol and further separated by column chromatography.", [["methyl alcohol", "CHEMICAL", 42, 56], ["methyl alcohol", "CHEMICAL", 42, 56], ["methyl alcohol", "SIMPLE_CHEMICAL", 42, 56], ["The remaining dry powder", "TREATMENT", 0, 24], ["methyl alcohol", "TREATMENT", 42, 56], ["dry", "OBSERVATION_MODIFIER", 14, 17], ["powder", "OBSERVATION", 18, 24]]], ["The structure was characterized by MS and 13 C-NMR and MS analyses.Preparation of the Medium and Coupling of the LigandThe medium, namely, epoxy amino hexyl (EAH)-activated sepharose 4B, was prepared according to the operation manual.", [["epoxy amino hexyl", "CHEMICAL", 139, 156], ["EAH", "CHEMICAL", 158, 161], ["C", "CHEMICAL", 45, 46], ["epoxy amino hexyl", "CHEMICAL", 139, 156], ["EAH", "CHEMICAL", 158, 161], ["epoxy amino hexyl", "SIMPLE_CHEMICAL", 139, 156], ["EAH", "SIMPLE_CHEMICAL", 158, 161], ["sepharose 4B", "SIMPLE_CHEMICAL", 173, 185], ["MS", "TEST", 35, 37], ["C-NMR and MS analyses", "TEST", 45, 66], ["the Medium", "TREATMENT", 82, 92], ["epoxy amino hexyl (EAH)", "TREATMENT", 139, 162], ["activated sepharose 4B", "TREATMENT", 163, 185]]], ["The lyophilized powder of EAH Sepharose 4B (2.5 g) was sufficiently swelled in 100 mL of 20% ethanol.", [["EAH Sepharose 4B", "CHEMICAL", 26, 42], ["ethanol", "CHEMICAL", 93, 100], ["ethanol", "CHEMICAL", 93, 100], ["EAH Sepharose 4B", "SIMPLE_CHEMICAL", 26, 42], ["ethanol", "SIMPLE_CHEMICAL", 93, 100], ["The lyophilized powder of EAH Sepharose 4B", "TREATMENT", 0, 42]]], ["When the medium swelled, the ethanol solution was decanted, and the required amount of the matrix was washed five times on a glass filter (porosity G3) with distilled water (pH 4.5).", [["matrix", "ANATOMY", 91, 97], ["ethanol", "CHEMICAL", 29, 36], ["ethanol", "CHEMICAL", 29, 36], ["ethanol", "SIMPLE_CHEMICAL", 29, 36], ["matrix", "CELLULAR_COMPONENT", 91, 97], ["the ethanol solution", "TREATMENT", 25, 45], ["the matrix", "TREATMENT", 87, 97], ["a glass filter (porosity G3", "TREATMENT", 123, 150], ["pH", "TEST", 174, 176]]], ["The matrix was subjected to sedimentation using 80 mL of 0.5 mol/L NaCl.Preparation of the Medium and Coupling of the LigandThe carbodiimide method was used for ligand coupling.", [["matrix", "ANATOMY", 4, 10], ["NaCl", "CHEMICAL", 67, 71], ["carbodiimide", "CHEMICAL", 128, 140], ["NaCl", "CHEMICAL", 67, 71], ["carbodiimide", "CHEMICAL", 128, 140], ["matrix", "CELLULAR_COMPONENT", 4, 10], ["L NaCl", "TREATMENT", 65, 71], ["the Medium and Coupling of the LigandThe carbodiimide method", "TREATMENT", 87, 147], ["ligand coupling", "PROBLEM", 161, 176]]], ["Periplocoside E-semi-succinic acid ester (ligand) was dissolved in the coupling solution (50% ethylene glycol solution) and added to the matrix (matrix:ligand = 1:1) to form a suspension.", [["Periplocoside", "CHEMICAL", 0, 13], ["E-semi-succinic acid ester", "CHEMICAL", 14, 40], ["ethylene glycol", "CHEMICAL", 94, 109], ["Periplocoside E-semi-succinic acid ester", "CHEMICAL", 0, 40], ["ethylene glycol", "CHEMICAL", 94, 109], ["Periplocoside E-semi-succinic acid ester", "SIMPLE_CHEMICAL", 0, 40], ["ethylene glycol solution", "SIMPLE_CHEMICAL", 94, 118], ["matrix", "CELLULAR_COMPONENT", 137, 143], ["matrix", "CELLULAR_COMPONENT", 145, 151], ["Periplocoside E-semi-succinic acid ester (ligand)", "TREATMENT", 0, 49], ["the coupling solution (50% ethylene glycol solution", "TREATMENT", 67, 118], ["the matrix (matrix:ligand", "TREATMENT", 133, 158], ["a suspension", "TREATMENT", 174, 186]]], ["Briefly, 0.1 mol/L carbodiimide was added to the suspension.", [["carbodiimide", "CHEMICAL", 19, 31], ["carbodiimide", "CHEMICAL", 19, 31], ["0.1 mol/L carbodiimide", "SIMPLE_CHEMICAL", 9, 31], ["L carbodiimide", "TREATMENT", 17, 31], ["the suspension", "TREATMENT", 45, 59]]], ["The superfluous medium was eluted with three cycles of an alternating pH elution buffer (buffer 1: 0.1 mol/L acetic acid/sodium acetate containing 0.5 mol/L NaCl, pH 4.0; buffer 2: 0.1 mol/L Tris-HCl containing 0.5 mol/L NaCl, pH 8.0).", [["acetic acid", "CHEMICAL", 109, 120], ["sodium acetate", "CHEMICAL", 121, 135], ["NaCl", "CHEMICAL", 157, 161], ["Tris-HCl", "CHEMICAL", 191, 199], ["NaCl", "CHEMICAL", 221, 225], ["acetic acid", "CHEMICAL", 109, 120], ["sodium acetate", "CHEMICAL", 121, 135], ["NaCl", "CHEMICAL", 157, 161], ["Tris-HCl", "CHEMICAL", 191, 199], ["NaCl", "CHEMICAL", 221, 225], ["acetic acid", "SIMPLE_CHEMICAL", 109, 120], ["sodium acetate", "SIMPLE_CHEMICAL", 121, 135], ["Tris-HCl", "SIMPLE_CHEMICAL", 191, 199], ["an alternating pH elution buffer", "TREATMENT", 55, 87], ["L acetic acid/sodium acetate", "TREATMENT", 107, 135], ["NaCl", "TREATMENT", 157, 161], ["pH", "TEST", 163, 165], ["buffer", "TEST", 171, 177], ["Tris", "TEST", 191, 195], ["HCl", "TREATMENT", 196, 199], ["NaCl", "TREATMENT", 221, 225], ["pH", "TEST", 227, 229], ["superfluous", "OBSERVATION_MODIFIER", 4, 15], ["medium", "OBSERVATION_MODIFIER", 16, 22]]], ["The volumes of each elution buffer were at least five times the medium volumes.Affinity ChromatographyThe prepared EAH sepharose 4B was packed to the column of an AKTA protein purification system (GE Healthcare, Beijing, China).", [["EAH", "CHEMICAL", 115, 118], ["EAH sepharose 4B", "CHEMICAL", 115, 131], ["AKTA", "SIMPLE_CHEMICAL", 163, 167], ["EAH sepharose 4B", "PROTEIN", 115, 131], ["each elution buffer", "TREATMENT", 15, 34], ["Affinity Chromatography", "TEST", 79, 102], ["The prepared EAH sepharose 4B", "TREATMENT", 102, 131], ["an AKTA protein purification system", "TREATMENT", 160, 195], ["volumes", "OBSERVATION_MODIFIER", 4, 11]]], ["The packing flow rate was maintained for three bed volumes after reaching a constant bed height was reached.", [["The packing flow rate", "TREATMENT", 0, 21], ["a constant bed height", "TREATMENT", 74, 95], ["packing", "OBSERVATION_MODIFIER", 4, 11], ["flow rate", "OBSERVATION", 12, 21]]], ["After loading the BBMVs of the M. separata, the medium was washed with the binding buffer (0.1 mol/L NaH 2 PO 4 /Na 2 HPO 4 , pH 7.4 containing 0.5 mol/L NaCl) until the base line become stable.", [["Na", "CHEMICAL", 113, 115], ["NaCl", "CHEMICAL", 154, 158], ["NaH 2 PO 4", "CHEMICAL", 101, 111], ["Na 2 HPO 4", "CHEMICAL", 113, 123], ["NaCl", "CHEMICAL", 154, 158], ["M. separata", "ORGANISM", 31, 42], ["Na 2 HPO 4", "SIMPLE_CHEMICAL", 113, 123], ["M. separata", "SPECIES", 31, 42], ["M. separata", "SPECIES", 31, 42], ["the M. separata", "TREATMENT", 27, 42], ["the binding buffer", "TREATMENT", 71, 89], ["Na", "TEST", 113, 115], ["pH", "TEST", 126, 128], ["0.5 mol/L NaCl", "TREATMENT", 144, 158], ["the base line", "TREATMENT", 166, 179], ["stable", "OBSERVATION_MODIFIER", 187, 193]]], ["For competitive elution, periplocoside E was dissolved in the binding buffer.", [["periplocoside E", "CHEMICAL", 25, 40], ["periplocoside E", "CHEMICAL", 25, 40], ["periplocoside E", "SIMPLE_CHEMICAL", 25, 40], ["periplocoside E", "TREATMENT", 25, 40]]], ["The elution peak was collected by washing the medium with the elution buffer.", [["The elution peak", "TEST", 0, 16], ["the elution buffer", "TREATMENT", 58, 76], ["elution", "OBSERVATION_MODIFIER", 4, 11], ["peak", "OBSERVATION_MODIFIER", 12, 16]]], ["The affinity medium was then washed with an alternating high pH (0.1 mol/L Tris-HCl, pH 8.0 containing 0.5 mol/L NaCl) and low pH (0.1 mol/L acetic acid/ sodium acetate, pH4.0 containing 0.5 mol/L NaCl) buffer solution to regenerate the medium.", [["Tris-HCl", "CHEMICAL", 75, 83], ["NaCl", "CHEMICAL", 113, 117], ["acetic acid", "CHEMICAL", 141, 152], ["sodium acetate", "CHEMICAL", 154, 168], ["NaCl", "CHEMICAL", 197, 201], ["Tris-HCl", "CHEMICAL", 75, 83], ["NaCl", "CHEMICAL", 113, 117], ["acetic acid", "CHEMICAL", 141, 152], ["sodium acetate", "CHEMICAL", 154, 168], ["NaCl", "CHEMICAL", 197, 201], ["Tris-HCl", "SIMPLE_CHEMICAL", 75, 83], ["acetic acid", "SIMPLE_CHEMICAL", 141, 152], ["sodium acetate", "SIMPLE_CHEMICAL", 154, 168], ["pH4.0", "SIMPLE_CHEMICAL", 170, 175], ["an alternating high pH", "TREATMENT", 41, 63], ["Tris", "TEST", 75, 79], ["HCl", "TREATMENT", 80, 83], ["pH", "TEST", 85, 87], ["L NaCl", "TREATMENT", 111, 117], ["low pH", "PROBLEM", 123, 129], ["L acetic acid", "TREATMENT", 139, 152], ["sodium acetate", "TREATMENT", 154, 168], ["pH4.0", "TREATMENT", 170, 175], ["L NaCl) buffer solution", "TREATMENT", 195, 218]]], ["This cycle was repeated three times.SDS-PAGE and LC/Q-TOF-MS AnalysisThe collected binding protein solution was dialyzed to decrease its high salt concentration.", [["salt", "SIMPLE_CHEMICAL", 142, 146], ["SDS", "TEST", 36, 39], ["LC", "TEST", 49, 51], ["MS Analysis", "TEST", 58, 69], ["The collected binding protein solution", "TREATMENT", 69, 107], ["high salt concentration", "OBSERVATION", 137, 160]]], ["The samples were then lyophilized.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11]]], ["SDS-PAGE (12% separating gel and 5% spacer gel) was conducted by dissolving the sample in the Tris-HCl (pH 7.2).", [["sample", "ANATOMY", 80, 86], ["Tris-HCl", "CHEMICAL", 94, 102], ["Tris-HCl", "CHEMICAL", 94, 102], ["Tris-HCl", "SIMPLE_CHEMICAL", 94, 102], ["SDS", "TEST", 0, 3], ["12% separating gel", "TREATMENT", 10, 28], ["5% spacer gel", "TREATMENT", 33, 46], ["pH", "TEST", 104, 106]]], ["The whole visible lane was obtained for protein MS identification.", [["protein MS identification", "TEST", 40, 65]]], ["Protein MS was implemented in Beijing Protein Institute (Beijing, China) by using LC/Q-TOF-MS.", [["Protein MS", "TEST", 0, 10]]]], "091bee770883e707522251b64cd0a0c0c7371d2a": [["and serves a diverse population of approximately 2.8 million residents, plus additional travelers.", [["diverse", "OBSERVATION_MODIFIER", 13, 20]]]]}